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  Abstract 
  I 
Abstract 
Modern agriculture couples the management of invasive weed species with enhancing 
crop yields through the intensive use of herbicides. As a result of herbicides being the 
primary method of weed control in agronomic crops, herbicide resistance has evolved and 
there has been a vast increase in the occurrence and distribution of herbicide resistant 
weeds. Many of the most problematic weeds have now evolved multiple herbicide 
resistance (MHR), which is associated with an enhanced ability to detoxify xenobiotics, 
enabling the weed to survive herbicide application irrespective of the mode of action. As 
herbicide resistance is a major limiting factor to food security in global agriculture, effective 
methods for weed management are sought. 
This work focuses on MHR in black grass (Alopecurus myosuroides), one of the most 
damaging weeds of winter cereals. Previous work by Edwards et al. described that black 
grass populations showing MHR, exhibit an upregulation in the expression of a specific 
phi-class glutathione transferase (AmGSTF1), which is thought to have a direct regulatory 
control on metabolism. The importance of AmGSTF1 in MHR has been confirmed both 
genetically by transgene experiments and chemically through inhibition experiments. This 
offers the opportunity to develop potential herbicide synergists, which are active towards 
AmGSTF1 and restore herbicide control in multiple herbicide resistant black grass. 
Considering the rapid spread of MHR in grass weeds and the limited development of new 
herbicides, synergists offer an important alternative strategy in counteracting resistance in 
the field. 
Recently a new class of AmGSTF1 inhibitors, derived from flavonoids, could be identified. 
Initial efforts focused on the synthesis of a series of flavone analogues, mainly with 
structural changes of the C-ring and different substituents in the 5-position. A particular 
emphasis was put on increasing the aqueous solubility and other physicochemical 
properties of the compounds, in order to increase the bioavailability in the plant. 
Although the potency of the initial lead molecule could not be increased in vitro, 
5,7-dimethoxy-2-(1’,3’-thiazol-2’-yl)-4H-chromen-4-one, with a significantly increased 
aqueous solubility, showed good results in in vivo studies in black grass and acted as a 
synergist to the herbicide pinoxaden. The black grass plants died, when pinoxaden (10µl 
of a 15 µM solution) was applied to plants, which were pre-treated with the thiazole (10 µl 
of a 2 mM solution), but survived the herbicide treatment, if no synergist was applied prior.  
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1 Introduction 
1.1 Overview 
The work in this thesis is aimed towards the development of a herbicide synergist, which 
inhibits the effects of multiple herbicide resistance in black grass (Alopecurus 
myosuroides).  
This thesis comprises 5 chapters. Chapter 2 will give an overview of previous work within 
the group and outline the aims of this project. Chapter 3 will discuss the work undertaken 
and a conclusion will be drawn in chapter 4. The chemical and biological experimental 
procedures will be detailed in chapter 5. The remainder of this chapter outlines the 
background to the project. 
1.2 Herbicide resistance 
1.2.1 Introduction to herbicide resistance 
In the last century herbicides have revolutionised the control of weeds and made a big 
contribution towards the increase of crop yields (Figure 1).1  
 
Figure 1: Increase in wheat yield from controlling weeds and diseases.2 
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However, the high selective pressure caused by the application of herbicides has resulted 
in the evolutionary adaption of weeds which over the last 40 years resulted in a dramatic 
increase in the frequency (Figure 2) and diversity of herbicide resistant weed biotypes. 
This poses a substantial threat to the sustainability of agriculture both locally and globally. 
With the growth in global population leading to increasing demands for food production, 
the fast rise of herbicide resistant weeds threatens food security.  
 
Figure 2: Chronological increase in unique herbicide resistant weed cases.1 
 
The International Survey of Herbicide Resistant Weeds3 reports the occurrence of 
herbicide resistant weeds worldwide and shows that there are currently 252 herbicide 
resistant weed species globally (147 dicots and 105 monocots). Weeds have evolved 
resistance to 23 of the 26 known herbicide sites of action and to 161 different herbicides, 
and there have been reports of herbicide resistant weeds in 91 crops in 67 countries.3 As 
not all countries or regions are equally represented in this survey, the actual occurrence of 
herbicide resistant weeds may well be much higher.  
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1.2.2 Herbicides 
Herbicides are chemicals that kill plants or inhibit their growth. They can either be selective 
or non-selective (Figure 3).  
 
 
Figure 3: Some of the most widely used selective (s) and non-selective (ns) 
herbicides; Numbers in brackets indicate herbicide class. 
 
Selective herbicides are toxic to some plant species but less toxic, or not toxic at all to 
others. They target specific weeds or weed categories without causing damage to the crop 
and therefore allow weed control. Herbicide selectivity can be enhanced through the use of 
herbicide safeners, which selectively protect crop plants from herbicide damage, without 
reducing the activity in the target weed.4 Non-selective herbicides, such as glyphosate,5 
eliminate all plants and are applied to control weeds before crop planting, or weeds in 
plantation crops like rubber or oil palm. They can also be used together with crops, which 
have been genetically engineered to be resistant to non-selective herbicides. 
Herbicides can be further classified based on their mode of action.6-7 They target only a 
couple of processes and proteins within a cell (Figure 4).  
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Figure 4: Herbicide sites of action (numbers indicate herbicide class 
(WSSA)). 
 
The Weed Science Society of America (WSSA) herbicide classification system assigns 
each herbicide group a number,6 whereas the Herbicide-Resistance Action Committee 
(HRAC) classification system allocates a letter to each group (Table 1).7 
Group Site of action Examples 
1 (A) Inhibitors of acetyl CoA carboxylase 
(ACCase) 
Clodinafop, Fenoxaprop, Pinoxaden 
2 (B) Inhibitors of acetolactate synthase (ALS) Nicosulfuron, Chlorsulfuron, Imazapyr 
3 (K1) Inhibitors of microtubule assembly Trifluralin, Thiazopyr 
4 (O) Synthetic auxins Dichlorprop, 2,4-D 
5 (C1) Inhibitors of photosynthesis at photosystem II 
(PS II) site A 
Atrazine, Simazine 
6 (C3) Inhibitors of photosynthesis at PS II site B Bentazon, Ioxynil 
7 (C2) Inhibitors of photosynthesis at PS II site A; 
different binding behaviour from group 5 
Chlortoluron, Diuron 
8 (N) Inhibitors of lipid synthesis; not ACCase 
inhibition 
Cycloate, Pebulate 
9 (G) Inhibitor of 5-enolypyruvyl-shikimate-3- 
phosphate synthase (EPSPS) 
Glyphosate 
10 (H) Inhibitor of glutamine synthase Glufosinate 
11 (F3) Inhibitors of carotenoid biosynthesis (unknown 
target) 
Amitrole, Aclonifen 
  Introduction 
  5 
12 (F1) Inhibitors of the phytoene desaturase (PDS) Norflurazon, Fluridone 
13 (F4) Inhibitor of 1-deoxy-D-xyulose 5-phosphate 
(DOXP) synthase 
Clomazone 
14 (E) Inhibitors of protoporphyrinogen oxidase 
(Protox) 
Lactofen, Sulfentrazone 
15 (K3) Inhibitors of synthesis of very long–chain fatty 
acids 
Alachlor, Flufenacet, Metolachlor 
16 (N) Unknown Ethofumesate 
17 (Z) Unknown DSMA, MSMA 
18 (I) Inhibitor of 7,8-dihydropteroate synthase 
(DHP) 
Asulam 
19 (P) Inhibitors of indoleacetic acid transport Naptalam, Diflufenzppyr 
20 (L) Inhibitor of cell wall synthesis site A Dichlobenil 
21 (L) Inhibitor of cell wall synthesis site B Isoxaben 
22 (D) Photosystem I (PS I) electron diverters Diquat, Paraquat 
23 (K2) Inhibitor of mitosis Carbetamide 
24 (M) Membrane disruptors (uncouplers) Dinoterb 
25 (Z) Unknown Flamprop 
26 (Z) Unknown Difenzoquat, Pelargonic acid 
27 (F2) Inhibitors of 4-hydroxyhenyl-
pyruvatedioxygenase (4-HPPD) 
Isoxaflutole, Mesotrione 
Table 1: Herbicide classification according to WSSA (numbers) and HRAC 
(letters in brackets). 6-7 
 
1.2.2.1 Herbicides prone to resistance 
The herbicide groups, which are most affected by herbicide resistance are ALS inhibitors, 
PS II site A inhibitors, ACCase inhibitors and EPSPS inhibitors (Table 2). 
Group Site of action Herbicide resistant 
monocots 
Herbicide resistant 
dicots 
Total 
2 ALS inhibitors 62 97 159 
5 PS II site A inhibitors 23 51 74 
1 ACCase inhibitors 48 0 48 
9 EPSPS inhibitor 17 19 36 
Table 2: Occurrence of herbicide-resistant weed species to herbicide sites 
of action.1 
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Evolution of resistance is based on several factors. Most importantly, it depends on the 
characteristics of the weed species treated, such as fecundity, breeding system, 
generation time, fitness in the absence of herbicide, seed longevity, gene flow by pollen 
and seed, and seed dormancy, and the number of individuals treated over time. The 
number, frequency, dominance and fitness of genes that confer resistance to each 
herbicide site of action play an important role as well.8 
1.2.2.1.1 Acetolactate Synthase (ALS) inhibitors (2) 
ALS-inhibiting herbicides, which can also be called acetohydroxy acid synthase inhibitors, 
include imidazolinone, pyrimidinylthio-benzoate, sulfonylamino-carbonyltriazolinone, 
sulfonylurea and triazolopyrimidine herbicides.6 The inhibition of ALS, a common enzyme 
which is essential for the biosynthesis of the branched-chain amino acids isoleucine, valine 
and leucine leads to starvation of the plants (Figure 5).9-10 
 
Figure 5: The branched-chain amino acid biosynthetic pathway. 
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The fact that ALS inhibitors are among the most widely used herbicides in the world, that 
they target many species and that ALS is very prone to gene point mutations that confer 
resistance, has led to a large number of resistant weeds.8-9 There are currently amino acid 
substitutions at eight sites conferring resistance to ALS herbicides. Substitutions at Pro 
197 are most common, followed by substitutions at Trp 574 and Ser 653 (Figure 6). Amino 
acid numbers are standardized to Arabadopsis thaliana L. ALS.  
 
Figure 6: Number of species with ALS mutations by amino acid residue.3 
 
Some of those mutations result in cross resistance (cf. Chapter 1.2.3.2.1).11 Even though 
target-site resistance is the most common form of resistance among ALS inhibitors, there 
have also been reports of multiple herbicide resistance12-13 and other non-target-site 
resistance mechanisms (cf. Chapter 1.2.3.2.2).14-15 
1.2.2.1.2 Photosystem II (PS II) inhibitors (5) 
Phenyl-carbamates, pyridazinones, triazines, triazinones, triazolinones, and uracils are 
examples for herbicides that inhibit photosynthesis.6 They bind to the QB-site of the PS II 
complex, herbicides from groups 5, 6 and 7 thereby only differ in the position of the pocket, 
where they bind to the QB-site on the D1 protein, and compete with the exchangeable 
plastoquinone within the QB binding domain which interrupts the electron flow (Figure 7).16 
38
36
12
8
8
6 2 1
Pro 197
Trp 574
Asp 376
Ala 122
Ser 653
Ala 205
Gly 654
Arg 377
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Figure 7: Scheme of the light-induced electron chain from water oxidation to the reduction of 
high-energy molecules. Photosystem II (PS II) uses light energy (through excitation of a special 
chlorophyll pair called P680) to oxidise two molecules of H2O into one molecule of molecular 
oxygen (catalysed by the oxygen-evolving complex (OEC)). Electrons are transferred to a 
pheophytin (F) from P680*, which in turn extracts electrons from H2O. Then electrons are further 
transferred step-wise to a plastoquinone at the QA site (D 2 protein), to a plastoquinone at the QB 
site (D 1 protein) and via a group of cytochrome proteins, called the b6-f complex (Cyt-b6f), and 
the electron-carrier molecule plastocyanin (PCy), through the chain to Photosystem I (PS I). At 
PSI, absorbed photons result in the excitation of the dimeric chlorophyll P700, which starts the 
electron transport and is then reduced by PCy. Electrons are rapidly transferred step-wise 
through a series of acceptors to the iron-sulfur proteins FeS-X, FeS-A and FeS-B, and finally to 
the ferredoxin (Fd), which in turn reduces NADP+ to NADPH in a reaction catalysed by 
ferrodoxin-NADP+-reductase (FNR).  
 
Plants die because of severe oxidative stress. The interruption of electron flow causes the 
generation of triplet chlorophyll, which can interact with oxygen to form singlet oxygen. 
Carotenoids, which would normally quench triplet chlorophyll or singlet oxygen, cannot 
cope with the abundance of those reactive species when the electron flow is blocked. 16-17 
PS II inhibitors have been used extensively, which made them prone to resistance. 
Atrazine (Figure 3) especially, has been used almost solely in the 1960s to 1990s to 
control weeds in maize in Europe and the USA.8 Most cases of resistance are due to one 
mutation (Ser264 to Gly) in the D1 protein, conferring resistance to triazines (e.g. 
atrazine). Different cross resistance patterns to other PS II inhibitors can be observed in 
different weed species.18 There are also reports of some multiple herbicide resistance 
cases.19 
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1.2.2.1.3 Acetyl Coenzyme A Carboxylase (ACCase) inhibitors (1) 
ACCase-inhibiting herbicides comprise two chemical families: aryloxyphenoxy propionates 
and cyclohexanediones.6  Over a long period wheat production was dependent on 
ACCase inhibitors for grass control over large areas.8 Herbicides in this class inhibit acetyl-
coenzyme A carboxylase in grasses, an enzyme that catalyses the first step in the 
synthesis of fatty acids through the ATP-dependent carboxylation of acetyl coenzyme A to 
malonyl coenzyme A (Figure 8).20  
 
Figure 8: Fatty acid biosynthesis. 
 
The blocked fatty acid biosynthesis alters the cell membrane integrity and the plant dies. 
Cytotoxic hydroperoxides, caused by the disrupted fatty acid biosynthesis, have also been 
proposed to be responsible for plant death.20  
Resistance to ACCase inhibitors occurs in many cases due to target-site amino acid 
substitutions in the ACCase gene, but multiple herbicide resistance based on enhanced 
metabolism is widespread (cf. Chapter 1.2.3.2.2.1).20 
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1.2.2.1.4 5-Enolypyruvyl-shikimate-3-phosphate synthase inhibitors (9) 
This group only consists of one herbicide, glyphosate.6 Glyphosate, however, is one of the 
most important herbicides. It inhibits EPSP synthase of all higher plants in the biosynthetic 
pathway of aromatic amino acids (Figure 9). 10, 21  
 
 
Figure 9: The aromatic amino acid biosynthetic pathway. 
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Plant death has been associated with the depletion of the aromatic amino acids 
phenylalanine, tyrosine and tryptophan or with shortage of carbon for other essential 
pathways due to the increased carbon flow to the shikimate pathway in the treated plant.5  
Since glyphosate was first introduced in 1974 it has become the most important herbicide 
worldwide. 90% of all transgenic plants worldwide are glyphosate resistant.5 Due to the 
reliance solely on glyphosate for weed control on massive areas in glyphosate resistant 
crops and orchards, there is a very high selection pressure for resistance and resistant 
weeds are evolving rapidly (Figure 10).22 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: Chronological increase in glyphosate-resistant weeds worldwide 
and commercial introduction of transgenic crops resistant to glyphosate. 
Resistance gene(s) are indicated in brackets; cp4 epsps: microbial EPSP 
encoding gene; zm-2mepsps: mutated maize EPSP encoding gene; gox: 
glyphosate oxidoreductase encoding gene.3 
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Weeds have evolved nine different mechanisms of resistance to glyphosate, most 
prominently target-site resistance and resistance due to reduced translocation in the plant 
(cf. Chapter 1.2.3.2.2).22 Worryingly a lot of glyphosate resistant weeds are reported to be 
also resistant to other herbicides.3, 22 
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1.2.3 Resistance Pathways 
1.2.3.1 Target-site resistance versus nontarget-site resistance 
There are two types of mechanism observed for herbicide resistance, target-site 
resistance (TSR) and non-target-site resistance (NTSR).23-24 TSR develops from mutations 
in the gene encoding the protein targeted by the herbicide, which causes the herbicide to 
be less efficient. NTSR describes mechanisms complementary to changes at the target-
site, enabling a plant to survive herbicide application.25-27 Herbicide action can be divided 
into three steps: 1. penetration of the herbicide into the plant; 2. translocation and 
accumulation of the herbicide at the target site; 3. binding of the herbicide to the biological 
target, causing a phenotypic response such as the disruption of vital metabolic pathways 
or structural function leading to plant death (Figure 11).28  
 
Figure 11: Steps of herbicide action and the corresponding resistance 
mechanisms. 
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To combat this, nature has developed resistance mechanisms for every single step. 
Mechanisms changing the efficacy of herbicide binding to the target enzyme belong to 
TSR. Any mechanisms interfering with at least one of the other steps belong to NTSR.  
1.2.3.2 Cross-resistance 
Cross-resistance occurs when plants have a single mechanism that provides resistance to 
two or more herbicides from different chemical families, this cross-resistance can be 
triggered by a single gene modification which contributes to a single mechanism, but also 
by more than one gene, all contributing to the same mechanism.11, 18, 24 The mechanism 
can be target-site-based (cf. Chapter 1.2.3.2.1) as well as non-target-site based (cf. 
Chapter 1.2.3.2.2). 
1.2.3.2.1 Cross resistance based on TSR 
Target-site-based cross resistance is normally restricted to herbicides with the same site of 
action. However, it does not always result in resistance to all herbicide classes with a 
similar mode of action or all herbicides within a certain class.18  
For example, resistance to ALS-inhibitors can be caused by numerous single-point 
mutations of the ALS-enzyme, with different cross resistance patterns depending on the 
mutation. The Asp376Glu (amino acid number standardized to Arabadopsis thaliana L. 
ALS) mutation can cause resistance to ALS-inhibitors from imidazolinone, 
pyrimidinylthiobenzoate, sulfonylaminocarbonyltriazolinone, sulfonylurea and 
triazolopyrimidine herbicide families (Figure 12).11, 29 Ser653 substitutions on the other 
hand confer resistance to imidazolinone herbicides and to a lesser extent to 
pyrimidinylthiobenzoate herbicides.11 
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Figure 12: Arabidopsis thaliana seedling growth on media containing no 
selection agent, chlorimuron, imazethapyr, cloransulam, and 
propoxycarbazone. Growth of wilde type (WT) and transgenic Arabidopsis 
expressing the ALS gene from an ALS inhibitor-susceptible (AS) and –
resistant (AR11) smooth pigweed biotype are shown.29  
 
1.2.3.2.2 Cross resistance based on NTSR 
NTSR weeds often show a central defence mechanism, which is responsible for cross 
resistance across herbicide sites of actions. One non-target-site based mechanism for 
cross resistance is enhanced metabolism, which is also referred to as multiple herbicide 
resistance (MHR).30 MHR is distinct from multiple resistance (cf. Chapter 1.2.3.3) which is 
a term used to describe weed populations that exhibit more than one resistance 
mechanism. Other non-target-site based mechanisms for cross resistance include reduced 
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herbicide penetration and translocation, enhanced levels of gibberellins, gene amplification 
or overexpression and protection against the damage of herbicide action. 
Reduced herbicide penetration is caused by different physical and chemical properties of 
the cuticle in resistant plants.25 For ALS-inhibitors from both imidazolinone, and 
sulfonylurea herbicide families, a reduction in penetration has been described in a 
common sunflower population.14 
Enhanced levels of gibberellins, plant hormones that regulate growth, confer resistance to 
triallate (thiocarbamate herbicide) and difenzoquat (pyrazolium herbicide), causing rapid 
shoot growth that prevents sufficient herbicide from reaching the site of action.31  
Reduced translocation is the major basis of resistance for glyphosate and the bipyridylium 
herbicides, paraquat and diquat, but there is also evidence for cross resistance. Reduced 
translocation has been suggested to be the resistance mechanism for the glutamine 
synthase inhibitor glufosinate and glyphosate in Lolium perenne.32 
Gene amplification or overexpression increases the production of the target enzyme. 
Therefore, higher concentrations of herbicide are needed to reach the target site to inhibit 
the enzyme and cause death. For example, herbicide resistance against sulfonylureas and 
a imidazolinone herbicide due to amplification of a mutant ALS gene has been shown in 
tobacco.15 
Protection against the damage of herbicide action is another NTSR mechanism. Two 
GSTs have been shown to confer protection against oxidative stress caused by ACCase 
inhibitors in black grass.33-34 These inhibitors not only disrupt fatty acid synthesis, but also 
cause the release of reactive oxygen species that damage cell components. The GSTs 
protect the cell against oxidative damage, thereby giving the resistant plant time to 
degrade the herbicide. 
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1.2.3.2.2.1 Multiple Herbicide Resistance (MHR) 
In the same way that multidrug resistance (MDR) is a major drawback to improved 
healthcare, MHR is a serious threat to weed management. In contrast to MDR, which is 
most frequently due to active transporters that pump a wide range of drugs, including 
antibiotics, antimalarials and cancer chemotherapeutics, out of human cells35, participation 
in MHR has been well established for four gene families: P450 monooxygenases 
(CYP450s), glutathione S-transferases (GSTs), to some extend UDP-dependent 
glycosyltransferases (UGTs) and ATP-binding cassette (ABC) transporters.26 
MHR is not only the most important aspect of NTSR it is also the most studied.26, 36 The 
detoxification of plants is a multistep process involving several types of enzymes. Most 
herbicides can be detoxified by plants to some extent, but the ability to metabolize the 
herbicide might be insufficient to stop the weed species from being killed. Selective 
herbicides often rely on the fact that the herbicide is more rapidly metabolised in the crop 
than in the weed, especially in grasses.37 MHR is most problematic in black grass and rye 
grass, which compete with cereal crops.23 There is still little known about the exact 
mechanisms that cause enhanced metabolism and many enzymes might be involved.26, 36 
Nevertheless, there are indications that MHR can be monogenic, but the coordinated 
regulation of detoxifying genes and interaction among the enzymes seem to be the more 
important mechanism.26  
1.2.3.3 Multiple resistance 
Multiple resistance refers to plants with more than one resistance mechanism. Multiple 
resistance can for example arise from pyramiding of multiple TSR-traits.11 It is usually 
caused through accumulation of resistance genes via pollen flow or is the result of 
selection of different resistance mechanisms by herbicides that differ in their sites of 
action. 
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Over the last 30 years the number of weeds resistant to 2 or more herbicide sites of action, 
caused by either cross resistance or multiple resistance, has increased dramatically and 
there are now reports of weeds resistant to herbicides with up to eleven different sites of 
action (Figure 13).3 
 
Figure 13: Increase in the number of weeds resistant to two or more 
herbicide sites of action.3 
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1.2.4 Herbicide resistance in black grass 
Black grass (Alopecurus myosuroides) is an annual or winter annual tufted grass weed, 
which propagates by seeds (Figure 14). 
Figure 14: Black Grass. 
 
Most seeds germinate in late summer or early autumn. It is perfectly adapted to winter 
cereal production, which has led to a rapid increase of black grass. The large populations 
and widespread distribution in cropping areas, rapid seed bank turnover, high reproductive 
capacity, allogamous reproduction and genetic and phenotypic plasticity all favour the 
accumulation of herbicide resistance mechanisms.18 Black grass has been reported as a 
problematic weed worldwide, but it is most serious in Europe, particularly England, France 
and Germany.38 It belongs to the weed species resistant to the most number of sites of 
action (Figure 15).3 
Figure 15: Resistant species by the number of sites of action.3 
  Introduction 
  20 
Numerous herbicide resistant biotypes have been documented and both TSR and NTSR 
occur frequently in field populations of black grass.39-43 A random survey in England in 
2002 indicated that 80% of the black grass samples demonstrated resistance to at least 
one herbicide such as fenoxaprop-P, sethoxydim (both ACCase inhibitor), chlorotoluron 
and isoproturon (both PSII inhibitor).44  
TSR mostly concerns ACCase inhibitors40, 45-48 and ALS inhibitors48-49, which is alarming 
because the control is mainly based on those two modes of action.50 Analysis of the 
geographical structure of resistance to ACCase inhibitors across six countries 
demonstrated the wide spread occurrence of seven mutant resistant ACCase alleles in 
black grass populations (Figure 16).40  
 
Figure 16: Geographical distribution of mutant herbicide-resistant variants of 
the target protein ACCase among 297 populations of black grass in Europe. Pie 
charts show the respective frequencies of the mutant acetyl-CoA carboxylase 
variants detected in populations. White, wild-type allele; yellow, C-L1781; 
orange, T-L1781; red, C-C2027; purple, T-C2027; green, N2041; blue, G2078; 
grey, A2096. Populations where no mutant variant was detected are shown as 
small, white circles.40 
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The study also reported that only a fraction of genes involved in resistance to ACCase 
inhibitors are mutant ACCase alleles and NTSR mechanisms are responsible for most of 
this resistance. 
NTSR in black grass is in many cases attributed to MHR, but protection against the 
damage of herbicide action has also been reported.33-34 MHR in black grass was first 
detected in a population from Peldon in Essex, England51-52 and has since been reported 
in populations across Europe. Herbicide resistance in the Peldon population could not be 
explained by reduced target site sensitivities and studies demonstrated that the more 
extensive metabolism in the resistant biotypes could be reduced by CYP450 inhibitors.51, 
53-54 Since then, the involvement of CYP450s in MHR was suggested for other black grass 
populations across Europe.55-58  
In addition, higher GST activities were shown to be responsible for MHR in some black 
grass populations.30, 34, 58-60 MHR was associated with an increased expression of 
AmGSTF1, a member of the plant-specific phi (F) class of GST. AmGSTF1 showed a 
higher activity as a glutathione peroxidase (GPOX), catalysing the reduction of peroxides, 
rather than detoxification of herbicides34 and seems to have a direct regulatory control on 
metabolism.30  
Compared to herbicide sensitive black grass, the plants from the Peldon population also 
contained higher levels of O-glucosyltransferases activity.61 
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1.2.5 Dealing with herbicide resistance 
With an increase in herbicide resistance, new developments and other methods are 
needed to control weeds. Up to a certain point agronomic practices can be very important 
tools for weed control. Strategies include rotating crops, optimization of planting dates and 
seeding rates, mechanical methods such as tillage24 and hand-weeding as a last resort. 
Methods to prevent, or at least delay herbicide resistance, include the rotation of herbicide 
mode of action and the use of herbicide mixtures.8 
TSR may be overcome using herbicides with a different mode of action, but this is 
increasingly difficult, as industry has not provided a herbicide with a new mode of action in 
more than 30 years. Although controversial, a solution to this could be new genetically 
modified herbicide resistant crops, as old herbicides could be used in new ways.8 
MHR however is the most difficult to deal with. One possibility could be the application of 
synergists, which inhibit the effects of MHR. A parallel could be drawn to MDR in cancer, 
where the inhibition of drug detoxifying proteins has been the focus of medicinal chemistry 
programs.62-63 There are a variety of compounds, which have been shown to inhibit 
herbicide detoxification caused by CYP450s. Malathion synergized imazethapyr activity in 
a resistant population of Digitaria sanguinalis64 and chlorosulfuron activity in herbicide 
resistant Lolium rigidum12-13. 1-Aminobenzotriazole has been shown to decrease the 
metabolism of simazine13, 65, chlorotoluron13 and diclofop13 in herbicide resistant Lolium 
rigidum and piperonyl butoxid reduced the metabolism of simazine13 and chlorotoluron13, 
also in Lolium rigidum. In the same way piperonyl butoxide and 1-aminobenzotriazole 
acted in synergism with the herbicides isoproturon, chlorproturon, haloxyfop and 
clodinafop propargyl and malathion with the herbicide flupysulfuron in MHR black grass.58  
The GST inhibitor 4-chloro-7-nitro-benzoxadiazole increased the toxicity of chlorotoluron, 
fenoxaprop-p-ethyl and clodinafop-propargyl, when applied as a synergist30 and tridiphane 
reduced the metabolism of fenoxaprop-p-ethyl58 in herbicide resistant black grass.   
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1.3 Herbicide Metabolism in Plants 
Herbicide metabolism is a multi-enzyme process that can be arranged into four phases 
(Figure 17). 26, 36, 66 
Figure 17: Schema of CYP450, GST, UGT and ABC transporter gene-
encoded detoxification activities. 
 
In phase I molecules are activated for further conjugation by other enzymes in phase II, 
which most commonly involves oxidations by cytochrome P450 monooxygenases 
(CYP450s) or mixed function oxidases and hydrolyses by carboxylesterases. With a few 
exceptions CYP450s are localized in the endoplasmic reticulum membrane with the 
remainder of the protein in the cytosol. CYP450s are heme protein-dependent oxidase 
systems, which need NADPH and/or NADH to cleave atmospheric oxygen and 
functionalize a molecule.67 CYP450s can catalyse different reactions, but common for 
herbicides are hydroxylations of aromatic rings and alkyl groups and dealkylations (Figure 
18).36 Through the incorporation of the oxygen, the activity towards phase II enzymes is 
enhanced. 
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Figure 18: Common CYP450 catalyzed reactions. 1) Aryl hydroxylation. 2) Alkyl 
hydrokylation. 3) Heteroatom release (N-dealkylation). 
 
 
In phase II xenobiotics are normally conjugated to bulky hydrophilic molecules such as 
thiols or sugars. One example for phase II enzymes are glycosyltransferases (GTs), which 
catalyse the conjugation of glucose to a variety of lipophilic small molecule acceptors, such 
as plant metabolites, phytotoxins and xenobiotics, altering their properties.68. Depending 
on the functional group, which is conjugated to the sugar (-OH, -COOH, -NH2), GTs can be 
divided into O-glycosyltransferases or N-glycosyltransferases. Usually uridindiphosphate-
glucose (UDPG) is required as a sugar-donor.36, 68 Another example is glutathione 
S-transferases (GSTs). Because MHR in black grass has been associated with an 
increased expression of AmGSTF1,30 GSTs are discussed in more detail below (cf. 
Chapter 1.3.1.1). 
In phase III conjugated molecules are actively transported to the vacuole or extracellular 
spaces by enzymes such as the ATP-binding cassette (ABC) drug transporter proteins. 
ABC transporters acquire their energy from hydrolysis of ATP, which takes place in the 
ATP binding cassette domain and use it to transport molecules through membranes. They 
can detoxify herbicides through compartmenting herbicides and their metabolites. ABC 
transporters are also responsible for the uptake of nutrients and a broad variety of other 
transport functions, such as sequestration of secondary metabolites, translocation of fatty 
acids and phospholipids or regulation of ion channels.69 
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Phase IV detoxification involves reactions such as further degradation, secondary 
conjugation and incorporation into cell wall constituents.  
Degradation of the ACCase inhibitor fenoxaprop illustrates how herbicide metabolism is a 
multistep process involving the coordinated action of the enzymes highlighted above 
(Figure 19). 
 
 
Figure 19: Metabolism of the ACCase inhibitor fenoxaprop in grasses.25 I, II 
and III refer to phase I, II and III in plant metabolism. 
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1.3.1.1 Glutathione S-transferases 
Plant GSTs are an ancient enzyme superfamily and have multiple and diverse functions. 
They catalyse the reaction of reduced glutathione (g-L-Glu-L-Cys-Gly; GSH) with an 
electrophilic substrate R-X by displacement of the leaving group to form a polar 
S-glutothionylated product R-SG (Figure 20). 70-72 
 
Figure 20: Glutathione. 
 
Soluble plant GSTs can be classified according to their sequence identity, genome 
organizations, reactivities and kinetic properties. This gives rise to seven evolutionary 
distinct classes, tau (U), phi (F), theta (T), zeta (Z), lambda (L), dehydroascorbat reductase 
(DHAR) and tetrachlorohydroquinone dehalogenase-like (TCHQD), the latter being only 
mentioned for completeness (Figure 21).72-73 Tau, phi, lambda and DHAR enzymes are 
plant specific whereas theta and zeta enzymes have animal counterparts.  Additionally, 
GST activity is shown by membrane associated proteins involved in eicosanoid and 
glutathione metabolism (MAPEGs)74, but those are not discussed in more detail.  
Figure 21: Classes of plant GSTs. 
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1.3.1.1.1 Structure of GSTs 
In general, soluble GSTs are hetero- or homodimeric proteins of about 50 kDa.70 Lambda 
and DHAR enzymes, however, appear monomeric by gel filtration. 75 Sequence identity 
within a class is >40%, between classes it is lower at less than 20%.72 Despite their 
diversity in the sequence, the overall structures are quite similar. Each subunit has a 
distinct folding pattern, the ‘GST fold’, which consists of an N-terminal domain, with b-
strands and a-helices and a C-terminal domain with right-handed a-helices (Figure 22).72 
 
Figure 22: GST structure and substrate binding. (a) GST subunit (ZmGSTF1), 
with the N-terminal domain in green and the C-terminal domain in blue. A 
glutathione conjugate of the herbicide atrazine is shown binding at the 
active site; the G site is highlighted in yellow and the H site is highlighted in 
blue. (b) Atrazine-glutathione conjugates bound to the active site of each 
subunit of the ZmGSTF1 homodimer.70  
 
Each catalytic subunit contains a GSH binding site (the G-site) in the N-terminal domain 
and a binding site for the hydrophobic substrate (the H-site) in the C-terminal domain 
connected by a linker region of 5-10 residues. The G-site is a highly-conserved region. 
Tau, phi, theta and zeta enzymes have a serine-residue at the target site, which is 
involved in the formation and stabilisation of the reactive thiolate anion of GSH. This 
thiolate anion acts as the nucleophile in the addition or substitution reaction with the 
hydrophobic co-substrate.70, 72 Lambda and DHAR enzymes have a cysteine residue at the 
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target site, which alters the function of the protein, as they cannot directly catalyse the 
S-glutathionylation of a substrate at the H-site any longer. 75 The H-site is not so strongly 
conserved and has a larger variability, which determines the substrate specificity. 70, 72 
Quite high mobility of the G and H site upon determination of the crystal structure, 
suggests that GST subunits might undergo significant changes when binding the 
substrate.70 
GSTs can also act as ligand-binding proteins, which means they can bind compounds 
such as plant hormones and flavonoids into a specific site, the L-site, in a non-substrate 
manner. There is still little known about L-sites in GSTs and their location can differ.72, 76 
1.3.1.1.2 Function of GSTs 
GSTs have a whole variety of functions, catalytic and non-catalytic, and the functions of 
many GSTs are still poorly understood (Figure 23).  
 
Figure 23: Functions of GSTs in plants. 
 
A key role is their ability to detoxify compounds such as herbicides by conjugation with 
GSH as part of phase II metabolism. Typical conjugation reactions include nucleophilic 
aromatic substitutions and Michael-type additions. The S-glutathionylated products are 
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then transported into the vacuole by phase III proteins such as ABC transporters prior to 
proteolytic processing (Figure 24, A).70 
 
Figure 24: GST functions in phase II metabolism. A: Detoxification of toxins 
by conjugation with GSH; B: Transport of flavonoid pigments to the vacuole. 
 
There is little evidence that natural products are S-glutathionylated in a similar way. Such 
activities are hard to show because of the instability and the fast turnover of potentially 
conjugated products, however, there is strong evidence that at least some function as 
GSH-conjugating enzymes.73 As mentioned before, GSTs also work as non-enzymatic 
carriers or ligandins, and are involved in the intercellular transport of flavonoids (Figure 24, 
B).77-78 AN9, a petunia GST, was shown to be involved in anthocyanin biosynthesis. It was 
suggested that AN9 is required for anthocyanin transport from the cytoplasm, where those 
flavonoid pigments are synthesized, to the vacuole for storage, as AN9 was shown to bind 
flavonoids, but no GSH conjugation could be detected.77 This hypothesis was further 
supported by studies on the cytoplasmic and tonoplast-localised Arabidopsis TT19 
(AtGSTF12), showing that the protein can directly bind cyanidin and cyanidin-3-O-
glucoside.79 Recently, evidence of non-catalytic ligand-binding sites in a GST from 
A B 
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Arabidopsis thaliana, AtGSTF2, was provided by X-ray crystallography. Two distinct non-
catalytic binding sites were identified for small heterocyclic ligands such camalexin and 
quercetin.76 
Especially theta, phi and tau GSTs also show GPOX activity (Figure 25, B). They use GSH 
to reduce organic hydroperoxides of fatty acids and nucleic acids to monohydroxyalcohols 
and therefore prevent the degradation of the hydroperoxides to cytotoxic aldehyde 
derivatives.70, 72 Another role of GSTs in stress metabolism has been demonstrated by 
expressing a tau GST from tomato in yeast and showing that it can suppress apoptosis 
induced by the Bax protein, preventing oxidative damage (Figure 25, A).80 
 
Figure 25: GST functions in stress metabolism. A: Protection against Bax-
induced cell death; B: GPOX activity. 
 
The fact, that a specific tau GST and GSH are required for the induction of the genes 
encoding enzymes of flavonoid biosynthesis by UV light in parsley, suggests GSTs could 
also be involved in stress tolerance through cell signalling (Figure 26, A).81 GSTs also 
show the ability to catalyse GSH dependent isomerizations. One example is the 
isomerization of maleylacetoacetate to fumarylacetoacetate, a part of the tyrosine 
degradation pathway (Figure 26, B).82 
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Figure 26: GST functions in signalling and phase I metabolism. A: Stress 
tolerance through cell signalling; B: GSH dependent isomerization of 
maleylacetoacetate to fumarylacetoacetate. 
 
As mentioned before DHARs and GSTLs have cysteine residues in their active site. These 
cysteines can reversibly form mixed disulfides with thiols. DHARs, as their name suggests, 
are known to reduce dehydroascorbate (DHA) to ascorbic acid (AA), as part of the 
ascorbate-glutathione cycle, by oxidizing glutathione to glutathione disulfide (Figure 27, B). 
GSTLs are believed to follow a similar catalytic mechanism, but with oxidized 
anthocyanidins and tocopherols as substrates.83 Furthermore DHARs and GSTLs show 
thioltransferase activity using 2-hydroxylethyl disulfide as a substrate, which means they 
could have a regulatory and protective role through reversible thiolation and dethiolation of 
proteins, but substrates are unknown (Figure 27, A).72 
 
Figure 27: Functions of DHARs and GSTLs. A: Thioltransferase activity; B: 
Reduction of DHA.  
A B 
A B 
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2  Previous work and aims 
2.1 Previous work 
The evolution of NTSR in black grass has led to a loss of chemical control in cereal crops. 
MHR in black grass was first reported in 1982 in Peldon, Essex and has since become a 
major problem in the UK and across Europe.38 MHR in black grass is associated with an 
enhanced level of detoxifying enzymes, particularly GSTs which seem to play an important 
part in this process (cf. Chapter 1.2.4).30, 33-34 The group of Robert Edwards first reported 
the enhanced level of GSTs in MHR black grass (“Peldon”).34 They showed that the level 
of AmGSTF1, as well as AmGSTU1, was increased in herbicide resistant black grass 
compared to the wild-type. AmGSTF1 was 20 times more present in crude plant extracts 
of MHR plants, which corresponds to 0.2% of the total protein of the MHR plants.30 
AmGSTF1, in contrast to AmGSTU1, showed only limited activity in detoxifying herbicides, 
but high GPOX activity, suggesting, the ability of GSTs to reduce organic hydroperoxides 
plays a role in addition to their ability to catalyse conjugation with glutathione. Another 
study showed that the use of safeners in wild-type black grass induces similar antioxidant 
and detoxifying pathways to those in MHR black grass.33  
This upregulation of AmGSTF1 in MHR black grass is similar to the enhanced expression 
of a pi class GST (GSTP1) in multiple drug resistant tumors in humans. GSTP1 detoxifies 
drugs directly and reduces organic hydroperoxides but also has important signalling 
functions promoting drug resistance.84 Further investigations were carried out to 
demonstrate this regulatory role in MHR weeds.30 AmGSTF1 was expressed in 
Arabidopsis thaliana and the AmGSTF1 transformants were tested for herbicide tolerance 
using a combination of spraying whole plants, as well as germination phytotoxicity studies 
(Figure 28). AmGSTF1 transformants (line 8 and 12) were more resistant to the herbicides 
chlorotoluron, alachlor and atrazine and showed changes in metabolism similar to those in 
NTSR weeds. These changes were not due to changes in gene expression, but regulatory 
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control of plant metabolism triggered by AmGSTF1, which led to an accumulation of 
protective compounds (glutathione, anthocyanins and flavonoids).30  
 
Figure 28: Herbicide resistance of transgenic Arabidopsis expressing 
AmGSTF1.	
 
The importance of AmGSTF1 was further confirmed by the identification of 4-chloro-7-
nitro-benzoxadiazole (CNBF) 1 acting as a synergist. CNBF 1 is a known inhibitor for 
GSTP1 and multiple drug resistance.84 It was shown to inhibit AmGSTF1 in a 4-Chloro-1,3-
dinitrobenzene (CDNB) assay and enhance the herbicidal activity of chlorotoluron (Figure 
29), fenoxaprop-p-ethyl and clodinafop-propargyl towards MHR black grass, when applied 
to MHR plants (“Peldon”).  
 
 
Figure 29: Effect of CNBF 1, a known GST inhibitor, on MHR in black-grass. 
(a) Sensitive and (b) MHR Peldon black grass plants were treated at 12 days 
with either formulation or CNBF, before an application of either formulation 
only (control) or the herbicide chlortoluron. A) Formulation control B) CNBF 
only C) Chlorotoluron only D) Chlorotoluron and CNBF. 
N
O
N
Cl
NO2
1
a) Wilde-type (WT) black grass     b) MHR black grass 
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Compounds that act as synergists and restore the activity of herbicides towards MHR 
weeds could offer a very important strategy to overcome MHR. Therefore, further work 
was carried out in our group to develop potential herbicide synergists.85 A range of CNBF 
1 analogues, compounds with the benzoxadiazole scaffold, substituted purines and 
different thiazopyrimidines were synthesized and tested for their activity in a CDNB assay 
and on plants in spray trials. However, no improvements to the initial hit could be made, 
the lead compound was difficult to optimize and the inherent toxicity of a lot of analogues 
was difficult to overcome. Ligand fishing was used as a high throughput method to find 
new potential synergists. Ligand fishing is an expedient method in which potential ligands 
can be screened for their ability to bind to a receptor. A compound cocktail is injected onto 
a strep-tactin column where an immobilized protein is present. Following elution of the 
solvent, the protein is removed from the column, precipitated and the remaining 
supernatant analyzed by HPLC.86 AmGSTF1 was found to be capable of binding a number 
of different flavonoids and inhibition could be confirmed by CDNB-assay and spray trials. 
The initial screening of a library of flavonoids afforded the quercetin analogue 2 as the lead 
compound, showing the highest inhibition and synergistic effects with pinoxaden on black 
grass (Figure 30). 
 
 
Figure 30: Effect of 2, a known GST inhibitor, on MHR in black-grass. MHR 
black grass plants were treated at 14 days with either formulation or 2, 
before an application of either formulation only (control) or the herbicide 
pinoxaden. A) Untreated, B) Formulation control, C) Pinoxaden only, D) 2 
only, E) Pinoxaden and 2. 
OHO
OH
OO
OH
OH
COOH
2
         A        B       C   (WT) C     D         E 
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To optimize the potential synergist, further analogues derived from chrysin were 
synthesized and tested with a focus on alkylation at the 7-hydroxy position, substitution of 
the 7-hydroxy group with a range of amines and some variation of the 5-oxyacetic acid 
derivatives. Early structure-activity relationships and the synthesis performed is 
summarized in Figure 31.  
 
 
 
 
 
 
Figure 31: Summary of early structure-activity relationships (blue) and 
synthesis performed (green). 
 
These studies afforded compound 3 (Figure 32) with a similar structure to 1 and the same 
level of inhibition towards AmGSTF1 (71% ± 5% inhibition in the CDNB assay at a 1 µM 
level). This work provides the basis of this project. 
 
Figure 32: Lead compound. 
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2.2 Project aims 
The primary objective of this project was to develop potential herbicide synergists through 
structure activity relationship studies. Having identified flavonoid 3 as the lead compound, 
initial work would focus on the synthesis of further analogues, especially with variations in 
the C ring and of the substituent in the 5-position (Figure 33) and on testing them for 
inhibition activity towards AmGSTF1. This data would inform the synthesis of further 
synergists. 
 
Figure 33: Investigation of flavonoid analogues. 
 
Furthermore, this project aimed to gain a deeper insight into the protein-ligand interactions 
between the flavonoid inhibitors and AmGSTF1 through photoaffinity labelling. 
 
Figure 34: Crystal structure of AmGSTF1. 
 
Identification of the binding pocket would allow to use the crystal structure of AmGSTF1 
(Figure 34) for a structure based design and a more targeted optimization of ligands. 
OMeO
OO
COOH
Variations of the substituent 
in the 2-position 
Variation of the alkyl 
chain and chain length 
  Results and Discussion 
  37 
3  Results and Discussion 
As flavonoids showed good inhibition of AmGSTF1 in the CDNB assay and synergising 
effects of herbicides in the spray trials, it was of interest to synthesise analogues in order 
to develop structure activity relationships (SAR). In particular it was deemed important to 
explore any variations of the substituent at the 2-position and 5-position, and investigate 
their ability to bind to AmGSTF1. Furthermore, efforts were put into gaining a deeper 
insight into the interactions between AmGSTF1 and its ligands.  
3.1 Chemical Synthesis 
3.1.1 Variations of the substituent in the 2-position 
One of the most common methods to synthesise flavones is the Baker-Venkataraman 
transformation (Scheme 1, a).87-89 In this procedure, a hydroxyacetophenone is reacted 
with a benzoyl chloride to form the ester. This benzoyl ester is then treated with base to 
form the 1,3-diketone. Under basic conditions the diketone cyclises to form the flavone.  
 
Scheme 1: Flavone synthesis. 
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Alternatively, 2-substituted 4H-chromen-4-ones can be obtained from the 
2-hydroxyacetophenone and a benzaldehyde via the corresponding hydroxychalcone 
(Scheme 1, b).90-93 In both cases the substituent in the 2-position is introduced in the first 
step of the linear synthesis. 
In order to obtain analogues with different substituents in the 2-position more efficiently, 
ways were sought to synthesise 5,7-dimethoxy-4H-chromen-4-ones with a leaving group in 
the 2-position This leaving group could then be displaced, which would allow diversification 
at a later step in the synthesis, compared to the more conventional synthetic routes. In 
order to accelerate the synthesis process, analogues were synthesised with a simple 
methoxy group in the 5-position. 
3.1.1.1 Synthesis of 2-amino-5,7-dimethoxy-4H-chromen-4-ones 
A review of the literature for the synthesis of 2-amino-4H-chromen-4-ones revealed a 
procedure by Griffin et al. suggesting the facile displacement of thioethers or sulfones with 
amines was possible, Scheme 2.94 Consequently the initial goal was the efficient 
preparation of a 2-thiochromenone. 
 
Scheme 2: Synthesis of 2-amino-benzo[h]chromen-4-ones by Griffin.94 
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The preparation of similar thioethers to 4 had previously been reported by Lee and Pak95 
and following this precedent, 2-hydroxy-4,6-dimethoxyacetophenone 7 was treated with 
lithium bis(trimethylsilyl)amide (LiHMDS). Subsequent, sequential addition of CS2, MeI and 
10 N KOH, followed by aqueous workup afforded, after recrystallization from THF, the pure 
product 5,7-dimethoxy-2-methylthio-4H-4-chromenone 8 in 70% yield (Scheme 3). The 
formation of the desired chromenone 8 was confirmed by presence of a peak in the liquid 
chromatography–mass spectrometry (LC-MS) spectrum (m/z (ES+) = 253 MH+) in 
combination with appearance of a 3H singlet at 2.53 ppm in the 1H-NMR spectrum for the 
SMe-group. 
 
Scheme 3: Synthesis of 5,7-dimethoxy-2-methylthio-4H-4-chromenone 8. 
 
Following the Griffin procedure, thiochromenone 8 was heated with N-methyl-piperazine in 
ethylene glycol at 160°C (Scheme 4). After 3 h, analysis by thin layer chromatography 
(TLC) showed that all starting material was consumed. Aqueous workup and column 
chromatography yielded 25% of the desired 2-amino-4H-chromen-4-one 9, which was 
confirmed by the corresponding peak in LC-MS (m/z (ES+) = 305 MH+) and a 
disappearance of the SMe-signal in the 1H-NMR spectrum. The low yield was attributed to 
decomposition arising from the high reaction temperature.  
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O
OHMeO
OMe O
i) LiHMDS (3.15 eq), dry THF,
    -78 °C, 30 min
ii) CS2, -78 °C - 0 °C, 1 h
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Scheme 4: Synthesis of 5,7-dimethoxy-2-(4’-methylpiperazin-1’-yl)-4H-
chromen-4-one 9. 
 
Due to the rather low yield, an alternative synthesis, which was also shown by Griffin et 
al.94, was used. They reported a method in which they had converted the thioether 4 to the 
corresponding sulfone 6 first, before reacting it with the amine (Scheme 2). 
However, initial attempts to reproduce the oxidation proved not to be straight-forward, as 
treatment with 2.4 equivalents of meta-chloroperoxybenzoic acid (m-CPBA) afforded a 
mixture of the desired sulfone 10 together with the intermediate sulfoxide 11 (Scheme 5) 
confirmed by two peaks in the LC-MS chromatogram (m/z (ES+) = 285 MH+ and m/z (ES+) 
= 269 MH+). The two compounds could be isolated in 34% (10) and 21% yield (11) 
respectively. The low combined yield can be explained by high losses during the 
purification and separation of the two compounds. 
Attempts to enhance the conversion of 10 by prolonged reaction times or higher 
stoichiometries of m-CPBA were not successful. 
 
Scheme 5: Synthesis of 5,7-dimethoxy-2-(methylsulfonyl)-4H-chromen-4-one 
10. 
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Consequently, it was decided to test whether the sulfoxide 11 would also act as a leaving 
group. A small-scale experiment in which 11 was reacted with morpholine afforded the 
desired 5,7-dimethoxy-2-morpholino-4H-chromen-4-one 12, as confirmed by a peak in 
LC-MS (m/z (ES+) = 292 MH+). As a result, the crude oxidation product was directly 
converted to the amine. 
 
Entry Starting material Product R Reaction 
conditions 
Yield over 
2 steps 
1 morpholine 12 
 
46 h, rt - reflux 32% 
2 piperidine 13 
 
20 h, rt 50% 
3 3-amino-propan-1-ol 14 
 
20 h, rt 33% 
4 4-aminophenol 15 
 
20 h, rt - 
Table 3: Synthesis of 2-amino-5,7-dimethoxy-4H-chromen-4-ones (12-15). 
 
A range of amines were reacted with the crude mixture of 10 and 11 until no starting 
material could be detected by TLC and LC-MS analyses or no further conversion was 
observed (Table 3). Simple aliphatic or alicyclic amines (entries 1 – 3) worked well, but 
less nucleophilic species such as 4-aminophenol (entry 4) were not viable. 
The potential synergists were tested for inhibition of AmGSTF1 in the CDNB assay (cf. 
Chapter 3.2.1.1). As the non-aromatic amines in the 2-position seem to lower inhibition, 
attention was turned to analogues with aryl substituents in the 2-position. 
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3.1.1.2 Synthesis of 2-aryl-5,7-dimethoxy-4H-chromen-4-ones 
3.1.1.2.1 Liebeskind-Srogl cross-coupling 
Analysis of the target suggested that cross-coupling of a suitable aryl nucleophile with a 
chromenone featuring a leaving group would offer a convenient approach for the synthesis 
of a variety of analogues. With thioether 8 already successfully synthesised, a cross-
coupling reaction described by Liebeskind and Srogl96, in which a new carbon-carbon 
bond is formed from a organosulfur compound, such as a thioester or thioether, and an 
aryl boronic acid using a metal catalyst (Scheme 6), was explored. 
 
 
Scheme 6: Liebeskind-Srogl cross coupling. 
 
Cross coupling of thioether 8 with phenylboronic acid was carried out under standard 
conditions reported by Liebeskind and Srogl96 (Scheme 7), using the 
tris(dibenzylideneacetone)dipalladium (Pd2(dba)3)/tris(2-furyl)phosphine (TFP) catalytic 
system and copper(I) thiophene-3-carboxylate (CuTC). Repeated checks by TLC and 
LC-MS showed mainly starting material and that no product was formed, even after 24 h.  
 
Scheme 7: Attempted synthesis of 5,7-dimethoxy-2-phenyl-4H-chromen-4-
one 16 using a Pd2(dba)3/TFP catalytic system. 
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A review of the literature revealed that the use of tetrakis(triphenylphosphine)palladium 
(Pd(Ph3)4) instead of Pd2(dba)3/TFP may be beneficial.97 However, attempts using this 
catalyst led to the same result (Scheme 8), suggesting that the starting material is not a 
suitable substrate for this cross coupling reaction, which works most efficiently in 
π-deficient heteroaromatic thioethers such as 2-(methylthio)pyrazines or 
2-(methylthio)benzothiazoles96. Consequently, the approach for the synthesis of 
2-substituted 4H-chromen-4-ones was modified. Since the thioether was not a good 
enough leaving group in the cross coupling reaction, a better leaving group in the 
2-position was needed. 
 
 
Scheme 8: Attempted synthesis of 5,7-dimethoxy-2-phenyl-4H-
chromen-4-one 16 using Pd(Ph3)4 as a catalyst. 
 
3.1.1.2.2 Suzuki Miyaura cross-coupling 
In the Suzuki Miyaura reaction halides are coupled with boronic acids, a large number of 
which are readily available. Since the Suzuki cross coupling also allowed a convergent 
synthesis of flavones, this was the approach of choice for the creation of a small library of 
compounds. A literature research revealed a procedure by Kraus et al.98, which gives 
access to 2-chloro-chromen-one 21 (Scheme 9) via esterification of phenol 17 with acid 18 
and subsequent Fries rearrangement and cyclisation.  
OMeO
OMe O
phenylboronic acid (1.1 eq), 
CuTC (1.3 eq), Pd(Ph3)4 (5 mol%)
THF, 50 °C, 15 h
16
OMeO
OMe
S
O
8
  Results and Discussion 
  44 
 
Scheme 9: Synthesis of 2-chloro-5,7-dimethoxy-4H-chromen-4-one 21 by 
Kraus et al.98 
 
Starting material 18 had to be synthesised, as it is not commercially available. Following a 
procedure by Schroth et al.99 (Scheme 10) ethyl vinyl ether 22 was reacted with 
tetrachloromethane (CCl4) through radical addition using benzoylperoxide to form ethyl-
(1,3,3,3-tetrachloropropyl)ether 23. Removal of excess CCl4 under reduced pressure 
afforded the crude product with only minor impurities. A doublet of doublets at 5.96 ppm in 
the 1H NMR spectrum, assigned to the CH-group and another two doublet of doublets at 
3.52 and 3.42 ppm assigned to the two protons of the CH2-group next to it, confirmed the 
formation of the product.  
 
Scheme 10: Synthesis of 3,3-dichloroacrylic acid 18 by Schroth et al.99 
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On the basis of NMR-analysis it was suspected that 23 was undergoing fast 
decomposition, consequently the crude product was not further purified by distillation and 
used directly in subsequent reactions in order to minimise further losses. 
Initial attempts to generate 3,3-dichloroacrylic acid 18 followed the one-pot procedure 
described by Schroth et al.99, combining the hydrolysis and the oxidation, using sulfuric 
acid and CrO3 (Scheme 10). However, despite multiple attempts and and paying particular 
attention to the temperature profile, no evidence for the desired product could be obtained. 
Analysis of the crude product by 1H-NMR spectroscopic analysis suggested that mostly 
3,3,3-trichloropropanoic acid was afforded, as the spectrum showed a single singlet at 
3.85 ppm.  
Consequently, a reaction with ethyl-(1,3,3,3-tetrachloropropyl)ether 23 and sulfuric acid 
was conducted. 1H-NMR spectroscopic analysis showed that 3,3,3-trichloropropanal was 
formed, with a doublet at 3.70 ppm and a triplet at 9.86 ppm in the 1H-NMR spectrum. This 
suggested that the elimination-step to give the double bond was not working. Therefore 
ethyl-(1,3,3,3-tetrachloropropyl)ether 34 was converted to 3,3-dichloroacrolein 24 in an 
independent step following a method described by Hanack et al.100. In this, crude 23 was 
mixed with acetone and H2O. The acetone was removed by distillation through a packed 
column. Aqueous workup followed by a vacuum distillation afforded the desired product 24 
in 30% yield over the two steps (Scheme 11), showing two doublets at 9.87 ppm and 6.44 
ppm in the 1H-NMR spectrum. The rather low yield can be explained due to losses in the 
distillation-process because of condensation reactions of the product. 
 
Scheme 11: Synthesis of 3,3-dichloroacrolein 24. 
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Attempts to oxidise the aldehyde 24 to the acid 18 using CrO3 failed, but a protocol by 
Stack et al.101 using Ag2O, prepared in situ from AgNO3, afforded the product in 49% yield 
after purification (Scheme 12). 1H-NMR spectroscopic analysis showed the characteristic 
singlet at 6.42 ppm. As this is an expensive method and the yield not high (even dropping 
to 33% when the reaction was conducted on a larger scale), other methods were sought 
from the literature.  
 
Scheme 12: Oxidation of aldehyde 24 to acid 18 using Ag2O. 
 
Dalcanale et al.102 describe a general, very mild method for the oxidation of aldehydes with 
sodium chlorite and hydrogen peroxide as a scavenger for the formed hypochlorous acid. 
These conditions were applied to 3,3-dichloroacrolein 24 (Scheme 13). Aqueous NaClO2 
was added to a solution of 24 and H2O2 in aqueous acetonitrile buffered with NaH2PO4. 
Purification yielded 93% of 3,3-dichloroacrylic acid 18.  
 
Scheme 13: Oxidation of aldehyde 24 to acid 18 using sodium chlorite. 
 
With 3,3-dichloroacrylic acid 18 in hand, the synthesis of 2-chloro-5,7-dimethoxy-4H-
chromen-4-one 21 could now be pursued. For the first step, the Steglich esterification 
(Scheme 14), 3,5-dimethoxyphenol 17, was coupled with 3,3-dichloroacrylic acid 18 using 
4-dimethylaminopyridine (DMAP) and diisopropylcarbodiimide (DIC), as it is easier to 
handle than DCC. Purification yielded 86% of 3,5-dimethoxyphenyl 3,3-dichloroacrylate 
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19, confirmed by the presence of the corresponding peak in the LC-MS chromatogram 
(m/z (ES+) = 277 MH+).  
 
Scheme 14: Synthesis of 3,5-dimethoxyphenyl 3,3-dichloroacrylate 19. 
 
For the second step, initial attempts to achieve a Fries rearrangement using 1.1 eq of AlCl3 
in 1,2-dichloroethane resulted in low conversion and it was found that higher conversion 
required more equivalents of AlCl3 than reported by Kraus et al.98 With 1.5 eq of AlCl3 
3,3-dichloro-1-(2-hydroxy-4,6-dimethoxyphenyl)prop-2-en-1-one 20 could be produced in 
55% yield (Scheme 15), characterized by a signal in the 1H-NMR at 13.46 ppm for the OH-
group, confirming the successful rearrangement. The two doublets at 6.08 and 5.92 ppm 
for the two aromatic protons confirmed the 1,2-rearrangement rather than the 
1,4-rearrangement.  
 
Scheme 15: Synthesis of 3,3-dichloro-1-(2-hydroxy-4,6-
dimethoxyphenyl)prop-2-en-1-one 20. 
 
First attempts to cyclise compound 20 involved dissolution in THF and addition of 0.02 N 
NaOH. This reaction however resulted in no conversion at all and only starting material 
was recovered. Several different attempts, which included a longer reaction time, elevated 
temperature and stronger base led to the same result. Significantly, if the base was too 
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strong, decomposition was observed. A search of the literature revealed a similar 
procedure by Levas et al.103, which suggested dispersion of the starting material 20 in H2O 
and then slow addition of aqueous NaOH. This approach (Scheme 16) turned out to work 
well and following purification the product 2-chloro-chromenone 21 was obtained in 82% 
yield, as confirmed by the appearance of the corresponding peak in the LC-MS 
chromatogram (m/z (ES+) = 263 MH+).  
 
Scheme 16: Synthesis of 2-chloro-5,7-dimethoxy-4H-chromen-4-one 17. 
 
With 21 successfully synthesised, it was then necessary to couple it with a range of aryl 
boronic acids. In a preliminary Suzuki-Miyaura cross coupling reaction, 21 was coupled 
with phenylboronic acid in the presence of Pd(PPh3)4 and K2CO3 following the Kraus98 
procedure. Product 16 was confirmed by the presence of the corresponding peak in the 
LC-MS chromatogram (m/z (ES+) = 283 MH+) and disappearance of the characteristic 
chlorine isotope pattern, albeit in only 53% yield (Scheme 17). In order to identify optimum 
cross coupling conditions, a condition screening was then undertaken. 
 
Scheme 17: Suzuki-coupling of 21 with phenylboronic acid. 
 
To determine the yield of the product in the optimization experiments, without the 
necessity to isolate the product in every case, a calibration using LC-MS was established. 
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For a quantitative analysis, for both the product (p) 16 and the starting material (sm) 21, an 
internal standard (is), chromone, was added to the samples. A good separation with 
retention times of about 1.9 (is), 2.6 (sm 21) and 2.9 min (p 16) could be achieved (Figure 
35).  
 
Figure 35: Total ion currant (TIC) chromatogram (ES+) and total 
absorbance chromatogram of a mixture of is, sm and p; Acquity UPLC 
(Waters Ltd, UK) with a 1.7 µm Acquity UPLC BEH C18 column; mobile 
phase of water containing formic acid (0.1%) (A):acetonitrile (B) 
(gradient: 0.2 min 5% B, then up to 95% B after 4 min, constant 95% B till 
4.5 min, down to 5% B after 5 min); constant flow rate of 0.6 ml/min; 
absorbance data was acquired from 210 to 400 nm using an Acquity 
photodiode array detector. 
 
Figure 36 and Figure 37 show the calibration curves for the starting material and the 
product, using chromone as an internal standard. In both cases it is linear for the ratio of 
cp/cis and csm/cis respectively, in a range from 0.025 – 1 with a very good correlation 
coefficient. 
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Figure 36: Calibration curve for the starting material 21. 
 
Figure 37: Calibration curve for the product 16. 
 
A literature search showed that the phosphine ligands (2-biphenyl)di-tert-butylphosphine 
(JohnPhos 22), (2-biphenyl)dicyclohexylphosphine (CyJohnPhos 23) and 
tricyclohexylphosphine (PCy3 24) (Figure 38) work very well for Suzuki-couplings with 
chlorides.104-105 Those ligands, together with the catalysts Pd2(dba)3 and 
palladium(II)acetate (Pd(OAc)2) and the bases KF, Cs2CO3 and K3PO4 were used in the 
screening. 
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Figure 38: Phosphine ligands 22, 23 and 24. 
 
In Table 4 the results of the screening are summarized. The yield of the product and the 
starting material were determined by LC-MS as described before using an internal 
standard. 
 
Entry Catalyst Ligand Base Yielda 
1 Pd(OAc)2 JohnPhos KF 84% 
2 Pd(OAc)2 CyJohnPhos KF 100% 
3 Pd(OAc)2 PCy3 KF 100% 
4 Pd(OAc)2 JohnPhos Cs2CO3 44% 
5 Pd(OAc)2 CyJohnPhos Cs2CO3 100% 
6 Pd(OAc)2 PCy3 Cs2CO3 100% 
7 Pd2(dba)3 JohnPhos KF 99% 
8 Pd2(dba)3 CyJohnPhos KF 100% 
9 Pd2(dba)3 PCy3 KF 100% 
10 Pd2(dba)3 JohnPhos Cs2CO3 49% 
11 Pd2(dba)3 CyJohnPhos Cs2CO3 92% 
12 Pd2(dba)3 PCy3 Cs2CO3 100% 
13b Pd(OAc)2 JohnPhos K3PO4 98% 
14b Pd(OAc)2 CyJohnPhos K3PO4 87% 
15b Pd(OAc)2 PCy3 K3PO4 96% 
Table 4: Condition screening for Suzuki-coupling reaction. a Determined by 
LC-MS using an internal standard. b Toluene was used instead of 1,4-
dioxane as solvent. 
 
PtBu tBu P P
22 23 24
MeO
OMe
O
O
phenylboronic acid (2 eq), base (3 eq) 
catalyst (3 mol%), ligand (6 mol%)
1,4-dioxane, 100 °C, 20 h
16
MeO
OMe
O
O
Cl
21
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Most conditions proved to work in excellent yield. Only some, where JohnPhos 22 was 
used as a ligand (Table 4, entries 1, 4 and 10) showed lower yields.  
Conditions from entry 12, using PCy3 24, Pd2(dba)3 and Cs2CO3 were chosen for further 
reactions and a library of compounds was synthesised. Satisfyingly, a variety of different 
2-aryl-5,7-dimethoxy-4H-chromen-4-ones (16, 25 - 32) could be obtained in good isolated 
yields (Table 5, entries 1 - 9). 
 
Entry Starting material Product R1 R2 Yield 
1 phenylboronic acid 16 H H 83% 
2 4-fluorophenylboronic acid 25 F H 50% 
3 4-methoxyphenylboronic acid 26 OMe H 92% 
4 3-biphenylboronic acid 27 H phenyl 63% 
5 4-ethylphenylboronic acid 28 ethyl H 74% 
6 3-methoxyphenylboronic acid 29 H OMe 75% 
7 3,4-dimethoxyphenylboronic acid 30 OMe OMe 71% 
8 3,4-(methylenedioxy)phenylboronic acid 31 methylenedioxy 30% 
9 4-methoxycarbonylphenylboronic acid 32 COOMe H 68% 
10 4-bromophenylboronic acid 33 Br H - 
11 3-hydroxyphenylboronic acid 34 H OH - 
12 4-(methylhydroxy)phenylboronic acid 35 CH2OH H - 
 
Table 5: Synthesis of different 2-aryl-5,7-dimethoxy-4H-chromen-4-ones (16, 
25-35). 
 
The attempt to couple 4-bromophenylboronic acid led to an inseparable mixture of mono 
and decoupled product, as detected by LC-MS (Table 5, entry 10). Cross coupling of 
3-hydroxyphenylboronic acid and 4-(methylhydroxy)phenylboronic acid worked but 
MeO
OMe
O
O
boronic acid (2 eq), Cs2CO3 (3 eq) 
Pd2(dba)3 (3 mol%), PCy3 (6 mol%)
1,4-dioxane, 100 °C, 22 h
16, 25 - 35
MeO
OMe
O
O
Cl
21
R1
R2
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because of the limited solubility of the products, no pure compound could be obtained 
(Table 5, entries 11 and 12).  
For the coupling reactions with 3-pyridineboronic acid, 4-pyridineboronic acid and 
2-furanylboronic acid, no formation of product could be detected under these conditions. 
Therefore, a further set of different conditions for the Suzuki coupling of heteroaromatic 
boronic acids was screened (Table 6). The screening was conducted on small scale and 
the conversion of the starting material was determined by 1H-NMR. Entries 1 and 2 are 
conditions, which are known to work well for heteroaromatic boronic acids106, using  
 
Figure 39: Phosphine ligands 36 and 37. 
 
2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos 36) and 
2-dicyclohexylphosphino-2′,4′,6′-triisopropylbiphenyl (XPhos 37) as ligands (Figure 39). 
Full conversion of starting material 21 and formation of the desired 2-pyridylchromenone 
38, by a peak in the LC-MS, could be observed for entry 1 and 2, but purification of a 
reaction on larger scale using conditions from entry 2 showed that mainly 2-butoxy-5,7-
dimethoxy-4H-chromen-4-one was formed. Changing the solvent to 1,4-dioxane led to 
poor conversion. Entries 3 - 5 are similar to conditions previously used (Table 4), which 
showed good results in the coupling of phenylboronic acid. With 4-pyridineboronic acid, 
however, those conditions led to poor conversion. 
36
P
MeO
OMe
P
iPr
iPr
iPr
37
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Entry Catalyst Ligand Base Solvent Conversion 
1 Pd2(dba)3 XPhos (8 mol%) K3PO4 (2 eq) n-butanol 100% 
2 Pd2(dba)3 SPhos (8 mol%) K3PO4 (2 eq) n-butanol 100% 
3 Pd2(dba)3 JohnPhos (8 mol%) KF (3 eq) 1,4-dioxane 7% 
4 Pd2(dba)3 CyJohnPhos (8 mol%) KF (3 eq) 1,4-dioxane 22% 
5a Pd(OAc)2 PCy3 (6 mol%) K3PO4 (3 eq) toluene 12% 
6 Pd2(dba)3 PCy3 (4.8 mol%) K3PO4 (1.7 eq) 1,4-dioxane 
/H2O 
100% 
Table 6: Condition screening for Suzuki-coupling reaction of heteroaromatic 
boronic acids. a 3 mol% Pd(OAc)2. 
 
Another literature search revealed a procedure by Kudo et al.107 for Suzuki cross-coupling 
reactions of nitrogen heterocycles (Table 6 ,entry 6) using Pd2(dba)3 as a catalyst, PCy3 as 
a ligand, K3PO4 as a base and a mixture of 1,4-dioxane and H2O as solvent. Pleasingly, 
these conditions resulted in 100% conversion of starting material. However, purification 
was difficult and eventually only successful following basic extraction and column 
chromatography leading to a low isolated yield of 38 (Scheme 18).  
 
Scheme 18: Synthesis of 5,7-dimethoxy-2-(pyrid-4’-yl)-4H-chromen-4-one 38. 
 
Similarly attempts to cross couple 21 and 3-pyridineboronic acid showed formation of 
product but no pure compound could be obtained. However, when 2-furanylboronic acid 
was used, no product could be observed. 
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The synthesised analogues were tested for inhibition of AmGSTF1 in the CDNB assay (cf. 
Chapter 3.2.1.1). The data indicates that a phenyl ring in the 2-position is beneficial for 
inhibition, but further modifications on the phenyl-ring did not significantly affect the activity 
of these compounds. Compound 27 with biphenyl in the 2-position and compound 28 with 
a 4-ethyl-substituted phenyl-ring, also show similar inhibition, which suggests that steric 
bulk does not have a major effect in this position. 
3.1.1.3 Synthesis of 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamides 
As a further addition to the structure activity relationship investigations, carboxamides, 
which can be derived from 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41, were 
synthesised. Following a procedure by Stoermer et al.108 for the synthesis of chromone-2-
carboxylic acids, addition of triethylamine and dimethylacetylenedicarboxylate (DMAD) to a 
solution of phenol 16 afforded a 1:0.9 mixture of E:Z isomer of the diester 39 in 81% yield 
(Scheme 19). Formation was confirmed by LC-MS (m/z (ES+) = 297 MH+).  
 
 
Scheme 19: Synthesis of dimethyl (E,Z)-2-(3’,5’-dimethoxyphenoxy)ethene-1-
2-dicarboxylate 39. 
 
In the next step the diester 39 was hydrolysed into the diacid 40 to afford a 1:0.8 mixture of 
E:Z isomers (Scheme 20), as indicated by a loss of the OCH3 signals in the 1H-NMR 
spectrum and the presence of the two corresponding peaks in the LC-MS chromatogram 
(m/z (ES+) = 269 MH+). 
OHMeO
OMe
DMAD (1.3 eq), Et3N (1.4 eq)
Et2O, rt, 5.5 h
17
OMeO
OMe
COOMe
COOMe
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Scheme 20: Synthesis of (E,Z)-2-(3’,5’-dimethoxyphenoxy)ethene-1-2-
dicarboxylic acid 40. 
 
The final cyclisation step was achieved by addition of sulfuric acid to a solution of diacid 40 
in acetyl chloride (Scheme 21). Purification afforded the product 41 in 40% yield, 
confirmed by the presence of the respective peak in the LC-MS chromatogram (m/z (ES+) 
= 297 MH+).  
 
Scheme 21: Synthesis of 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxylic 
acid 41. 
 
For the formation of aromatic amides from chromone-2-carboxylic acid 41, a literature 
search revealed a microwave assisted synthesis by Cagide et al.109, whereby the acyl 
chloride was synthesised in situ from acid 41 and POCl3 and then further converted to the 
carboxamide with the amine. This procedure proved to be viable and the reaction was 
carried out for different amines, affording the desired carboxamides 42 – 44 in moderate 
yields (Table 7). 
As this set of carboxamides did not show significantly higher inhibition of AmGSTF1 in the 
CDNB assay (cf. Chapter 3.2.1.1) and the solubility proved to be an issue, no further 
carboxamide analogues were synthesised and the method was not further optimised. 
Attention was shifted to analogues with different substituents in the 5-position. 
NaOH (4eq)
H2O, reflux, 3 h
OMeO
OMe
COOMe
COOMe
39
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95%
acetyl chloride, H2SO4
60 °C, 40 min
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COOH
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40%
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Entry Starting material Product R1 R2 R3 Yield 
1 aniline 42 H H H 48% 
2 3,5-dimethoxyaniline 43 OMe H OMe 32% 
3 p-methylaniline 44 H Me H 44% 
Table 7: Synthesis of carboxamides 42 – 44. 
 
3.1.2 Variations of the substituent in the 5-position 
As discussed in Chapter 2.1, replacing the methyl group of the methoxy substituent in the 
5-position with a-substituted dodecanoic acid, improves the inhibition activity towards 
AmGSTF1 significantly. To further extend the structure activity relationship investigations, 
methods were sought to synthesise different acids with a leaving group in the a-position, 
which could be used in an alkylation reaction with 5-hydroxy-7-methoxy-2-phenyl-4H-
chromen-4-one 46. 46 was easily accessible from chrysin 45 by the selective alkylation of 
the hydroxyl-group in the 7-position with MeI (Scheme 22), which was described in the 
literature before.110 LC-MS showed the formation of product (m/z (ES+) = 269 MH+) with 
full conversion of starting material and only insignificant amounts of the dialkylated 
product.  
 
Scheme 22: Synthesis of 5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one 
46. 
1) POCl3, DMF, rt - 50 °C, 1 h
2) amine, µw, 160 °C, 5 min
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3 was synthesised as previously reported by Straker, 85 to use it as a reference in 
biological testing. Following this precedent, methyl 2-bromododecanoate 48 could be 
obtained from the commercially available 2-bromododecanoic acid 47 by methylation with 
TMS-diazomethane in 49% yield (Scheme 23), confirmed by the additional peak in the 
1H-NMR spectrum at 3.78 ppm. 
 
 
Scheme 23: Methylation of acid 47 to form ester 48. 
 
46 was alkylated at 60 °C with methyl 2-bromododecanoate 48 using K2CO3 as a base, full 
conversion was confirmed by the corresponding peak in LC-MS (m/z (ES+) = 467 MH+). 
Subsequently the crude ester was hydrolysed using LiOH.H2O in a 1:1 mixture of THF and 
H2O (Scheme 24), affording 3 in 95% yield over 2 steps. Successful hydrolysis was 
verified by disappearance of the methyl signal at ∂ = 3.75 ppm in 1H-NMR. 
 
Scheme 24: Synthesis of 2-(7-methoxy-4-oxo-2-phenyl-4H-chromen-5-
oxy)dodecanoic acid 3. 
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3.1.2.1 Synthesis of a-bromo acids from amino acids 
Not many a-bromo acids are commercially available. A well-known method to obtain 
a-bromo acids is from the corresponding amino acid by diazotization of the amine in the 
presence of a bromide source.111-112 Lysine 49 was the amino acid of choice, as it could 
serve as a building block, offering the ability to elongate the chain by amide coupling with 
the side chain amino group. Starting from DL-lysine 49, H-Lys(Cbz)-OH 51 was prepared 
by a method similar to that described by Balajthy et al.113 reacting the primary amino and 
carboxyl group with CuSO4 to form the stable chelate complex, which facilitates the 
selective protection of the side chain amino-group (Scheme 25). 
Ethylenediaminetetraacetic acid (EDTA) was used in order to liberate the Cbz-protected 
amino acid from the copper complex 50. 
 
Scheme 25 Cbz-protection of lysine. 
 
Following a procedure by Ellman et al.112 for amino acids with diverse, protected side chain 
functionality, KBr, followed by NaNO2, was added to a 0.75 M HBr solution at -7 °C, and 
after slow addition of 51, the mixture was stirred for 3 h at -7 °C (Scheme 26). LC-MS 
analysis showed almost full conversion of the starting material, but in addition to small 
amounts of the product 54 (m/z (ES-) = 342 ([M-H]-, Br79), 344 ([M-H]-, Br81)), another two 
peaks with m/z (ES-) = 371 ([M-H]-, Br79), 373 ([M-H]-, Br81), being the major one, and m/z 
(ES-) = 309 [M-H]- could be observed. The increment of 29 Da compared to the expected 
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mass for the starting material 51 and the desired product 54 respectively, suggested the 
formation of the nitroso equivalents 52 and 53. The position of the nitroso-group in 
compound 52 is somewhat ambiguous, but following the reaction by LC-MS over 5 h, 
showed that in the beginning mainly nitroso compound 52 was formed which was 
consequently transformed into 53. This data confirms the suggested structure for 52. 
Compound 53 was isolated and 1H-NMR spectroscopic analysis showed the characteristic 
downfield shift of the 6-H2 signal to 3.75 ppm, due to the nitrosamine. 
 
Scheme 26: a-Bromo acid synthesis. 
 
Using the Boc-protected version of lysine, which was previously used by Ellman et al.112 
showed similar results. 
 
Scheme 27: Synthesis of a-bromo ester 55. 
 
Better yields could be obtained, when the order of addition was changed and conditions 
previously reported by Angelovski et al.114 were applied. KBr and H-Lys(Cbz)-OH 51 were 
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dissolved in HBr (1 M). Then NaNO2 was added portionwise at 0 °C over 1 h and the 
mixture was stirred for 3.5 h at 0 °C. Although 53 could still be observed by LC-MS, 
a-bromo ester 55 could be obtained in 46% yield over two steps after methylation with 
TMS-diazomethane, confirmed by the corresponding peak in LC-MS (m/z (ES+) = 358 
(MH+, Br79), 360 (MH+, Br81). 
With 55 successfully synthesised, it was used to alkylate 5-hydroxy-7-methoxy-2-phenyl-
4H-chromen-4-one 46 with K2CO3 as a base in 93% yield (Scheme 28), full conversion 
was confirmed by LC-MS (m/z (ES+) = 546 MH+). Subsequent deprotection afforded the 
ammonium bromide salt 57 in 98% yield (Scheme 28).  
 
Scheme 28: Synthesis of 6-methoxy-2-(7-methoxy-4-oxo-2-phenyl-4H-
chromen-5-oxy)-6-oxo-hexylammonium bromide 57. 
 
In order to maintain a chain length of 10, which would allow to compare the inhibition 
activity towards AmGSTF1 with 3, 57 was coupled to valeric acid, using standard amide 
coupling conditions (Scheme 29). LC-MS (m/z (ES+) = 496 MH+) showed full conversion of 
starting material and product 58 was obtained in 70% yield. Hydrolysis with LiOH.H2O 
afforded the final product 59 in 94% yield. Successful hydrolysis was verified by 
disappearance of the methyl signal in 1H-NMR. 
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Scheme 29: Synthesis of 2-(7-methoxy-4-oxo-2-phenyl-4H-chromen-5-oxy)-6-
((1-oxo-pentylamino)hexanoic acid 59. 
 
As the amide functionality led to a drop in inhibition activity (cf. Chapter 3.2.1.1), attempts 
were undertaken to elongate the chain by reductive amination. Therefore, the amine salt 
was stirred in MeOH with KOH and valeraldehyde before adding NaBH4 (Scheme 30). 
 
Scheme 30: Reductive amination of 57. 
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LC-MS analysis showed two main signals, one for starting material 57 (m/z (ES+) = 
412-MH+) and another peak (m/z (ES+) = 380 MH+), whose mass corresponds to the e-
lactam 61. 
Following a one pot procedure by Abdel-Magid et al.,115 where sodium 
triacetoxyborohydride was used as a reducing agent , no product was observed either and 
mainly starting material 57 was detected by LC-MS. 
3.1.2.2 Chiral synthesis 
2-(7-Methoxy-4-oxo-2-phenyl-4H-chromen-5-oxy)dodecanoic acid 3 has a stereogenic 
centre in the 2-position and it was of interest to test whether the configuration of the 
molecule has an effect on the activity. The two enantiomers can either be obtained by 
chiral synthesis of an analogue or by chiral HPLC-separation of the racemic compound. 
 
Scheme 31: Retrosynthetic analysis of (R)-62. 
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As previously discussed in Chapter 3.1.2.1 a-bromo acids can be obtained from amino 
acids and if chiral amino acids are used, they can be converted into enantiomerically 
enriched a-bromo acids with retention of configuration.111-112 So the analogue (R)-62 can 
be obtained from L-Serine (Scheme 31). 
 
 
Scheme 32: Attempt of enantioselective synthesis. 
 
In order to access both enantiomers Boc-D-Ser-OH (R)-66 and Boc-L-Ser-OH (S)-66 were 
alkylated with 1-iodooctane using NaH as a base, resulting in low conversion and 23% of 
(R)-67 and 10% of (S)-67 respectively. Boc-Deprotection, bromination and methylation by 
TMS-diazomethane afforded (R)-63 and (S)-63 in 32% and 33% over three steps. The 
same conditions as discussed before were applied for the bromination. The final alkylation 
step with 46 needed some optimization, as surprisingly neither the use of K2CO3 nor NaH 
in dimethylformamide (DMF) gave any product. The reasons for this difference in reactivity 
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compared to the non-oxygenated analogue were not obvious. Ultimately using CsCO3 
resulted in product formation confirmed by the corresponding peak in LC-MS (m/z (ES+) = 
483 MH+). Hydrolysis with LiOH.H2O proceeded in full conversion (LC-MS (m/z (ES+) = 
469 MH+)) and afforded (S)-62 in 60% and (R)-62 in 64% yield (Scheme 32). 
Disappointingly, at this step chiral HPLC analysis showed low ee for both (S)-62 and 
(R)-62 (Figure 40). It is assumed that enantiomeric erosion occurred during the 
bromination step, but the reasons are not obvious. 
 
 
Figure 40: Chiral HPLC analysis of (S)-62 (A) and (R)-62 (B) using a Daical 
Chiralpak IA column. 
 
An alternative method to access a chiral analogue was the use of (+)-methyl D-lactate 
(R)-68 as a chiral starting material (Scheme 33). It could be easily converted into the 
triflate (R)-69, using triflic anhydride and 2,6-lutidine, confirmed by the characteristic 
quartet at 118.6 for CF3 in the 13C-NMR spectrum. SN2-type alkylation of 46 with K2CO3 or 
CsCO3 in DMF at 60 °C led to no product formation, but using K2CO3 in MeCN at rt and 
subsequent hydrolysis afforded the product (S)-71 (LC-MS (m/z (ES+) = 341 MH+)) in 42% 
yield and 94% ee, which was again determined by chiral HPLC (Figure 41). 
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Scheme 33: Chiral synthesis of R-2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-
chromen-5’-oxy)propionic acid (S)-71. 
 
Following the same steps, 2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionic 
acid (±)-71 was prepared from methyl DL-lactate (±)-68 (Figure 33), in order to have the 
racemic compound as a comparison in biological testing. 
 
 
Figure 41: Chiral HPLC analysis of (S)-71 using a Daical Chiralpak ID-3 
column. 
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Compounds (S)-71 and (±)-71 were tested for inhibition of AmGSTF1 in the CDNB assay 
(cf. Chapter 3.2.1.1) and showed an inhibition of 5% ± 4% and 14% ± 3% at a 10 µM level 
respectively. Although the relative difference in activity is quite big, a conclusion was 
difficult to draw because of the low absolute inhibition. In order to validate this result, 3 was 
resolved by chiral HPLC.116 These two enantiomers were tested as well and showed 
similar inhibition values (further discussed in Chapter 3.2.1.1). As the configuration of the 
molecule has, if any, only a very small effect on the activity, the chiral synthesis of 
analogues was not further pursued.  
3.1.2.3 Cross metathesis 
Due to the decrease in activity, which was observed for 2-(7-methoxy-4-oxo-2-phenyl-4H-
chromen-5-oxy)-6-((1-oxo-pentylamino)hexanoic acid 59 compared to 2-(7-methoxy-4-oxo-
2-phenyl-4H-chromen-5-oxy)dodecanoic acid 3 (cf. Chapter 3.1.2.1), methods were sought 
to synthesise alkanoic acids of varying chain length with a leaving group in the a-position.  
 
Scheme 34: Retrosynthetic analysis of 72. 
 
Retrosynthetic analaysis (Scheme 34) suggested that chain elongation could be achieved 
by cross metathesis of Boc-protected methyl 2-amino-pent-4-enoate 74 with different 
alkenes, followed by reduction, Boc-deprotection and bromination (described in Chapter 
3.1.2.1). 74 can be obtained by alkylation of the benzophenone imine of glycine 76 and 
n COOMe
72
Br
n COOMe73
NH2
COOMe
74
NHBoc
COOMe
N
COOMe
NNH2.HClMeOOC
77
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subsequent imine hydrolysis and Boc-protection. Asymmetric alkylation methods for 76 are 
established by Corey, Lygo and others, 117-120 so this method could be potentially used for 
a chiral synthesis as well.  
Following a literature procedure, glycine methyl ester hydrochloride 77 was stirred in DCM 
with benzophenone imine to afford 76 in good yield. The Schiff base was alkylated with 
allylbromide using LDA as a base and Boc-protected methyl 2-amino-pent-4-enoate 74 
was obtained by imine hydrolysis with HCl and Boc-protection using Boc2O under basic 
conditions (Scheme 35).121 
 
Scheme 35: Synthesis of Boc-protected methyl 2-amino-pent-4-enoate 74. 
 
With 74 in hand, standard olefin cross metathesis conditions122 were applied to elongate 
the carbon chain with 1-heptene and 10-bromodec-1-ene respectively, the bromo-group of 
which could be used for further functionalizations (Scheme 36). However, no product 
formation could be observed in either reaction. This might be due to chelation by the 
carbonyl group to the ruthenium, sequestering the catalyst in an unproductive form. 
Fürstner et al. reported such chelation for g,d-unsaturated carbonyl compounds. 123-124  
benzophenone imine (1 eq)
DCM, rt, 21 h
i) n-BuLi (1.1 eq)
DIPA (1.1 eq)
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THF, -78 °C-rt
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77
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N 76
68%
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N75
65%
COOMe
NHBoc
i) 4 N HCl, MeOH
reflux, 1 h
ii) Boc2O (1.5 eq)
NaHCO3, rt, 2.5 h 74 
72%
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Scheme 36: Cross metathesis. 
 
Attempts to alkylate Schiff base 76 with non-allylic alkyl bromides were not successful. As 
this synthesis route did not seem to be viable, alternative ways were pursued. 
3.1.2.4 Ene-reaction 
The ene-reation is a useful synthetic method for carbon-carbon bond formation. It refers to 
the reaction of an alkene with an allylic hydrogen (ene) with a compound containing a 
double or triple bond (enophile) to form a new bond with migration of the ene double bond 
by 1,5-hydrogen shift (Scheme 37,1)). Lewis acids can accelerate the reaction for 
enophiles containing basic groups through complexation.125 If glyoxylate is used as an 
enophile, a-hydroxy acids can be obtained (Scheme 37, 2)), the hydroxyl-group of which 
could be transformed into a leaving group by triflation.  
 
Scheme 37: Ene-reaction. 
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Using similar conditions to those reported by Agouridas et al.126, ethyl glyoxalate was 
reacted with 10-bromodec-1-ene and an excess of ferric chloride (3 eq) in DCM. Ethyl 
glyoxalate was obtained from diethyl L-tartrate 80 by treatment with periodic acid127 and 
used in the next step without further purification. Formation of ethyl 12-bromo-2-hydroxy-
dodec-4-enoate 81 was confirmed by GC-MS (m/z = 320 (M+, Br79), 322 (M+, Br81), but the 
reaction gave unreliable results, which depended on the batch of ferric chloride used.  
 
 
Figure 42: GC spectra of ene reaction using different equivalents of H2O. 
 
As ferric chloride is very hygroscopic, the influence of H2O on the reaction was 
investigated. The reaction was conducted under an argon atmosphere using newly 
purchased anhydrous ferric chloride. No reaction could be observed for anhydrous ferric 
chloride alone. When 1.125 or 2.25 eq of H2O were added to the reaction, GC-MS analysis 
EtOOC COOEt
OH
OH
1) H5IO6, Et2O
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showed full conversion of starting material to product, but for 4.5 and 9 eq only partial 
conversion and for 18 eq H2O no reaction was observed (Figure 42), indicating that the 
fully hydrated FeCl3.6H2O is not accelerating the reaction. The use of 3 eq of H2O proved 
to give good results and was applied in all subsequent ene reactions. 
With 81 successfully synthesised, methods to reduce the double bond were sought. As 
expected, 10% Pd/C under hydrogen atmosphere in methanol, not only reduced the 
alkene, but also led to some debromination. Using the more selective, homogeneous 
hydrogenation catalyst, Wilkinson’s catalyst (RhCl(PPh3)3)128 under hydrogen atmosphere 
in toluene gave almost full conversion of 81 to 82 (GC-MS (m/z = 322 (M+, Br79), 324 (M+, 
Br81)), but a very high catalyst loading of 30 mol% was necessary. Changing to the more 
active cationic Crabtree’s catalyst ([Ir(cod)(PCy3)(py)]PF6)129 under hydrogen atmosphere 
in DCM resulted in full conversion from 81 to 82 with a catalyst loading of only 2 mol% and 
82 could be afforded in 49% yield over three steps (Scheme 38). 82 was subsequently 
used for the synthesis of photoaffinity label 160 (cf. Chapter 3.1.4).  
 
Scheme 38: Synthesis of ethyl 12-bromo-2-hydroxy-dodecanoate 82. 
 
In order to investigate the influence of the alkyl chain length on the inhibition activity 
towards AmGSTF1, a-hydroxy acids with 5, 7, 9 and 12 carbons were synthesised, 
following the same steps, but using Pd/C for the hydrogenation (Scheme 39).  
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Scheme 39: Synthesis of 87 – 90. 
 
Ethyl 2-hydroxy-tetradecanoate 90 could be afforded in a good yield of 56% over 3 steps, 
but the yield dropped for ethyl 2-hydroxy-undecanoate 89, ethyl 2-hydroxy-nonanoate 88 
and ethyl 2-hydroxy-heptanoate 87 with 31, 20 and 18% respectively, which probably can 
be attributed to the volatility of pentene, heptane and nonene. 
 
Scheme 40: Synthesis of 95 – 99. 
 
The a-hydroxy acids 87 – 90 were then used to synthesise the flavonoid analogues 95 – 
98 in good yields (Scheme 40), applying the same reaction conditions as described before 
(cf. Chapter 3.1.2.2). 87 – 90 were converted into the respective triflate analogue, using 
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triflic anhydride and 2,6-lutidine, confirmed in each case by the characteristic quartet 
around 118.6 for CF3 in the 13C-NMR spectrum. Subsequent alkylation and hydrolysis 
afforded the products 95 – 98 in good to excellent yield.  
The analogues showed an increase in inhibition of AmGSTF1 in the CDNB assay (cf. 
Chapter 3.2.1.1) with an increase of the alkyl chain length.  
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3.1.3 Improving Aqueous Solubility 
Improving the aqueous solubility of the flavonoid compounds became an important issue 
of this project and different approaches are discussed below.  
Similar ranges of simple physicochemical parameters (molecular mass, logP, hydrogen-
bond donors and acceptors, rotatable bonds), which have been correlated with oral 
bioavailability of drugs by Lipnski’s rule of 5130, apply to the bioavailability of agrochemicals 
in plants. The most significant difference is that agrochemicals have a lower number of 
hydrogen bond donors.131-132 Lipinski’s rule of 5 indicates that logP, the logarithm of the 
octanol/water partition coefficient, should be £ 5, 3, however, has an estimated logP of 7.1 
and it’s aqueous solubility is too low to detect.133  
Four different approaches to potentially improve the aqueous solubility were chosen. The 
phenyl group was replaced by a variety of different heterocycles and an SO2Me-
substituent, which can lower the lipophilicity of a compound, was incorporated. 
Furthermore, substituents were introduced to possibly change the overall planar structure 
of 16 and disrupt π-π stacking interactions and attempts were undertaken to replace the 
long alkyl chain with a polyethylene glycol (PEG)-like chain. 
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3.1.3.1 Heterocyclic analogues 
In order to improve the logP value, analogues of 16 with a variety of different heterocycles 
in the 2-position were synthesised, focusing on those for which initial predictions, using the 
ChemAxon program Instant JChem, had shown a lowering of logP values (Table 8). Even 
though these predicted logP values are only an approximation, the decrease in 
comparison to the predicted logP value of 16 can serve as a guideline. 
Entry Compound Compound Number Predicted logP 
1 
 
16 2a 
2 
 
99 0 
3 
 
100 0 
4 
 
101 0 
5 
 
102 1 
6 
 
103 0 
7 
 
104 1 
OMeO
OMeO
OMeO
OMeO
N
N
O
OMeO
OMeO
N
O
OMeO
OMeO
N
H
N
NN
OMeO
OMeO
N
S
OMeO
OMeO
N
H
N
OMeO
OMeO
N
H
N
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8 
 
105 0 
9 
 
106 1 
10 
 
107 0 
11 
 
108 0 
Table 8: Predicted logP values using the ChemAxon program Instant 
JChem;  
a Measured logP of 3.19133. 
 
Retrosynthetic analysis showed, that analogues 99, 100, 101 and 102 could all be traced 
back to 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41. The 1,3,4-oxadiazole 
analogue 99 could be obtained by cyclisation of the carboxylic acid, 2-acetylhydrazide 109. 
Initially synthesis of 109 was attempted via formation of the acid chloride intermediate and 
subsequent addition of acethydrazide (Table 9, Entries 1 - 5). Heating acid 41 in thionyl 
chloride with a few drops of DMF at reflux before concentrating the reaction mixture and 
adding acethydrazide, led to decomposition of the starting material and no product could 
be detected by LC-MS (Table 9, Entry 1). Using the much milder oxalyl chloride in DCM 
instead, gave a very low conversion (Table 9, Entry 2), probably due to the low solubility of 
41 in DCM. The same conditions used in Chapter 3.1.1.3 for the synthesis of 
carboxamides (Table 9, Entry 3), afforded a complex mixture of the desired product 109, 
cyclised product 99 and side products, the most abundant being N,N-dimethyl 
5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide, which forms due to decomposition of 
the solvent DMF. Attempts to drive the reaction towards cyclised product 99 using different 
OMeO
OMeO
N
N
OMeO
OMeO
N
N
OMeO
OMeO
N
N
OMeO
OMeO
N
N
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temperatures and reaction times were unsuccessful, as N,N-dimethyl 5,7-dimethoxy-4-
oxo-4H-chromene-2-carboxamide was the main product. 
 
Entry Conditions acid chloride 
formation 
Conditions hydrazide 
formation 
Yield 
1a SOCl2 (20 eq), DMF (cat) 
reflux, 3 h 
acethydrazide (1.2 eq) 
N-methylmorpholine (1 eq) 
DCM, rt, 18 h 
decompositionb 
2a oxalyl chloride (5 eq) DMF 
(cat) 
DCM, 0 °C - rt, 4 h 
acethydrazide (1.2 eq) 
N-methylmorpholine (1 eq) 
DCM, rt, 18 h 
low conversionb 
3 POCl3 (1 eq), DMF 
rt – 50 °C, 1 h 
acethydrazide (1 eq) 
µw, 160°C, 5 min 
Complex mixture of 
109, cyclised product 
99 and side productsb 
4 POCl3 (1 eq), DMF 
rt – 50 °C, 1 h 
acethydrazide (1 eq) 
rt, 18 h 
71%c 
5 POCl3 (1 eq), DMF (cat) 
DCM, rt – 35 °C, 3 h 
acethydrazide (1 eq) 
rt, 18 h 
low conversionb 
6 - PyBOP (1.1 eq), DIPEA (2.2 eq) 
acethydrazide (1.1 eq) 
DMF, rt, 18 h 
71% 
Table 9: Hydrazide synthesis. a reaction mixture concentrated after 1. step;      
b Analysis by LC-MS; c 0.25 mmol scale, more side products on larger scale. 
 
At small scale, 109 could be obtained in good yield, as confirmed by the presence of the 
corresponding peak in the LC-MS chromatogram (m/z (ES+) = 307 MH+), when 
acethydrazide was added to the acid chloride at rt and stirred overnight (Table 9, Entry 4). 
If the reaction was conducted at large scale, more side products formed, which made 
purification difficult. Using DCM as a solvent and only catalytic amounts of DMF for the 
acid chloride formation with POCl3 resulted in a very low conversion (Table 9, Entry 5), 
OMeO
OMe O
O
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H
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OH
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again probably due to the low solubility of 41 in DCM. Alternatively classic amide coupling 
conditions134 were applied, with (benzotriazol-1-yloxy)tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) as the coupling reagent (Table 9, Entry 6). 109 was 
obtained in 71% yield (LC-MS (m/z (ES+) = 307 MH+)).  
With 109 in hand, different cyclisation conditions were adopted. There are several 
methods for the cyclodehydration of diacylhydrazines135, one of the most popular is the 
use of POCl3 as a dehydrating agent.136 However, stirring 109 with POCl3 at 80 °C 
overnight, led to decomposition of the starting material (Table 10, Entry 1). 
 
Entry Conditions  Yield 
1 POCl3 (15 eq) 
80 °C, 18 h 
 
decompositiona 
2 tosyl chloride (5.25 eq)  
pyridine, 80 °C, 18 h 
9% 
3 triflic anhydride (1.5 eq) 
PH3PO (3 eq), DCM 
rt – 50 °C, 20 h 
Low conversiona 
4 Burgess reagent (1.5 eq) 
THF, µw, 110 °C, 3.5 h 
21% 
Table 10: 1,3,4-Oxadiazole synthesis; a Analysis by LC-MS. 
 
Using tosyl chloride/pyridine137 instead, showed full conversion of 109 to 99 in LC-MS (m/z 
(ES+) = 289 MH+), but 99 could be obtained in only 9% yield after purification (Table 10, 
Entry 2). Cyclising 109 with triflic anhydride and Ph3PO,138 resulted in some product 
formation, observed by LC-MS, but even after 20 h, only low conversion (Table 10, Entry 
3). Using the dehydrating agent Burgess reagent (Methyl N-(triethylammoniosulfonyl)-
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carbamate) under microwave conditions for the cyclisation,139 gave 99 in 21% yield (Table 
10, Entry 4). Changing the solvent to 1,2-dichloroethane and using a higher temperature 
afforded 99 in 36% yield over two steps (Scheme 41). 
 
Scheme 41: Synthesis of 5,7-dimethoxy-2-(5’-methyl-1’,3’,4’-oxadiazol-2’-yl)-
4H-chromen-4-one 99. 
 
A literature review revealed that oxazoles can be directly obtained from the corresponding 
N-(2,2-dimethoxyethyl)-carboxamide using Eaton’s reagent (phosphorus pentoxide, 
7.7 wt% in methanesulfonic acid).140  
 
Scheme 42: Synthesis of N-(2’,2’-diethoxyethyl)-5,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamide 110. 
 
Therefore, N-(2’,2’-diethoxyethyl)-5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 110 
was synthesised using the same coupling conditions as for 109 (Scheme 42) (LC-MS (m/z 
(ES+) = 366 MH+)). 110 was then heated with Eaton’s reagent to 140 °C (Scheme 43). 
LC-MS analysis showed full conversion of the starting material, but in addition to small 
amounts of the product (m/z (ES+) = 274 MH+), another two peaks with (m/z (ES+) = 
251 MH+) and (m/z (ES+) = 250 MH+), as the major one, could be observed, probably 
corresponding to the acid 41 and the primary amide, respectively. 
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Scheme 43: Attempt of oxazole synthesis using Eaton’s reagent. 
 
As Burgess reagent was successfully used in the synthesis of oxadiazole 99, acetal 110 
was deprotected using trifluoroacetic acid (TFA) and directly cyclised applying the same 
conditions (Scheme 44). Oxazole 100 was obtained in 28 % yield, confirmed by the 
corresponding peak in the LC-MS (m/z (ES+) = 274 MH+) spectrum. 
 
Scheme 44: Synthesis of 5,7-dimethoxy-2-(1’,3’-oxazol-2’-yl)-4H-chromen-4-
one 100. 
 
Nitriles can act as a starting material for both tetrazoles141 and thiazoles142 and can 
themselves be synthesised from the corresponding carboxamide. Carboxamide 111 was 
obtained, by slowly dropping the in situ synthesised acid chloride into 35% NH4OH, in 73% 
yield (LC-MS (m/z (ES+) = 250 MH+)) (Scheme 45). 
 
Scheme 45: Synthesis of 5,7-dimethoxy-4H-chromen-4-one-2-carboxamide 
111. 
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111 could be converted into nitrile 112 using trifluoroacetic anhydride and pyridine.143 The 
product was obtained in excellent yield and formation was confirmed by the appearance of 
a peak in the LC-MS chromatogram (m/z (ES+) = 232 MH+). 
 
Scheme 46: Synthesis of 5,7-dimethoxy-4H-chromen-4-one-2-carbonitrile 
112. 
 
 
Scheme 47: Synthesis of 5,7-dimethoxy-2-(1H-1’,2’,3’,4’-tetrazol-5’-yl)-4H-
chromen-4-one 101. 
 
Tetrazole 102 (LC-MS (m/z (ES+) = 275 MH+)) was afforded by the reaction of sodium 
azide with nitrile 101, in the presence of an ammonium salt (Scheme 47).141 
The thiazole ring of compound 102 was assembled via Hantzsch thiazole synthesis. The 
thioamide precursor 113 was prepared from nitrile 112. Following a literature procedure142, 
addition of sodium hydrogen sulfide and magnesium chloride to a solution of nitrile 112 in 
DMF readily afforded thioamide 113, albeit heating was required. As suggested by 
Käsnänen et al.,144 reacting thioamide 113 with bromoacetaldehyde diethyl acetal under 
microwave conditions afforded thiazole 102 (LC-MS (m/z (ES+) = 290 MH+)) (Scheme 
48).142 Addition of small amounts of H2O improved the conversion significantly. A mixture 
of THF and EtOH was used as a solvent, in order to reach a higher reaction temperature in 
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the microwave, which also improved the conversion of the starting material. In addition to 
the desired product 102, the demethylated thiazole 114 (LC-MS (m/z (ES+) = 276 MH+)), 
could be isolated in 37% yield. Stereochemistry was confirmed in 2D-NMR. The HMBC 
experiment showed a correlation between the C-4a, the C-5 and the C-6 carbon signal and 
the signal for the OH-group. 
 
Scheme 48: Synthesis of 5,7-dimethoxy-2-(1’,3’-thiazol-2’-yl)-4H-chromen-4-
one 102. 
 
Another method to obtain 4H-chromen-4-ones with various substituents in the 2-position, 
is to prepare them from the corresponding hydroxychalcones.90, 145  
 
Scheme 49: Attempted synthesis of pyrazole 103. 
 
In order to afford the hydroxychalcone, acetophenone 7, together with 1H-pyrazole-5-
carbaldehyde, was stirred in 3 M KOH in ethanol. No reaction occurred at rt, but at 50 °C 
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product was formed in an aldol condensation (Scheme 49), confirmed by both LC-MS (m/z 
(ES+) = 275 MH+) and 1H-NMR analysis with the two characteristic doublets at 8.03 and 
7.55 ppm corresponding to the two alkene protons. No product could be obtained from the 
oxidative cyclisation reaction with I2 in dimethyl sulfoxide (DMSO). The main product 
observed by LC-MS (m/z (ES+) = 275 MH+), which was also confirmed by 1H-NMR, was 
the flavanone. 
Using the same conditions with 1H-pyrazole-5-carbaldehyde, product 104 (LC-MS (m/z 
(ES+) = 273 MH+)) was obtained in 11% yield over the two steps. The rather low yield is 
due to a low conversion in the first step. 
 
Scheme 50: Synthesis of pyrazole 104. 
 
To see how an alkylation might affect the activity, 104 was methylated with MeI, using NaH 
as a base to afford the two isomers 105 and 106 in 16 and 33% yield respectively 
(Scheme 51). The constitutional isomers were characterized by 2D-NMR. A correlation 
between the signal for the proton in the 3-position and the signal for the NCH3-group in the 
NOESY experiment for 105 confirmed the structure of the isomer.  
 
Scheme 51: Methylation of 104. 
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As no product formation could be observed in the aldol condensation between 
acetophenone 7 and pyrimidine-5-carbaldehyde (Scheme 52), which might be due to 
decomposition of the aldehyde, a different synthetic pathway was pursued to obtain a 
pyridazine analogue. 
 
Scheme 52: Attempted synthesis of 107. 
 
The pyridazine analogue 111 was obtained by a tandem one-pot C-H-borylation, Suzuki-
Miyaura cross coupling reaction (Scheme 53).146-147 3-Methylpyridazine 116 was 
selectively borylated in the 5-position due to the steric hindrance of the methyl group. The 
reaction mixture was then concentrated and to the crude boronate ester was added 
Pd(amphos)Cl2, K3PO4, chloride 21 and a mixture of dimethylacetamide (DMAC) and H2O. 
108 was afforded in 31% yield (LC-MS (m/z (ES+) = 299 MH+)). 
 
Scheme 53: Synthesis of 5,7-dimethoxy-2-(6’-methylpyridazin-4’-yl)-4H-
chromen-4-one 108. 
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Calculated logP values and aqueous solubility for all heterocyclic analogues are 
summarised in Table 11. As predicted, the logP decreased for all the heterocyclic 
analogues. The aqueous solubility slightly decreased the different pyrazole analogues 104, 
105 and 106, but improved for all the other compounds, most significantly for the thiazole 
analogue 102, for which the aqueous solubility increased almost twenty-fold. For tetrazole 
101 the aqueous solubility was measured around pH 2 to obtain the solubility of the non-
ionized form, but solubility is higher at higher pH values. 
 
Entry Compound Compound 
Number 
logP Aqueous 
solubility (ppm) 
Aqueous 
solubility pH 
1 
 
16 3.19 25.0 7.22 
2 
 
99 0.99 70.1 7.21 
3 
 
100 1.59 88.3 7.19 
4 
 
101 1.23 15.9 2.15 
5 
 
102 2.1 467.7 7.20 
6 
 
104 1.82 16.7 7.23 
OMeO
OMeO
OMeO
OMeO
N
N
O
OMeO
OMeO
N
O
OMeO
OMeO
N
H
N
NN
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N
S
OMeO
OMeO
N
H
N
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7 
 
105 1.84 16.9 7.22 
8 
 
106 1.83 21.4 7.22 
9 
 
108 1.32 148.6 7.22 
Table 11: LogP values and aqueous solubility for heterocyclic analogues 
compared to 16; all measurements were conducted by Syngenta at Jealotts 
Hill. 
 
The heterocyclic analogues were also tested for inhibition of AmGSTF1 in the CDNB 
assay (cf. Chapter 3.2.1.1). They all showed a comparable, but slightly lower inhibition in 
comparison to 5,7-dimethoxy-2-phenyl-4H-chromen-4-one 16, with the exception of 
thiazole 102, which showed a slightly higher inhibition of AmGSTF1. 
 
3.1.3.2 Analogues with an SO2Me-substituent 
As the SO2Me-substituent can lower the lipophilicity of a compound, two analogues of 16 
with said group in the meta or para position of the phenyl ring, 120 and 121, were 
synthesised (Scheme 54) to improve the aqueous solubility. In order to compare the 
activity with 3, a-substituted dodecanoic acid was attached.  
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N
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Scheme 54: Synthesis of 124 and 125. 
 
Compound 21 was coupled with 4- and 3-methylthiophenylboronic acid respectively, 
conditions were selected from the previous screening of Suzuki coupling conditions (Table 
4). Microwave heating instead of conventional heating was chosen to shorten reaction 
times. Products 118 and 119 were obtained in 58 and 67% yield, formation of both was 
shown by LC-MS (m/z (ES+) = 329 MH+). Oxidation of the thioether with an excess of 
Oxone® afforded 120 and 121 in good yield. A shift of the 13C-NMR methyl-signal from 
around 15 ppm to about 45 ppm in both cases confirmed the oxidation. Selective 
demethylation with BBr3 in the 5-position, which is known in literature148 and subsequent 
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alkylation with 48 and hydrolysis of the ester afforded 124 and 125 in 16 and 21% over 3 
steps (LC-MS (m/z (ES+) = 545 MH+)).  
The logP values for the two analogues are summarised in Table 12. 
Entry Compound Compound 
Number 
logP 
1 
 
3 7.1 
2 
 
125 6.92 
3 
 
124 6.91 
Table 12: LogP values for the SO2Me –analogues 124 and 124 compared to 
3; all measurements were conducted by Syngenta at Jealotts Hill; values are 
estimates, due to difficulties measuring them accurately as they are very 
high. 
 
Although the logP values improved slightly, the aqueous solubility for 124 and 125 was still 
too low to detect. Both potential synergists 124 and 125 were tested for inhibition of 
AmGSTF1 in the CDNB assay (cf. Chapter 3.2.1.1). In both cases the inhibition dropped 
compared to 3 although less for 125.  
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3.1.3.3 Change of the planar structure 
The crystal structure of 16 shows that the phenyl ring is only slightly twisted in respect to 
the essentially planar 4H-chromen-4-one.149 Therefore the introduction of substituents in 
the ortho-position of the phenyl ring or 3-position of the 4H-chromen-4-one could improve 
the aqueous solubility by twisting the phenyl ring further and disrupting π-π stacking 
interactions. 
Compound 128, with a methyl group in the ortho-position of the phenyl ring, was 
synthesised in a similar manner as for 124 and 125 (Scheme 55). Suzuki coupling of 21 
with o-tolylboronic acid, followed by selective demethylation, alkylation and hydrolysis 
afforded 128 (LC-MS (m/z (ES+) = 481 MH+)) with moderate to good yields in the 
individual steps. 
 
Scheme 55: Synthesis of 128. 
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In order to introduce a substituent in the 3-position of the 4H-chromen-4-one, the 
heterocyclic skeleton was build up starting from propiophenone 130. Following a 
procedure by Rocha et al.150, propiophenone 130 was reacted with benzoyl chloride in the 
presence of an excess amount of LiHMDS, which was made in situ from n-Buli and 
1,1,1,3,3,3-hexamethyldisilazane, and then treated with HCl (Scheme 56). Under these 
conditions 131 was obtained in 70% yield with the 1H-NMR spectrum in accordance to 
literature.150  
Propiophenone 130 itself was obtained from phenol 17 using similar Steglich esterification 
and Fries rearrangement conditions (Scheme 56) to the ones used in Chapter 3.1.1.2.2. 
 
Scheme 56: Synthesis of 5,7-dimethoxy-3-methyl-2-phenyl-4H-chromen-4-
one 131. 
 
Again selective demethylation, alkylation and hydrolysis afforded 134 (LC-MS (m/z (ES+) 
= 481 MH+)) as an analogue of 3 in good yield (Scheme 57). 
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Scheme 57: Synthesis of 134. 
 
 
The logP values for 128 and 134 are summarised in  Table 13. The logP value decreased 
for 128 by almost 1.5, but inhibition of AmGSTF1 in the CDNB assay (cf. Chapter 3.2.1.1) 
was also significantly lower compared to 3, both might be attributed to a twisted structure. 
For 134 neither the logP value nor the inhibition of AmGSTF1 in the CDNB assay (cf. 
Chapter 3.2.1.1) changed significantly.  
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Entry Compound Compound 
Number 
logP 
1 
 
3 7.1 
2 
 
128 5.75 
3 
 
134 7.4 
 Table 13: LogP values for analogues 128 and 134 compared to 3; all 
measurements were conducted by Syngenta at Jealotts Hill; values are 
estimates, due to difficulties measuring them accurately as they are very 
high. 
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3.1.3.4 Incorporation of a PEG-like chain 
Another approach to improve the aqueous solubility of 3 was to replace the long alkyl 
chain with a PEG-like chain. Therefore, alkene 136 was synthesised (Scheme 58) and 
used in an ene-reaction (Scheme 59), however no formation of product 137 could be 
observed in GC-MS or crude 1H-NMR. 
 
Scheme 58: Synthesis of 3-(2’’-methoxy-(2’-ethoxyethoxy))-1-propene 136. 
 
 
Scheme 59: Ene-reaction with 136. 
 
As the allyl ether might be responsible for that, alkene 138 was synthesised, featuring an 
additional CH2-group (Scheme 60). 
 
Scheme 60: Synthesis of 4-(2’-methoxyethoxy)-1-butene 138. 
 
Using 138 instead of 136 in the ene-reaction proved to be successful and 139 could be 
obtained (GC-MS (m/z = 232 M+)), which was directly reduced to 140 (GC-MS (m/z = 
234 M+)) (Scheme 61). Crabtree’s catalyst was used for the hydrogenation instead of Pd/C 
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as the later conditions resulted in no product formation. The rather low yield can be 
explained by the difficult purification. 
 
Scheme 61: Synthesis of ethyl 2-hydroxy-6-(2’-methoxyethoxy)hexanoate 
140. 
 
140 was converted into the triflate 141, using triflic anhydride and 2,6-lutidine (Scheme 
62), confirmed by the characteristic quartet at 118.6 for CF3 in the 13C-NMR spectrum. 46 
was alkylated at rt with 141 using K2CO3 as a base, product formation was confirmed by 
LC-MS (m/z (ES+) = 485 MH+).  
 
Scheme 62: Attampted synthesis of 142. 
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Attempts to hydrolyse the crude ester using LiOH.H2O in a 1:1 mixture of THF and H2O 
failed and no conversion of the starting material could be observed by LC-MS. When KOH, 
which is less prone to complexation, in a 2:1 mixture of MeOH and H2O was used instead, 
142 could be detected in LC-MS (m/z (ES+) = 457 MH+) and the formation was confirmed 
in the crude 1H-NMR spectrum, however no pure product could be obtained by flash 
column chromatography. 
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3.1.4 Synthesis of photoaffinity labels 
Photoaffinity labelling is an important method to study protein-ligand interactions and to 
identify binding sites in proteins.151-153 Photolabile ligands can be used as chemical probes, 
which covalently bind their target upon activation by light. MALDI-MS and LC-MS analysis 
of the ligand-labelled protein can be used to identify mass additions due to ligand 
attachment. Through subsequent tryptic digestion and MS-based sequencing the amino 
acid sequence of the ligand-binding region can be obtained which offers valuable 
information about the binding site (Figure 43).154 
 
Figure 43: Photoaffinity labelling 
 
The main groups used for photoaffinity labelling are azides, diazirines, and 
benzophenones, which form nitrenes, carbenes and radicals as reactive intermediates, 
respectively, when irradiated with light (Figure 44).155 
 
Figure 44: Photoaffiniy functional groups and their reactive intermediates. 
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Benzophenone analogues were the probes of choice, as they are chemically more stable 
than azides or diazarines and can be manipulated in ambient light. Benzophenones can be 
activated at rather high wavelengths of 350 – 360 nm, which reduces the potential damage 
to the protein and they preferentially react with C-H bonds, even in the presence of solvent 
water and bulk nucleophiles. They can, however, require longer irradiation times and their 
bulkiness can affect the interaction between the ligand and the target protein.156-158 
In order to see the how the benzophenone group affects the activity towards AmGSTF1, 
four analogues with the group attached at different parts of the molecule were synthesised. 
 
Scheme 63: Synthesis of photoaffinity label 145. 
 
Suzuki coupling of chloride 21 with 4-benzoylphenylboronic acid gave access to an 
analogue with the benzophenone moiety directly attached to the 4H-chromen-4-one core. 
143 (LC-MS (m/z (ES+) = 387 MH+)) was obtained in excellent yield and selective 
demethylation, alkylation and hydrolysis afforded 145 (LC-MS (m/z (ES+) = 571 MH+)) in 
21 143
90%
OMeO
OMe O
Pd2(dba)3 (3 mol%)
CyJohnPhos (6 mol%), Cs2CO3 (3 eq) 
4-benzoylphenylboronic acid (2 eq)
dioxane, 100 °C, 17 h
OMeO
OMe O
Cl
O
OMeO
OH O
BBr3 (1.5 eq)
1,2-dichloroethane 
-78 °C - rt, 2.5 h
O
1) 48 (2 eq), K2CO3 (2 eq)
DMF, 60 °C, 17 h
2) LiOH.H2O (2 eq)
THF: H2O 1:1, rt, 2.5 h
OMeO
OO
COOH
O
144
64%
145
92%
9
  Results and Discussion 
  98 
good yield (Scheme 63). Photoaffinity label 153, where the benzophenone group is 
attached further away from the core structure, was synthesised using chromenone 149 as 
a starting material (Scheme 66).  
 
Scheme 64: Synthesis of 5-hydroxy-7-methoxy-2-(4’-hydroxyphenyl)-4H-
chromen-4-one 149. 
 
149 was obtained following a literature procedure.145 Base-catalyzed aldol condensation of 
2-hydroxyacetophenone 7 with 4-allyloxybenzaldehyde 151 afforded chalcone 146 in 60% 
yield (Scheme 64). 4-Allyloxybenzaldehyde 151, required as starting material was 
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synthesised by alkylation of 4-hydroxybenzaldehyde 150 with allyl bromide using K2CO3 in 
acetone (Scheme 65).  
 
Scheme 65: Synthesis of 4-allyloxybenzaldehyde 151. 
 
146 was then cyclized with catalytic amounts of iodine in DMSO to give the desired 
product 147 in excellent yield (Scheme 64). Appearance of a singlet at 6.72 instead of the 
two doublets at 7.81 and 7.66 in the 1H-NMR spectrum confirmed the cyclisation. The allyl 
protecting group was cleaved with catalytic amounts of Pd(PPh3)4 using K2CO3 in methanol 
at reflux to obtain 148 in good yield. Selective demethylation with BBr3 in the 5-position 
gave 5-hydroxy-7-methoxy-2-(4’-hydroxyphenyl)-4H-chromen-4-one 149 (LC-MS (m/z 
(ES+) = 285 MH+)) in 53% yield (Scheme 64). 
 
Scheme 66: Synthesis of photoaffinity label 153. 
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4-Hydroxybenzophenone attached to a linker was used in an alkylation reaction with 149 
to give 152 in good yield (Scheme 66). Formation was confirmed by the corresponding 
peak in LC-MS (m/z (ES+) = 509 MH+) and stereoselectivity was verified by 2D-NMR. The 
HMBC experiment showed a correlation between the C-4’ carbon signal and the signal for 
the CH2-group. Alkylation with 48 in the 5-position and hydrolysis of the methyl ester 
afforded photoaffinity label 153 in 92% yield over the two steps (LC-MS (m/z (ES+) = 707 
MH+)). 
The alkyl linker was connected to 4-hydroxybenzophenone by reaction with an excess of 
1,2-dibromoethane and K2CO3 in DMF (Scheme 67). 
 
Scheme 67: Synthesis of 4-(2’’-bromoethoxy)benzophenone 155. 
 
Compound 155 was also used to attach the benzophenone moiety in the 7-position of the 
4H-chromen-4-one (Scheme 68). Reaction of 45 with 155 and K2CO3 in DMF resulted in 
the stereoselective alkylation, though elevated temperatures were required to improve the 
conversion. Formation of 156 was confirmed by the presence of the corresponding peak in 
LC-MS (m/z (ES+) = 479 MH+) and 2D-NMR. The HMBC experiment showed a correlation 
between the C-5 carbon signal and the signal for the CH2-group. 
Alkylation with 48 in the 5-position and hydrolysis of the methyl ester afforded 157 in 55% 
yield over the two steps (LC-MS (m/z (ES+) = 677 MH+)). The alkylation conditions had to 
be changed, however, Cs2CO3 was used instead of K2CO3 as no product formation was 
observed using the latter. 
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Scheme 68: Synthesis of photoaffinity label 157. 
 
For the last photoaffinity probe, the benzophenone group was attached at the long alkyl 
chain (Scheme 69). a-Hydroxy acid 82, whose synthesis was described in Chapter 3.1.2.4, 
was stirred with 154 and K2CO3 in DMF in an alkylation reaction to afford 158 in 65% yield 
(LC-MS (m/z (ES+) = 441 MH+)). Using the same conditions as before, to form the triflate, 
158 was reacted with triflic anhydride and 2,6-lutidine. Product formation was confirmed by 
the characteristic quartet at 118.6 for the CF3 group in the 13C-NMR spectrum. Subsequent 
alkylation and hydrolysis afforded the product 160 (LC-MS (m/z (ES+) = 663 MH+)) in 
moderate yield.  
All the photoaffinity labels were tested for inhibition of AmGSTF1 in the CDNB assay (cf. 
Chapter 3.2.1.1). 153 and 157 showed a lower inhibition than 3, but for 145 and 160 the 
inhibition was unchanged. Therefore, those two labels were considered for further labelling 
experiments. (cf. Chapter 3.2.2.1) 
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Scheme 69: Synthesis of photoaffinity label 154. 
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3.2 Biological Testing 
3.2.1 Synergist evaluation 
3.2.1.1 CDNB assay 
In order to determine whether a compound acts as a GST inhibitor or not, a CDNB assay 
was performed. A CDNB assay is a colorimetric assay, which is based on the GST-
catalysed conjugation of GSH to 1-chloro-2,4-dinitrobenzene (CDNB 161) (Scheme 70). 
This reaction forms the dinitrophenyl thioether 162 that can be spectrophotometrically 
detected at 340 nm.159 As almost all GSTs have an affinity for CDNB, the CDNB assay is 
commonly used to determine GSH conjugating activity. 
 
Scheme 70: Reaction in the CDNB assay. 
 
AmGSTF1 was obtained by overexpression in Escherichia coli (E. coli) cells. Therefore, 
competent E. coli cells were transformed using strep-tagged-AmGSTF1, cloned into a pET 
Strep vector. Selection and propagation of the transformed cells was followed by Isopropyl 
β-D-1-thiogalactopyranoside (IPTG) induction of protein expression. AmGSTF1 was 
purified by fast protein liquid chromatography (FPLC) using a streptacin column. All 
inhibitors were tested at a final concentration of 1, 10 or 100 µM in the CDNB assay. 
Values were reported as % inhibition of the specific enzyme activity and are summarized 
in Table 14. The results are discussed in more detail below. 
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Entry Compound Number Inhibition 100 µM 
Inhibition 
10 µM 
Inhibition 
1 µM 
1 
 
2 100% ± 13% 96% ± 2% 70% ± 1% 
2 
 
3 100% ± 4% 99% ± 6% 71% ± 5% 
3 
E1 
3 E1 n.d. n.d. 46% ± 8% 
4 
E2 
3 E2 n.d. n.d. 68% ± 3% 
5 
 
9 16% ± 3% n.d. n.d. 
6 
 
12 37% ± 4% 0% ± 3% n.d. 
7 
 
13 67% ± 5% 12% ± 4% n.d. 
8 
 
14 12% ± 1% n.d. n.d. 
9 
 
16 70% ± 12% 20% ± 3% n.d. 
10 
 
25 78% ± 13% 23% ± 11% n.d. 
11 
 
26 100% ± 3% 15% ± 4% n.d. 
12 
 
27 87% ± 7% 12% ± 2% n.d. 
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13 
 
28 80% ± 7% 11% ± 7% n.d. 
14 
 
29 79% ± 3% 15% ± 8% n.d. 
15 
 
30 100% ± 3% 11% ± 6% n.d. 
16 
 
31 33% ± 4% 12% ± 5% n.d. 
17 
 
32 58% ± 14% 20 % ±5% n.d. 
18 
 
38 50% ± 6% 10 % ±4% n.d. 
19 
 
42 49% ± 3% 26% ± 14% n.d. 
20 
 
43 56% ± 5% 19% ± 6% n.d. 
21 
 
44 64% ± 6% 33% ± 13% n.d. 
22 
 
45 100% ± 10% 47% ± 5% n.d. 
23 
 
57 n.d. 25% ± 10% n.d. 
24 
 
59 n.d. 39% ± 2% 6% ± 1% 
25 
 
(S)-71 n.d. 5% ± 4% n.d. 
26 
 
(±)-71 n.d. 14% ± 3% n.d. 
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27 
 
95 n.d. 69% ± 6% 4% ± 7% 
28 
 
96 n.d. 86% ± 1% 40% ± 3% 
29 
 
97 n.d. 97% ± 7% 58% ± 4% 
30 
 
98 n.d. 90% ± 3% 75% ± 3% 
31 
 
99 53% ± 3% 8% ± 2% n.d. 
32 
 
100 64% ± 2% 11% ± 1% n.d. 
33 
 
101 53% ± 5% 13% ± 7% n.d. 
34 
 
102 83% ± 3% 23% ± 3% n.d. 
35 
 
104 59% ± 2% 6% ± 3% n.d. 
36 
 
105 58% ± 7% 9% ± 7% n.d. 
37 
 
106 64% ± 3% 19% ± 8% n.d. 
38 
 
108 64% ± 5% 8% ± 2% n.d. 
39 
 
120 60% ± 7% 11% ± 3% n.d. 
40 
 
121 35% ± 10% 14% ± 2% n.d. 
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41 
 
124 n.d. 83% ± 1% 24% ± 3% 
42 
 
125 n.d. 94% ± 2% 40% ± 2% 
43 
 
126 36% ± 1% 9% ± 5% n.d. 
44 
 
128 n.d. 82% ± 1% 27% ± 2% 
45 
 
131 n.d. 17% ± 1% n.d. 
46 
 
134 n.d. 100% ± 2% 70% ± 1% 
47 
 
145 n.d. 81% ± 4% 71% ± 3% 
48 
 
153 n.d. 30% ± 6% n.d. 
49 
 
157 n.d. 47% ± 5% n.d. 
50 
 
160 n.d. 78% ± 4% 57% ± 4% 
 
Table 14: Inhibition of AmGSTF1 in the CDNB assay. Values are reported as 
% inhibition of the specific enzyme activity. Each value is the result of three 
replicate measurements. 
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Figure 45: Inhibition of AmGSTF1 caused by 2-amino-5,7-dimethoxy-4H-
chromen-4-ones in the CDNB assay compared to phenyl analogue 16. Each 
value is the result of three replicate measurements. 
 
With the exception of 13, the non-aromatic amines in the 2-position (Table 14, entries 5-8) 
seem to lower the inhibition of AmGSTF1 significantly compared to 5,7-dimethoxy-2-
phenyl-4H-chromen-4-one 16 (Figure 45), suggesting that either the electron donating 
effect of the amine is unfavourable or the aromatic ring in this position is important. 
 
Figure 46: Inhibition of AmGSTF1 caused by 5,7-dimethoxy-4-oxo-4H-
chromene-2-carboxamides in the CDNB assay compared to phenyl analogue 
16. Each value is the result of three replicate measurements. 
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Carboxamides 42 – 44 (Table 14, entries 19-21) had a similar potency to compound 16 at 
a 10 µM level, but a slightly lower inhibition at a 100 µM level (Figure 46). As the amide 
group is planar, it is a linker between the C ring and the aryl group, but does not change 
the overall planar structure of the molecule. 
 
Figure 47: Inhibition of AmGSTF1 caused by 2-aryl-5,7-dimethoxy-4H-
chromen-4-ones in the CDNB assay. Each value is the result of three 
replicate measurements. 
 
Most substituents on the phenyl-ring of the 2-aryl-5,7-dimethoxy-4H-chromen-4-ones did 
not significantly affect the activity of these compounds (Figure 47). Compound 27 with a 
biphenyl in the 2-position and compound 28 with a 4-ethyl-substituted phenyl ring, retained 
their activity and showed a similar inhibition, which indicates that steric bulk in those 
positions is tolerated. The p-OMe substituent (26, 30) slightly improved the inhibition of 
AmGSTF1 at 100 µM, which might suggest that a hydrogen bond acceptor in this position 
is beneficial. The 1,3-benzodioxole analogue 31 an alternative to the dimethoxy derivative 
30, however, had a significantly lower potency at 100 µM. A p-CO2Me substituent (32), as 
well as a SO2Me group in the para (121) or meta (120) position led to a decrease in activity 
at 100 µM. As the o-methyl substituent of analogue 126 possibly twists the phenyl ring in 
respect to the planar 4H-chromen-4-one, the low inhibition of AmGSTF1 might be 
explained by a different molecular geometry. 
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Figure 48: Inhibition of AmGSTF1 caused by 2-heteroaryl-5,7-dimethoxy-4H-
chromen-4-ones in the CDNB assay compared to phenyl analogue 16. Each 
value is the result of three replicate measurements. 
 
All heteroaryl analogues, except thiazole 102, had a marginally lower potency compared to 
compound 16 at a 10 and 100 µM level (Figure 48). Thiazole 102 showcased a slightly 
higher activity than 12 at both concentrations.  
  
 
Figure 49: Inhibition of AmGSTF1 caused by 2-(4-oxo-4H-chromen-5-
oxy)dodecanoic acid analogues in the CDNB assay. Each value is the result 
of three replicate measurements. 
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As discussed in Chapter 2.1, compound 2 and 3 have a very similar activity towards 
AmGSTF1 in the CDNB assay at 10 and 1 µM (Figure 49). The same is true for compound 
134, the methyl substituent in the 3-position of the 4H-chromen-4-one had no effect on 
potency. The decreased activity of the o-methyl substituted analogue 128 and the 
p-SO2Me and m-SO2Me substituted analogues 125 and 124 compared to 3, especially at a 
1 µM level, was consistent with the loss in activity for compounds 121, 120 and 126 
compared to 16. 
 
Figure 50: Influence of the alkyl chain length on the inhibition of AmGSTF1 
in the CDNB assay. Each value is the result of three replicate 
measurements. 
 
The inhibition activity of analogues of 3 with varying alkyl chain length at 10 and 1 µM 
increased with the number of carbon atoms (Figure 50). The heptanoic acid analogue 95 
had a significantly higher activity than the propanoic acid compound (±)-71. Extending the 
chain by a further two (96) and four (97) carbons led to another huge increase in potency, 
which then slightly levelled for the dodecanoic (3) and tetradecanoic (98) acid analogue.  
In order to determine a possible effect of the configuration on the inhibition activity, the two 
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enantiomer showed a slightly decreased activity at 1 µM, suggesting, that, if any, the 
stereochemistry has a small influence on activity. 
 
Figure 51: Influence of the configuration on the inhibition of AmGSTF1 in the 
CDNB assay. Each value is the result of three replicate measurements. 
 
 
 
 
Figure 52: Inhibition of AmGSTF1 caused by the photoaffinity labels in the 
CDNB assay. Each value is the result of three replicate measurements. 
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The inhibition activity of the photoaffinity labels is shown in Figure 52. Both label 145 and 
160 retained most of their potency, suggesting the bulkiness of the benzophenone moiety 
is not affecting the interaction between the ligand and the protein. For the other two labels 
the activity decreased significantly.  
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3.2.1.2 Thermal shift assay 
A different method to analyse potential synergists is the thermal shift assay, which 
measures the change in protein melting temperature upon binding of a ligand to the 
protein.160 In the thermofluor assay, a dye, SYPRO orange161, with a low fluorescence in a 
polar environment, but a high fluorescence in a non-polar environment, is added to a 
protein solution and the fluorescence of the solution is monitored while heating. As the 
protein is unfolding, the hydrophobic core is exposed and the signal increases until the 
protein is completely denatured. The melting temperature Tm can be determined by the 
temperature where half the protein population is unfolded. The assay can be performed in 
96-well plate using a standard quantitative PCR instrument.162 
A preliminary test was performed to see how much DMSO could be added without 
destabilizing the enzyme (Figure 53) and the results indicated that less than about 1.5 % 
should be used, as higher concentrations decreased Tm. 
 
 
 
 1 2 3 4 5 6 7 8 9 10 11 12 
A 0.2 50.2 25.2 12.7 6.45 3.325 1.763 0.981 0.591 0.395 0.298 0.249 
B 0.2 50.2 25.2 12.7 6.45 3.325 1.763 0.981 0.591 0.395 0.298 0.249 
 
Figure 53: a) Results of the thermal shift assay showing Tm for each well. 
Decreases in melting temperature are indicated by a colour change from 
yellow to red (largest decrease). b) Final concentration of DMSO [%]. 
Experiments were done in duplicate. 
 
The results of the compound screen (Figure 54) indicated three areas that increase the 
thermal stability, positions D1-D3, D7-D9 and E1-E3, corresponding to compounds 3, 134 
and 2 at a 10 µM concentration. Those three compounds are the only aryloxydodecanoic 
acid analogues in this screen, which again emphasises the importance of this substituent 
a) 
b) 
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in the 5-position and confirms those compounds as the most potent binding partners of 
AmGSTF1. All other compounds showed, if any only a very low increase or decrease in 
melting temperature.  
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Figure 54: a) Results of the thermal shift assay showing Tm for each well. 
Increases in melting temperature are indicated by a colour change from 
light-blue to dark–blue (largest increase), decreases from yellow to red 
(largest decrease). b) Compound tested; final concentration of either 1 or 
10 µM; Experiments were done in triplicate. 
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These initial results suggested the use of the thermal shift assay as an alternative 
orthogonal screening method for ligand identification and a full screening of all synthesised 
analogues was conducted by Becky Eno, the results of which are summarised in Table 15.  
Entry Compound Number ∆Tm 100 µM 
∆Tm 
10 µM 
∆Tm 
1 µM 
1 
 
2 1.10 2.17 0.20 
2 
 
3 1.17 0.23 0.30 
3 
E1 
3 E1 0.47 0.23 0.20 
4 
E2 
3 E2 1.20 0.47 0.20 
5 
 
9 0.20 -0.03 0 
6 
 
12 0.20 0.23 0.06 
7 
 
13 0.30 0.13 0.23 
8 
 
14 0.07 0.17 0.23 
9 
 
16 0.3 0.33 0.23 
10 
 
25 0.27 0.33 0.17 
11 
 
26 0.70 0.17 0.23 
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12 
 
27 -0.1 0.13 0.13 
13 
 
28 0 0.10 30 
14 
 
29 -0.17 0.2 0.33 
15 
 
30 0.17 -0.03 0.30 
16 
 
31 0.33 0.17 0.27 
17 
 
32 0.27 0.30 0.27 
18 
 
38 0.23 0.27 0.23 
19 
 
42 0.03 0.03 0.17 
20 
 
43 0.13 0.50 0.20 
21 
 
44 0.33 0.10 0.20 
22 
 
45 0.13 0.03 0.20 
23 
 
57 0.57 0.43 0.20 
24 
 
59 1.10 0.30 0.13 
25 
 
(S)-71 0.47 0.23 0.30 
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26 
 
(±)-71 1.10 0.20 0.20 
27 
 
95 2.33 0.43 0.17 
28 
 
96 2.93 0.70 0.27 
29 
 
97 0.90 0.70 0.40 
30 
 
98 1.43 0.73 0.20 
31 
 
99 -0.27 -0.17 -0.10 
32 
 
100 -0.23 -0.17 -0.10 
33 
 
101 -0.43 -0.27 -0.23 
34 
 
102 -0.50 -0.47 -0.40 
35 
 
104 -0.03 -0.07 -0.30 
36 
 
105 -0.10 -0.03 0 
37 
 
106 -0.17 -0.03 0 
38 
 
108 -0.33 -0.13 -0.07 
39 
 
120 0.30 0.10 0.20 
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40 
 
121 0.30 0.20 0.13 
41 
 
125 0.87 0.17 0.17 
42 
 
126 -0.03 -0.03 -0.13 
43 
 
131 0.20 0.23 0.07 
Table 15: Results of the thermal shift assay showing ∆Tm for each 
compound at a final concentration of 1, 10 or 100 µM. Increases in melting 
temperature are indicated in blue. 
 
 
As observed in the preliminary results, ∆Tm, the difference between protein melting 
temperature and the melting temperature upon binding of a ligand, increases most 
significantly for the aryloxyacetic acid analogues.  
 
 
Figure 55: Influence of the alkyl chain length on ∆Tm at a final concentration 
of 1, 10 or 100 µM. 
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∆Tm of nonanoic acid analogue 96 was significantly higher than ∆Tm of propanoic acid 
compound (±)-71 and heptanoic acid analogue 95, which was comparable with the activity 
of those analogues in the CDNB assay. The decrease of ∆Tm for analogue 97 with an even 
longer alkyl chain might be due to the limited aqueous solubility, which decreases with the 
chain length.  
Other than in the CDNB assay, the configuration of the flavonoid seemed to have as 
slightly bigger effect on ∆Tm (Table 15, Entries 3 and 4). 
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3.2.2 Target site identification 
It is important to gain a deeper insight into the interactions between AmGSTF1 and its 
inhibitors. Although the crystal structure of AmGSTF1 has been solved, the ligand binding 
site is unknown. Identification of the binding pocket would allow a structure based design 
and a more targeted optimization of ligands. 
3.2.2.1 Photoaffinity labelling experiments 
As mentioned in Chapter 3.1.4, photoaffinity labelling is an effective method in identifying 
binding sites in proteins. The evaluation of the four synthesised photoaffinity labels in the 
CDNB assay for their ability to inhibit AmGSTF1 (cf. Chapter 3.2.1.1) showed that 
compounds 145 and 160 have very similar activity to that of the parent structure 3, 
indicating that the benzophenone moiety does not affect the binding. Therefore those two 
labels were used for crosslinking experiments.  
 
Figure 56: UV-Absorbance spectra of 145 and 3 (solution in H2O + 2% 
DMSO); Spectra were measured at room temperature. 
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Figure 57: UV-Absorbance spectra of 160 and 3 (solution in H2O + 2% 
DMSO); Spectra were measured at room temperature. 
 
Benzophenones are activated at wavelengths between 350 and 360 nm, a range that 
avoids damage of the target protein.156 UV-Absorbance spectra of the two compounds 
(Figure 56 and Figure 57) illustrate absorbance at higher wavelengths compared to 
compound 3 though maybe not as pronounced as hoped.  
To form a protein ligand-complex AmGSTF1 was incubated with an approximately 10-fold 
molar excess of compound 145 or 160 respectively in PBS-buffer and 1% DMSO for 
10 min on ice. The protein ligand complex was irradiated for 10 or 30 min with either a 
laser (355 nm) or an UV-LED lamp (365 nm) at rt. Control experiments with no label were 
performed to rule out protein damage from the irradiation. Samples were desalted and 
analysed by electrospray ionization on a QTOF instrument. Unfortunately, no proof of 
labelling was observed. The photoaffinity labels only seemed to facilitate decomposition of 
the protein compared to the control experiments. 
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3.2.2.2 Tests for dimer dissociation 
As mentioned in Chapter 1.3.1.1.2, GSTs can act as carrier proteins or ligandins of 
compounds including plant hormones, plant metabolites and flavonoids.71-72 Those 
molecules bind to GSTs in a non-substrate manner at a specific site, the L-site and the 
exact localisation and nature of this site can vary hugely. Recently Ahmad et al. reported 
structural evidence for non-catalytic binding sites in the arapidopsis thaliana GST 
AtGSTF2.76 Two L-sites were identified, one at the periphery of the dimer (L1) and one 
situated at the dimer interface (L2). In the complex of the flavonoid quercetin and 
AtGSTF2, quercetin was found only at the L2 site (Figure 58). This poses the question, of 
whether the flavonoid inhibitors of AmGSTF1 bind in the same manner. As the inhibition 
activity towards AmGSTF1 in the CDNB assay (cf. Chapter 3.2.1.1) increases significantly 
with the alkyl chain length of aryloxyacetic acid analogues ((±)-71, 95, 96, 97, 3 and 97), it 
was speculated that the alkyl chain might be sticking out of a binding pocket and disrupting 
the protein-protein interactions at the dimer interface. As most GSTs are only active as 
dimers, any disruption of the interface could lead to dissociation and this may be the 
mechanism of the observed inhibition. Consequently, experiments were conducted to test 
this theory. 
 
Figure 58: Quercetin-complex with AtGSTF2-dimer, showing location of the 
two binding sites L1 and L2.76 
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3.2.2.2.1 Native Protein Gel 
The simplest and most direct way to test whether the inhibitors are disrupting protein-
protein interactions and causing GST-dimer dissociation was running a native protein gel. 
Proteins are usually separated by polyacrylamide gel electrophoresis (PAGE) under 
denaturing and often reducing conditions in the presence of a detergent like sodium 
dodecyl sulfate (SDS). Consequently, in SDS PAGE, AmGSTF1 is present in its 
monomeric form. SDS shields the respective charge of the proteins and provides all 
proteins with a negative charge, which results in a separation according to the protein 
weight. In native protein gels the mobility of proteins depends on a number of factors in 
addition to molecular weight, including protein shape and charge. Because no detergent is 
present and no denaturing or reducing conditions are applied, the tertiary and quaternary 
structure of proteins is retained.163  
 
Figure 59: Native-PAGE of AmGSTF1 in the  
presence of different concentrations of inhibitor 44. 
 
AmGSTF1 was incubated with two different concentrations of inhibitor 3 (10 and 500 µM) 
and subsequently a native PAGE was performed (Figure 59). At the higher inhibitor 
concentration, the protein band travels faster within the gel, which could be due to dimer 
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dissociation. However, as only very high concentrations of inhibitor showed a positive 
result, further experiments were conducted, looking into a possible dimer dissociation of 
AmGSTF1. 
3.2.2.2.2 Fluorescence anisotropy 
To confirm the dimeric nature of AmGSTF1 in the presence of inhibitor 3, a steady state 
fluorescence anisotropy experiment was performed (Figure 60). Fluorescence anisotropy 
correlates to the rotational diffusion of a macromolecule and therefore to its molecular 
weight. AmGSTF1 was labelled with the fluorophore HiLyte Fluor 488, which was used by 
Fabrini et al.164 to examine the monomer-dimer equilibrium of GSTs in a fluorescence 
anisotropy experiment.  
 
Figure 60: Theory behind the fluorescence anisotropy experiment. 
 
Upon excitation with polarized light the emission of HiLyte Fluor 488-labeled AmGSTF1 is 
also polarized. Anisotropy describes the extent of polarization and its origin is the 
existence of transition moments for absorption and emission, that lie along specific 
directions within the fluorophore. The anisotropy depends on the viscosity of the solvent 
and the size and shape of the molecule, as it depends on the angular displacement 
between absorption and emission of the photon, which is caused by rotational diffusion. 
Hence the anisotropy of the dimer is expected to be higher than for the monomer. Small 
molecules, such as the unbound fluorophore, are fast tumbling and the rate of rotational 
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diffusion is faster than the rate of emission, which is therefore depolarized and the 
anisotropy is close to zero. The maximum anisotropy value that can theoretically be 
observed is 0.4, when there are no depolarization processes and absorption and emission 
dipoles are colinear. 165 The fluorescence anisotropy was measured for two different 
protein concentrations (20 and 100 nm) and four different concentrations of inhibitor 3 (1, 
10, 100 and 200 µM).  
 
Figure 61: Steady-state anisotropy of the HiLyte Fluor 488 emission of 
labelled AmGSTF1 in the presence of different concentrations of inhibitor 3. 
Appropriate controls with buffer only and DMSO only were performed and 
each value is the result of eight replicate measurements. 
 
No appreciable variations in the steady-state anisotropy were found (Figure 61). The 
measured fluorescence anisotropy was not dependent on the inhibitor concentration and 
the expected decrease in anisotropy for the dimer dissociation could not be observed, 
suggesting that no such dissociation is taking place. 
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3.2.2.3 Tests on plants 
The CDNB assay is a relatively quick and easy method to screen a number of compounds, 
but as AmGSTF1 shows only limited GSH conjugation activity and most importantly is 
believed to have important signalling functions promoting MHR, it can only give a first 
indication. The assay cannot reflect the complicated mechanisms in MHR black grass. 
3.2.2.3.1 Maize 
It is well established that GSTs in maize play an important role in protecting the crop from 
phytotoxic effects caused by herbicides.60, 166-167 Herbicide selectivity for weeds versus 
maize can be caused by either a higher constitutive GST expression or an accumulation of 
GSTs following a treatment with herbicide safeners.168-169 One of the two major GST 
enzymes in maize identified to be responsible for herbicide detoxification is the 
constitutively expressed GSTI169, which is now described as ZmGSTF1 due to a new 
classification system.60  
 
Figure 62: Comparison of the ZmGSTF1 and AmGSTF1 crystal structure. 
 
ZmGSTF1 has a 63.4% sequence identity to AmGSTF1 and its crystal structure170 is very 
similar to that of AmGSTF1 (Figure 62).  
ZmGSTF1 
AmGSTF1 
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Because of those properties in maize, it was considered whether synergists might have a 
similar effect on maize and if they could be tested on maize instead of black grass. This 
would simplify the testing, as maize is much easier to germinate and grows faster.  
Previous tests on black grass had been conducted using a Potter Precision spray tower, a 
chemical spraying apparatus, to achieve some reproducibility. The spray tower was 
increased in height by 10 cm to accommodate a plant instead of a petri dish, which it was 
built for (Figure 63). Measuring the collected volume following spraying of a known start 
volume allowed to calculate an approximate field rate in l/ha (Figure 63). It is, however, 
difficult to translate this into an actual field rate and to know how much of the solution is 
hitting the plant. It was deemed more appropriate to describe the dosage in terms of 
standard measurements such as concentration of active ingredient and volume of 
formulation.  
  
Figure 63: Calculated approximate field rate using the spray tower at 15 psi 
and modified Potter spray tower. 
 
Before any synergists could be tested, experiments focused on finding an appropriate 
herbicide concentration, which would not kill the plant. The herbicides were formulated as 
an emulsion using 2 % DMSO, and 0.5 % Agridex, a non-ionic surfactant, in H2O. Multiple 
concentrations of the herbicides mesotrione 163 (7.8125 µM to 500 µM), nicosulfuron 164 
(15.625 µM to 1 mM), chlortoluron 165 (31.25 µM to 1 mM), pinoxaden 166 (31.25 µM to 
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1 mM) and clodinafop-propargyl 167 (31.25 µM to 1 mM) were sprayed on maize (Figure 
64 to Figure 68). Mesotrione 163 and nicosulforon 164 are used to control weeds in maize 
fields and chlortoluron 165, pinoxaden 166 and clodinafop-propargyl 167 are herbicides 
MHR black grass is resistant to and have previously been used for synergist tests on black 
grass. The plants were sprayed 7 days after planting and 20 ml of every solution was 
used. Appropriate controls including untreated plants and formulation only were included. 
Pictures were taken 7 days after the treatment.  
 
Mesotrione 
Figure 64: U: Untreated; F: Formulation only; M: Mesotrione; 1: 7.8125 µM; 2: 
15.625 µM; 3:  31.25 µM; 4: 62.5 µM; 5: 125 µM; 6: 250 µM; 7: 500 µM; 
 
Nicosulfuron 
Figure 65: U: Untreated; F: Formulation only; N: Nicosulfuron; 1: 15.625 µM; 
2: 31.25 µM; 3: 62.5 µM; 4: 125 µM; 5: 250 µM; 6: 500 µM; 7: 1 mM; 
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Chlortoluron 
Figure 66: U: Untreated; F: Formulation only; Ch: Chlortoluron; 1: 31.25 µM; 
2: 62.5 µM; 3: 125 µM; 4: 250 µM; 5: 500 µM; 6: 1 mM; 
 
Pinoxaden 
Figure 67: U: Untreated; F: Formulation only; P: Pinoxaden; 1: 31.25 µM; 2: 
62.5 µM; 3: 125 µM; 4: 250 µM; 5: 500 µM; 6: 1 mM; 
 
Clodinafop-propargyl 
Figure 68: U: Untreated; F: Formulation only; C: Clodinafop-propargyl; 1: 
31.25 µM; 2: 62.5 µM; 3: 125 µM; 4: 250 µM; 5: 500 µM; 6: 1 mM; 
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In order to see if DMSO alone could have an impact on the plant, different concentrations 
of DMSO were sprayed on maize (1 to 20%, Figure 69), but no effect could be observed. 
Figure 69: U: Untreated; % DMSO in H2O. 
 
As for mesotrione 163 (Figure 64) and nicosulfuron 164 (Figure 65) only high herbicide 
concentrations led to stunted growth and discolouration in the case of mesotrione 163, 
concentrations of 30 µM and 250 µM were picked for further experiments. Concentrations 
of 30 µM and 60 µM were chosen for chlortoluron 165 (Figure 66) and because pinoxaden 
166 (Figure 67) and clodinafop-propargyl 167 (Figure 68) showed effects on the plant at 
much lower concentrations, concentrations of 7.5 µM and 15 µM were selected for the 
spray trials. 
Having optimised the herbicide concentrations, synergism spray trials were carried out 
with flavonoid 3 and CNBF 1. The synergists were formulated identically to the herbicides 
at a 2 mM concentration. 20 ml of the synergist or formulation only emulsion were sprayed 
on the plant 7 days after planting. 24 h later either a herbicide solution or a formulation 
only control was applied. The plants were assessed 7 days after the treatment and again 
appropriate controls were carried out. 
            U         1%       2%        5%       10%     15%   20% 
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Mesotrione 
Figure 70: U: Untreated; F: Formulation only; M1: 30 µM Mesotrione; M2: 
250 µM Mesotrione; 3: 2 mM synergist; 1: 2 mM synergist; 
 
Nicosulfuron 
Figure 71: U: Untreated; F: Formulation only; M1: 30 µM Nicosulfuron; M2: 
250 µM Nicosulfuron; 3: 2 mM synergist; 1: 2 mM synergist.  
  U          F+F      1+F    F+M1    1+M1    F+M2       1+M2 
   U       F+F      3+F      F+M1   3+M1     F+M2      3+M2 
  U            F+F        1+F       F+N1     1+N1     F+N2       1+N2 
  U            F+F      3+F      F+N1       3+N1     F+N2     3+N2 
A 
B 
A 
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Figure 72: U: Untreated; F: Formulation only; 1: 31.25 µM; 2: 62.5 µM; 3: 
125 µM; 4: 250 µM; 5: 500 µM; 6: 1 mM; 7: 2 mM; 
 
Because the 2 mM solution of CNBF 1 caused the maize leaves to bend down and their 
tips to eventually die in the spray trials with mesotrione 163 (Figure 70, A) and nicosulfuron 
164 (Figure 71, A), different concentrations of CNBF 1 were assessed for their effects on 
maize (Figure 72). The concentration was reduced to 1 mM for the next experiments. 
 Chlortoluron 
Figure 73: U: Untreated; F: Formulation only; CH1: 30 µM Chlortoluron; CH2: 
60 µM Chlortoluron; 3: 2 mM synergist; 1: 1 mM synergist;  
 U       F       1        2       3        4        5          6          7 
    U      F+F    1+F  F+CH1 1+CH1  F+CH2     1+CH2 
     U        F+F    3+F     F+CH1  3+CH1  F+CH2  3+CH2 
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Pinoxaden 
Figure 74: U: Untreated; F: Formulation only; P1: 7.5 µM Pinoxaden; P2: 
15 µM Pinoxaden; 3: 2 mM synergist; 1: 1 mM synergist;  
 
Clodinafop-propargyl 
Figure 75: U: Untreated; F: Formulation only; C1: 7.5 µM Clodinafop-
propargyl; C2: 15 µM Clodinafop-propargyl; 3: 2 mM synergist; 1: 1 mM 
synergist;  
       U        F+F       1+F   F+P1     1+P1    F+P2      1+P2 
     U        F+F    3+F      F+P1     3+P1   F+P2     3+P2 
     U        F+F       1+F      F+C1    1+C1    F+C2    1+C2 
     U       F+F    3+F        F+C1  3+C1      F+C2    3+C2 
A 
B 
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However, no synergistic effects could be observed for either flavonoid 3 or CNBF 1 with 
any of the herbicides used (Figure 70, Figure 71 and Figure 73 to Figure 75). 
Consequently, potential synergists were tested on black grass. 
3.2.2.3.2 Black Grass 
In order to evaluate their ability to act in synergism with the herbicide pinoxaden 166, a 
number of compounds were tested directly on black grass.  
Pinoxaden 166 is a selective post emergence herbicide, that inhibits the enzyme Acetyl-
CoA-Carboxylase. It was developed to control annual grass weeds, including black grass, 
in cereal crops.171 In order to determine the lethal pinoxaden 166 dose in WT black grass, 
different concentrations of pinoxaden 166, ranging from 12.5 µM to 10 mM, were applied 
to the plant (Figure 76). 
 
 
 
  U     F      12.5 µM 166        25 µM 166 
      50 µM 166      100 µM 166      250 µM 166      500 µM 166 
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Figure 76: Determination of a lethal pinoxaden 166 dose in WT black grass;  
U: Untreated, F: Formulation; 
 
The herbicide was formulated as an emulsion in water, using 5 % acetone and 0.5 % 
Adigor, which is a methylated rapeseed oil based adjuvant. Five 2 µl drops of the emulsion 
were applied with a micropipette 14 days after germination at the two leaf stage. This form 
of application, rather than spraying the plants using the spray tower, was chosen because 
of the easy reproducibility and the much lower amount of synergist that is needed.  
For comparison one plant was left untreated and one was treated with formulation only. All 
experiments were done in duplicate and plants were assessed 21 days after the treatment.  
  
      750 µM 166       1 mM 166       1.5 mM 166        2 mM 166 
       3 mM 166       4 mM 166         5 mM 166       10 mM 166 
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As even the lowest concentration of 12.5 µM proved to be lethal, another set of 
experiments was designed, this time also taking the formulation parameters into account 
(Figure 77). 
 
Figure 77: Set of experiments to determine a lethal pinoxaden dose in WT 
black grass; each dot represents an experiment; Ad: Adigor, Ac: Acetone,  
P: Pinoxaden 166;  
 
The concentration of pinoxaden ranged from 0.5 µM to 30 µM, using the same formulation 
parameters as before. Additionally, the percentage of Adigor and acetone were varied for 
5 µM, 10 µM and 15 µM pinoxaden.  
No big differences were observed, comparing the WT black grass plants treated with 
different formulations to untreated WT black grass (Figure 78) after a period of 21 days.  
10 µM (Figure 80) and 15 µM (Figure 81) pinoxaden 166 proved to be lethal for WT black 
grass regardless of the formulation used. For 5 µM pinoxaden (Figure 79), however, some 
plants seemed to survive the treatment for formulations F1, F3, F5 and F7. Stunted growth 
was observed but not all of the plants died. With formulation F9 5 µM pinoxaden was a 
lethal dose for all three plants. Further reduction of the pinoxaden concentration to 1 µM 
and 0.5 µM proved to be not lethal (Figure 82). 
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Figure 78: Comparison of WT black grass treated with different formulations  
(F1 – F9) to untreated WT black grass (U); Ad: Adigor, Ac: Acetone; 
 
  
     F1 (1% Ac, 0.1% Ad)         F2 (3% Ac, 0.1% Ad)           F3 (5% Ac, 0.1% Ad) 
U 
     F4 (1% Ac, 0.3% Ad)         F5 (3% Ac, 0.3% Ad)           F6 (5% Ac, 0.3% Ad) 
     F7 (1% Ac, 0.5% Ad)         F8 (3% Ac, 0.5% Ad)           F9 (5% Ac, 0.5% Ad) 
  Results and Discussion 
  139 
 
 
 
 
Figure 79: Comparison of different formulations for the treatment of WT 
black grass (F1, F3, F5, F7, F9) with a 5 µM pinoxaden 166 concentration; 
 
 
 
 
Figure 80: Comparison of different formulations for the treatment of WT 
black grass (F2, F4, F5, F6, F8) with a 10 µM pinoxaden 166 concentration; 
  
5 µM 166 (F1)     5 µM 166 (F3)      5 µM 166 (F5) 
5 µM 166 (F7)     5 µM 166 (F9)  
         10 µM 166 (F2)    10 µM 166 (F4)      10 µM 166 (F5) 
          10 µM 166 (F6)   10 µM 166 (F8) 
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Figure 81: Comparison of different formulations for the treatment of WT 
black grass (F1, F3, F5, F7, F9) with a 15 µM pinoxaden 166 concentration; 
 
 
 
 
Figure 82: Determination of a lethal pinoxaden 166 dose in WT black grass;  
F9 (5% Ac, 0.5% Ad); 
 
  
          15 µM 166 (F1)   15 µM 166 (F3)     15 µM 166 (F5) 
          15 µM 166 (F7)   15 µM 166 (F9) 
         0.5 µM 166 (F9)    1 µM 166 (F9)       5 µM 166 (F9) 
         10 µM 166 (F9)    15 µM 166 (F9)      30 µM 166 (F9) 
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To test the ability of compounds to act in synergism with pinoxaden 166 on MHR black 
grass, seven inhibitors were selected for trials. Compound 16 was chosen in order to have 
a comparison to the other compounds and see the effects of structural changes. To find 
out if the alkyl chain length of the substituent in the 5-position has an impact on the 
synergistic effect, analogues (±)-71, 95 and 3 were picked. Compound 125 was selected 
to see if the SO2Me-group might have an effect on plant uptake and show different results 
compared to compound 3. Both tetrazole 101 and thiazole 102 were selected for their 
better physicochemical properties compared to 16.  
As 5 µM pinoxaden 166 was the lowest lethal dose for WT black grass and it showed 
consistent results with formulation F9, this herbicide formulation was chosen for the tests 
on MHR black grass. Additionally, experiments were carried out using 15 µM pinoxaden 
166 with formulation F9. The synergists were formulated identically at a 2 mM 
concentration. Compound 102 was additionally tested at a 6 mM, 0.6 mM and 0.2 mM 
concentration. Appropriate controls were carried out, including untreated plants, 
formulation only and herbicide only for WT black grass (Figure 83) and MHR black grass 
(Figure 84). In all cases 10 µl of the emulsion/suspension were applied with a micropipette. 
The black grass plants were treated 14 days post emergence with either a synergist or a 
formulation only control. 24 h later either a herbicide solution or a formulation only control 
was applied. The synergistic effect and consequently herbicide damage on the plant was 
rated from no damage (N) to low damage (L), medium damage (M) and high damage (H). 
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As expected, a dose of 5 or 15 µM pinoxaden 166 was lethal for WT black grass (Figure 
83), but not MHR black grass (Figure 84). 
WT Black Grass  
 
 
Figure 83: Effects of pinoxaden 166 on WT black grass; U: Untreated,  
F: Formulation; 
 
MHR Black Grass 
 
 
Figure 84: Effects of pinoxaden 166 on MHR black grass; U: Untreated,  
F: Formulation; 
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Dimethoxychromenone 16 was not effective at synergising the effects of pinoxaden 166 in 
MHR black grass (Figure 85, A), which is consistent with the lower inhibition activity in the 
CDNB assay. A clear relationship between synergising activity and alkyl chain length of 
the substituent in the 5-position could be observed. Compound (±)-71 was inactive (Figure 
85, B), but compounds 95 (Figure 85, C) and 3 (Figure 85 ,D) showed some synergising 
effect in combination with a 15 µM pinoxaden 166 solution, though not big enough to kill 
the plant. The same is true for compound 125 (Figure 85, E). Compound 95 (Figure 85, C) 
also enhanced the effects of pinoxaden 166 at a 5 µM concentration, which might be 
explained with a slightly better solubility and uptake compared to 3 due to the shorter 
chain. Tetrazole 101 showed some synergising effect, especially in combination with a 
15 µM pinoxaden 166 solution (Figure 85, F). The plants were not killed, but stunted 
growth was observed. Thiazole 102 enhanced the effects of pinoxaden 166 significantly 
(Figure 85, G-1). All the plants died, when 2 mM 102 was used in combination with a 
15 µM pinoxaden 166 solution and the plants showed at least severely stunted growth 
when 2 mM 102 was used in combination with a 5 µM pinoxaden 166 solution. At a 0.6 
mM concentration 102 still showed some synergising effect in combination with a 15 µM 
pinoxaden 166 solution, but for the lower concentration no effect was apparent (Figure 85, 
G-2). The higher activity on plants compared to 16 for both 101, which shows a slightly 
lower inhibition activity in the CDNB assay than 16, and 102, which shows a slightly higher 
inhibition activity, can probably be explained by better solubility and uptake. Pleasingly 
none of the synergists caused damage to the plant, if applied alone, which allows to rule 
out inherent toxicity. 
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Figure 85: Synergising effects of compounds 16, (±)-71, 95, 3, 125, 101 and 
102 on MHR black grass treated with pinoxaden 166; F: Formulation; Rating 
from no damage (N) to low damage (L), medium damage (M) and high 
damage (H). 
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4  Conclusion and Future Work 
4.1 Binding site identification 
Although photoaffinity labels, which maintained inhibition activity towards AmGSTF1 in the 
CDNB assay, were successfully synthesized, no proof of labeling could be observed in the 
irradiation experiments.  
Future work should focus on the incorporation of alternative photoreactive groups. 
Especially flavonoid derivatives featuring a aryldiazarine, the most commonly used 
photoaffinity group, may offer a promising alternative, as diazarines are much easier 
activated than benzophenones. 
Alternatively, obtaining a crystal structure of the protein-ligand complex through 
cocrystallization or soaking techniques could be a possible way to gain a better 
understanding of the protein ligand interactions between the flavonoid inhibitors and 
AmGSTF1, informing a more targeted optimization of the inhibitors. 
A preliminary steady state fluorescence anisotropy experiment did not confirm the initial 
theory, that the inhibitors are disrupting protein-protein interactions and causing GST-
dimer dissociation. 
4.2 Synergist development 
A library of 44 flavonoid analogues was synthesised, focusing on different substituents in 
the 2-position and modifications of the long alkyl chain. Each analogue was screened for 
its ability to inhibit AmGSTF1 in a CDNB assay, which led to a number of interesting SAR 
discoveries summarised below (Figure 86). 
  Conclusion and Future Work 
  147 
A variety of alternative 2-substituents including amides, cyclic amines and a variety of 
arenes were introduced from the corresponding acid 41, thioether 8 and chloride 21. 
Whilst a broad range of substituents could be tolerated at C-2, higher activity appeared to 
reside in aromatic substituents. The high tolerance to structural changes suggests that the 
flavonoids might not bind to AmGSTF1 in a tight binding pocket 
A series of derivatives bearing a long alkyl chain with an a-carboxylate group in the 
5-position were successfully prepared using the iron promoted ene reaction between 
glyoxalate and the appropriate terminal alkene as a key step. Activity increased with 
increasing chain length, from an inhibition of only 14% ±3% at a 10 µM level for the 
propanoic acid analogue (±)-71 to 75% ±3% inhibition at a 1 µM level for the tetradecanoic 
acid analogue 98, plateauing at lengths beyond 10 carbons. Reduction of flexibility through 
incorporation of an amide in the chain was not advantageous.  
 
 
 
 
 
 
 
Figure 86: Summary of SARs. 
 
A particular emphasis was put on increasing the aqueous solubility, as the synergist has to 
reach the target site in the plant in order to be effective, intrinsic potency is not sufficient. 
Four different strategies were explored: replacing the long alkyl chain with comparably 
sized and equally flexible but more soluble PEG unit, introducing substituents to change 
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the overall planar structure of the molecule, incorporating an SO2Me-substituent, which 
can lower the lipophilicity of a compound and exploring more polar heteroaromatic nuclei 
at the 2-position. Whilst the former three strategies were not successful, replacing the 
phenyl group of 5,7-dimethoxy-2-phenyl-chromen-4-one 16 with heteroarenes improved 
the aqueous solubility. Oxadiazole 99, oxazole 100, terazole 101 and thiazole 102 were 
generated following conventional heterocycle synthesis strategies starting from acid 41. 
Pyridazine 108 could be obtained by cross-coupling with the boronate ester generated in 
one pot by Ir-catalysed C-H borylation and pyrazole 104 could be accessed via the 
corresponding hydroxychalcone. All heteroarenes showed a comparable inhibition of 
AmGSTF1 in the CDNB assay (53-83% at 100µM) in comparison to the phenyl analogue 
16 (70% ±12% at 100µM). Initial testing of these compounds for aqueous solubility 
revealed that most of the heterocycles showed enhancements relative to the parent phenyl 
compound, but thiazole 102 was dramatically more soluble.  
 
 
Figure 87: Synergising effects of thiazole 102 on MHR black grass treated 
with pinoxaden 166; F: Formulation; 
 
Even though the potency of the initial lead molecule in the CDNB assay could not be 
increased, analogues with improved physicochemical properties were obtained, which is 
crucial for the application on plants. In plant experiments with black grass, 102 acted as a 
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synergist to the herbicide pinoxaden 166 (Figure 87) and exhibited better results than 
other analogues, with higher activity in the CDNB assay, which might be associated with 
the better physicochemical properties.  
4.2.1 Testing of synergists 
As the tests directly on black grass showed, biochemical activity does not necessarily 
translate to efficacy in the plant. With the role of AmGSTF1 in black grass not yet 
completely understood, judging the relevance of the CDNB assay is difficult and as is 
designing a new assay with more relevance to assess synergists. Although the thermal 
shift assay offers an orthogonal method to the CDNB assay, the same problems persist. 
This makes evaluation of new synergists challenging, as black grass experiments cannot 
be used for high throughput screening. 
4.2.2 Synergist selectivity 
For future applications of the synergists it was important to test whether the synergists 
selectively inhibit AmGSTF1 over other GSTs and whether the activity profile differs. 
Therefore, a preliminary experiment was conducted and a couple of compounds were 
tested for their inhibition of AtGSTF8 in the CDNB assay. AtGSTF8 is a phi-class GST in 
Arabidopsis thaliana.172 It was selected because of its relatively high CDNB conjugating 
activity, its accessibility and because it originates from the same GST class as AmGSTF1. 
The AtGSTF8 construct was provided by Robert Edwards (Newcastle University) and 
overexpression and purification of the protein was conducted by Becky Eno (Durham 
University). 
Four different inhibitors were selected for tests. Dimethoxychromenone 16 was chosen as 
a simple flavonoid whose inhibition towards AmGSTF1 is not very high. The 
aryloxytetradecanoic acid analogue 98 was selected as it showed the highest inhibition 
towards AmGSTF1 out of all synergists and compound (±)-71 was picked to see if the alkyl 
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chain length of the substituent in the 5-position had a similar effect on the activity towards 
AtGSTF8. Thiazole 102 was included because of its remarkable synergistic effects in black 
grass.  
The inhibition of dimethoxychromenone 16 towards AtGSTF8 is similar to the one towards 
AmGSTF1 in the CDNB assay at a 10 µM level (Figure 88). Compound (±)-71 with 
a-substituted propanoic acid showed a higher inhibition towards AmGSTF1 and the 
aryloxytetradecanoic acid analogue 98 is significantly more active towards AmGSTF1. 
Thiazole 102, however, showed a higher inhibition activity towards AtGSTF8 compared to 
AmGSTF1. This high inhibition activity towards other GSTs could potentially be 
problematic in future applications, because it could lead to undesirable effects in other 
plants. 
 
Figure 88: A Inhibition of AtGSTF8 compared to AmGSTF1 at 10 µM in a 
CDNB assay; Experiments are conducted in triplicate. 
 
As the substitution with a-substituted acids in the 5-position could establish a selectivity for 
AmGSTF1 over AtGSTF8 for the phenyl analogue, 5-substituted thiazole 168 was 
synthesised (Scheme 71) and tested. 
-10%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
16 (±)-71 95 102
In
hi
bi
tio
n 
[%
]
Selectivity (10 µM)
AtGSTF8
AmGSTF1
  Conclusion and Future Work 
  151 
 
 
Scheme 71: Synthesis of analogue 168. 
 
Pleasingly 168 showed a higher inhibition activity towards AmGSTF1 compared to 
AtGSTF8 (Figure 89, A). The inhibition is also comparable to the corresponding phenyl 
analogue 3 (Figure 89, B). 
 
Figure 89: A Inhibition of AtGSTF8 compared to AmGSTF1 by compounds 
102 and 168 at 10 µM in a CDNB assay; B Inhibition of AmGSTF1 by 
compounds 3 and 168 at 10 and 1 µM in a CDNB assay; Experiments are 
conducted in triplicate. 
 
In order to investigate the synergistic effects of 168, the compound needs to be tested 
directly on black grass in the future. Modifications to further improve the physicochemical 
properties might be necessary. 
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5  Experimental Part 
5.1 Chemical Synthesis 
5.1.1 General Notes 
Chemicals: All chemicals were purchased from commercial suppliers and were used 
without further purification unless otherwise stated. 
Dry Solvents: 1,2-Dichloroethane and methyl-tert-butyl-ether (MTBE) were purchased 
anhydrous from Sigma Aldrich or Acros respectively. All other dry reaction solvents were 
dried using an Innovative Technology Solvent Purification System and stored under argon. 
Column chromatography: Flash column chromatography was performed on a 
CombiFlash® System from Teledyne Isco equipped with an UV-light detector using 
prepacked silica RediSep Rf cartridges with the stated solvent gradient. Crude mixtures to 
be purified were dry loaded onto silica prior to loading on the column. 
LC-MS: Purity of all final compounds was checked by LC-MS. LC-MS analyses were 
conducted on a TQD mass spectrometer (Waters Ltd, UK), which was equipped with an 
Acquity UPLC, using an Acquity UPLC BEH C18 (2.1 mm × 50 mm, 1.7 µm) column, and 
an electrospray ion source. Absorbance data were acquired from 210 to 400 nm using an 
Acquity photodiode array detector.  
GC-MS: GC-MS analyses were performed on a Shimadzu QP2010-Ultra using electron 
ionization (EI). The mass spectrometer was equipped with either an Rxi-5Sil MS column 
(0.15 µm × 10 m × o.15 mm) for non-polar compounds or an Rxi-17Sil MS column 
(0.15 µm × 10 m × o.15 mm) for polar compounds. 
ASAP: ASAP measurements were performed on a LCT Premier XE mass spectrometer 
and ASAP ion source. 
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Chiral HPLC-analysis: Chiral analyses were conducted on a PerkinElmer Series 200 
HPLC equipped with a diode array detector analysing at 254 nm, using a Daicel Chiralpak 
IA column (250 × 4.6 mm, 5 μm) or a Chiralpak ID-3 column (250 × 4.6 mm, 3 μm). 
Chiral separation: Chiral separation was performed on a Waters 2525 preparative HPLC, 
equipped with a 2767 sample manager and a Waters 2996 UV detector PhotoArray 
fraction manager, using a Daicel Chiralpak IC column (250 × 21 mm, 5 μm). 
HRMS: HRMS measurements were carried out on a QToF Premier mass spectrometer 
(Waters Ltd, UK) with an electrospray ion source or a LCT Premier XE mass spectrometer 
with an ASAP ion source. 
IR spectroscopy: Infrared (IR) spectra were recorded on a Perkin-Elmer RX I FT-IR 
spectrometer via use of a Pike ATR accessory in the range of 3500 – 600 cm-1. Assigned 
peaks are reported in wavenumbers (cm-1). 
Melting points: Melting points were measured in open capillary tubes using a Thermo 
Scientific™ Melting Point Apparatus and are uncorrected. 
Microwave: Microwave reactions were performed in septum-containing, crimp capped, 
sealed vials in a EmrysTM Optimizer microwave unit from Personal Chemistry. The 
reported times are hold times. 
NMR-spectroscopy: NMR-spectra were recorded in CDCl3, d6-DMSO, CD3OD or D2O 
solutions on a Bruker Advance-400 (1H, 13C, 19F, DEPT, COSY), Varian Inova-600 (1H, 
13C, 19F, HSQC, HMBC, COSY, NOESY) or Varian VNMRS-700 (1H, 13C, 19F, HSQC, 
HMBC, COSY, NOESY) spectrometer, using the solvent peak (CDCl3: δ = 7.26 ppm (1H), 
δ = 77.16 ppm (13C), d6-DMSO: δ = 2.50 ppm (1H), δ = 39.52 ppm (13C) CD3OD: δ = 3.31 
ppm (1H), δ = 49.00 ppm (13C), D2O: δ = 4.79 ppm (1H)) as reference. For some spectra 
tetramethylsilane (TMS) was used as an internal standard. 13C spectra were run in proton-
decoupled mode. Chemical shift values (δ) are reported in parts per million (ppm) and 
coupling constants (J) are given in Hertz (Hz). The multiplicity is indicated by singlet (s), 
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doublet (d), triplet (t), quartet (q), multiplet (m), broad (br) or a combination thereof. 
Assignment of spectra was carried out using 2D HSQC, HMBC, COSY and NOESY 
techniques. 
Optical Rotation: Measurements were performed on an AA-10 polarimeter from Optical 
Activity Ltd. and are stated alongside temperature, solvent and concentration in mg ml-1. 
TLC: TLC analyses were performed on pre-coated aluminium-backed plates (Silica gel 60 
F254, Merck). Signals were visualized with UV-light (254 nm and 365 nm) or by staining 
with potassium permanganate in water where necessary. 
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5.1.2 Variations of the substituent in the 2-position 
5.1.2.1 Synthesis of 2-amino-5,7-dimethoxy-4H-chromen-4-ones 
5,7-Dimethoxy-2-methylthio-4H-chromen-4-one 8 
 
n-BuLi (15.1 ml of a 2.5 M solution in hexane, 37.8 mmol, 3.15 eq) was added dropwise 
over 30 min to a solution of 1,1,1,3,3,3-hexamethyldisilazane (8.25 ml, 39.6 mmol, 3.3 eq) 
in dry THF (30 ml) under an argon atmosphere at -78 °C. After 10 min the mixture was 
allowed to warm to 0 °C and stirred for another 10 min. The reaction mixture was recooled 
to -78°C and a solution of 2-hydroxy-4,6-dimethoxyacetophenone (2.36 g, 12 mmol, 1 eq) 
in dry THF (9 ml) added dropwise. After stirring for 30 min, CS2 (1.08 ml, 18 mmol, 1.5 eq) 
was added in one portion and the reaction mixture allowed to warm to 0°C. After 1 h MeI 
(1.65 ml, 26.4 mmol, 2.2 eq) was added dropwise over 10 min and stirring continued for 
another 1 h at rt. 10 N KOH (6 ml) was added and the reaction mixture heated under reflux 
for 1 h. Then H2O (20 ml) was added and THF removed under reduced pressure. DCM 
(20 ml) was added to dissolve the precipitated product and the reaction mixture extracted 
with DCM (3 × 10 ml). The combined organic layers were dried over Mg2SO4 and 
concentrated. Recrystallization from THF then afforded the title chromenone (2.11 g, 70%) 
as a pale orange solid. 
m.p.: 189 - 191 °C; nmax (ATR): 1621 (C=O), 1585, 1427, 1319, 1304, 1154, 1126, 1106, 
1064, 917, 831, 821 cm-1; δH (d6-DMSO, 400 MHz): 6.65 (d, J = 2.3 Hz, 1H, 8-H), 6.48 (d, 
J = 2.3 Hz, 1H, 6-H), 6.00 (s, 1H, 3-H), 3.85 (s, 3H, OCH3), 3.80 (s, 3H, OCH3), 2.53 (s, 
3H, SCH3); δC (d6-DMSO, 100 MHz): 173.1 (C-4), 166.3 (C-2), 163.5 (C-7), 160.3 (C-5), 
OMeO
OMe
S
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159.5 (C-8a), 108.1 (C-3), 107.6 (C-4a), 96.3 (C-6), 92.9 (C-8), 56.1 (OCH3), 56.0 (OCH3), 
13.3 (SCH3); HRMS (ES+) found [M+H]+ 253.0537, C12H12O4S requires M 253.0535. 
 
5,7-Dimethoxy-2-(4’-methylpiperazin-1’-yl)-4H-chromen-4-one 9 
 
A round bottom flask was charged with 5,7-dimethoxy-2-methylthio-4H-4-chromenone 8 
(130 mg, 0.5 mmol, 1 eq), N-methyl-piperazine (0.55 ml, 5 mmol, 10 eq) and ethylene 
glycol (5 ml). The reaction mixture was heated to 160 °C and stirred for 3 h. After cooling 
to rt, H2O (5 ml) was added and the reaction mixture extracted with DCM (3 × 2 ml). The 
combined organic layers were washed with H2O (1.5 ml) and dried over Na2SO4 and 
concentrated under reduced pressure. Flash column chromatography (12 g silica gel, 
DCM:MeOH 50:1 - 9:1) yielded the title amine (39 mg, 25%) as a colourless solid. 
m.p.:  71 – 73 °C; nmax (ATR): 1634 (C=O), 1589, 1558, 1412, 1247, 1162, 1110, 1000, 
808 cm-1; δH (CDCl3, 400 MHz): 6.33 (d, J = 2.3 Hz, 1H, 8-H), 6.32 (d, J = 2.3 Hz, 1H, 6-H), 
5.33 (s, 1H, 3-H), 3.91 (s, 3H, OCH3), 3.84 (s, 3H, OCH3), 3.45 (t, J = 5.2 Hz, 4H, CH2), 
2.50 (t, J = 5.2 Hz, 4H, CH2), 2.34 (s, 3H, CH3); δC (CDCl3, 100 MHz): 177.7 (C-4), 163.0 
(C-2), 161.3 (C-7), 160.7 (C-5), 157.5 (C-8a), 107.6 (C-4a), 95.9 (C-6), 92.5 (C-8), 88.6 (C-
3), 56.5 (OCH3), 55.7 (OCH3), 54.2 (CH2), 46.2 (NCH3), 44.7 (CH2); HRMS (ES+) found 
[M+H]+ 305.1516, C16H20N2O4 requires M 305.1501. 
General Procedure A 
5,7-Dimethoxy-2-methylthio-4H-chromen-4-one 8 (1.009 g, 4 mmol, 1 eq) was suspended 
in DCM (28 ml). Meta-chloroperoxybenzoic acid (75%, 2.945 g, 12.8 mmol, 3.2 eq) was 
slowly added at 0 °C and the reaction mixture heated to 35 °C and stirred for 5.5 h. H2O 
OMeO
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N
O
N
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(16 ml) was added and the reaction mixture extracted with DCM (4 × 15 ml). The 
combined organic layers were washed consecutively with saturated (sat.) aqueous 
Na2S2O5 (15 ml), sat. aqueous NaHCO3 (2 × 15 ml) and sat. aqueous NH4Cl (15 ml), dried 
over Na2SO4 and concentrated. A fraction of the crude 5,7-dimethoxy-2-(methylsulfonyl)-
4H-chromen-4-one (1/8, 96 mg) was mixed with the amine (3.4 mmol) in DCM and stirred 
at rt or under reflux respectively. 
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5,7-Dimethoxy-2-morpholino-4H-chromen-4-one 12 
 
5,7-Dimethoxy-2-morpholino-4H-chromen-4-one 12 was synthesised according to General 
procedure A, using morpholine (296 mg) and stirring for 20 h at rt followed by 26 h heating 
under reflux. The crude reaction mixture was concentrated and purified by flash column 
chromatography (12 g silica gel, DCM:MeOH 97:3 - 19:1), which afforded the title product 
(47 mg, 32%) as a colourless solid. 
 
m.p.: 165 - 168 °C; nmax (ATR): 1634 (C=O), 1593, 1558, 1242, 1242, 1108, 810 cm-1; δH 
(CDCl3, 400 MHz): 6.36 - 6.30 (m, 2H, 6-H, 8-H), 5.33 (s, 1H, 3-H), 3.92 (s, 3H, OCH3), 
3.85 (s, 3H, OCH3), 3.80 (t, J = 5.0 Hz, 4H, 3’-H2, 5’-H2), 3.40 (t, J = 5.0 Hz, 4H, 2’-H2, 6’-
H2); δC (CDCl3, 100 MHz): 177.6 (C-4), 163.1 (C-7), 161.4 (C-2), 160.8 (C-5), 157.5 (C-8a), 
107.7 (C-4a), 96.0 (C-6), 92.5 (C-8), 88.8 (C-3), 66.1 (C-3’, C-5’), 56.6 (OCH3), 55.7 
(OCH3), 44.9 (C-2’, C-6’); HRMS (ES+) found [M+H]+ 292.1186, C15H17NO5 requires M 
292.1185. 
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5,7-Dimethoxy-2-(piperidin-1-yl)-4H-chromen-4-one 13 
 
5,7-Dimethoxy-2-(piperidin-1-yl)-4H-chromen-4-one 13 was synthesised according to 
General procedure A, using piperidine (290 mg) and stirring for 20 h at rt. The crude 
reaction mixture was concentrated and EtOAc (20 ml) added. The organic layer was 
washed with sat. aqueous NaHCO3 (2 × 15 ml) and the reaction mixture was concentrated 
again. Flash column chromatography (12 g silica gel, DCM:MeOH 97:3 - 19:1) yielded the 
title amine (72 mg, 50%) as a colourless solid. 
 
m.p.: 79 - 81 °C; nmax (ATR): 1627 (C=O), 1595, 1556, 1397, 1245, 1202, 1159, 1140, 
1117, 807, 744, 742 cm-1; δH (CDCl3, 400 MHz): 6.34 (d, J = 2.3 Hz, 1H, 8-H), 6.32 (d, J = 
2.3 Hz, 1H, 6-H), 5.37 (s, 1H, 3-H), 3.91 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.45 - 3.38 (m, 
4H, 2’-H2, 6’-H2), 1.70 - 1.61 (m, 6H, 3’-H2, 4’-H2, 5’-H2); δC (CDCl3, 100 MHz): 177.6 (C-4), 
162.9 (C-7), 161.2 (C-2), 160.7 (C-5), 157.5 (C-8a), 107.5 (C-4a), 95.8 (C-6), 92.5 (C8), 
88.1 (C-3), 56.6 (OCH3), 55.7 (OCH3), 46.0 (C-2’, C-6’), 25.3 (C-3’, C-5’), 24.3 (C-4’); 
HRMS (ES+) found [M+H]+ 290.1377, C16H19NO4 requires M 290.1392. 
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2-(3’-Hydroxypropylamino)-5,7-dimethoxy-4H-chromen-4-one 14 
 
2-(3’-Hydroxypropylamino)-5,7-dimethoxy-4H-chromen-4-one 14 was synthesised 
according to General procedure A, using 3-aminopropan-1-ol (290 mg) and stirring for 20 h 
at rt. The crude reaction mixture was concentrated, H2O (20 ml) added, and the precipitate 
collected by filtration. The aqueous layer was extracted with DCM (4 × 15 ml), the 
combined organic layers were dried over Na2SO4 and the extracts were combined with the 
precipitated product. The reaction mixture was concentrated and purified by flash column 
chromatography (12 g silica gel, DCM:MeOH 9:1), which yielded the title product (47 mg, 
33%) as a colourless solid. 
 
m.p.: 143 - 146 °C; nmax (ATR): 3380, 3196, 1640 (C=O), 1593, 1549, 1330, 1202, 1077, 
804 cm-1; δH (CD3OD, 400 MHz): 6.52 (d, J = 2.3 Hz, 1H, 8-H), 6.46 (d, J = 2.3 Hz, 1H, 6-
H), 5.21 (s, 1H, 3-H), 3.88 (s, 3H, OCH3), 3.86 (s, 3H, OCH3), 3.67 (t, J = 6.1 Hz, 2H, 3’-H), 
3.34 (t, 7.1 Hz, 2H, 1’-H), 1.89 – 1.81 (m, 2H, 2’-H2); δC (CD3OD, 100 MHz): 179.6 (C-4), 
165.0 (C-2), 164.5 (C-7), 161.7 (C-5), 158.6 (C-8a), 107.3 (C-4a), 96.7 (C-6), 93.8 (C-8), 
85.62 (C-3), 60.2 (C-3’), 56.4 (OCH3), 56.3 (OCH3), 39.5 (C-1’), 32.7 (C-2’); HRMS (ES+) 
found [M+H]+ 280.1183, C14H17NO5 requires M 280.1185. 
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5.1.2.2 Synthesis of 2-aryl-5,7-dimethoxy-4H-chromen-4-ones 
3,3-Dichloroacrolein100 24 
 
Benzoyl peroxide (70%, 714 mg, 2 mmol, 0.008 eq) in CCl4 (300 ml) was heated under 
reflux. Ethyl vinyl ether (24.0 ml, 250 mmol, 1 eq) was added dropwise over 10 min and 
the reaction mixture stirred for 2.5 h. The remaining CCl4 was removed under reduced 
pressure. The synthesised ethyl-(1,3,3,3-tetrachloropropyl)ether 23 was diluted with 
acetone (90 ml) and added dropwise to a mixture of acetone (90 ml) and H2O (136 ml). 
Acetone was removed by distillation through a packed column at 95 °C. The residue was 
extracted with Et2O (4 × 30 ml). The combined organic layers were dried over Na2SO4 and 
concentrated. The title aldehyde (9.5 g, 30%) could be obtained by vacuum distillation as a 
light yellow liquid. 
 
b.p.: 35 °C (10 mbar) (lit.100 b.p. 124 °C/1 bar); δH (CDCl3, 400 MHz): 9.87 (d, J = 6.8 Hz, 
1H, 1-H), 6.44 (d, J = 6.8 Hz, 1H, 2-H); δC (CDCl3, 100 MHz): 188.3 (C-1), 144.9 (C-3), 124 
(C-2); m/z GC-MS 126 (M+, Cl35), 128 (M+, Cl35/Cl37), 143 (M+, Cl37). 
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3,3-Dichloroacrylic acid 18 
 
A round bottom flask was charged with 3,3-dichloroacrolein 24 (3.125 g, 25 mmol, 1 eq), 
MeCN (25 ml), a solution of NaH2PO4.H2O (931 mg, 6.75 mmol, 0.27 eq) in H2O (10 ml) 
and H2O2 (2.24 ml of a 35 wt. % solution in H2O, 26 mmol, 1.04 eq). To the resulting 
mixture was added a solution of NaClO2 (80 %, 3.957 g, 3.5 mmol, 1.4 eq) in H2O (35 ml) 
over 2 h whilst maintaining the temperature at 10 °C. The reaction mixture was stirred for 
another 2 h at 10 °C and then allowed to warm to rt and stirred for 1 h, until evolution of O2 
ceased. Na2S2O3 was added and the reaction mixture acidified with 1 M HCl and extracted 
with EtOAc (3 × 30 ml). The combined organic layers were dried over Na2SO4 and 
concentrated, which afforded the title acid (3.262 g, 93%) as a colourless solid. 
 
m.p.: 76 - 77 °C (lit.99 m.p. 77°C); nmax (ATR): 3064 (COO-H), 2862 (COO-H), 2693 (COO-
H), 2589 (COO-H), 1678 (C=O), 1581, 1213, 894, 851, 666 cm-1; δH (CDCl3, 400 MHz): 
6.42 (s, 1H, 2-H); δC (CDCl3, 100 MHz): 167.4 (C-1), 140.9 (C-3), 119.32 (C-2); m/z LC-MS 
(ES-) 139 ([M-H]-, Cl35), 141 ([M-H]-, Cl35/Cl37), 143 ([M-H]-, Cl37). 
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3’,5’-Dimethoxyphenyl 3,3-dichloroacrylate98 19 
 
A round bottom flask was charged with 3,5-dimethoxyphenol (3.31 g, 21.5 mmol, 1 eq), 
3,3-dichloroacrylic acid 18 (3.33 g, 23.6 mmol, 1.1 eq) and 4-(dimethylamino)-pyridine 
(DMAP) (260 mg, 2.15 mmol, 0.1 eq) and evacuated and flushed with argon three times. 
DCM (18 ml) and DMF (3.6 ml) were added and the solution was cooled to 0 °C. 
Diisopropylcarbodiimide (3.33 ml, 21.5 mmol, 1 eq) was added dropwise and after 10 min, 
the reaction mixture was allowed to warm to rt and stirred for another 2 h. The mixture was 
filtered through Celite® and washed with 1 M HCl (2 × 10 ml), sat. aqueous NaHCO3 (2 × 
10 ml) and with brine (10 ml). The organic layer was dried over Na2SO4 and concentrated. 
The title product (5.09 g, 86%) was afforded by flash column chromatography (40 g silica 
gel, hexane:EtOAc 93:7 - 4:1) as a colourless solid. 
 
m.p.: 50 - 52 °C; nmax (ATR): 1745 (C=O), 1591, 1456, 1135, 1046, 963, 825 cm-1; δH 
(CDCl3, 400 MHz): 6.58 (s, 1H, 2-H), 6.36 (t, J = 2.2 Hz, 1H, 4’-H), 6.30 (d, J = 2.2 Hz, 2H, 
2’-H, 6’-H), 3.77 (s, 6H, 2 × OCH3); δC (CDCl3, 100 MHz): 161.3 (C-3’, C-5’), 160.6 (C-1), 
151.7 (C-1’), 140.1 (C-3), 119.3 (C-2), 100.1 (C-2’, C-6’), 98.7 (C-4’), 55.7 (2 × OCH3); m/z 
LC-MS (ES+) 155 [M-Cl2CCO+H]+, 277 ([M+H]+, Cl35), 279 ([M+H]+, Cl35/Cl37), 281 ([M+H]+, 
Cl37). 
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3,3-Dichloro-1-(2’-hydroxy-4’,6’-dimethoxyphenyl)prop-2-en-1-one98 20 
 
3’,5’-Dimethoxyphenyl 3,3-dichloroacrylate 19 (5.01 g, 18.1 mmol, 1 eq) was dissolved in 
dry 1,2-dichloroethane (300 ml) and added to a slurry of AlCl3 (3.61, 27.1 mmol, 1.5 eq) in 
dry 1,2-dichloroethane (100 ml) under an argon atmosphere at 0 °C. Then the reaction 
mixture was heated under reflux and stirred for 1 h. After cooling down, the mixture was 
poured over a 1:1 mixture of ice and 1 M HCl (approx. 500 ml) and stirred for 30 min. The 
organic layer was separated and the aqueous layer was extracted with DCM (3 × 250 ml). 
The combined organic layers were washed with H2O (200 ml) and brine (200 ml), dried 
over Na2SO4 and concentrated. The title product (2.76 g, 55%) was obtained by flash 
column chromatography (40 g silica gel, hexane:EtOAc 20:1 - 10:1) as a yellow solid. 
 
m.p.: 85 - 87 °C; nmax (ATR): 3090 (OH), 3010 (OH), 2951 (OH), 1621 (C=O), 1588, 1557, 
1216, 1164, 1110, 948, 820, 736, 753 cm-1; δH (CDCl3, 400 MHz): 13.46 (s, 1H, OH), 7.36 
(s, 1H, 2-H), 6.08 (d, J = 2.3 Hz, 1H, Ar-H), 5.92 (d, J = 2.3 Hz, 1H, Ar-H), 3.87 (s, 3H, 
OCH3), 3.83 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 189.3 (C-1), 168.3 (C-4’), 167.2 (C-6’), 
162.3 (C-2’), 131.5 (C-3), 129.2 (C-2), 106.0 (C-1’), 94.0 (C-5’), 91.4 (C-3’), 56.2 (OCH3), 
55.9 (OCH3); m/z LC-MS (ES+) 181 [M-Cl2CCH]+, 277 ([M+H]+, Cl35), 279 ([M+H]+, 
Cl35/Cl37), 281 ([M+H]+, Cl37). 
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2-Chloro-5,7-dimethoxy-4H-chromen-4-one 98 21 
 
3,3-Dichloro-1-(2’-hydroxy-4’,6’-dimethoxyphenyl)prop-2-en-1-one 20 (2.64 g, 9.5 mmol, 
1 eq) was dispersed in H2O (95 ml). The reaction mixture was stirred vigorously for 4 h, 
adding 1 N NaOH (9.5 ml) over the first hour. 1 N HCl was added to neutralize the reaction 
mixture and the addition of EtOAc (100 ml) dissolved the precipitated product. The 
aqueous layer was extracted with EtOAc (3 × 50 ml) and the combined organic layers 
were washed with H2O (50 ml) and brine (50 ml), dried over Na2SO4 and concentrated. 
Flash column chromatography (40 g silica gel, DCM:MeOH 97:3) yielded the title product 
(1.88 g, 82%) as a light yellow solid. 
 
m.p.: 158 - 160 °C; nmax (ATR): 1643 (C=O), 1602, 1319, 1160, 1114, 1088, 914, 847, 828 
cm-1; δH (CDCl3, 400 MHz): 6.46 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 
6.25 (s, 1H, 3-H), 3.93 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 176.2 (C-
4), 164.4 (C-7), 161.2 (C-5), 160.1 (C-2), 153.5 (C-8a), 112.5 (C-3), 108.4 (C-4a), 97.0 (C-
6), 92.9 (C-8), 56.6 (OCH3), 56.0 (OCH3); m/z LC-MS (ES+) 241 ([M+H]+, Cl35), 243 
([M+H]+, Cl37), 263 ([M+Na]+, 265 ([M+Na]+, Cl37). 
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General procedure B 
In a reaction tube of a carousel reactor 2-chloro-5,7-dimethoxy-4H-chromen-4-one 21 
(60 mg, 0.25 mmol, 1 eq), boronic acid (0.50 mmol, 2 eq), Pd2(dba)3 (6.9 mg, 3 mol%), 
PCy3 (4.2 mg, 6 mol%) and Cs2CO3 (244 mg, 0.75 mmol, 3 eq) were suspended in dry 
dioxane (1.25 ml) under a nitrogen atmosphere. The reaction mixture was heated to 
100 °C and stirred for 22 h. 
 
  
  Experimental Part 
  168 
5,7-Dimethoxy-2-phenyl-4H-chromen-4-one98 16 
 
5,7-Dimethoxy-2-phenyl-4H-chromen-4-one 16 was synthesised according to General 
procedure B, using phenylboronic acid (61 mg). DCM (2 ml) and H2O (2 ml) were added to 
the reaction mixture and the layers separated using a phase separator. The organic layer 
was concentrated and the residue was diluted with DCM (1 ml). The title product (59 mg, 
83%) was obtained as a colourless solid by filtration through silica gel, using DCM (10 ml) 
to wash and then a 1:1 mixture of DCM and MeOH (10 ml) to elute the product. 
 
m.p.: 135 - 138 °C; nmax (ATR): 1644 (C=O), 1606, 1345, 1156, 1116, 820, 764, 694 cm-1; 
δH (CDCl3, 400 MHz): 7.95 - 7.85 (m, 2H, 2’-H, 6’-H), 7.57 - 7.47 (m, 3H, 3’-H, 4’-H, 5’-H), 
6.71 (s, 1H, 3-H), 6.60 (d, J = 2.3 Hz, 1H, 8-H), 6.41 (d, J = 2.3 Hz, 1H, 6-H), 3.99 (s, 3H, 
OCH3), 3.94 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 177.6 (C-4), 164.1 (C-7), 160.9 (C-5), 
160.7 (C-2), 159.9 (C-8a), 131.6 (C-1’), 131.2 (C-4’), 129.0 (C-3’, C-5’), 126.0 (C-2’, C-6’), 
109.4 (C-4a), 109.1 (C-3), 96.2 (C-6), 92.8 (C-8), 56.5 (OCH3), 55.8 (OCH3); m/z LC-MS 
(ES+) 283 [M+H]+. 
  
OMeO
OMe O
  Experimental Part 
  169 
2-(4’-Fluorophenyl)-5,7-dimethoxy-4H-chromen-4-one173 25 
 
2-(4’-Fluorophenyl)-5,7-dimethoxy-4H-chromen-4-one 25 was synthesised according to 
General procedure B, using 4-fluorophenylboronic acid (70 mg). DCM (2 ml) and H2O 
(2 ml) were added to the reaction mixture and the layers separated using a phase 
separator. The organic layer was concentrated and the residue was diluted in DCM (1 ml). 
The mixture was filtrated through silica gel, using DCM (10 ml) followed by 1:1 
DCM:MeOH (10 ml) to elute the product. Flash column chromatography (4 g silica gel, 
DCM:MeOH 1:0 - 24:1) yielded the title product (38 mg, 50%) as a colourless solid. 
m.p.: 235 - 237 °C (lit.173 m.p. 236.5 – 238.5 °C); nmax (ATR): 1650 (C=O), 1602, 1343, 
1216, 1198, 1163, 1117, 1100, 832, 812 cm-1; δH (CDCl3, 400 MHz): 7.91 - 7.85 (m, 2H, 2’-
H, 6’-H), 7.24 - 7.15 (m, 2H, 3’-H, 5’-H), 6.63 (s, 1H, 3-H), 6.57 (d, J = 2.3 Hz, 1H, 8-H), 
6.39 (d, J = 2.3 Hz, 1H, 6-H), 3.97 (s, 3H, OCH3), 3.93 (s, 3H, OCH3); δC (CDCl3, 100 
MHz): 177.4 (C-4), 164.5 (d, 1JCF = 252.5 Hz, C-4’), 164.1 (C-7), 160.9 (C-5), 159.8 (C-2), 
159.7 (C-8a), 128.1 (d, 3JCF = 8.7 Hz, C-2’, C-6’), 127.8 (d, 4JCF = 3.3 Hz, C-1’), 116.2 (d, 
2JCF = 22.0 Hz, C-3’, C-5’), 109.2 (C-4a), 108.9 (d, J = 1.0 Hz, C-3), 96.2 (C-6), 92.8 (C-8), 
56.5 (OCH3), 55.8 (OCH3); δF (CDCl3, 400 MHz): 107.94; m/z LC-MS (ES+) 301 [M+H]+.  
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5,7-Dimethoxy-2-(4’-methoxyphenyl)-4H-chromen-4-one98 26 
 
5,7-Dimethoxy-2-(4’-methoxyphenyl)-4H-chromen-4-one 26 was synthesised according to 
General procedure B, using 4-methoxyphenylboronic acid (76 mg). DCM (2 ml) and H2O 
(2 ml) were added to the reaction mixture and the layers separated using a phase 
separator. The organic layer was concentrated and the residue was diluted in DCM (1 ml). 
The mixture was filtrated through silica gel, using DCM (10 ml) to wash and then a 1:1 
mixture of DCM and MeOH (10 ml) to elute the product. Flash column chromatography 
(4 g silica gel, DCM:MeOH 1:0 - 24:1) afforded the title product (72 mg, 92%) as a 
colourless solid. 
 
m.p.: 155 - 157 °C; nmax (ATR): 1640 (C=O), 1602, 1594, 1347, 1254, 1214, 1194, 1162, 
1120, 1100, 1030, 830 cm-1; δH (CDCl3, 400 MHz): 7.85 - 7.79 (m, 2H, 3’-H, 5’-H), 7.03 - 
6.97 (m, 2H, 2’-H, 6’-H), 6.59 (s, 1H, 3-H), 6.56 (d, J = 2.3 Hz, 1H, 8-H), 6.37 (d, J = 2.3 
Hz, 1H, 6-H), 3.96 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 3.89 (s, 3H, OCH3); δC (CDCl3, 100 
MHz): 177.6 (C-4), 163.9 (C-7), 162.0 (C-4’), 160.9 (C-5), 160.6 (C-2), 159.8 (C-8a), 127.6 
(C-3’,C-5’), 123.8 (C-1’), 114.3 (C-2’, C-6’), 109.2 (C-4a), 107.7 (C-3), 96.1 (C-6), 92.8 (C-
8), 56.4 (OCH3), 55.7 (OCH3), 55.5 (OCH3); m/z LC-MS (ES+) 313 [M+H]+. 
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2-(3’-Biphenyl)-5,7-dimethoxy-4H-chromen-4-one 27 
 
2-(3’-Biphenyl)-5,7-dimethoxy-4H-chromen-4-one 27 was synthesised according to 
General procedure B, using 3-biphenylboronic acid (99 mg). DCM (2 ml) and H2O (2 ml) 
were added to the reaction mixture and the layers separated using a phase separator. The 
organic layer was concentrated and the residue was diluted in DCM (1 ml). The mixture 
was filtrated through silica gel, using DCM (10 ml) to wash and then a 1:1 mixture of DCM 
and MeOH (10 ml) to elute the product. Flash column chromatography (4 g silica gel, 
DCM:MeOH 1:0 - 24:1) yielded the title product (57 mg, 50%) as a colourless solid. 
 
m.p.: 190 - 193 °C; nmax (ATR): 1649 (C=O), 1603, 1336, 1213, 1154, 1119, 1103, 818, 
762, 700 cm-1; δH (CDCl3, 400 MHz): 8.05 (td, J = 1.9, 0.5 Hz, 1H, 2’-H), 7.82 (ddd, J = 7.8, 
1.9, 1.1 Hz, 1H, 6’-H), 7.70 (ddd, J = 7.8, 1.9, 1.1 Hz, 1H, 4’-H), 7.67 - 7.59 (m, 2H, 2’’-H, 
6’’-H), 7.57 - 7.37 (m, 4H, 5’-H, 3’’-H, 4’’-H, 5’’-H), 6.73 (s, 1H, 3-H), 6.57 (d, J = 2.3 Hz, 
1H, 8-H), 6.36 (d, J = 2.3 Hz, 1H, 6-H), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3); δC (CDCl3, 
100 MHz): 177.6 (C-4), 164.1 (C-7), 160.9 (C-5), 160.5 (C-2), 159.9 (C-8a), 142.1 (C-3’), 
140.3 (C-1’’), 132.1 (C-1’), 129.9 (C-Ar), 129.4 (C-Ar), 129.0 (C-Ar), 127.9 (C-Ar), 127.2 
(C-Ar), 124.8 (C-Ar), 124.7 (C-Ar), 109.4 (C-4a), 109.3 (C-3), 96.3 (C-6), 92.9 (C-8), 56.5 
(OCH3), 55.8 (OCH3); HRMS (ES+) found [M+H]+ 359.1295, C23H18O4 requires M 
359.1283. 
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2-(4’-Ethylphenyl)-5,7-dimethoxy-4H-chromen-4-one 28 
 
2-(4’-Ethylphenyl)-5,7-dimethoxy-4H-chromen-4-one 28 was synthesised according to 
General procedure B, using 4-ethylphenylboronic acid (0.0750 g). DCM (2 ml) and H2O 
(2 ml) were added to the reaction mixture and the layers separated using a phase 
separator. The organic layer was concentrated and the residue was diluted in DCM (1 ml). 
The mixture was filtrated through silica gel, using DCM (10 ml) to wash and then a 1:1 
mixture of DCM and MeOH (10 ml) to elute the product. Flash column chromatography 
(4 g silica gel, DCM:MeOH 1:0 - 24:1) afforded the title product (57 mg, 74%) as a 
colourless solid. 
 
m.p.: 126 - 129 °C; nmax (ATR): 1644 (C=O), 1606, 1343, 1214, 1158, 1114, 838, 820 cm-1; 
δH (CDCl3, 400 MHz): 7.82 - 7.77 (m, 2H, 2’-H, 6’-H), 7.36 - 7.31 (m, 2H, 3’-H, 5’-H), 6.66 
(s, 1H, 3-H), 6.58 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 3.97 (s, 3H, 
OCH3), 3.92 (s, 3H, OCH3), 2.73 (q, J = 7.6 Hz, 2H, CH2), 1.29 (t, J = 7.6 Hz, 3H, CH3); δC 
(CDCl3, 100 MHz): 177.7 (C-4), 164.0 (C-7), 160.9 (C-5), 160.8 (C-2), 159.9 (C-8a), 148.0 
(C-4’), 128.9 (C-1’), 128.5 (C-3’, C5’), 126.0 (C-2’, C-6’), 109.3 (C-4a), 108.5 (C-3), 96.1 
(C-6), 92.8 (C-8), 56.4 (OCH3), 55.8 (OCH3), 28.8 (CH2), 15.3 (CH3); HRMS (ES+) found 
[M+H]+ 311.1280, C19H18O4 requires M 311.1283. 
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5,7-Dimethoxy-2-(3’-methoxyphenyl)-4H-chromen-4-one174 29 
 
5,7-Dimethoxy-2-(3’-methoxyphenyl)-4H-chromen-4-one 29 was synthesised according to 
General procedure B, using 3-methoxyphenylboronic acid (76 mg). The reaction mixture 
was filtered through Celite® and concentrated. DCM (2 ml) and H2O (2 ml) were added and 
the layers separated using a phase separator. The organic layer was concentrated and the 
title product (58 mg, 75%) was afforded by flash column chromatography (4 g silica gel, 
DCM:MeOH 1:0 - 19:1) as a light yellow solid. 
 
m.p.: 143 - 146 °C (lit.174 m.p. 147 – 148 °C); nmax (ATR): 1634 (C=O), 1592, 1456, 1350, 
1279, 1120, 1107, 1058, 818 cm-1; δH (CDCl3, 400 MHz): 7.45 (dt, J = 8.0, 1.2 Hz, 1H, 6’-
H), 7.43 - 7.35 (m, 2H, 2’-H, 5’-H), 7.03 (ddd, J = 7.8, 2.5, 1.2 Hz, 1H, 4’-H), 6.66 (s, 1H, 3-
H), 6.56 (d, J = 2.3 Hz, 1H, 8-H), 6.37 (d, J = 2.3 Hz, 1H, 6-H), 3.95 (s, 3H, OCH3), 3.91 (s, 
3H, OCH3), 3.88 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 177.7 (C-4), 164.2 (C-7), 161.0 (C-
5), 160.5 (C-2), 160.1 (C-8a), 160.0 (C-3’), 133.0 (C-1’), 130.1 (C-5’), 118.5 (C-6’), 117.0 
(C-4’), 111.4 (C-2’), 109.5 (C-4a), 109.4 (C-3), 96.3 (C-6), 93.0 (C-8), 56.6 (OCH3), 55.9 
(OCH3), 55.6 (OCH3); m/z LC-MS (ES+) 313 [M+H]+. 
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5,7-Dimethoxy-2-(3’,4’-dimethoxyphenyl)-4H-chromen-4-one98 30 
 
5,7-Dimethoxy-2-(3’,4’-dimethoxyphenyl)-4H-chromen-4-one 30 was synthesised 
according to General procedure B, using 3,4-dimethoxyphenylboronic acid (91 mg). The 
reaction mixture was filtered through Celite® and concentrated. DCM (2 ml) and H2O (2 ml) 
were added and the layers separated using a phase separator. The organic layer was 
concentrated and the title product (61 mg, 71%) was obtained by flash column 
chromatography (4 g silica gel, DCM:MeOH 1:0 - 19:1) as a colourless solid. 
 
m.p.: 191 - 192 °C; nmax (ATR): 1644 (C=O), 1600, 1355, 1254, 1220, 1138, 1118, 1018, 
831, 805 cm-1; δH (CDCl3, 400 MHz): 7.51 (dd, J = 8.5, 2.1 Hz, 1H, 6’-H), 7.32 (d, J = 2.1 
Hz, 1H, 2’-H), 6.96 (d, J = 8.5 Hz, 1H, 5’-H), 6.61 (s, 1H, 3-H), 6.56 (d, J = 2.3 Hz, 1H, 8-
H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 3.99 - 3.94 (m, 9H, 3 × OCH3), 3.92 (s, 3H, OCH3); δC 
(CDCl3, 100 MHz): 177.8 (C-4), 164.1 (C-7), 161.0 (C-5), 160.8 (C-2), 160.0 (C-8a), 151.8 
(C-4’), 149.4 (C-3’), 124.2 (C-1’), 119.6 (C-6’), 111.2 (C-5’), 109.4 (C-4a), 108.7 (C-2’), 
108.1 (C-3), 96.2 (C-6), 93.0 (C-8), 56.6 (OCH3), 56.2 (OCH3), 56.2 (OCH3), 55.9 (OCH3); 
m/z LC-MS (ES+) 343 [M+H]+. 
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5,7-Dimethoxy-2-(3’,4’-methylenedioxyphenyl)-4H-chromen-4-one 31 
 
5,7-Dimethoxy-2-(3’,4’-methylenedioxyphenyl)-4H-chromen-4-one 31 was synthesised 
according to General procedure B, using 3,4-methylenedioxyphenylboronic acid (83 mg). 
The reaction mixture was filtered through Celite® and concentrated. DCM (2 ml) and H2O 
(2 ml) were added and the layers separated using a phase separator. The organic layer 
was concentrated and the pure title product (25 mg, 30%) was afforded by flash column 
chromatography (4 g silica gel, DCM:MeOH 1:0 - 19:1) as a colourless solid. 
 
m.p.: 233 - 236 °C; nmax (ATR): 1652 (C=O), 1612, 1451, 1328, 1105, 921, 807 cm-1; δH 
(CDCl3, 400 MHz): 7.43 (dd, J = 8.2, 1.8 Hz, 1H, 6’-H), 7.31 (d, J = 1.8 Hz, 1H, 2’-H), 6.91 
(d, J = 8.2 Hz, 1H, 5’-H), 6.58 - 6.53 (m, 2H, 3-H, 8-H), 6.37 (d, J = 2.3 Hz, 1H, 6-H), 6.06 
(s, 2H, OCH2O), 3.95 (s, 3H, OCH3), 3.91 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 177.7 (C-
4), 164.1 (C-7), 161.1 (C-5), 160.5 (C-2), 159.9 (C-8a), 150.4 (C-4’), 148.5 (C-3’), 125.7 
(C-1’), 121.1 (C-6’), 109.4 (C-4a), 108.8 (C-5’), 108.3 (C-3), 106.2 (C-2’), 102.0 (CH2), 96.3 
(C-6), 92.9 (C-8), 56.6 (OCH3), 55.9 (OCH3); m/z LC-MS (ES+) 327 [M+H]+. 
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5,7-Dimethoxy-2-(4’-methoxycarbonylphenyl)-4H-chromen-4-one 32 
 
5,7-Dimethoxy-2-(4’-methoxycarbonylphenyl)-4H-chromen-4-one 32 was synthesised 
according to General procedure B, using 4-methoxycarbonylphenylboronic acid (90 mg). 
The reaction mixture was filtered through Celite® and concentrated. DCM (2 ml) and H2O 
(2 ml) were added and the layers separated using a phase separator. The organic layer 
was concentrated and flash column chromatography (4 g silica gel, DCM:MeOH 1:0 - 19:1) 
yielded the title product (58 mg, 68%) as a colourless solid. 
m.p.: 202 - 204 °C; nmax (ATR): 1715 (C=O), 1640 (C=O), 1594, 1567, 1277, 1218, 1109, 
1058, 826, 772, 699 cm-1; δH (CDCl3, 400 MHz): 8.18 - 8.13 (m, 2H, 4’-H, 5’-H), 7.97 - 7.92 
(m, 2H, 2’-H, 6’-H), 6.74 (s, 1H, 3-H), 6.59 (d, J = 2.3 Hz, 1H, 8-H), 6.40 (d, J = 2.3 Hz, 1H, 
6-H), 3.99 - 3.95 (m, 6H, COOCH3, OCH3), 3.93 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 
177.5 (C-4), 166.4 (COOCH3), 164.4 (C-7), 161.1 (C-5), 160.0 (C-2), 159.5 (C-8a), 135.8 
(C-1’), 132.4 (C-4’), 130.2 (C-3’, C-5’), 126.0 (C-2’, C-6’), 110.5 (C-3), 109.5 (C-4a), 96.5 
(C-6), 93.0 (C-8), 56.6 (OCH3), 56.0 (OCH3), 52.6 (COOCH3); HRMS (ES+) found [M+H]+ 
341.1035, C19H16O6 requires M 341.1025. 
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5,7-Dimethoxy-2-(pyrid-4’-yl)-4H-chromen-4-one107 38 
 
2-Chloro-5,7-dimethoxy-4H-chromen-4-one 21 (60 mg, 0.25 mmol, 1 eq), 
4-pyridineboronic acid (62 mg, 0.50 mmol, 2 eq), Pd2(dba)3 (4.6 mg, 2 mol%), Cy3P (3.4 
mg, 4.8 mol%), K3PO4 (0.33 ml of a 1.27 M solution in H2O, 0.425 mmol, 1.7 eq) and 
dioxane (0.67 ml) were mixed in a reaction tube of a carousel reactor under a nitrogen 
atmosphere. The reaction mixture was heated to 100°C and stirred for 22 h. After allowing 
to cool to rt, the crude mixture was filtered through Celite® and concentrated The residue 
was dissolved in 1 N HCl (5 ml) and washed with DCM (3 ml). Then 1 N NaOH was added 
to the aqueous layer until it was basic and the product was extracted DCM (3 × 5 ml). The 
combined organic layers were dried over Na2SO4 and concentrated. Flash column 
chromatography (4 g silica gel, DCM:MeOH 1:0 - 19:1) yielded the title product (11 mg, 
15%) as a colourless solid. 
 
m.p.: 229 - 230 °C; nmax (ATR): 1652 (C=O), 1594, 1413, 1349, 1322, 1200, 1166, 1119, 
822, 646 cm-1; δH (CDCl3, 400 MHz): 8.84 - 8.75 (m, 2H, 3’-H, 5’-H), 7.77 - 7.71 (m, 2H, 2’-
H, 6’-H), 6.79 (s, 1H, 3-H), 6.60 (d, J = 2.3 Hz, 1H, 8-H), 6.42 (d, J = 2.3 Hz, 1H, 6-H), 3.98 
(s, 3H, OCH3), 3.95 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 177.1 (C-4), 164.6 (C-7), 161.1 
(C-5), 159.9 (C-2), 157.9 (C-8a), 150.9 (C-3’, C-5’), 139.1 (C-1’), 119.6 (C-2’, C-6’), 111.1 
(C-3), 109.6 (C-4a), 96.6 (C-6), 93.0 (C-8), 56.6 (OCH3), 56.0 (OCH3); HRMS (ES+) found 
[M+H]+ 284.0903, C16H13NO4 requires M 284.0923. 
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5.1.2.3 Synthesis of 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamides 
Dimethyl (E,Z)-2-(3’,5’-dimethoxyphenoxy)ethene-1-2-dicarboxylate 39 
 
3,5-Dimethoxyphenol 17 (920 mg, 6 mmol, 1 eq) was dissolved in dry diethylether (9 ml) 
under an argon atmosphere. First Et3N (1.17 ml, 8.4 mmol, 1.4 eq) and then 
dimethylacetylenedicarboxylate (0.96 ml, 7.8 mmol, 1.3 eq) were added and the solution 
was stirred at rt for 5.5 h. The reaction mixture was washed with 1 N HCl (3 ml), H2O (3 ml) 
and brine (3 ml), dried over Na2SO4 and concentrated. Flash column chromatography 
(40 g silica gel, hexane:EtOAc 9:1 - 4:1) afforded the title ester (1:0.9 mixture of E:Z 
isomers, 1.439 g, 81 %) as a colourless solid. 
 
m.p.: 56 - 58 °C; δH (CDCl3, 400 MHz): 6.57 (s, 1H, 1-H (E)), 6.33 (t, J = 2.2 Hz, 1H, 4’-H 
(Z)), 6.26 (d, J = 2.2 Hz, 2H, 2’-H, 6’-H (Z)), 6.17 (t, J = 2.2 Hz, 1H, 4’-H (E)), 6.12 (d, J = 
2.2 Hz, 2H, 2’-H, 6’-H (E)), 5.24 (s, 1H, 1-H (Z)), 3.92 (s, 3H, COOCH3 (Z)), 3.77 - 3.74 (m, 
15H, 5 × OCH3), 3.71 (s, 3H, COOCH3 (E)), 3.67 (s, 3H, COOCH3 (Z)); δC (CDCl3, 100 
MHz): 166.0 (C-2 (E/Z)), 163.9 (C-2 (E/Z)), 163.4 (COOCH3 (Z)), 162.7 (COOCH3 (E)), 
161.8 (C-3’, C-5’ (Z)), 161.6 (C-3’, C-5’ (E)), 160.5 (COOCH3 (Z)), 158.3 (C-1’ (E)), 154.6 
(C-1’ (Z)), 149.6 (COOCH3 (E)), 115.5 (C-1 (E)), 99.3 (C-1 (Z)), 99.2 (C-2’, C-6’ (Z)), 98.7 
(C-4’ (Z)), 95.7(C-4’ (E)), 95.0 (C-2’, C-6’ (E)), 55.7 (2 × OCH3 (E/Z)), 55.5 (2 × OCH3 
(E/Z)), 53.2 (COOCH3 (E)), 53.2 (COOCH3 (Z)), 52.1 (COOCH3 (E)), 51.89(COOCH3 (Z)); 
HRMS (ES+) found [M+H]+ 297.0995, C14H16O7 requires M 297.0974.  
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(E,Z)-2-(3’,5’-Dimethoxyphenoxy)ethene-1-2-dicarboxylic acid 40 
 
A 1:0.9 mixture of the E and Z isomer of dimethyl 2-(3’,5’-dimethoxyphenoxy)ethene-1-2-
dicarboxylate 39 (1.25 g, 4.2 mmol, 1 eq) was heated under reflux with NaOH (680 mg, 
16.9 mmol, 4 eq) in H2O (6.3 ml) for 3 h. The reaction was allowed to cool to rt, washed 
with Et2O (3 ml) and acidified to pH 1 with concentrated HCl. Et2O (7 ml) was added to 
dissolve the precipitated product and the aqueous layer was extracted with Et2O (3 × 
5 ml). The combined organic layers were dried over Na2SO4 and concentrated, which 
afforded the title acid (1:0.8 mixture of E:Z isomers, 1.08 g, 95 %) as a yellow solid. 
 
m.p.: 147 - 148 °C; δH (d6-DMSO, 400 MHz): 6.51 (s, 1H, 1-H (E)), 6.44 (t, J = 2.2 Hz, 1H, 
4’-H (Z)), 6.28 (d, J = 2.2 Hz, 2H, 2’-H, 6’-H (Z)), 6.122 (t, J = 2.2 Hz, 1H, 4’-H (E)), 6.05 (d, 
J = 2.2 Hz, 2H, 2’-H, 6’-H (E)), 5.23 (s, 1H, 1-H (Z)), 3.75 (s, 6H, OCH3 (Z)), 3.71 (s, 6H, 
OCH3 (E)); δC (d6-DMSO, 100 MHz): 165.9 (C-2 (E/Z)), 164.5 (C-2 (E/Z)), 163.3 (COOCH3 
(Z)), 163.0 (COOCH3 (E)), 161.4 (C-3’, C-5’ (Z)), 161.1 (C-3’, C-5’ (E)), 159.0 (COOCH3 
(Z)), 158.2 (C-1’ (E)), 155.0 (C-1’ (Z)), 148.3 (COOCH3 (E)), 116.8 (C-1 (E)), 101.9 (C-1 
(Z)), 98.4 (C-2’, C-6’ (Z)), 97.7 (C-4’ (Z)), 94.7 (C-4’ (E)), 94.5 (C-2’, C-6’ (E)), 55.7 (2 × 
OCH3 (Z)), 55.4 (2 × OCH3 (E)),; HRMS (ES+) found [M+H]+ 269.0691, C12H12O7 requires 
M 269.0661. 
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5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41 
 
A 1:0.8 mixture of dimethyl 2-(3',5’-dimethoxyphenoxy)fumaric acid and dimethyl 
2-(3',5’-dimethoxyphenoxy)maleic acid (1.04 g, 3.9 mmol, 1 eq) was dissolved in acetyl 
chloride (22 ml) and concentrated H2SO4 (0.88 ml) slowly added. The reaction mixture was 
heated to 60 °C and stirred for 10 min. The reaction was allowed to cool to rt and the 
acetyl chloride removed under reduced pressure (the removed acetyl chloride was 
carefully destroyed with H2O). The reaction mixture was cooled with an ice bath and H2O 
(approx. 65 ml) slowly added. The precipitate was collected by filtration and dried over 
Na2SO4 to afford the title acid (390 mg, 40 %) as a colourless solid. 
 
m.p.: 248 - 250 °C; nmax (ATR): 2934 (COO-H), 1748 (C=O), 1640 (C=O), 1594, 1219, 
1139, 811, 672 cm-1; δH (d6-DMSO, 400 MHz):  6.72 (d, J = 2.3 Hz, 1H, 8-H), 6.64 (s, 1H, 
3-H), 6.54 (d, J = 2.3 Hz, 1H, 6-H), 3.89 (s, 3H, OCH3), 3.83 (s, 3H, OCH3); δC (d6-DMSO, 
100 MHz): 175.5 (C-4), 164.4 (C-7), 161.5 (COOH), 160.4 (C-5), 159.1 (C-8a), 150.6 (C-
2), 115.4 (C-3), 109.1 (C-4a), 96.7 (C-6), 93.4 (C-8), 56.2 (OCH3), 56.1 (OCH3); HRMS 
(ES+) found [M+H]+ 251.0587, C12H10O6 requires M 251.0556. 
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General Procedure C 
To a solution of 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41 (62 mg, 
0.25 mmol, 1 eq) in dry DMF (0.34 ml) in a microwave vial, POCl3 (38 g, 0.25 mmol, 1 eq) 
was added. The reaction mixture was stirred at rt for 10 min and successively heated to 
50 °C and stirred for another 50 min. The amine (0.25 mmol, 1 eq) was added and the 
mixture heated for 5 min to 160 °C in a microwave. H2O (4.5 ml) was added, after the 
reaction was allowed to cool to rt and the precipitated product isolated by filtration. Flash 
column chromatography (4 g silica gel, hexane:acetone 3:1 - 1:1 (3% Et3N)) afforded the 
desired product. 
 
N-Phenyl 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 42 
 
N-Phenyl 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 42 was synthesised 
according to General procedure C, using aniline (23 mg). The title product (39 mg, 48%) 
was obtained as a colourless solid. 
 
m.p.: 203 - 205 °C; nmax (ATR): 1641 (C=O), 1595 (N-C=O), 1418, 1328, 1222, 1161, 
1103, 857, 749, 692 cm-1; δH (d6-DMSO, 400 MHz): 10.57 (s, 1H, NH), 7.81 - 7.74 (m, 2H, 
2’-H, 6’-H), 7.46 - 7.37 (m, 2H, 3’-H, 5’-H), 7.23 - 7.16 (m, 1H, 4’-H), 6.87 (d, J = 2.3 Hz, 
1H, 8-H), 6.72 (s, 1H, 3-H), 6.57 (d, J = 2.3 Hz, 1H, 6-H), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, 
OCH3); δC (d6-DMSO, 100 MHz): 175.3 (C-4), 164.2 (C-7), 160.4 (C-5), 158.7 (C-8a), 
157.7 (CONH), 153.0 (C-2), 137.5 (C-1’), 128.8 (C-3’, C-5’), 124.9 (C-4’), 121.1 (C-2’, C-
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6’), 112.8 (C-3), 108.9 (C-4a), 96.7 (C-6), 93.6 (C-8), 56.2 (OCH3), 56.0 (OCH3); HRMS 
(ES+) found [M+H]+ 326.1044, C18H15NO5 requires M 326.1028. 
 
 
N-(3’,5’-Dimethoxyhenyl) 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 43 
 
N-(3’,5’-Dimethoxyhenyl) 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 43 was 
synthesised according to General procedure C, using 3,5-dimethoxyaniline (38 mg). The 
title product (31 mg, 32%) was obtained as a colourless solid. 
 
m.p.: 220 - 222 °C; nmax (ATR): 1651 (C=O), 1601 (N-C=O), 1543, 1455, 1418, 1338, 
1262, 1202, 1151, 1054, 822 cm-1; δH (d6-DMSO, 400 MHz): 10.47 (s, 1H, NH), 7.07 (d, J 
= 2.2 Hz, 2H, 2’-H, 6’-H), 6.87 (d, J = 2.3 Hz, 1H, 8-H), 6.71 (s, 1H, 3-H), 6.57 (d, J = 2.3 
Hz, 1H, 6-H), 6.35 (t, J = 2.2 Hz, 1H, 4’-H), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 3.76 
(s, 6H, 2x OCH3); δC (d6-DMSO, 100 MHz): 175.3 (C-4), 164.2 (C-7), 160.4 (C-5), 160.4 
(C-3’), 158.7 (C-8a), 157.7 (CONH), 152.8 (C-2), 139.2 (C-1’), 112.8 (C-3), 108.9 (C-4a), 
99.2 (C-2’, C-6’), 96.8 (C-4’), 96.7 (C-6), 93.6 (C-8), 56.2 (OCH3), 56.1 (OCH3), 55.2 
(OCH3); HRMS (ES+) found [M+H]+ 386.1249, C20H19NO7 requires M 386.1240. 
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N-(4’-Methylphenyl) 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 44 
 
N-(4’-Methylphenyl) 5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 44 was 
synthesised according to General procedure C, using p-methylaniline (27 mg). The title 
product (38 mg, 44%) was obtained as a colourless solid. 
 
m.p.: 198 - 200 °C; nmax (ATR): 1645 (C=O), 1597 (N-C=O), 1531, 1316, 1163, 1122, 
1104, 1071, 806 cm-1; δH (d6-DMSO, 400 MHz): 10.51 (s, 1H, NH), 7.67 - 7.63 (m, 2H, 2’-
H, 6’-H), 7.23 - 7.19 (m, 2H, 3’-H, 5’-H), 6.87 (d, J = 2.3 Hz, 1H, 8-H), 6.70 (s, 1H, 3-H), 
6.57 (d, J = 2.3 Hz, 1H, 6-H), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, OCH3), 2.30 (s, 3H); δC (d6-
DMSO, 100 MHz): 175.3 (C-4), 164.2 (C-7), 160.4 (C-75, 158.7 (C-8a), 157.5 (CONH), 
153.1 (C-2), 135.0 (C-1’), 134.0 (C-4’), 129.2 (C-3’, C-5’), 121.1 (C-2’, C-6’), 112.7 (C-3), 
108.9 (C-4a), 96.7 (C-6), 93.6 (C-8), 56.2 (OCH3), 56.0 (OCH3), 20.5 (CH3); HRMS (ES+) 
found [M+H]+ 340.1202, C19H17NO5 requires M 340.1185. 
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5.1.3 Variations of the substituent in the 5-position 
5-Hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one175 46 
 
To a solution of chrysin 45 (1.53 g, 6 mmol, 1 eq) in dry DMF (30 ml), K2CO3 (1.24 g, 
9 mmol, 1.5 eq) and iodomethane (0.56 ml, 9 mmol, 1.5 eq) were added and the reaction 
mixture was stirred for 6.5 h at rt. 0.1M HCl (60 ml) was added to the mixture and the 
product was extracted with DCM (3 × 60 ml). The combined organic layers were washed 
with H2O (3 × 40 ml), dried over Na2SO4 and the solvent was removed under reduced 
pressure. The title product (1.39 g, 86%) was obtained by flash column chromatography 
(40 g silica gel, hexane:EtOAc 9:1 - 0:10) as a yellow solid. 
 
m.p.: 166 - 167 °C (lit.175 m.p. 252 – 254 °C); νmax (ATR): 3072 (OH), 2952 (OH), 1663 
(C=O), 1587, 1351, 1201, 1159, 1040, 848, 806, 768, 693 cm-1; δH (CDCl3, 400 MHz): 
12.73 (s, 1H, OH), 7.93 - 7.85 (m, 2H, 2’-H, 6’H), 7.59 - 7.48 (m, 3H, 3’-H, 4’-H, 5’-H), 6.67 
(s, 1H, 3-H), 6.51 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 3.89 (s, 3H, 
OCH3); δC (CDCl3, 100 MHz): 182.7 (C-4), 165.8 (C-7), 164.1 (C-2), 162.4 (C-5), 158.0 (C-
8a), 132.0 (C-4’), 131.5 (C-1’), 129.2 (C-3’, C-5’), 126.5(C-2’, C-6’), 106.1 (C-3), 105.9 (C-
4a), 98.4 (C-6), 92.9 (C-8), 56.0 (OCH3); m/z LC-MS (ES+) 269 [M+H]+. 
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2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)dodecanoic acid85 3 
 
A solution of methyl 2-bromododecanoate 48 (294 mg, 1 mmol, 2 eq) in dry DMF (1 ml) 
was added to a mixture of 5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one (134 mg, 
0.5 mmol, 1 eq) and K2CO3 (138 mg, 1 mmol, 2 eq) in dry DMF (5 ml) under an argon 
atmosphere. The reaction mixture was stirred at 60 °C for 18 h. H2O (6 ml) was added and 
the product was extracted with EtOAc (3 × 15 ml). The combined organic layers were 
washed with H2O (10 ml), dried over Na2SO4 and concentrated. The crude product was 
dissolved in a 1:1 mixture of THF (6.5 ml) and H2O (6.5 ml) and LiOH.H2O (42 mg, 1 mmol, 
2 eq) was added. The reaction mixture was stirred for 3.5 h at rt. The mixture was acidified 
with 1M HCl to pH 3 - 4 and extracted with EtOAc (3 × 15 ml). The combined organic 
layers were washed with brine (20 ml), dried over Na2SO4 and concentrated. Flash column 
chromatography (12 g silica gel, DCM:MeOH 1:0 - 4:1) afforded the title product (222 mg, 
95%) as a colourless solid. 
m.p.: 98 - 99 °C (lit.85 m.p. 97 – 101 °C); νmax (ATR): 2917 (COOH), 2848, 1748 (C=O), 
1640 (C=O), 1598, 1353, 1194, 1159, 1107 cm-1; δH (CDCl3, 400 MHz): 7.95 - 7.88 (m, 2H, 
2’’-H, 6’’-H), 7.62 - 7.51 (m, 3H, 3’’-H, 4’’-H, 5’’-H), 6.79 (s, 1H 3’-H), 6.75 (d, J = 2.2 Hz, 
1H, 8’-H), 6.50 (d, J = 2.2 Hz, 1H, 6’-H), 4.86 (t, J = 5.3 Hz, 1H, 2-H), 3.96 (s, 3H, OCH3), 
2.23 - 2.11 (m, 2H, 3-H2), 1.67 – 1.51 (m, 2H, 4-H2), 1.43 - 1.23 (m, 14H, 7 × CH2), 0.89 (t, 
J=6.9 Hz, 3H, 12-H3); δC (CDCl3, 100 MHz): 179.0 (C-4’), 172.5 (C-1), 164.9 (C-7’), 162.9 
(C-2’), 159.6 (C-8a’), 159.0 (C-5’), 132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 
(C-2’’, C6’’), 109.6 (C-4a’), 108.4 (C-3’), 101.4 (C-6’), 95.3 (C-8’), 82.0 (C-2), 56.2 (OCH3), 
33.1 (C-3), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.8 (C-
4), 22.8 (CH2), 14.3 (C-12); m/z LC-MS (ES+) 467 [M+H]+.  
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Synthesis of a-bromo acids from amino acids 
Methyl 2-bromododecanoate176 48 
 
 
 
α-Bromododecanoic acid 47 (2.23 g, 8 mmol, 1 eq) was dissolved in a 1:1 mixture of 
EtOAc (40 ml) and MeOH (40 ml) and TMS-diazomethane (8 ml, 16 mmol, 2 eq) was 
added at 0 °C. The reaction mixture was stirred for 17 h while allowing to warm to rt. The 
solvent was removed under reduced pressure, sat. aqueous NaHCO3 (100 ml) was added 
and the product was extracted with DCM (4 × 80 ml). The combined organic layers were 
dried over Na2SO4 and concentrated. The title product (1.14 g, 49%) was obtained by flash 
column chromatography (24 g silica gel, hexane:EtOAc 1:0 - 4:1) as a colourless oil. 
 
νmax (ATR): 2924, 2854, 1743 (C=O), 1150 cm-1; δH (CDCl3, 400 MHz): 4.22 (dd, J = 7.8, 
7.0 Hz, 1H, 2-H2), 3.78 (s, 3H, COOCH3), 2.11 - 1.87 (m, 2H, 3-H2), 1.48 - 1.18 (m, 16H, 4-
H2, 5-H2, 6-H2, 7-H2, 8-H2, 9-H2, 10-H2, 11-H2), 0.88 (t, J = 6.8 Hz, 3H, 12-H3); δC (CDCl3, 
100 MHz): 170.6 (C-1), 53.0 (COOCH3), 45.9 (C-2), 35.1 (CH2), 32.0 (CH2), 29.7 (CH2), 
29.6 (CH2), 29.5 (2 × CH2), 29.0 (CH2), 27.4 (CH2), 22.8 (CH2), 14.3 (C-12); m/z ASAP 
(ES) 293 ([M+H]+,Br79), 295 ([M+H]+,Br81). 
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6-((Benzyloxycarbonyl)amino)-2-aminohexanoic acid177 51 
 
 
A solution of D,L-lysine.HCl 49 (3.65 g, 20 mmol, 1 eq) in aqueous NaOH (20 ml of a 2M 
solution, 40 mmol, 2 eq) was added to a solution of CuSO4.5H2O (2.50 g, 10 mmol, 0.5 eq) 
in H2O (8 ml) and cooled to 0°C. NaHCO3 (2.18 g, 26 mmol, 1.3 eq) and benzyl 
chloroformate (3.75 g, 3.14 ml, 22 mmol, 1.1 eq) were added and the reaction mixture was 
stirred for 1 h at 0 °C and a further 17 h at rt. The blue precipitate Cu[lys(Cbz)]2 50 was 
collected, washed with H2O and added to a boiling suspension of EDTA (6.08 g, 
20.8 mmol, 1.04 eq) in H2O (40 ml). The mixture was stirred for 3 h under reflux. After 
cooling to rt, 3N NaOH was added in order to neutralize the mixture and precipitate the 
crude product, which was collected by filtration. Recrystallization from H2O afforded the 
title product (3.05 g, 54%) as a white solid. 
 
m.p.: 250 - 252°C (decomposition) (lit.177 m.p. 252 – 254 °C); νmax (ATR): 3311, 2925, 
1685 (C=O), 1576, 1539, 1282 cm-1; δH (D2O, 400 MHz): 7.49 - 7.34 (m, 5H, 2’-H, 3’-H, 4’-
H, 5’-H, 6’-H), 5.10 (s, 2H, ArCH2), 3.72 (t, J = 6.2 Hz, 1H, 2-H), 3.13 (t, J = 6.7 Hz, 2H, 6-
H2), 1.92 – 1.79 (m, 2H, 3-H2), 1.57 – 1.48 (m, 2H, 5-H2), 1.44 - 1.31 (m, 2H, 4-H2); δC (d6-
DMSO, 100 MHz): 171.0 (C-1), 156.2 (NH-COOR), 137.3 (C-1’), 128.4 (C-3’, C-5’), 127.8 
(C-4’), 127.8 (C-2’, C-6’), 65.2 (ArCH2), 51.9 (C-2), 40.0 (C-6), 29.6 (C-3), 28.9 (C-5), 21.7 
(C-4); m/z LC-MS (ES+) 281 [M+H]+. 
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Methyl 6-((benzyloxycarbonyl)amino)-2-bromohexanoate178 55 
 
 
6-((Benzyloxycarbonyl)amino)-2-aminohexanoic acid 51 (1.85 g, 6.6 mmol, 1 eq) and KBr 
(1.38 g, 11.6 mmol, 1.75 eq) were dissolved in HBr (14.87 ml of a 1M solution in H2O, 
14.9 mmol, 2.25 eq). NaNO2 (0.55 g, 14.9 mmol, 1.2 eq) was added at 0 °C over 1 h and 
the mixture was stirred for 3.5 h at 0 °C. After the addition of concentrated (conc.) H2SO4 
(6.6 ml), the reaction mixture was stirred for another 10 min at 0 °C and then allowed to 
warm to rt. H2O (10 ml) was added and the product was extracted with EtOAc (3 × 15 ml). 
The combined organic layers were dried over MgSO4 and the solvent was evaporated. The 
crude intermediate was dissolved in EtOAc (25 ml) and MeOH (25 ml) and TMS-
diazomethane (6.6 ml, 13.2 mmol, 2 eq) was added at 0 °C. The reaction mixture was 
stirred for 22.5 h while allowing to warm to rt. The solvent was removed under reduced 
pressure and flash column chromatography (40 g silica gel, hexane:EtOAc 9:1 - 7:3) 
yielded the title product (1.08 g, 46%) as a colourless oil. 
νmax (ATR):3340 (NH), 2952 (NH), 1695 (C=O), 1521, 1243, 1151, 696 cm-1; δH (CDCl3, 
700 MHz): 7.38 - 7.29 (m, 5H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H), 5.09 (s, 2H, ArCH2), 4.82 (br s, 
1H, NH), 4.21 (t, J = 7.3 Hz, 1H, 2-H), 3.77 (s, 3H, COOCH3), 3.20 (q, J = 6.4 Hz, 2H, 6-
H2), 2.11 - 1.96 (m, 2H, 3-H2), 1.58 - 1.46 (m, 3H, 4-H2, 5-H2), 1.42 - 1.34 (m, 1H, 4-H2); δC 
(CDCl3, 175 MHz): 170.3 (C-1), 156.5 (NH-COOR), 136.7 (C-1’), 128.6 (C-3’, C-4’, C-5’), 
128.2 (C-2’, C-6’), 66.8 (ArCH2), 53.1 (COOCH3), 45.5 (C-2), 40.8 (C-6), 34.5 (C-3), 29.3 
(C-5), 24.5 (C-4); m/z LC-MS (ES-) 242 ([M-H]-,Br79), 244 ([M-H]-,Br81).  
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Methyl 6-((benzyloxycarbonyl)amino)-2-(7’’-methoxy-4’’-oxo-2’’-phenyl-4’’H-chromen-5’’-
oxy)hexanoate 56 
 
A solution of methyl 6-((benzyloxycarbonyl)amino)-2-bromohexanoate 55 (637 mg, 
1.8 mmol, 1.5 eq) in dry DMF (3 ml) was added to a mixture of 7-methoxychrysin 46 
(318 mg, 1.2 mmol, 1 eq) and K2CO3 (327 mg, 2.4 mmol, 2 eq) in dry DMF (7 ml) under an 
argon atmosphere. The reaction mixture was stirred at 60°C for 16 h. H2O (10 ml) was 
added and the product was extracted with EtOAc (3 × 30 ml). The combined organic layers 
were washed with H2O (10 ml) and brine (10 ml), dried over Na2SO4 and the solvent was 
evaporated. Flash column chromatography (40 g silica gel, hexane:EtOAc 9:1 - 0:1) 
afforded the title product (600 mg, 93%) as a colourless solid. 
m.p.: 109 - 111 °C; νmax (ATR): 3406 (NH), 2951 (NH), 1721 (C=O), 1640 (C=O), 1598, 
1163, 1120, 769 cm-1; δH (CDCl3, 700 MHz): 7.83 – 7.80 (m, 2H, 2’’’-H, 6’’’-H), 7.54 - 7.47 
(m, 3H, 3’’’-H, 4’’’-H, 5’’’-H), 7.38 - 7.23 (m, 5H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H), 6.61 (d, J = 2.3 
Hz, 1H, 8’’-H), 6.57 (s, 1H, 3’’-H), 6.22 (d, J = 2.3 Hz, 1H, 6’’-H), 5.60 - 5.56 (br m, 1H, 
NH), 5.11 - 5.05 (m, 2H, ArCH2), 4.67 (dd, J = 7.6, 4.3 Hz, 1H, 2-H), 3.88 (s, 3H, OCH3), 
3.75 (s, 3H, COOCH3), 3.33 – 3.23 (m, 2H, 6-H2), 2.17 – 2.03 (m, 2H, 3-H2), 1.80 - 1.57 
(m, 4H, 4-H2, 5-H2); δC (CDCl3, 175 MHz): 177.2 (C-4’’), 171.6 (C-1), 163.9 (C-7’’), 160.9 
(C-2’’), 160.0 (C-8a’’), 159.0 (C-5’’), 156.8 (NHC=O), 137.1 (C-1’), 131.7 (C-1’’’), 131.3 (C-
4’’’), 129.1 (C-3’’’, C-5’’’), 128.5 (C-3’, C-5’), 128.0 (C-2’, C-6’), 128.0 (C-4’), 126.1 (C-2’’’, 
C-6’’’), 110.1 (C-4a’’), 109.3 (C-3’’), 99.2 (C-6’’), 94.3 (C-8’’), 78.2 (C-2), 66.5 (ArCH2), 55.9 
(OCH3), 52.5 (COOCH3), 40.4 (C-6), 32.0 (C-3), 29.0 (C-5), 21.8 (C-4); HRMS (ES+) found 
[M+H]+ 546.2136, C31H32NO8 requires M 546.2128. 
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6-Methoxy-5-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-6-oxo-hexylammonium 
bromide 57 
 
HBr (0.5 ml, 33 wt. % solution in AcOH) was added to methyl 
6-((benzyloxycarbonyl)amino)-2-(7’’-methoxy-4’’-oxo-2’’-phenyl-4’’H-chromen-5’’-oxy) 
hexanoate 56 (259 mg, 0.5 mmol, 1 eq) under an argon atmosphere and the mixture was 
stirred for 2 h. After adding dry Et2O (25 ml) and stirring for another 10 min, the solid was 
collected by filtration, washed with Et2O and dried, which yielded the title product (230 mg, 
98%) as a yellow solid. 
m.p.: 144 - 145 °C (decomposition); νmax (ATR): 2851 (NH), 1739 (C=O), 1631 (C=O), 
1593, 1366, 1208 cm-1; δH (d6-DMSO, 700 MHz): 8.08 - 8.02 (m, 2H, 2’’-H, 6’’-H), 7.68 (br 
s, 3H, NH3+), 7.62 - 7.54 (m, 3H, 3’’-H, 4’’-H, 5’’-H), 6.95 (d, J = 2.3 Hz, 1H, 8’-H), 6.75 (s, 
1H, 3’-H), 6.30 (d, J = 2.3 Hz, 1H, 6’-H), 4.98 (t, J = 5.9 Hz, 1H, 5-H), 3.88 (s, 3H, OCH3), 
3.70 (s, 3H, COOCH3), 2.85 – 2.80 (m, 2H, 1-H2), 1.98 – 1.93 (m, 2H, 4-H2), 1.68 - 1.51 
(m, 4H, 2-H2, 3-H2); δC (d6-DMSO, 175 MHz): 175.5 (C-4’), 170.9 (C-6), 163.4 (C-7’), 159.8 
(C-2’), 159.2 (C-8a’), 158.1 (C-5’), 131.5 (C-4’’), 130.8 (C-1’’), 129.1 (C-3’’, C-5’’), 126.0 
(C-2’’, C-6’’), 108.8 (C-4a’), 108.2 (C-3’), 98.4 (C-6’), 94.3 (C-8’), 76.4 (C-5), 56.1 (OCH3), 
52.2 (COOCH3), 38.7 (C-1), 31.4 (C-4), 26.5 (C-2), 21.3 (C-3); HRMS (ES+) found [M+H]+ 
412.1765, C23H26NO6 requires M 412.1760. 
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Methyl 2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-6-((1’’’-oxo-
pentylamino)hexanoate 58 
 
Valeric acid (0.11 ml, 1.02 mmol, 2 eq) was added to a solution of 
N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (214 mg, 1.12 mmol, 
2.2 eq) in dry DCM (7.5 ml) at 0 °C and the mixture was stirred for 30 min. After the 
addition of DMAP (25 mg, 0.20 mmol, 0.4 eq), N,N-diisopropylethylamine (164 mg, 
1.27 mmol, 2.5 eq) and 6-methoxy-5-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-6-
oxo-hexylammonium bromide 57 (250 mg, 0.51 mmol, 1 eq) the reaction mixture was 
stirred for 2.5 h at rt. Sat. aqueous NH4Cl solution (20 ml) was added and the mixture was 
diluted with EtOAC (60 ml). The organic layer was separated and washed with sat. 
aqueous NH4Cl solution (2 × 30 ml), sat. aqueous NaHCO3 solution (30 ml) and brine 
(30 ml) and dried over Na2SO4. The solvent was removed under reduced pressure and 
flash column chromatography (24 g silica gel, EtOAc) yielded the title product (175 mg, 
70%) as a colourless solid. 
m.p.: 108 - 110 °C; νmax (ATR): 3280 (NH), 2954, 2930, 2862, 1756 (C=O), 1646 (C=O), 
1609, 1163, 1124 cm-1; δH (CDCl3, 400 MHz): 7.92 - 7.82 (m, 2H, 2’’-H, 6’’-H), 7.58 - 7.45 
(m, 3H, 3’’-H, 4’’-H, 5’’-H), 6.90 – 6.83 (br m, 1H, NH), 6.61 (d, J = 2.3 Hz, 1H, 8’-H), 6.59 
(s, 1H, 3’-H), 6.18 (d, J = 2.3 Hz, 1H, 6’-H), 4.67 (dd, J = 7.6, 4.0 Hz, 1H, 2-H), 3.87 (s, 3H, 
OCH3), 3.76 (s, 3H, COOCH3), 3.44 - 3.23 (m, 2H, 6-H2), 2.27 - 2.19 (m, 2H, 2’’’-H2), 2.19 - 
1.98 (m, 2H, 3-H2), 1.87 - 1.53 (m, 6H, 4-H2, 5-H2, 3’’’-H2), 1.37 – 1.27 (m, 2H, 4’’’-H2), 0.87 
(t, J = 7.3 Hz, 3H, 5’’’-H3); δC (CDCl3, 100 MHz): 177.4 (C-4’), 174.2 (C-1’’’), 171.5 (C-1), 
164.2 (C-7’), 161.5 (C-2’), 160.2 (C-8a’), 159.1 (C-5’), 131.6 (C-4’’), 131.5 (C-1’’), 129.2 
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(C-3’’, C-5’’), 126.2 (C-2’’, C-6’’), 109.6 (C-4a’), 108.8 (C-3’), 98.7 (C-6’), 94.1 (C-8’), 77.8 
(C-2), 56.0 (OCH3), 52.5 (COOCH3), 38.4 (C-6), 36.4 (C-2’’’), 31.6 (C-3), 28.3 (C-5/C-3’’’), 
28.1 (C-5/C-3’’’), 22.7 (C-4’’’), 21.6 (C-4), 14.0 (C-5’’’); HRMS (ES+) found [M+H]+ 
496.2344, C28H34NO7 requires M 496.2335. 
 
2-(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-6-((1’’’-oxo-pentylamino)-hexanoic 
acid 59 
 
Methyl 2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-6-((1’’’-oxo-pentylamino)-
hexanoate 58 (110 mg, 0.22 mmol, 1 eq) was dissolved in a 1:1 mixture of THF (5 ml) and 
H2O (5 ml) and LiOH.H2O (19 mg, 0.44 mmol, 2 eq) was added. The reaction mixture was 
stirred for 1.5 h at rt and then neutralized with 1M HCl. The solvent was removed under 
reduced pressure. Flash column chromatography (24 g silica gel, DCM:MeOH 19:1 - 7:3) 
afforded the title product (100 mg, 94%) as a colourless solid. 
m.p.: 186 - 188 °C (decomposition); νmax (ATR): 3265 (NH), 2934, 2870, 1635 (C=O), 
1628 (C=O), 1591, 1162, 1109 cm-1; δH (d6-DMSO, 700 MHz): 8.09 - 7.99 (m, 2H, 2’’-H, 
6’’-H), 7.74 (t, J = 5.6 Hz, 1H, NH), 7.63 - 7.53 (m, 3H, 3’’-H, 4’’-H, 5’’-H), 6.83 (br s, 1H, 8’-
H), 6.78 (s, 1H, 3’-H), 6.43 (br s, 1H, 6’-H), 4.52 (br t, J = 5.7 Hz, 1H, 2-H), 3.85 (s, 3H, 
OCH3), 3.01 – 2.91 (m, 2H, 6-H2), 1.99 (t, J = 7.5 Hz, 2H, 2’’’-H2), 1.88 – 1.78 (m, 2H, 3-
H2), 1.46 – 1.31 (m, 6H, 4-H2, 5-H2, 3’’’-H2), 1.22 – 1.16 (m, 2H, 4’’’-H2), 0.80 (t, J = 7.4 Hz, 
3H, 5’’’-H2); δC (d6-DMSO 175 MHz): 176.8 (C-4’), 172.3 (C-1), 171.8 (C-1’’’), 163.9 (C-7’), 
160.2 (C-2’), 159.2 (C-8a’), 158.7 (C-5’), 131.6 (C-4’’), 130.7 (C-1’’), 129.1 (C-3’’, C-5’’), 
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126.0 (C-2’’, C-6’’), 108.4 (C-4a’), 107.9 (C-3’), 97.9 (C-6’), 93.0 (C-8’), 79.5 (C-2), 55.9 
(OCH3), 38.4 (C-6), 35.1 (C-2’’’), 30.9 (C-3), 29.1 (C-5), 27.4 (C-3’’’), 22.0 (C-4), 21.8 (C-
4’’’), 13.7 (C-5’’’); HRMS (ES+) found [M+H]+ 482.2184, C27H32NO7 requires M 482.2179. 
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5.1.3.1 Chiral synthesis 
(S)-2-(t-Butyloxycarbonylamino)-3-(octyloxy)propanoic acid (S)-67 
 
 
Boc-L-Ser-OH (S)-66 (718 mg, 3.5 mmol, 1 eq) was dissolved in dry DMF (17.5 ml) under 
an argon atmosphere and cooled to 0 °C. NaH (308 mg, 7.7 mmol, 2.2 eq) was added and 
the reaction mixture was stirred for 45 min before the addition of 1-iodooctane (0.63 ml, 
3.5 mmol, 1 eq). The mixture was allowed to warm to rt and stirred at rt for 24 h. H2O 
(60 ml) was added and the reaction mixture was washed with Et2O (50 ml) prior to 
acidifying with 3M HCl to pH 2-3. The product was extracted with EtOAc (5 × 50 ml). The 
combined organic layers were dried over Na2SO4 and concentrated. Flash column 
chromatography (24 g silica gel, DCM:MeOH 1:0 - 9:1 + 1% AcOH) yielded the title 
product (255 mg, 23%) as a colourless oil. 
 
[a]20D (c = 1.00 g/100 ml, CHCl3): +19; νmax (ATR): 2928, 2857, 1717 (C=O), 1161, 1118 
cm-1; δH (CDCl3, 400 MHz): 5.36 (br d, J = 8.3 Hz, 1H, NH), 4.48 - 4.36 (br m, 1H, 2-H), 
3.88 (dd, J = 9.4, 3.4 Hz, 1H, 3-H), 3.64 (dd, J = 9.4, 4.2 Hz, 1H, 3-H), 3.46 (t, J = 6.7 Hz, 
2H, 1’-H2), 1.58 – 1.52 (m, 2H, 2’-H2), 1.45 (s, 9H, 3 × CH3), 1.37 - 1.18 (m, 10H, 5 × H2), 
0.88 (t, J = 6.8 Hz, 3H, 8’-H3); δC (CDCl3, 150 MHz): 174.5 (C-1), 155.9 (NHCOOR), 80.6 
(C(CH3)3), 72.1 (C-1’), 70.1 (C-3), 53.7 (C-2), 32.0 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 
(CH2), 28.5 (3 × CH3), 26.1 (CH2), 22.8 (CH2), 14.2 (C-8’); HRMS (ASAP) found [M+H]+ 
318.2286, C16H32NO5 requires M 318.2280.  
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(R)-2-(t-Butyloxycarbonylamino)-3-(octyloxy)propanoic acid (R)-67 
 
 
Boc-D-Ser-OH (R)-66 (3.08 g, 15 mmol, 1 eq) was dissolved in dry DMF (75 ml) under an 
argon atmosphere and cooled to 0 °C. NaH (1.32 g, 33 mmol, 2.2 eq) was added and the 
reaction mixture was stirred for 40 min before the addition of 1-iodooctane (5.4 ml, 
30 mmol, 2 eq). The mixture was allowed to warm to rt and stirred at rt for 20 h. H2O 
(200 ml) was added and the reaction mixture was washed with Et2O (200 ml) prior to 
acidifying with 3M HCl to pH 2-3. The product was extracted with EtOAc (5 × 80 ml). The 
combined organic layers were dried over Na2SO4 and concentrated. Flash column 
chromatography (24 g silica gel, DCM:MeOH 1:0 - 9:1 + 1%AcOH) afforded the title 
product (460 mg, 10%) as a colourless oil. 
 
[a]20D (c = 1.00 g/100 ml, CHCl3): -18; νmax (ATR): 2928, 2857, 1717 (C=O), 1161, 1118 
cm-1; δH (CDCl3, 600 MHz): 5.36 (br d, J = 7.7 Hz, 1H, NH), 4.47 - 4.38 (br m, 1H, 2-H), 
3.88 (dd, J = 9.0, 2.9 Hz, 1H, 3-H), 3.64 (dd, J = 9.0, 4.4 Hz, 1H, 3-H), 3.46 (t, J = 6.7 Hz, 
2H, 1’-H2), 1.59 – 1.52 (m, 2H, 2’-H2), 1.46 (s, 9H, 3 × CH3), 1.33 - 1.17 (m, 10H, 5 × H2), 
0.88 (t, J = 7.0 Hz, 3H, 8’-H3); δC (CDCl3, 150 MHz): 174.8 (C-1), 155.9 (NHCOOR), 80.5 
(C(CH3)3), 72.0 (C-1’), 70.1 (C-3), 53.7 (C-2), 32.0 (CH2), 29.5 (CH2), 29.4 (CH2), 29.4 
(CH2), 28.4 (3 × CH3), 26.1 (CH2), 22.8 (CH2), 14.2 (C-8’); HRMS (ASAP) found [M-H]- 
316.2112, C16H30NO5 requires M 316.2124. 
 
  
NHBoc
COOHO
  Experimental Part 
  196 
Methyl (S)-2-(bromo)-3-(octyloxy)propanoate (S)-63 
 
For the Boc-deprotection (S)-2-(t-butyloxycarbonylamino)-3-(octyloxy)propanoic acid  
(S)-67 (470 mg, 1.48 mmol, 1 eq) was dissolved in DCM (22 ml), triflouroacetic acid 
(1.48 ml) was added and the reaction mixture was stirred for 4.5 h at rt. The solvent was 
removed under reduced pressure and the intermediate together with KBr (529 mg, 
4.44 mmol, 3 eq) was dissolved in HBr (3.33 ml of a 1M solution in H2O, 3.33 mmol, 
2.25 eq). NaNO2 (123 mg, 1.78 mmol, 1.2 eq) was added at 0 °C over 1 h and the mixture 
was stirred for 3.5 h at 0 °C. After the addition of conc. H2SO4 (0.15 ml), the reaction 
mixture was stirred for another 10 min at 0 °C and then allowed to warm to rt. H2O (10 ml) 
was added and the product was extracted with EtOAc (3 × 15 ml). The combined organic 
layers were dried over Na2SO4 and concentrated. The crude intermediate was dissolved in 
EtOAc (4.5 ml) and MeOH (4.5 ml) and TMS-diazomethane (2.22 ml, 4.44 mmol, 3 eq) 
was added at 0 °C. The reaction mixture was stirred for 15 h while allowing to warm to rt. 
The solvent was removed under reduced pressure and flash column chromatography 
(24 g silica gel, hexane:EtOAc 1:0 - 4:1) yielded the title product (138 mg, 32%) as a 
colourless oil. 
[a]20D (c = 1.00 g/100 ml, CHCl3): -21; νmax (ATR): 2926, 2856, 1747 (C=O), 1114 cm-1; δH 
(CDCl3, 600 MHz): 4.31 (dd, J = 8.5, 5.8 Hz, 1H, 2-H), 3.92 (dd, J = 10.3, 8.5 Hz, 1H, 3-H), 
3.79 (s, 3H, COOCH3), 3.74 (dd, J = 10.3, 5.8 Hz, 1H, 3-H), 3.52 – 3.44 (m, 2H, 1’-H2), 
1.58 - 1.49 (m, 2H, 2’-H2), 1.36 - 1.19 (m, 10H, 5 × H2), 0.87 (t, J = 7.0 Hz, 3H, 8’-H); δC 
(CDCl3, 150 MHz): 169.3 (C-1), 72.0 (C-1’), 71.6 (C-3), 53.2 (COOCH3), 41.8 (C-2), 32.0 
(CH2), 29.6 (C-2’), 29.5 (CH2), 29.4 (CH2), 26.1 (CH2), 22.8 (CH2), 14.2 (C-8’); HRMS 
(ASAP) found [M+H]+ 295.0901, C12H24O379Br requires M 295.0909.  
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Methyl (R)-2-(bromo)-3-(octyloxy)propanoate (R)-63 
 
For the Boc-deprotection (R)-2-(t-butyloxycarbonylamino)-3-(octyloxy)propanoic acid  
(R)-67 (410 mg, 1.29 mmol, 1 eq) was dissolved in DCM (20 ml), triflouroacetic acid 
(1.29 ml) was added and the reaction mixture was stirred for 4.5 h at rt. The solvent was 
removed under reduced pressure and the intermediate together with KBr (461 mg, 
3.87 mmol, 3 eq) was dissolved in HBr (2.91 ml of a 1M solution in H2O, 2.91 mmol, 
2.25 eq). NaNO2 (107 mg, 1.55 mmol, 1.2 eq) was added at 0 °C over 1 h and the mixture 
was stirred for 3.5 h at 0 °C. After the addition of conc. H2SO4 (0.13 ml), the reaction 
mixture was stirred for another 10 min at 0 °C and then allowed to warm to rt. H2O (10 ml) 
was added and the product was extracted with EtOAc (3 × 15 ml). The combined organic 
layers were dried over Na2SO4 and concentrated. The crude intermediate was dissolved in 
EtOAc (4 ml) and MeOH (4 ml) and TMS-diazomethane (1.94 ml, 3.88 mmol, 3 eq) was 
added at 0 °C. The reaction mixture was stirred for 15 h while allowing to warm to rt. The 
solvent was removed under reduced pressure and flash column chromatography (24 g 
silica gel, hexane:EtOAc 1:0 - 4:1) yielded the title product (125 mg, 33%) as a colourless 
oil. 
[a]20D (c = 1.00 g/100 ml, CHCl3): +40; νmax (ATR): 2926, 2856, 1747 (C=O), 1114 cm-1; δH 
(CDCl3, 600 MHz): 4.31 (dd, J = 8.5, 5.8 Hz, 1H, 2-H), 3.92 (dd, J = 10.3, 8.5 Hz, 1H, 3-H), 
3.80 (s, 3H, COOCH3), 3.74 (dd, J = 10.3, 5.8 Hz, 1H, 3-H), 3.53 – 3.44 (m, 2H, 1’-H2), 
1.58 - 1.50 (m, 2H, 2’-H2), 1.34 - 1.20 (m, 10H, 5 × H2), 0.88 (t, J = 7.0 Hz, 3H, 8’-H); δC 
(CDCl3, 150 MHz): 169.3 (C-1), 72.0 (C-1’), 71.6 (C-3), 53.2 (COOCH3), 41.8 (C-2), 32.0 
(CH2), 29.6 (C-2’), 29.5 (CH2), 29.4 (CH2), 26.1 (CH2), 22.8 (CH2), 14.2 (C-8’); HRMS 
(ASAP) found [M+H]+ 295.0917, C12H24O379Br requires M 295.0909.  
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(R)-2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-3’-(octyloxy)propanoic acid (R)-62 
 
 
A solution of methyl (S)-2-(bromo)-3-(octyloxy)propanoate (S)-63 (55 mg, 0.19 mmol, 1 eq) 
in dry DMF (1 ml) was added to a mixture of 7-methoxy-chrysin 46 (65 mg, 0.24 mmol, 
1.3 eq) and Cs2CO3 (158 mg, 0.48 mmol, 2.6 eq) under an argon atmosphere. The 
reaction mixture was stirred at rt for 19 h. H2O (15 ml) was added and the product was 
extracted with DCM (3 × 20 ml). The combined organic layers were dried over Na2SO4 and 
concentrated. The crude intermediate was dissolved in a 1:1 mixture of THF (9.2 ml) and 
H2O (9.2 ml) and LiOH.H2O (16 mg, 0.37 mmol, 2 eq) was added. The reaction mixture 
was stirred for 2 h at rt. The mixture was acidified with 1M HCl to pH 6 and extracted with 
EtOAc (3 × 10 ml). The combined organic layers were washed with brine (10 ml), dried 
over Na2SO4 and concentrated. Flash column chromatography (4 g silica gel, DCM:MeOH 
1:0 - 9:1) afforded the title product (52 mg, 60%) as a colourless solid. 
 
[a]20D (c = 1.00 g/100 ml, CHCl3): -17; 11% ee (determined by chiral HPLC analysis);  m.p.: 
126 - 127°C; νmax (ATR): 2916, 2854, 1730 (C=O), 1631, 1616, 1596, 1363, 1166, 1123, 
843 cm-1; δH (CDCl3, 600 MHz): 7.93 - 7.85 (m, 2H, 2’’-H, 6’’-H), 7.59 - 7.48 (m, 3H, 3’’-H, 
4’’-H, 5’’-H), 7.06 (d, J = 2.3 Hz, 1H, 6’-H), 6.77 (s, 1H, 3’-H), 6.75 (d, J = 2.3 Hz, 1H, 8’-H), 
4.94 (dd, J = 8.8, 2.2 Hz, 1H, 2-H), 4.23 (dd, J = 10.9, 2.2 Hz, 1H, 3-H), 3.92 (s, 3H, 
OCH3), 3.87 (dd, J = 10.9, 8.8 Hz, 1H, 3-H), 3.62 – 3.51 (m, 2H, 1’’’-H2), 1.66 - 1.59 (m, 
2H, 2’’’-H2), 1.40 - 1.19 (m, 10H, 5 × H2), 0.87 (t, J = 7.0 Hz, 3H, 8’’’-H3); δC (CDCl3, 150 
MHz): 179.0 (C-4’), 170.2 (C-1), 165.1 (C-7’), 163.0 (C-2’), 159.7 (C-5’), 159.2 (C-8a’), 
OMeO
O O
COOHO
  Experimental Part 
  199 
132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 (C-2’’, C-6’’), 109.4 (C-4a’), 108.1 (C-
3’), 103.1 (C-6’), 96.3 (C-8’), 83.3 (C-2), 72.2 (C-1’’’), 72.0 (C-3), 56.2 (OCH3), 32.0 (CH2), 
29.8 (C-2’’’), 29.6 (CH2), 29.4 (CH2), 26.3 (CH2), 22.8 (CH2), 14.2 (C-8’’’); HRMS (ES+) 
found [M+H]+ 469.2240, C27H33O7 requires M 469.2226. 
 
(S)-2-(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)-3-(octyloxy)propanoic acid (S)-62 
 
A solution of methyl (R)-2-(bromo)-3-(octyloxy)propanoate (R)-63 (55 mg, 0.19 mmol, 
1 eq) in dry DMF (1 ml) was added to a mixture of 7-methoxy-chrysin 46 (65 mg, 
0.24 mmol, 1.3 eq) and Cs2CO3 (158 mg, 0.48 mmol, 2.6 eq) under an argon atmosphere. 
The reaction mixture was stirred at rt for 19 h. H2O (15 ml) was added and the product was 
extracted with DCM (3 × 20 ml). The combined organic layers were dried over Na2SO4 and 
concentrated. The crude intermediate was dissolved in a 1:1 mixture of THF (9.2 ml) and 
H2O (9.2 ml) and LiOH.H2O (16 mg, 0.37 mmol, 2 eq) was added. The reaction mixture 
was stirred for 2 h at rt. The mixture was acidified with 1M HCl to pH 6 and extracted with 
EtOAc (3 × 10 ml). The combined organic layers were washed with brine (10 ml), dried 
over Na2SO4 and concentrated. Flash column chromatography (4 g silica gel, DCM:MeOH 
1:0 - 9:1) afforded the title product (56 mg, 64%) as a colourless solid. 
[a]20D (c = 1.00 g/100 ml, CHCl3): +23; 22% ee (determined by chiral HPLC analysis); m.p.: 
126 - 127 °C; νmax (ATR): 2916, 2854, 1730 (C=O), 1631, 1616, 1596, 1363, 1166, 1123, 
843 cm-1; δH (CDCl3, 600 MHz): 7.932 - 7.87 (m, 2H, 2’’-H, 6’’-H), 7.59 - 7.50 (m, 3H, 3’’-H, 
4’’-H, 5’’-H), 7.06 (d, J = 2.2 Hz, 1H, 6’-H), 6.76 (s, 1H, 3’-H), 6.75 (d, J = 2.2 Hz, 1H, 8’-H), 
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4.93 (dd, J = 8.8, 1.9 Hz, 1H, 2-H), 4.22 (dd, J = 10.9, 2.2 Hz, 1H, 3-H), 3.92 (s, 3H, 
OCH3), 3.87 (dd, J = 10.9, 8.8 Hz, 1H, 3-H), 3.62 – 3.50 (m, 2H, 1’’’-H2), 1.66 - 1.59 (m, 
2H, 2’’’-H2), 1.40 - 1.20 (m, 5 × H2), 0.87 (t, J = 7.0 Hz, 3H, 8’’’-H3); δC (CDCl3, 150 MHz): 
179.0 (C-4’), 170.2 (C-1), 165.1 (C-7’), 163.0 (C-2’), 159.5 (C-5’), 159.1 (C-8a’), 132.1 (C-
4’’), 131.0 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 (C-2’’, C-6’’), 109.4 (C-4a’), 108.1 (C-3’), 103.0 
(C-6’), 96.3 (C-8’), 83.2 (C-2), 72.1 (C-1’’’), 72.0 (C-3), 56.1 (OCH3), 31.9 (CH2), 29.8 (C-
2’’’), 29.5 (CH2), 29.4 (CH2), 26.3 (CH2), 22.8 (CH2), 14.2 (C-8’’’); HRMS (ES+) found 
[M+H]+ 469.2236, C27H33O7 requires M 469.2226. 
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(R)-Methyl 2-(((trifluoromethyl)sulfonyl)oxy)propanoate179 (R)-69 
 
(+)Methyl D-lactate (R)-68 (0.19 ml, 2 mmol, 1 eq) was dissolved in dry DCM (2 ml) at 0 °C 
under a nitrogen atmosphere. 2,6-Lutidine (0.28 ml, 2.4 mmpl, 1.2 eq) and subsequently 
triflic anhydride (0.37 ml, 2.2 mmol, 1.1 eq) were added and the reaction was stirred at 0°C 
for 1.5h. H2O (2 ml) was slowly added and the two layers were separated. The organic 
layer was dried over MgSO4 and concentrated. Flash column chromatography (12 g silica 
gel, iso-hexane:EtOAc 1:0 - 4:1) afforded the title product (321 mg, 68%) as a colourless 
oil. 
 
νmax (ATR): 1755 (C=O), 1201, 1143, 931 cm-1; δH (CDCl3, 400 MHz): 5.24 (q, J = 7.0 Hz, 
1H, 2-H), 3.86 (s, 3H, COOCH3), 1.72 (d, J = 7.0 Hz, 3H, 3-H); δC (CDCl3, 101 MHz): 
168.0 (C-1), 118.6 (q, 1JCF = 319.4 Hz, CF3), 80.0 (C-2), 53.5 (COOCH3), 18.2 (C-3); δF 
(CDCl3, 376 MHz): -75.2;  
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(S)-Methyl 2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionate (S)-70 
 
A mixture of 5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one 46 (161 mg, 0.6 mmol, 
1 eq), (R)-Methyl 2-(((trifluoromethyl)sulfonyl)oxy)propanoate (R)-69 (213 mg, 0.9 mnmol, 
1.5 eq) and K2CO3 (166 mg, 1.2 mmol, 2 eq) in dry MeCN (1 ml) under a nitrogen 
atmosphere was stirred at rt overnight. H2O (2 ml) was added to the reaction mixture. The 
aqueous phase was extracted with EtOAc (3 × 2 ml), the organic extracts collected, 
washed with brine, dried over MgSO4 and concentrated. Flash column chromatography 
(12 g silica gel, iso-hexane:EtOAc 7:3 - 0:1) yielded the title product (160 mg, 75%) as a 
colourless solid. 
 
[a]20D (c = 1.00 g/100 ml, CHCl3): -42 ; m.p.: 149 – 150 °C; νmax (ATR): 3060, 3000, 2947, 
1753 (C=O), 1633 (C=O), 1606, 1202, 1135, 1109 cm-1; δH (CDCl3, 400 MHz): 7.93 - 7.81 
(m, 2H, 2’’-H, 6’’-H), 7.5 - 7.43 (m, 3H, 4’’-H, 3’’-H, 5’’-H), 6.66 (d, J = 2.3 Hz, 1H, 8’-H), 
6.64 (s, 1H, 3’-H), 6.39 (d, J = 2.3 Hz, 1H, 6’-H), 4.81 (q, J = 6.8 Hz, 1H, 2-H), 3.88 (s, 3H, 
OCH3), 3.77 (s, 3H,COOCH3), 1.76 (d, J = 6.8 Hz, 3H, 3-H); δC (CDCl3, 101 MHz): 177.1 
(C-4’), 172.4 (C-1), 163.7 (C-7’), 160.9 (C-2’), 159.9 (C-8a’), 158.7 (C-5’), 131.7 (C1’’), 
131.4 (C-4’’), 129.1 (C-3’’, C-5’’), 126.1 (C-2’’, C-6’’), 110.6 (C-4a’), 109.1 (C-3’), 101.6 (C-
6’), 95.3 (C-8’), 75.7 (C-2), 55.9 (OCH3), 52.4 (COOCH3), 18.6 (C-3); HRMS (ES+) found 
[M+H]+ 355.1168, C20H19O6 requires M 355.1182. 
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(S)-2-(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionic acid (S)-71 
 
(S)-Methyl 2-(7’-methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionate (S)-70 (89 mg, 
0.25 mmol, 1 eq) and LiOH.H2O (21 mg, 0.5 mmol, 2 eq) were stirred in a 1:1 mixture of 
H2O (2 ml) and THF (2 ml) at rt for 20 h. Sat. aqueous NaHCO3 (5 ml) was added and the 
mixture was washed with EtOAc (2 × 5 ml). The aqueous layer was acidified to pH 2 with 
2N HCl and the product was extracted with DCM (3 × 5 ml). The organic extracts were 
collected, dried over MgSO4 and concentrated. The title product (36 mg, 42%) was 
obtained as a colourless solid without further purification. 
 
[a]20D (c = 1.00 g/100 ml, CHCl3): +103; 94% ee (determined by chiral HPLC analysis);  
m.p.: 161 – 163 °C; νmax (ATR): 2992 (COOH), 1739 (C=O), 1625 (C=O), 1598, 1363, 
1161, 1113cm-1; δH (CDCl3, 400 MHz): 13.64 (br. s, 1H, COOH), 7.95 - 7.84 (m, 2H, 2’’-H, 
6’’-H), 7.62 - 7.48 (m, 3H,4’’-H, 3’’-H, 5’’-H), 6.76 (s, 1H, 3’-H), 6.73 (d, J = 2.3 Hz, 1H, 8’-
H), 6.47 (d, J = 2.3 Hz, 1H, 6’-H), 4.82 (q, J = 6.9 Hz, 1H, 2-H), 3.94 (s, 3H, OCH3), 1.81 
(d, J = 6.9 Hz, 3H, 3-H3); δC (CDCl3, 101 MHz): 178.8 (C-4’), 172.8 (C-1), 164.9 (C-7’), 
162.9 (C-2’), 159.6 (C-8a’), 158.6 (C-5’), 132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 
126.4 (C-2’’, C-6’’), 109.5 (C-4a’), 108.4 (C-3’), 101.3 (C-6’), 95.3 (C-8’), 78.0 (C-2), 56.3 
(OCH3), 19.1 (C-3); HRMS (ES+) found [M+H]+ 341.1015, C19H17O6 requires M 341.1025. 
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Methyl 2-(((trifluoromethyl)sulfonyl)oxy)propanoate179 (±)-69 
 
Methyl lactate (±)-68 (0.19 ml, 2 mmol, 1 eq) was dissolved in dry DCM (2 ml) at 0 °C 
under a nitrogen atmosphere. 2,6-Lutidine (0.28 ml, 2.4 mmpl, 1.2 eq) and subsequently 
triflic anhydride (0.37 ml, 2.2 mmol, 1.1 eq) were added and the reaction was stirred at 
0 °C for 1.5 h. H2O (2 ml) was slowly added and the two layers were separated. The 
organic layer was dried over MgSO4 and concentrated. Flash column chromatography 
(12 g silica gel, iso-hexane:EtOAc 1:0 - 4:1) afforded the title product (322 mg, 68%) as a 
colourless oil. 
 
νmax (ATR): 1733 (C=O), 1206, 1144, 936 cm-1; δH (CDCl3, 400 MHz): 5.24 (q, J = 7.0 Hz, 
1H, 2-H), 3.85 (s, 3H, COOCH3), 1.71 (d, J = 6.9 Hz, 3H, 3-H); δC (CDCl3, 101 MHz): 168.0 
(C-1), 118.6 (q, 1JCF = 319.4 Hz, CF3), 80.0 (C-2), 53.5 (COOCH3), 18.2 (C-3); δF (CDCl3, 
376 MHz): -75.3; 
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2-(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionate (±)-70 
 
A mixture of 5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one 46 (161 mg, 0.6 mmol, 
1 eq), methyl 2-(((trifluoromethyl)sulfonyl)oxy)propanoate (±)-69 (213 mg, 0.9 mnmol, 
1.5 eq) and K2CO3 (166 mg, 1.2 mmol, 2 eq)in dry MeCN (1 ml) under a nitrogen 
atmosphere was stirred at rt overnight. H2O (2 ml) was added to the reaction mixture. The 
aqueous phase was extracted with EtOAc (3 × 2 ml), the organic extracts collected, 
washed with brine, dried over MgSO4 and concentrated. Flash column chromatography 
(12 g silica gel, iso-hexane:EtOAc 7:3 - 0:1) yielded the title product (154 mg, 72%) as a 
colourless solid. 
 
m.p.: 149 – 150 °C; νmax (ATR): 3066, 3001, 2945, 1754 (C=O), 1641 (C=O), 1608, 1215, 
1134, 1106 cm-1; δH (CDCl3, 400 MHz): 7.94 - 7.80 (m, 2H, 2’’-H, 6’’-H), 7.60 - 7.42 (m, 3H, 
4’’-H, 3’’-H, 5’’-H), 6.66 (d, J = 2.3 Hz, 1H, 8’-H), 6.64 (s, 1H, 3’-H), 6.39 (d, J = 2.3 Hz, 1H, 
6’-H), 4.81 (q, J = 6.8 Hz, 1H, 2-H), 3.88 (s, 3H, OCH3), 3.77 (s, 3H,COOCH3), 1.76 (d, J = 
6.8 Hz, 3H, 3-H); δC (CDCl3, 101 MHz): 177.1 (C-4’), 172.4 (C-1), 163.7 (C-7’), 160.9 (C-
2’), 159.9 (C-8a’), 158.7 (C-5’), 131.7 (C1’’), 131.4 (C-4’’), 129.1 (C-3’’, C-5’’), 126.1 (C-2’’, 
C-6’’), 110.6 (C-4a’), 109.1 (C-3’), 101.6 (C-6’), 95.3 (C-8’), 75.7 (C-2), 55.9 (OCH3), 52.4 
(COOCH3), 18.6 (C-3); HRMS (ES+) found [M+H]+ 355.1177, C20H19O6 requires M 
355.1182. 
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2-(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionic acid (±)-71 
 
2-(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-oxy)propionate (±)-70 (89 mg, 0.25 mmol, 
1 eq) and LiOH.H2O (21 mg, 0.5 mmol, 2 eq) were stirred in a 1:1 mixture of H2O (2 ml) 
and THF (2 ml) at rt for 20 h. Sat. aqueous NaHCO3 (5 ml) was added and the mixture was 
washed with EtOAc (2 × 5 ml). The aqueous layer was acidified to pH 2 with 2N HCl and 
the product was extracted with DCM (3 × 5 ml). The organic extracts were collected, dried 
over MgSO4 and concentrated. The title product (36 mg, 42%) was obtained as a 
colourless solid without further purification. 
 
m.p.: 161 – 163 °C; νmax (ATR): 2946 (COOH), 1741 (C=O), 1613 (C=O), 1589, 1361, 
1165, 1125 cm-1; δH (CDCl3, 400 MHz): 13.64 (br. s, 1H, COOH), 7.95 - 7.84 (m, 2H, 2’’-H, 
6’’-H), 7.60 - 7.47 (m, 3H,4’’-H, 3’’-H, 5’’-H), 6.75 (s, 1H, 3’-H), 6.73 (d, J = 2.3 Hz, 1H, 8’-
H), 6.47 (d, J = 2.3 Hz, 1H, 6’-H), 4.81 (q, J = 6.9 Hz, 1H, 2-H), 3.94 (s, 3H, OCH3), 1.81 
(d, J = 6.9 Hz, 3H, 3-H3); δC (CDCl3, 101 MHz): 178.8 (C-4’), 172.8 (C-1), 164.9 (C-7’), 
162.9 (C-2’), 159.6 (C-8a’), 158.6 (C-5’), 132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 
126.4 (C-2’’, C-6’’), 109.5 (C-4a’), 108.4 (C-3’), 101.3 (C-6’), 95.3 (C-8’), 78.0 (C-2), 56.3 
(OCH3), 19.1 (C-3); HRMS (ES+) found [M+H]+ 341.1026, C19H17O6 requires M 341.1025. 
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5.1.3.2 Cross metathesis 
Methyl 2-[(diphenylmethylene)amino]acetate121 76 
 
Benzophenone imine (2 ml, 12 mmol, 1 eq) was added to a suspension of glycine methyl 
ester hydrochloride 77 (1.51 g, 12 mmol, 1 eq) in dry DCM (40 ml) and the reaction 
mixture was stirred for 21 h at rt. NH4Cl was removed by filtration and the solution was 
concentrated. The crude product was dissolved in Et2O (50 ml) and washed with H2O 
(50 ml). The organic layer was dried over dried over Na2SO4 and concentrated. Flash 
column chromatography (80 g silica gel, hexane:EtOAc 9:1 - 3:2) yielded the title product 
(2.07 g, 68%) as a colourless waxy solid. 
 
νmax (ATR): 1754 (C=O), 1625, 1385, 1197, 691 cm-1; δH (CDCl3, 400 MHz): 7.71 - 7.61 
(m, 2H, Ar-H), 7.51 - 7.30 (m, 6H, Ar-H), 7.23 - 7.11 (m, 2H, Ar-H), 4.22 (s, 2H, 2-H), 3.75 
(s, 3H, COOCH3); δC (CDCl3, 101 MHz): 172.0 (C-1), 171.2 (Ph2C=N), 139.4 (C-1’), 136.1 
(C-1’’), 130.6 (C-4’), 129.0 (C-4’’), 128.9 (C-Ar), 128.8 (C-Ar), 128.2 (C-Ar), 127.8 (C-Ar), 
55.8 (C-2), 52.1 (COOCH3); m/z LC-MS (ES+) 254 [M+H]+. 
 
  
N COOMe
  Experimental Part 
  208 
Methyl 2-[(diphenylmethylene)amino]pent-4-enoate121 75 
 
n-BuLi (1.6 M solution in hexanes, 1.38 ml, 2.2 mmol, 1.1 eq) was slowly added to a 
solution of DIPA (0.31 ml, 2.2 mmol, 1.1 eq) in dry THF (18 ml) at 0°C under an argon 
atmosphere and stirred for 40 min. The solution was cooled to -78°C and methyl 
2-[(diphenylmethylene)amino]acetate 76 (507 mg, 2 mmol, 1 eq) dissolved in dry THF 
(2ml) was added dropwise. After stirring for 40 min, allyl bromide (0.19 ml, 2.2 mmol, 1.1 
eq) was added dropwise and the reaction was stirred another 1.5 h at -78°C. The mixture 
was further stirred overnight, while allowing to warm to rt and the poured onto a 1:1 
mixture of H2O and water (50 ml). The product was extracted with EtOAc (3 × 50 ml) and 
the combined organic layers were dried over Na2SO4 and concentrated. Flash column 
chromatography (40 g silica gel, toluene:EtOAc 1:0 - 9:1) afforded the title product (381 
mg, 65%) as a colourless oil. 
 
νmax (ATR): 2955, 2384, 1702 (C=O), 1491, 1167, 841 cm-1; δH (CDCl3, 600 MHz): 7.69 - 
7.60 (m, 2H, Ar-H), 7.49 - 7.29 (m, 6H, Ar-H), 7.21 - 7.13 (m, 2H, Ar-H), 5.67 (ddt, J = 
17.2, 10.2, 7.1 Hz, 1H, 4-H), 5.10 - 5.00 (m, 2H, 5-H), 4.17 (dd, J = 7.9, 5.2 Hz, 1H, 2-H), 
3.72 (s, 3H, COOCH3), 2.73 - 2.59 (m, 2H, 3-H); δC (CDCl3, 151 MHz): 172.5 (C-1), 170.8 
(Ph2C=N), 139.7 (C-1’), 136.5 (C-1’’), 134.4 (C-4), 130.5 (C-4’), 129.0 (C-Ar), 128.8 (C-4’’), 
128.6 (C-Ar), 128.2 (C-Ar), 128.1 (C-Ar), 117.8 (C-5), 65.4 (C-2), 52.2 (COOCH3), 38.3 (C-
3); m/z LC-MS (ES+) 294 [M+H]+. 
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Methyl 2-[(tert-butoxycarbonyl)amino]pent-4-enoate121 74 
 
A mixture of methyl 2-[(diphenylmethylene)amino]pent-4-enoate 75 (359 mg, 1.22 mmol, 
1 eq) and 4N HCl (1.51 ml) in MeOH (5 ml) was heated under reflux for 1 h and 
subsequently allowed to cool to rt. The reaction mixture was extracted with Et2O (2 × 4 ml). 
The aqueous layer was basified with NaHCO3 to pH 8, followed by addition of Boc2O 
(534 mg, 2.45 mmol, 1.5 eq) and the reaction was stirred at rt for 2.5 h. The reaction 
volume was reduced under vacuum, H2O (10 ml) was added and the product was 
extracted with EtOAc (3 × 10 ml). The combined organic layers were washed with brine 
(10 ml), dried over Na2SO4 and concentrated. The title product (203 mg, 72%) was 
obtained by flash column chromatography (24 g silica gel, hexane:EtOAc 1:0 - 4:1) as a 
colourless oil. 
 
νmax (ATR): 3376 (NH), 29770, 2879, 1714 (C=O), 1490, 1172, 838 cm-1; δH (CDCl3, 700 
MHz): 5.72 - 5.65 (m, 1H, 4-H), 5.15 - 5.10 (m, 2H, 5-H2), 5.03 (br. d, J = 8.2 Hz, 1H, NH), 
4.42 - 4.33 (m, 1H, 2-H), 3.73 (s, 3H, COOCH3), 2.58 – 2.43 (m , 2H, 3-H), 1.43 (s, 9H, 
C(CH3)3); δC (CDCl3, 175 MHz): 172.7 (C-1), 155.3 (C=O), 132.4 (C-4), 119.2 (C-5), 80.1 
(C(CH3)3), 53.1 (C-2), 52.4 (COOCH3), 36.9 (C-3), 28.5 (C(CH3)3); m/z LC-MS (ES+) 230 
[M+H]+. 
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5.1.3.3 Ene-reaction 
Ethyl 12-bromo-2-hydroxydodecanoate 82 
 
To a solution of (+)-diethyl L-tartrate 80 (0.31 ml, 1.8 mmol, 0.6 eq) in dry Et2O (1.5 ml) at 
0°C, periodic acid (410 mg, 1.8 mmol, 0.6 eq) was slowly added over 30 min. The reaction 
mixture was stirred another 20 min at rt, filtered through Celite® and concentrated. The 
crude product was dissolved in dry DCM (10 ml) and added to a slurry of ferric chloride 
(1.460 g, 9 mmol, 3 eq) in dry DCM (14 ml) and H2O (0.16 ml, 9 mmol, 3 eq). The mixture 
was cooled to 0 °C and 10-bromo-1-decene (0.60 ml, 3 mmol, 1 eq) was added before the 
mixture was stirred for 3 h at rt. The reaction mixture was washed with 0.1 N HCl (25 ml), 
dried over MgSO4, filtered through silica gel and concentrated. 
The hydrogenator flask was charged with Crabtree catalyst (48 mg, 2 mol%) and the crude 
product from the previous step, dissolved in dry DCM (12 ml). The flask was purged with 
nitrogen and then flushed with hydrogen (1.5 bar) and stirred for 2.5 h at rt. The reaction 
mixture was concentrated and the title product (478 mg, 49%) was afforded as a 
colourless oil by flash column chromatography (40 g silica gel, iso-hexane:EtOAc 1:0 - 
7:3). 
νmax (ATR): 3508 (OH), 2925, 2854, 1730 (C=O), 1208, 1094 cm-1; δH (CDCl3, 400 MHz): 
4.28 - 4.20 (m, 2H, O-CH2-CH3), 4.16 (ddd, J = 7.4, 5.6, 4.1 Hz, 1H, 2-H), 3.40 (t, J = 6.9 
Hz, 2H, 12-H2), 2.74 (d, J = 5.6 Hz, 1H, OH), 1.92 - 1.70 (m, 3H, 11-H2, 3-H), 1.68 - 1.56 
(m, 1H, 3-H), 1.55 - 1.13 (m, 17H, 7 × CH2, O-CH2-CH3); δC (CDCl3, 101 MHz): 175.6 (C-
1), 70.6 (C-2), 61.7 (O-CH2-CH3), 34.6 (C-3), 34.2 (C-12), 33.0 (C-11), 29.5 (CH2), 29.5 
(CH2), 29.4 (CH2), 28.9 (CH2), 28.3 (CH2), 24.8 (CH2), 14.4 (O-CH2-CH3); HRMS (ASAP) 
found [M+H]+ 323.1217, C14H28O379Br requires M 323.1222. 
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General Procedure D 
To a solution of (+)-diethyl L-tartrate 80 (0.17 ml, 1.5 mmol, 0.6 eq) in dry Et2O (1.5 ml) at 
0 °C, periodic acid (342 mg, 1.5 mmol, 0.6 eq) was slowly added over 30 min. The reaction 
mixture was stirred another 20 min at rt, filtered through Celite® and concentrated. The 
crude product was dissolved in dry DCM and added to a slurry of ferric chloride (1.217 g, 
7.5 mmol, 3 eq) in dry DCM and H2O (0.14 ml, 7.5 mmol, 3 eq). The mixture was cooled to 
0 °C and alkene (2.5 mmol, 1 eq) was added before the mixture was stirred for 3 h at rt. 
The reaction mixture was washed with 0.1 N HCl, dried over MgSO4, filtered through silica 
gel and concentrated. 
The hydrogenator flask was charged with 5% Pd/C (62% H2O, 80 mg) and the crude 
product from the previous step, dissolved in dry MeOH. The flask was purged with nitrogen 
and then flushed with hydrogen (1.5 bar) and stirred for 2.5 h at rt. The reaction mixture 
was concentrated and the title product was afforded by flash column chromatography. 
 
Ethyl 2-hydroxyheptanoate180 87 
 
The reaction was carried out according to General procedure D using 1-pentene (0.27 ml, 
2.5 mmol, 1 eq). Flash column chromatography (24 g silica gel, iso-hexane:EtOAc 1:0 - 
4:1) yielded the title product (137 mg, 31%)) as a colourless oil. 
νmax (ATR): 3472 (OH), 2931, 2862, 1730 (C=O), 1199, 1132 cm-1; δH (CDCl3, 400 MHz): 
4.28 - 4.20 (m, 2H, O-CH2-CH3), 4.16 (ddd, J = 7.5, 5.7, 4.2 Hz, 1H, 2-H), 2.79 - 2.65 (m, 
1H, OH), 1.84 - 1.70 (m, 1H, 3-H), 1.67 - 1.58 (m, 1H, 3-H), 1.52 - 1.23 (m, 9H, 3 × CH2, 
O-CH2-CH3), 0.94 - 0.83 (m, 3H, 7-H3); δC (CDCl3, 101 MHz): 175.6 (C-1), 70.6 (C-2), 61.7 
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(O-CH2-CH3), 34.5 (CH2), 31.6 (CH2), 24.5 (CH2), 22.6 (CH2), 14.4 (O-CH2-CH3), 14.1 (C-
7); HRMS (ASAP) found [M+H]+ 175.1326, C9H19O3 requires M 175.1334. 
 
Ethyl 2-hydroxynonanoate 88 
 
The reaction was carried out according to General procedure D using 1-heptene (0.35 ml, 
2.5 mmol, 1 eq). Flash column chromatography (24 g silica gel, iso-hexane:EtOAc 1:0 - 
4:1) yielded the title product (100 mg, 20%)) as a colourless oil. 
 
νmax (ATR): 3480 (OH), 2925, 2857, 1731 (C=O), 1204, 1132, 1092 cm-1; δH (CDCl3, 400 
MHz): 4.30 - 4.20 (m, 2H, O-CH2-CH3), 4.16 (ddd, J = 7.3, 5.3, 4.2 Hz, 1H, 2-H), 2.73 (d, J 
= 5.3 Hz, 1H, OH), 1.84 - 1.71 (m, 1H, 3-H), 1.69 - 1.56 (m, 1H, 3-H), 1.55 - 1.10 (m, 13H, 
5 × CH2, O-CH2-CH3), 0.94 - 0.79 (m, 3H, 9-H3); δC (CDCl3, 101 MHz): 175.6 (C-1), 70.6 
(C-2), 61.7 (O-CH2-CH3), 34.6 (CH2), 31.9 (CH2), 29.4 (CH2), 29.3 (CH2), 24.9 (CH2), 22.8 
(CH2), 14.4 (O-CH2-CH3), 14.2 (C-9); HRMS (ASAP) found [M+H]+ 203.1632, C11H23O3 
requires M 203.1647. 
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Ethyl 2-hydroxyundecanoate181 89 
 
The reaction was carried out according to General procedure D using 1-nonene (0.43 ml, 
2.5 mmol, 1 eq). Flash column chromatography (24 g silica gel, iso-hexane:EtOAc 1:0 - 
4:1) yielded the title product (103 mg, 18%)) as a colourless oil. 
 
νmax (ATR): 3438 (OH), 2916, 2849, 1734 (C=O), 1195, 1087 cm-1; δH (CDCl3, 400 MHz): 
4.28 - 4.21 (m, 2H, O-CH2-CH3), 4.16 (ddd, J = 7.4, 5.8, 4.2 Hz, 1H, 2-H), 2.72 (dd, J = 5.8, 
2.2 Hz, 1H, OH), 1.84 - 1.71 (m, 1H, 3-H), 1.68 - 1.56 (m, 1H, 3-H), 1.53 - 1.10 (m, 17H, 7 
× CH2, O-CH2-CH3), 0.87 (t, J = 6.8 Hz, 3H, 11-H3); δC (CDCl3, 101 MHz): 175.6 (C-1), 
70.6 (C-2), 61.8 (O-CH2-CH3), 34.6 (CH2), 32.0 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 
29.4 (CH2), 24.9 (CH2), 22.8 (CH2), 14.4 (O-CH2-CH3), 14.3 (C-11); HRMS (ASAP) found 
[M+H]+ 231.1959, C13H27O3 requires M 231.1960. 
 
Ethyl 2-hydroxytetradecanoate 90 
 
The reaction was carried out according to General procedure D using 1-dodecene 
(0.56 ml, 2.5 mmol, 1 eq). Flash column chromatography (24 g silica gel, iso-
hexane:EtOAc 1:0 - 4:1) yielded the title product (379 mg, 56%)) as a colourless solid. 
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m.p.: 48 – 50 °C; νmax (ATR): 3460 (OH), 2917, 2849, 1732 (C=O), 1197, 1093 cm-1; δH 
(CDCl3, 400 MHz): 4.28 - 4.21 (m, 2H, O-CH2-CH3), 4.19 - 4.11 (m, 1H, 2-H), 2.71 (d, J = 
5.7 Hz, 1H, OH), 1.83 - 1.72 (m, 1H, 3-H), 1.68 - 1.56 (m, 1H, 3-H), 1.54 - 1.12 (m, 23H, 
10 × CH2, O-CH2-CH3), 0.88 (t, J = 6.7 Hz, 3H, 14-H3); δC (CDCl3, 101 MHz): 175.6 (C-1), 
70.6 (C-2), 61.8 (O-CH2-CH3), 34.6 (CH2), 32.1 (CH2), 29.8 (CH2), 29.8 (CH2), 29.8 (CH2), 
29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 24.9 (CH2), 22.8 (CH2), 14.4 (O-CH2-CH3), 
14.3 (C-14); HRMS (ASAP) found [M+H]+ 273.2427, C16H33O3 requires M 273.2430.  
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Ethyl 2-(((trifluoromethyl)sulfonyl)oxy)heptanoate 91 
 
Ethyl 2-hydroxyheptanoate 87 (87 mg, 0.5 mmol, 1 eq) was dissolved in dry DCM (1 ml) at 
0 °C under a nitrogen atmosphere. 2,6-Lutidine (0.07 ml, 0.6 mmol, 1.2 eq) and 
subsequently triflic anhydride (0.09 ml, 0.55 mmol, 1.1 eq) were added and the reaction 
was stirred at 0 °C for 2 h. H2O was slowly added and the two layers were separated. The 
organic layer was dried over MgSO4 and concentrated. Flash column chromatography 
(12 g silica gel, iso-hexane:EtOAc 1:0 - 4:1) afforded the title product (121 mg, 79%) as a 
colourless oil. 
νmax (ATR): 2936, 2876, 1736 (C=O), 1417, 1199, 1144, 954 cm-1; δH (CDCl3, 400 MHz): 
5.10 (t, J = 6.2 Hz, 1H, 2-H), 4.39 - 4.22 (m, 2H, O-CH2-CH3), 2.06 - 1.90 (m, 2H, 3-H), 
1.53 - 1.19 (m, 9H, 3 × CH2, O-CH2-CH3), 1.00 - 0.82 (m, 3H, 7-H3); δC (CDCl3, 101 MHz): 
167.3 (C-1), 118.5 (q, 1JCF = 319.5 Hz, CF3), 83.9 (C-2), 62.9 (O-CH2-CH3), 32.0 (CH2), 
30.9 (CH2), 24.1 (CH2), 22.3 (CH2), 14.0 (O-CH2-CH3), 13.9 (C-7); δF (CDCl3, 376 MHz): -
74.95. 
 
Ethyl 2-(((trifluoromethyl)sulfonyl)oxy)nonanoate 92 
 
Ethyl 2-hydroxynonanoate 88 (81 mg, 0.4 mmol, 1 eq) was dissolved in dry DCM (0.8 ml) 
at 0 °C under a nitrogen atmosphere. 2,6-Lutidine (0.06 ml, 0.48 mmol, 1.2 eq) and 
subsequently triflic anhydride (0.07 ml, 0.44 mmol, 1.1 eq) were added and the reaction 
was stirred at 0 °C for 2 h. H2O was slowly added and the two layers were separated. The 
organic layer was dried over MgSO4 and concentrated. Flash column chromatography 
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(12 g silica gel, iso-hexane:EtOAc 1:0 - 4:1) afforded the title product (110 mg, 82%) as a 
colourless oil. 
νmax (ATR): 2932, 2861, 1763 (C=O), 1417, 1200, 1144, 922 cm-1; δH (CDCl3, 400 MHz): 
5.10 (t, J = 6.1 Hz, 1H, 2-H), 4.37 - 4.22 (m, 2H, O-CH2-CH3), 2.10 - 1.88 (m, 2H, 3-H), 
1.53 - 1.17 (m, 13H, 5 × CH2, O-CH2-CH3), 0.95 - 0.82 (m, 3H, 9-H3); δC (CDCl3, 101 MHz): 
167.4 (C-1), 118.6 (q, 1JCF = 319.5 Hz, CF3), 84.0 (C-2), 62.8 (O-CH2-CH3), 32.1 (CH2), 
31.7 (CH2), 29.0 (CH2), 28.9 (CH2), 24.6 (CH2), 22.7 (CH2), 14.2 (O-CH2-CH3), 14.1 (C-9); 
δF (CDCl3, 376 MHz): -74.94. 
 
Ethyl 2-(((trifluoromethyl)sulfonyl)oxy)undecanoate 93 
 
Ethyl 2-hydroxyundecanoate 89 (81 mg, 0.35 mmol, 1 eq) was dissolved in dry DCM 
(0.8 ml) at 0 °C under a nitrogen atmosphere. 2,6-Lutidine (0.05 ml, 0.48 mmol, 1.2 eq) 
and subsequently triflic anhydride (0.06 ml, 0.44 mmol, 1.1 eq) were added and the 
reaction was stirred at 0 °C for 2 h. H2O was slowly added and the two layers were 
separated. The organic layer was dried over MgSO4 and concentrated. Flash column 
chromatography (12 g silica gel, iso-hexane:EtOAc 1:0 - 4:1) afforded the title product 
(116 mg, 91%) as a colourless oil. 
νmax (ATR): 2929, 2858, 1764 (C=O), 1418, 1201, 1145, 921 cm-1; δH (CDCl3, 400 MHz): 
5.10 (t, J = 6.1 Hz, 1H, 2-H), 4.40 - 4.20 (m, 2H, O-CH2-CH3), 2.13 - 1.82 (m, 2H, 3-H), 
1.50 - 1.20 (m, 17H, 7 × CH2, O-CH2-CH3), 0.88 (t, 1JCF = 6.7 Hz, 3H, 11-H3); δC (CDCl3, 
101 MHz): 167.4 (C-1), 118.6 (q, J = 319.7 Hz, CF3), 84.0 (C-2), 62.8 (O-CH2-CH3), 32.1 
(CH2), 32.0 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 28.9 (CH2), 24.6 (CH2), 22.8 (CH2), 
14.2 (O-CH2-CH3), 14.1 (C-11); δF (CDCl3, 376 MHz): -74.92.  
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Ethyl 2-(((trifluoromethyl)sulfonyl)oxy)tetradecanoate 94 
 
Ethyl 2-hydroxy-tetradecanoate 90 (163 mg, 0.6 mmol, 1 eq) was dissolved in dry DCM 
(1.5 ml) at 0 °C under a nitrogen atmosphere. 2,6-Lutidine (0.08 ml, 0.72 mmol, 1.2 eq) 
and subsequently triflic anhydride (0.11 ml, 0.66 mmol, 1.1 eq) were added and the 
reaction was stirred at 0 °C for 2 h. H2O was slowly added and the two layers were 
separated. The organic layer was dried over MgSO4 and concentrated. Flash column 
chromatography (12 g silica gel, iso-hexane:EtOAc 1:0 - 4:1) afforded the title product 
(219 mg, 90%) as a colourless oil. 
 
νmax (ATR): 2926, 2856, 1764 (C=O), 1418, 1201, 1144, 921 cm-1; δH (CDCl3, 400 MHz): 
5.10 (t, J = 6.1 Hz, 1H, 2-H), 4.38 - 4.22 (m, 2H, O-CH2-CH3), 2.05 - 1.92 (m, 2H, 3-H), 
1.54 - 1.06 (m, 23H, 10 × CH2, O-CH2-CH3), 0.88 (t, J = 6.8 Hz, 3H, 14-H3); δC (CDCl3, 101 
MHz): 167.4 (C-1), 118.6 (q, 1JCF = 319.5 Hz, CF3), 84.0 (C-2), 62.8 (O-CH2-CH3), 32.1 
(CH2), 32.1 (CH2), 29.8 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.3 (CH2), 
28.9 (CH2), 24.6 (CH2), 22.8 (CH2), 14.3 (O-CH2-CH3), 14.1 (C-14); δF (CDCl3, 376 MHz): -
74.94. 
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General Procedure E 
A mixture of 5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one 46 (101 mg, 0.375 mmol, 
1.5 eq), triflate (0.25 mnmol, 1 eq) and K2CO3 (104 mg, 0.75 mmol, 3 eq) in dry MeCN 
(1 ml) under a nitrogen atmosphere was stirred at rt overnight. H2O (2 ml) was added to 
the reaction mixture. The aqueous phase was extracted with EtOAc (3 × 2 ml), the organic 
extracts collected, washed with brine, dried over MgSO4 and concentrated. The crude 
product together with LiOH.H2O (31 mg, 0.75 mmol, 3 eq) was stirred in a 1:1 mixture of 
H2O (3 ml) and THF (3 ml) at rt for 3 h. The mixture was acidified to pH 2-3 with 1N HCl 
and the aqueous phase was extracted with DCM (3 × 5 ml). The combined organic layers 
were dried over MgSO4 and concentrated. Flash column chromatography (12 g silica gel, 
DCM:MeOH 1:0 - 19:1) yielded in the product. 
 
2-[(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-yl)oxy]heptanoic acid 95 
 
 
Following General procedure E using ethyl 2-(((trifluoromethyl)sulfonyl)oxy)heptanoate 91 
(77 mg, 0.25 mnmol, 1 eq) gave the title product (61 mg, 62%) as a colourless solid. 
m.p.: 104 – 105 °C; νmax (ATR): 2929, 2860, 1743 (C=O), 1630 (C=O), 1592, 1354, 1161, 
1110, 768 cm-1; δH (CDCl3, 400 MHz): 13.67 (br. s, 1H, COOH), 7.95 - 7.84 (m, 2H, 2’’-H, 
6’’-H), 7.60 - 7.47 (m, 3H, 4’’-H, 3’’-H, 5’’-H), 6.76 (s, 1H, 3’-H), 6.73 (d, J = 2.2 Hz, 1H, 8’-
H), 6.47 (d, J = 2.2 Hz, 1H, 6’-H), 4.83 (t, J = 5.3 Hz, 1H, 2-H), 3.94 (s, 3H, OCH3), 2.23 - 
2.07 (m, 2H, 3-H2), 1.66 - 1.45 (m, 2H, 4-H2), 1.42 - 1.22 (m, 4H, 2 × CH2), 0.89 (t, J = 7.1 
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Hz, 3H, 7-H3); δC (CDCl3, 101 MHz): 179.0 (C-4’), 172.5 (C-1), 164.9 (C-7’), 162.9 (C-2’), 
159.6 (C-8a’), 159.0 (C-5’), 132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 (C-2’’, C-
6’’), 109.6 (C-4a’), 108.4 (C-3’), 101.4 (C-6’), 95.2 (C-8’), 82.0 (C-2), 56.2 (OCH3), 33.0 (C-
3), 31.7 (CH2), 24.5 (C-4), 22.6 (CH2), 14.1 (C-7); HRMS (ES+) found [M+H]+ 397.1663, 
C23H25O6 requires M 397.1651. 
 
2-[(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-yl)oxy]nonanoic acid 96 
 
Following General procedure E using ethyl 2-(((trifluoromethyl)sulfonyl)oxy)nonanoate 92 
(84 mg, 0.25 mnmol, 1 eq) gave the title product (65 mg, 61%) as a colourless solid. 
 
m.p.: 143 – 145 °C; νmax (ATR): 2926, 2852, 1739 (C=O), 1610 (C=O), 1591, 1357, 1168, 
766 cm-1; δH (CDCl3, 400 MHz): 13.59 (br. s, 1H, COOH), 7.96 - 7.83 (m, 2H, 2’’-H, 6’’-H), 
7.61 - 7.47 (m, 3H, 4’’-H, 3’’-H, 5’’-H), 6.76 (s, 1H, 3’-H), 6.73 (d, J = 2.2 Hz, 1H, 8’-H), 
6.47 (d, J = 2.2 Hz, 1H, 6’-H), 4.83 (t, J = 5.3 Hz, 1H, 2-H), 3.94 (s, 3H, OCH3), 2.25 - 2.06 
(m, 2H, 3-H2), 1.67 - 1.46 (m, 2H, 4-H2), 1.42 - 1.21 (m, 8H, 4 × CH2), 0.87 (t, J = 6.7 Hz, 
3H, 9-H3); δC (CDCl3, 101 MHz): 179.0 (C-4’), 172.6 (C-1), 164.9 (C-7’), 162.9 (C-2’), 159.6 
(C-8a’), 159.0 (C-5’), 132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 (C-2’’, C-6’’), 
109.6 (C-4a’), 108.4 (C-3’), 101.4 (C-6’), 95.2 (C-8’), 82.0 (C-2), 56.2 (OCH3), 33.0 (C-3), 
31.9 (CH2), 29.5 (CH2), 29.2 (CH2), 24.8 (C-4), 22.8 (CH2), 14.2 (C-9); HRMS (ES+) found 
[M+H]+ 425.1967, C25H29O6 requires M 425.1964. 
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2-[(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-yl)oxy]undecanoic acid 97 
 
Following General procedure E using ethyl 2-(((trifluoromethyl)sulfonyl)oxy)undecanoate 
93 (91 mg, 0.25 mnmol, 1 eq) gave the title product (90 mg, 80%) as a colourless solid. 
 
m.p.: 96 – 98 °C; νmax (ATR): 2914, 2851, 1728 (C=O), 1617 (C=O), 1597, 1363, 1165, 
1111, 855 cm-1; δH (CDCl3, 400 MHz): 13.68 (br. s, 1H, COOH), 7.95 - 7.82 (m, 2H, 2’’-H, 
6’’-H), 7.64 - 7.46 (m, 3H, 4’’-H, 3’’-H, 5’’-H), 6.76 (s, 1H, 3’-H), 6.73 (d, J = 2.2 Hz, 1H, 8’-
H), 6.47 (d, J = 2.2 Hz, 1H, 6’-H), 4.83 (t, J = 5.3 Hz, 1H, 2-H), 3.94 (s, 3H, OCH3), 2.30 - 
1.99 (m, 2H, 3-H2), 1.70 - 1.44 (m, 2H, 4-H2), 1.43 - 1.16 (m, 12H, 6 × CH2), 0.87 (t, J = 6.6 
Hz, 3H, 11-H3); δC (CDCl3, 101 MHz): 179.0 (C-4’), 172.5 (C-1), 164.9 (C-7’), 162.9 (C-2’), 
159.6 (C-8a’), 159.0 (C-5’), 132.1 (C-4’’), 131.1 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 (C-2’’, C-
6’’), 109.6 (C-4a’), 108.4 (C-3’), 101.4 (C-6’), 95.2 (C-8’), 82.0 (C-2), 56.2 (OCH3), 33.0 (C-
3), 32.0 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.8 (C-4), 22.8 (CH2), 14.3 
(C-11) ; HRMS (ES+) found [M+H]+ 453.2285, C27H33O6 requires M 453.2277. 
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2-[(7’-Methoxy-4’-oxo-2’-phenyl-4’H-chromen-5’-yl)oxy]tetradecanoic acid 98 
 
Following General procedure E using ethyl 2-(((trifluoromethyl)sulfonyl)oxy)-
tetradecanoate 94 (101 mg, 0.25 mmol, 1 eq) gave the title product (0.103 g, 83%) as a 
colourless solid. 
 
m.p.: 99 – 101 °C; νmax (ATR): 2916, 2848, 1745 (C=O), 1639 (C=O), 1597, 1355, 1194, 
1159 cm-1; δH (CDCl3, 400 MHz): 13.68 (br. s, 1H, COOH), 7.93 - 7.86 (m, 2H, 2’’-H, 6’’-H), 
7.60 - 7.49 (m, 3H, 4’’-H, 3’’-H, 5’’-H), 6.76 (s, 1H, 3’-H), 6.73 (d, J = 2.2 Hz, 1H, 8’-H), 
6.47 (d, J = 2.2 Hz, 1H, 6’-H), 4.83 (t, J = 5.3 Hz, 1H, 2-H), 3.94 (s, 3H, OCH3), 2.22 - 2.07 
(m, 2H, 3-H2), 1.66 - 1.46 (m, 2H, 4-H2), 1.45 - 1.10 (m, 12H, 6 × CH2), 0.87 (t, J = 6.8 Hz, 
3H, 14-H3); δC (CDCl3, 101 MHz): 179.0 (C-4’), 172.6 (C-1), 164.9 (C-7’), 162.9 (C-2’), 
159.6 (C-8a’), 159.0 (C-5’), 132.1 (C-4’’), 131.0 (C-1’’), 129.3 (C-3’’, C-5’’), 126.4 (C-2’’, C-
6’’), 109.5 (C-4a’), 108.3 (C-3’), 101.4 (C-6’), 95.2 (C-8’), 82.0 (C-2), 56.2 (OCH3), 33.0 (C-
3), 32.1 (CH2), 29.8 (2 × CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 
24.8 (C-4), 22.8 (CH2), 14.3 (C-14); HRMS (ES+) found [M+H]+ 495.2762, C30H39O6 
requires M 495.2747. 
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5.1.4 Improving Solubility 
5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid, 2’-acetylhydrazide 109 
 
5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41 (125 mg, 0.5 mmol, 1 eq), 
acethydrazide (41 mg, 0.55 mmol, 1.1 eq) and PyBOP (286 mg, 0.55 mmol, 1.1 eq) were 
dissolved in dry DMF (1.5 ml) and DIPEA (0.19 ml, 1.1 mmol, 2.2 eq) was added. The 
reaction mixture was stirred at rt overnight and then concentrated. The title product 
(108 mg, 71%) was obtained by flash column chromatography (12 g silica gel, DCM:MeOH 
1:0-9:1) and subsequent trituration with DCM as a colourless solid. 
 
m.p.: 282 – 285 °C (decomposition); νmax (ATR): 3241 (NH), 1657 (C=O), 1606 (C=O), 
1352, 1164, 1110, 495 cm-1; δH (d6-DMSO, 700 MHz): 10.82 (br. s, 1H, NH), 10.08 (s, 1H, 
NH), 6.76 (d, J = 2.4 Hz, 1H, 8-H), 6.58 (s, 1H, 3-H), 6.56 (d, J = 2.4 Hz, 1H, 6-H), 3.89 (s, 
3H, OCH3), 3.84 (s, 3H, OCH3), 1.94 (s, 3H, CH3); δC (d6-DMSO, 176 MHz): 175.0 (C-4), 
168.3 (CH3C=O), 164.2 (C-7), 160.4 (C-5), 158.6 (C-8a), 158.2 (C=O), 152.0 (C-2), 112.8 
(C-3), 108.9 (C-4a), 96.6 (C-6), 93.4 (C-8), 56.2 (OCH3), 55.9 (OCH3), 20.5 (CH3); HRMS 
(ES+) found [M+H]+ 307.0941, C14H15N2O6 requires M 307.0930. 
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5,7-Dimethoxy-2-(5’-methyl-1’,3’,4’-oxadiazol-2’-yl)-4H-chromen-4-one 99 
 
5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41 (125 mg, 0.5 mmol, 1 eq), 
acethydrazide (41 mg, 0.55 mmol, 1.1 eq) and PyBOP (286 mg, 0.55 mmol, 1.1 eq) were 
dissolved in dry DMF (1.5 ml) and DIPEA (0.19 ml, 1.1 mmol, 2.2 eq) was added. The 
reaction mixture was stirred at rt overnight and then concentrated. The crude product and 
Burgess reagent (238 mg, 1 mmol, 2 eq) were dissolved in dry 1,2-dichloroethane under 
an argon atmosphere and heated to 140 °C for 3 h in a microwave. The title product 
(51 mg, 36%) was obtained by flash column chromatography (24 g silica gel, DCM:MeOH 
1:0-19:1) and subsequent trituration with DCM as a colourless solid. 
 
m.p.: 231 – 234 °C (decomposition); νmax (ATR): 1637 (C=O), 1608, 1569, 1315, 1136, 
1073, 819 cm-1; δH (CDCl3, 700 MHz): 6.90 (s, 1H, 3-H), 6.64 (d, J = 2.3 Hz, 1H, 8-H), 6.40 
(d, J = 2.3 Hz, 1H, 6-H), 3.95 (s, 3H, OCH3), 3.89 (s, 3H, OCH3), 2.67 (s, 3H, CH3); δC 
(CDCl3, 176 MHz): 176.0 (C-4), 165.4 (C-4’), 165.0 (C-7), 161.2 (C-5), 159.7 (C-8a), 159.1 
(C-1’), 146.7 (C-2), 114.0 (C-3), 110.0 (C-4a), 97.1 (C-6), 93.2 (C-8), 56.6 (OCH3), 56.1 
(OCH3), 11.3 (CH3); HRMS (ES+) found [M+H]+ 289.0828, C14H13N2O5 requires M 
289.0824. 
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N-(2’,2’-Diethoxyethyl)-5,7-dimethoxy-4-oxo-4H-chromene-2-carboxamide 110 
 
5,7-Dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41 (250 mg, 1 mmol, 1 eq), 
aminoacetaldehyde diethyl acetal (0.15 ml, 1.1 mmol, 1.1 eq) and PyBOP (572 mg, 
1.1 mmol, 1.1 eq) were dissolved in dry DMF (3 ml) and DIPEA (0.38 ml, 2.2 mmol, 2.2 eq) 
was added. The reaction mixture was stirred at rt overnight and then concentrated. The 
title product (330 mg, 90%) was obtained by flash column chromatography (40 g silica gel, 
DCM:MeOH 1:0-19:1) as a colourless solid. 
 
m.p.: 106 – 108 °C (decomposition); νmax (ATR): 3497 (NH), 2976, 1658 (C=O), 1608 
(C=O), 1345, 1057, 826 cm-1; δH (CDCl3, 700 MHz): 7.04 (t, J = 6.0 Hz, 1H, NH), 6.96 (s, 
1H, 3-H), 6.47 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 4.62 (t, J = 5.1 Hz, 
1H, 2’-H), 3.93 (s, 3H, OCH3), 3.90 (s, 3H, OCH3), 3.81 - 3.73 (m, 2H, 1’-H), 3.67 - 3.51 
(m, 4H, 2 × OCH2CH3), 1.25 (t, J = 7.0 Hz, 6H, 2 × OCH2CH3); δC (CDCl3, 176 MHz): 177.1 
(C-4), 164.7 (C-7), 161.3 (C-5), 159.6 (C=O), 159.1 (C-8a), 152.4 (C-2), 114.1 (C-3), 109.9 
(C-4a), 100.6 (C-2’), 96.7 (C-6), 93.0 (C-8), 63.5 (C-1’), 56.6 (OCH3), 56.0 (OCH3), 42.4 (2 
× OCH2CH3), 15.5 (2 × OCH2CH3); HRMS (ES+) found [M+H]+ 366.1552, C18H24NO7 
requires M 366.1553. 
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5,7-Dimethoxy-2-(1’,3’-oxazol-2’-yl)-4H-chromen-4-one 100 
 
TFA (1.68 ml, 22 mmol, 110 eq) was added to a solution of N-(2’,2’-diethoxyethyl)-5,7-
dimethoxy-4-oxo-4H-chromene-2-carboxamide 110 (73 mg, 0.2 mmol, 1 eq) in dry DCM 
(2.5 ml) under an argon atmosphere. The reaction mixture was stirred at rt for 2.5 h and 
then concentrated. The crude product and Burgess reagent (238 mg, 1 mmol, 2 eq) were 
dissolved in dry 1,2-dichloroethane under an argon atmosphere and heated to 140 °C for 
3 h in a microwave. The reaction mixture was concentrated and the title oxazole (16 mg, 
28%) obtained by flash column chromatography (12 g silica gel, Et2O:MeOH 1:0-9:1) as a 
colourless solid. 
 
m.p.: 205 – 208 °C (decomposition); νmax (ATR): 1657 (C=O), 1610, 1332, 1116, 828 cm-
1; δH (CDCl3, 700 MHz): 7.84 (d, J = 0.8 Hz, 1H, 4’-H), 7.39 (d, J = 0.8 Hz, 1H, 3’), 6.94 (s, 
1H, 3-H), 6.66 (d, J = 2.3 Hz, 1H, 8-H), 6.40 (d, J = 2.3 Hz, 1H, 6-H), 3.95 (s, 3H, OCH3), 
3.89 (s, 3H, OCH3); δC (CDCl3, 176 MHz): 176.6 (C-4), 164.7 (C-7), 161.1 (C-5), 159.8 (C-
8a), 155.1 (C-1’), 149.1 (C-2), 140.9 (C-4’), 129.8 (C-3’), 112.5 (C-3), 110.0 (C-4a), 96.9 
(C-6), 93.2 (C-8), 56.6 (OCH3), 56.1 (OCH3); HRMS (ES+) found [M+H]+ 274.0686, 
C14H12NO5 requires M 274.0715. 
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5,7-Dimethoxy-4H-chromen-4-one-2-carboxamide182 111 
 
Phosphorus oxychloride (0.15 ml, 1.6 mmol, 1 eq) was added to a solution of 
5,7-dimethoxy-4-oxo-4H-chromene-2-carboxylic acid 41 (400 mg, 1.6 mmol, 1 eq) in dry 
DMF (3.2 ml). The reaction mixture was stirred 10 min at rt and another 50 min at 50 °C 
and then added to ammonium hydroxide solution (35% NH3 in H2O, 3.2 ml) at 0 °C and 
stirred for 1 h. The resulting precipitate was collected by filtration and dried. The title 
carboxamide (291 mg, 73%) was obtained by flash column chromatography (40 g silica 
gel, DCM:MeOH 1:0-9:1) as a colourless solid. 
 
m.p.: 268 – 269 °C (decomposition) (lit.182 m.p.: 268 – 270 °C); νmax (ATR): 3519 (NH), 
3385 (NH), 3144 (NH), 1652 (C=O), 1608 (C=O), 1330, 1069, 639 cm-1; δH (d6-DMSO , 
700 MHz): 8.40 (s, 1H, NH), 8.07 (s, 1H, NH), 6.77 (d, J = 2.4 Hz, 1H, 8-H), 6.56 (s, 1H, 3-
H), 6.54 (d, J = 2.4 Hz, 1H, 6-H), 3.88 (s, 3H, OCH3), 3.83 (s, 3H, OCH3); δC (d6-DMSO, 
176 MHz): 175.5 (C-4), 164.1 (C-7), 160.7 (CONH2), 160.4 (C-5), 158.7 (C-8a), 153.1 (C-
2), 112.2 (C-3), 108.8 (C-4a), 96.5 (C-6), 93.4 (C-8), 56.2 (OCH3), 55.9 (OCH3); HRMS 
(ES+) found [M+H]+ 250.0686, C12H12NO5 requires M 250.0715. 
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5,7-Dimethoxy-4H-chromen-4-one-2-carbonitrile182 112 
 
Trifluoroacetic anhydride (0.21 ml, 1.54 mmol, 2.2 eq) and pyridine (0.23 ml, 2.81 mmol, 
4 eq) were added to a solution of 5,7-dimethoxy-4H-chromen-4-one-2-carboxamide 111 
(175 mg, 0.70 mmol, 1 eq) in dry DMF (3.5 ml) at 0 °C under an argon atmosphere. The 
reaction mixture was stirred at rt overnight and concentrated. Flash column 
chromatography (24 g silica gel DCM:MeOH 1:0-19:1) afforded the title nitrile (145 mg, 
90%) as a colourless solid. 
 
m.p.: 188 – 190 °C (lit.182 m.p.: 189 – 191 °C); νmax (ATR): 2253 (CN), 1652 (C=O), 1608, 
1341, 1157, 1078, 852, 799 cm-1; δH (CDCl3, 400 MHz): 6.66 (s, 1H, 3-H), 6.46 (d, J = 2.3 
Hz, 1H, 8-H), 6.40 (d, J = 2.3 Hz, 1H, 6-H), 3.94 (s, 3H, OCH3), 3.90 (s, 3H, OCH3); δC 
(CDCl3, 176 MHz): 174.2 (C-4), 165.3 (C-7), 161.3 (C-5), 159.9 (C-8a), 135.9 (C-2), 122.1 
(C-3), 111.9 (CN), 110.3 (C-4a), 97.4 (C-6), 93.0 (C-8), 56.7 (OCH3), 56.2 (OCH3); HRMS 
(ES+) found [M+H]+ 232.0614, C12H10NO4 requires M 232.0610. 
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5,7-Dimethoxy-2-(1H-1’,2’,3’,4’-tetrazol-5’-yl)-4H-chromen-4-one182 101 
 
Dry toluene (0.75 ml) was added to 5,7-dimethoxy-4H-chromen-4-one-2-carbonitrile 112 
(75 mg, 0.33 mmol, 1 eq), NaN3 (28 mg, 0.43 mmol, 1.3 eq) and Et3N.HCl (59 mg, 
0.43 mmol, 1.3 eq) under an argon atmosphere. The reaction mixture was stirred at 95 °C 
for 48 h. H2O (10 ml) was added, the aqueous phase was separated and the organic 
phase was further washed with H2O. The combined aqueous layers were cooled to 0 °C, 
aqueous sodium nitrite solution (20 wt%, 0.1 ml) and sulfuric acid (20 wt%, 0.1 ml) were 
added and the solution was stirred for 30 min. The product was extracted with EtOAc (5 × 
20 ml) and the combined organic layers were dried over Na2SO4 and concentrated. The 
title tetrazole (15 mg, 17%) was obtained by recrystallization from MeOH as a colourless 
solid. 
 
m.p.: 242 – 243 °C (lit.182 m.p.: 244 – 245 °C); νmax (ATR): 1651 (C=O), 1602, 1312, 1161, 
1092, 834 cm-1; δH (d6-DMSO, 700 MHz): 6.80 (s, 1H, 3-H), 6.73 (d, J = 2.3 Hz, 1H, 8-H), 
6.57 (d, J = 2.3 Hz, 1H, 6-H), 3.92 (s, 3H, OCH3), 3.85 (s, 3H, OCH3); δC (d6-DMSO, 176 
MHz): 174.6 (C-4), 164.2 (C-7), 160.5 (C-5), 159.0 (C-8a), 152.8 (C-1’), 149.7 (C-2), 111.8 
(C-3), 108.8 (C-4a), 96.7 (C-6), 93.3 (C-8), 56.2 (OCH3), 56.1 (OCH3); HRMS (ES+) found 
[M+H]+ 275.0787, C12H11N4O4 requires M 275.0780. 
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5,7-Dimethoxy-4H-chromen-4-one-2-carbothioamide 113 
 
5,7-Dimethoxy-4H-chromen-4-one-2-carbonitrile (1.340 g, 5.8 mmol, 1 eq) was added to a 
slurry of NaHS.xH2O (70%, 1.392 g, 17.4 mmol, 3 eq) and MgCl2.6H2O (1.296 g, 
6.4 mmol, 1.1 eq) in DMF (10 ml) and stirred at 60 °C for 20 h. H2O (50 ml) was added and 
the resulting precipitate was collected, washed with H2O, resuspended in 1N HCl and 
stirred for 30 min. The precipitate was collected again, washed with CHCl3 to remove 
unreacted starting material, and dried. Flash column chromatography (40 g silica gel 
DCM:MeOH 19:1-17:3) afforded the title carbothioamide (629 mg, 41%) as a yellow solid. 
 
m.p.: 247 - 249 °C (decomposition); νmax (ATR): 3382, 3301, 3198, 1623 (C=O), 1595, 
1416, 1224, 1125, 826 cm-1; δH (d6-DMSO, 700 MHz): 10.51 (s, 1H, NH), 10.06 (s, 1H, 
NH), 6.87 (s, 1H, 3-H), 6.87 (d, J = 2.3 Hz, 1H, 8-H), 6.54 (d, J = 2.3 Hz, 1H, 6-H), 3.88 (s, 
3H, OCH3), 3.83 (s, 3H, OCH3); δC (d6-DMSO, 176 MHz): 187.9 (CSNH2) 175.3 (C-4), 
164.2 (C-7), 160.3 (C-5), 158.2 (C-8a), 155.0 (C-2), 114.0 (C-3), 108.5 (C-4a), 96.6 (C-6), 
93.5 (C-8), 56.2 (OCH3), 55.9 (OCH3); HRMS (ES+) found [M+H]+ 266.0500, C12H12NO4S 
requires M 266.0487. 
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5,7-Dimethoxy-2-(1’,3’-thiazol-2’-yl)-4H-chromen-4-one 102 & 5-Hydroxy-7-methoxy-2-
(1’,3’-thiazol-2’-yl)-4H-chromen-4-one 114 
 
5,7-Dimethoxy-4H-chromen-4-one-2-carbothioamide (121 mg, 0.46 mmol, 1 eq) and 
bromoacetaldehyde diethyl acetal (226 mg, 1.14 mmol, 2.5 eq) were suspended in THF 
(2 ml) and EtOH (0.57 ml) and a drop of H2O was added. The reaction mixture was heated 
to 140 °C for 1 h in a microwave and subsequently concentrated. The title thiazole 102 
(45 mg, 34%) and the demethylated product 114 (47 mg, 37%) were obtained by flash 
column chromatography (24 g silica gel, hexane:(EtOAc:EtOH 3:1) 9:1-2:3), both as a light 
yellow solid.  
 
5,7-Dimethoxy-2-(1’,3’-thiazol-2’-yl)-4H-chromen-4-one 102: m.p.: 169 – 171 °C; 
νmax (ATR): 3107, 3067, 2945, 1644 (C=O), 1604, 1331, 1158, 1096, 829 cm-1; δH (CDCl3, 
700 MHz): 8.01 (d, J = 3.1 Hz, 1H, 3’-H), 7.60 (d, J = 3.1 Hz, 1H, 4’-H), 7.02 (s, 1H, 3-H), 
6.58 (d, J = 2.3 Hz, 1H, 8-H), 6.39 (d, J = 2.3 Hz, 1H, 6-H), 3.95 (s, 3H, OCH3), 3.91 (s, 
3H, OCH3); δC (CDCl3, 176 MHz): 176.9 (C-4), 164.5 (C-7), 161.2 (C-5), 159.7 (C-1’), 
159.6 (C-8a), 154.6 (C-2), 145.1 (C-3’), 122.5 (C-4’), 109.9 (C-3), 109.9 (C-4a), 96.7 (C-6), 
93.0 (C-8), 56.6 (OCH3), 56.0 (OCH3); HRMS (ES+) found [M+H]+ 290.0489, C14H12NO4S 
requires M 290.0487. 
 
5-Hydroxy-7-methoxy-2-(1’,3’-thiazol-2’-yl)-4H-chromen-4-one 114: m.p.: 204 - 206 °C; 
νmax (ATR): 3112, 3087, 3059, 1658 (C=O), 1613, 1579, 1321, 1193, 1155, 968  cm-1; δH 
(CDCl3, 700 MHz): 12.60 (s, 1H, OH), 8.05 (d, J = 3.1 Hz, 1H, 3’-H), 7.66 (d, J = 3.1 Hz, 
1H, 4’-H), 7.09 (s, 1H, 3-H), 6.52 (d, J = 2.3 Hz, 1H, 8-H), 6.40 (d, J = 2.3 Hz, 1H, 6-H), 
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3.90 (s, 3H, OCH3); δC (CDCl3, 176 MHz): 182.2 (C-4), 166.0 (C-7), 162.5 (C-5), 159.2 (C-
1’), 157.5 (C-8a), 157.4 (C-2), 145.4 (C-3’), 123.3 (C-4’), 106.6 (C-3), 106.4 (C-4a), 98.8 
(C-6), 93.0 (C-8), 56.1 (OCH3); HRMS (ES+) found [M+H]+ 276.0338, C13H10NO4S requires 
M 276.0331. 
 
  
  Experimental Part 
  232 
5,7-Dimethoxy-2-(1’H-pyrazol-3’-yl)-4H-chromen-4-one 104 
 
KOH (10 ml of a 3M solution in EtOH, 12 mmol, 6 eq) was added to a mixture of 
2-hydroxy-4,6-dimethoxyacetophenone 7 (392 mg, 2 mmol, 1 eq) and 1H-pyrrazole-5-
carbaldehyde (0.19 ml, 2 mmol, 1 eq). The reaction mixture was stirred for 36 h at 50 °C 
and subsequently acidified to pH 2 with 3M HCl and extracted with DCM (3 × 10 ml). The 
combined organic layers were dried over Na2SO4 and concentrated. Iodine (15 mg, 
0.3 mol%) was added to a stirred solution of the crude product in DMSO (3 ml) at 50 °C. 
Then the reaction mixture was heated to 140 °C and stirred for 2.5 h. After cooling to rt, 
H2O (20 ml) and DCM (20 ml) were added. The layers were separated and the aqueous 
layer was extracted two more times with DCM (2 × 20 ml). The combined organic layers 
were washed with aqueous Na2S2O3 solution (0.5%, 50 ml), dried over MgSO4 and 
concentrated. The title product (62 mg, 11%) was obtained by flash column 
chromatography (24 g silica gel, Et2O:MeOH 1:0-8:2) as a colourless solid. 
 
m.p.: 255 – 257 °C (decomposition); νmax (ATR): 3250 (NH), 1651 (C=O), 1606, 1324, 
1132, 818, 766 cm-1; δH (d6-DMSO, 700 MHz 13.49 (s, 1H, NH), 7.99 - 7.91 (m, 1H, 4’-H), 
6.95 - 6.88 (m, 1H, 5’-H), 6.75 (d, J = 2.4 Hz, 1H, 8-H), 6.56 (s, 1H, 3-H), 6.51 (d, J = 2.4 
Hz, 1H, 6-H), 3.89 (s, 3H, OCH3), 3.83 (s, 3H, OCH3); δC (d6-DMSO, 176 MHz): 175.3 (C-
4), 163.6 (C-7), 160.3 (C-5), 159.1 (C-8a), 156.3 (C-2), 143.4 (C-1’), 130.6 (C-4’), 108.7 
(C-4a), 107.2 (C-3), 104.3 (C-5’), 96.3 (C-6), 93.3 (C-8), 56.1 (OCH3), 56.0 (OCH3); HRMS 
(ES+) found [M+H]+ 273.0903, C14H13N2O4 requires M 273.0875.  
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5,7-Dimethoxy-2-(1’-methyl-1’H-pyrazol-5’-yl)-4H-chromen-4-one 105 & 5,7-Dimethoxy-2-
(1’-methyl-1’H-pyrazol-3’-yl)-4H-chromen-4-one 106 
 
5,7-Dimethoxy-2-(1’H-pyrazol-3’-yl)-4H-chromen-4-one 104 (95 mg, 0.35 mmol, 1 eq) was 
added to a slurry of NaH (60% dispersed in mineral oil, 22 mg, 0.56 mmol, 1.6 eq) in dry 
DMF (1 ml) at 0 °C under an argon atmosphere and the resulting mixture was stirred for 
15 min at 0 °C and another 15 min at rt. MeI (0.03 ml, 0.42 mmol, 1.2 eq) was added at 
0 °C and the mixture was stirred another at rt overnight. H2O (1 ml) was added and the 
product was extracted with DCM (3 × 2 ml). The combined organic layers were dried over 
Na2SO4 and concentrated. Flash column chromatography (24 g silica gel, 
hexane:(EtOAc:EtOH 3:1) 4:1-1:4) afforded the title products 105 (16 mg, 16%) and 106 
(33 mg, 33%) as colourless solids. 
 
5,7-Dimethoxy-2-(1’-methyl-1’H-pyrazol-5’-yl)-4H-chromen-4-one 105: m.p.: 180 – 181 °C; 
νmax (ATR): 1651 (C=O), 1607, 1354, 1112, 840, 783 cm-1; δH (CDCl3, 400 MHz): 7.52 (d, 
J = 2.1 Hz, 1H, 4’-H), 6.69 (d, J = 2.1 Hz, 1H, 5’-H), 6.53 - 6.42 (m, 2H, 8-H, 3-H), 6.39 (d, 
J = 2.3 Hz, 1H, 6-H), 4.16 (s, 3H, CH3), 3.95 (s, 3H, OCH3), 3.90 (s, 3H, OCH3); δC (CDCl3, 
151 MHz): 176.8 (C-4), 164.5 (C-7), 161.2 (C-5), 159.7 (C-8a), 153.0 (C-2), 138.8 (C-4’), 
134.8 (C-1’), 112.0 (C-3), 109.3 (C-4a), 108.8 (C-5’), 96.6 (C-6), 92.8 (C-8), 56.6 (OCH3), 
56.0 (OCH3), 39.8 (CH3); HRMS (ES+) found [M+H]+ 287.1034, C15H15N2O4 requires M 
287.1032. 
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5,7-Dimethoxy-2-(1’-methyl-1’H-pyrazol-3’-yl)-4H-chromen-4-one 106: m.p.: 169 – 171 °C; 
νmax (ATR): 1650 (C=O), 1604, 1328, 1202, 1079, 772 cm-1; δH (CDCl3, 400 MHz): 7.44 (d, 
J = 2.3 Hz, 1H, 4’-H), 6.74 - 6.65 (m, 2H, 5’-H, 3-H), 6.62 (d, J = 2.3 Hz, 1H, 8-H), 6.36 (d, 
J = 2.3 Hz, 1H, 6-H), 4.01 (s, 3H, CH3), 3.94 (s, 3H, OCH3), 3.88 (s, 3H, OCH3); δC (CDCl3, 
151 MHz): 177.6 (C-4), 164.0 (C-7), 161.0 (C-5), 159.9 (C-8a), 156.2 (C-2), 144.6 (C-1’), 
131.9 (C-4’), 109.8 (C-4a), 109.0 (C-3), 105.6 (C-5’), 96.4 (C-6), 93.2 (C-8), 56.6 (OCH3), 
55.9 (OCH3), 39.8 (CH3); HRMS (ES+) found [M+H]+ 287.1035, C15H15N2O4 requires M 
287.1032. 
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5,7-Dimethoxy-2-(6’-methylpyridazin-4’-yl)-4H-chromen-4-one 108 
 
To a solution of [Ir(COD)OMe]2 (7.5 mg, 3 mol%), dtbpy (6 mg, 6 mol%) and B2pin2 
(286 mg, 1.125 mmol, 3 eq) in degassed, dry MTBE (1.9 ml) under an argon atmosphere, 
3-methylpyridazine (0.07 ml, 0.75 mmol, 2 eq) was added. The reaction was stirred at 
50 °C overnight and subsequently concentrated. To the crude intermediate under an argon 
atmosphere were added Pd(amphos)Cl2 (13.3 mg, 5 mol%), K3PO4 (159 mg, 0.75 mmol, 
2 eq), 5,7-dimethoxy-2-chloro-4H-chromen-4-one 21 (90 mg, 0.375 mmol, 1 eq) and a 9:1 
mixture of DMAC (0.9 ml) and H2O (0.1 ml) as solvent. The mixture was stirred at 70 °C for 
4 h and then filtered through Celite® and concentrated. The reaction mixture was diluted 
with H2O and extracted with DCM (3 × 5 ml). The organic extracts were collected, dried 
over MgSO4 and concentrated. Flash column chromatography (12 g silica gel, 
hexane:(EtOAc:EtOH 3:1) 4:1 - 0:1) gave the title product (35 mg, 31 %) as a colourless 
solid. 
 
m.p.: 279 – 282 °C (decomposition); νmax (ATR): 1652 (C=O), 1613, 1341, 1162, 1124, 
831 cm-1; δH (CDCl3, 600 MHz): 9.45 (d, J = 2.1 Hz, 1H, 2’-H), 7.71 (d, J = 2.1 Hz, 1H, 6’-
H), 6.82 (s, 1H, 3-H), 6.59 (d, J = 2.3 Hz, 1H, 8-H), 6.42 (d, J = 2.3 Hz, 1H, 6-H), 3.97 (s, 
3H, OCH3), 3.94 (s, 3H, OCH3), 2.85 (s, 3H, CH3); δC (CDCl3, 151 MHz): 176.5 (C-4), 
164.8 (C-7), 161.3 (C-5), 160.7 (C-5’), 159.9 (C-8a), 155.8 (C-2), 145.0 (C-2’), 130.0 (C-
1’), 122.1 (C-6’), 112.2 (C-3), 109.7 (C-4a), 96.9 (C-6), 93.0 (C-8), 56.7 (OCH3), 56.1 
(OCH3), 22.7 (CH3); HRMS (ES+) found [M+H]+ 299.1014, C16H15N2O4 requires M 
299.1032. 
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5,7-Dimethoxy-2-(3’-methylthiophenyl)-4H-chromen-4-one 118 
 
In a microwave vial 2-chloro-5,7-dimethoxy-4H-chromen-4-one 21 (120 mg, 0.5 mmol, 
1 eq) 3-(methylthio)phenylboronic acid (168 mg, 1 mmol, 2 eq), Pd2(dba)3 (14 mg, 
3 mol%), CyJohnPhos (11 mg, 6 mol%) and Cs2CO3 (489 mg, 1.5 mmol, 3 eq) were 
suspended in dioxane (2.5 ml) under a nitrogen atmosphere. The reaction mixture was 
heated in the microwave to 150 °C for 30 min. After allowing to cool to rt, the crude mixture 
was filtered through Celite® and concentrated The residue was dissolved in H2O (15 ml) 
and EtOAc (15 ml). The layers were separated and the aqueous layer was extracted two 
more times with EtOAc (2 × 25 ml). The combined organic layers were washed with H2O 
(25 ml), dried over Mg2SO4 and concentrated. The title product (96 mg, 58%) was afforded 
by reversed phase column chromatography (H2O:MeCN 0:1 - 1:0, 0.1% TFA) as a light 
yellow solid. 
 
m.p.: 169 – 171 °C; νmax (ATR): 1639 (C=O), 1607, 1345, 1212, 1119, 816 cm-1; δH 
(CDCl3, 400 MHz): 7.76 - 7.68 (m, 1H, 2’-H), 7.65 - 7.56 (m, 1H, 6’-H), 7.45 - 7.30 (m, 2H, 
5’-H, 4’-H), 6.67 (s, 1H, 3-H), 6.57 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 
3.96 (s, 3H, OCH3), 3.92 (s, 3H, OCH3), 2.55 (s, 3H, SCH3); δC (CDCl3, 101 MHz): 177.7 
(C-4), 164.3 (C-7), 161.0 (C-5), 160.3 (C-2), 160.0 (C-8a), 140.0 (C-3’), 132.3 (C-1’), 129.4 
(C-5’), 129.1 (C-4’), 123.8 (C-2’), 122.7 (C-6’), 109.5 (C-3), 109.4 (C-4a), 96.4 (C-6), 93.0 
(C-8), 56.6 (OCH3), 56.0 (OCH3), 15.9 (SCH3); HRMS (ES+) found [M+H]+ 329.0842, 
C18H17O4S requires M 329.0842. 
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5,7-Dimethoxy-2-(4’-methylthiophenyl)-4H-chromen-4-one 119 
 
In a microwave vial 2-chloro-5,7-dimethoxy-4H-chromen-4-one 21 (60 mg, 0.25 mmol, 
1 eq) 4-(methylthio)phenylboronic acid (84 mg, 0.5 mmol, 2 eq), Pd2(dba)3 (7 mg, 3 mol%), 
CyJohnPhos (5 mg, 6 mol%) and Cs2CO3 (244 mg, 0.75 mmol, 3 eq) were suspended in 
dioxane (1.25 ml) under a nitrogen atmosphere. The reaction mixture was heated in the 
microwave to 150 °C for 30 min. After allowing to cool to rt, the crude mixture was filtered 
through Celite® and concentrated The residue was dissolved in H2O (10 ml) and EtOAc 
(10 ml). The layers were separated and the aqueous layer was extracted two more times 
with EtOAc (2 × 25 ml). The combined organic layers were washed with H2O (25 ml), dried 
over Mg2SO4 and concentrated. The title product (55 mg, 67%) was afforded by reversed 
phase column chromatography (H2O:MeCN 0:1 - 1:0, 0.1% TFA) as a light yellow solid. 
 
m.p.: 163 – 165 °C; νmax (ATR): 1643 (C=O), 1599, 1347, 1119, 817 cm-1; δH (CDCl3, 400 
MHz): 7.86 - 7.71 (m, 2H, 2’-H, 6’-H), 7.40 - 7.28 (m, 2H, 3’-H, 5’-H), 6.64 (s, 1H, 3-H), 
6.56 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 3.96 (s, 3H, OCH3), 3.91 (s, 
3H, OCH3), 2.54 (s, 3H, SCH3).; δC (CDCl3, 101 MHz): 177.8 (C-4), 164.2 (C-7), 161.0 (C-
5), 160.6 (C-2), 160.0 (C-8a), 143.5 (C-4’), 127.8 (C-1’), 126.3 (C-3’, C-6’), 125.9 (C-3’, C-
5’), 109.4 (C-4a), 108.4 (C-3), 96.3 (C-6), 93.0 (C-8), 56.6 (OCH3), 55.9 (OCH3), 15.2 
(SCH3); HRMS (ES+) found [M+H]+ 329.0843, C18H17O4S requires M 329.0848. 
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2-(3’-Methanesulfonylphenyl)-5,7-dimethoxy-4H-chromen-4-one 120 
 
To a solution of the 5,7-dimethoxy-2-(3’-methylthiophenyl)-4H-chromen-4-one 118 (82 mg, 
0.25 mmol, 1 eq) in MeOH (1.25 mL) and THF (1.25 mL) was added a solution of Oxone® 
(768 mg, 2.5 mmol, 10 eq) in H2O (2 mL) dropwise at 0 °C. The resulting mixture was 
stirred at rt overnight. The solution was extracted with DCM (3 × 5 ml), the combined 
organic layers washed with brine and dried over anhydrous Mg2SO4. The resulting solution 
was filtered and concentrated under reduced pressure. The title product, a colourless 
solid, (81 mg, 90%) was used in the following step without further purification. 
 
m.p.: 239 – 241 °C (decomposition; νmax (ATR): 1650 (C=O), 1611, 1349, 1299, 1144, 
1121 cm-1; δH (CDCl3, 400 MHz): 8.55 - 8.44 (m, 1H, 2’-H), 8.18 - 8.02 (m, 2H, 4’-H, 6’-H), 
7.80 - 7.67 (m, 1H, 5’-H), 6.75 (s, 1H, 3-H), 6.63 (d, J = 2.3 Hz, 1H, 8-H), 6.41 (d, J = 2.3 
Hz, 1H, 6-H), 3.95 (d, J = 10.5 Hz, 6H, 2 × OCH3), 3.13 (s, 3H, SO2CH3); δC (CDCl3, 101 
MHz): 177.2 (C-4), 164.6 (C-7), 161.1 (C-5), 160.0 (C-8a), 158.3 (C-2), 141.9 (C-3’), 133.4 
(C-1’), 130.9 (ArC), 130.4 (C-5’), 129.7 (ArC), 125.0 (C-2’), 110.4 (C-3), 109.4 (C-4a), 96.8 
(C-6), 93.0 (C-8), 56.6 (OCH3), 56.1 (OCH3), 44.7 (SO2CH3); HRMS (ES+) found [M+H]+ 
361.0750, C18H17O6S requires M 361.0746. 
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2-(4’-Methanesulfonylphenyl)-5,7-dimethoxy-4H-chromen-4-one 121 
 
To a solution of 5,7-dimethoxy-2-(4’-methylthiophenyl)-4H-chromen-4-one 119 (33 mg, 
0.1 mmol, 1 eq) in MeOH (0.5 mL) and THF (0.5 mL) was added a solution of Oxone® 
(184 mg, 0.6 mmol, 6 eq) in H2O (1 mL) dropwise at 0 °C. The resulting mixture was stirred 
at rt. After 24 h LC-MS analysis still showed the presence of starting material. Another 
4 eq of Oxone® (123 mg, 4 mmol, 4 eq) in H2O (0.5 ml) were added and the mixture was 
stirred for another 24 h. The solution was then extracted with DCM (2 × 5 ml), the 
combined organic layers washed with brine and dried over anhydrous Mg2SO4. The 
resulting solution was filtered and concentrated under reduced pressure. Flash column 
chromatography (12 g silica gel, DCM:MeOH 1:0 - 19:1) afforded the title product (32 mg, 
89%) as a colourless solid. 
 
m.p.: 299  – 300 °C (decomposition); νmax (ATR): 1640 (C=O), 1343, 1148, 1120, 839, 
775 cm-1; δH (CDCl3, 400 MHz): 8.15 - 8.00 (m, 4H, 2’-H, 6’-H, 3’-H, 5’-H), 6.75 (s, 1H, 3-
H), 6.59 (d, J = 2.3 Hz, 1H, 8-H), 6.41 (d, J = 2.3 Hz, 1H, 6-H), 3.97 (s, 3H, OCH3), 3.93 (s, 
3H, OCH3), 3.11 (s, 3H, CH3); δC (CDCl3, 101 MHz): 177.2 (C-4), 164.6 (C-7), 161.2 (C-5), 
160.0 (C-8a), 158.4 (C-2), 142.6 (C-4’), 136.9 (C-1’), 128.2 (2 × ArC), 126.9 (2 × ArC), 
111.1 (C-3), 109.5 (C-4a), 96.7 (C-6), 93.0 (C-8), 56.7 (OCH3), 56.0 (OCH3), 44.6 (CH3); 
HRMS (ES+) found [M+H]+ 361.0749, C18H17O6S requires M 361.0746. 
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2-{[2’-(3’’-Methanesulfonylphenyl)-7’-methoxy-4’-oxo-4’H-chromen-5’-yl]oxy}dodecanoic 
acid 124 
 
BBr3 (1 M solution in DCM, 0.3 ml, 0.3 mmol, 1.5 eq) was added to a solution of 
2-(3’-methanesulfonylphenyl)-5,7-dimethoxy-4H-chromen-4-one 120 (72 mg, 0.2 mmol, 
1 eq) in dry 1,2-dichloroethane (2 ml) under a nitrogen atmosphere, while cooling in a dry 
ice/acetone-bath. The reaction mixture was allowed to warm to rt and stirred for 3 h, before 
pouring over a 1:1 mixture of ice and H2O (approx. 20 ml). The product was extracted with 
DCM (3 × 20 ml) and the combined organic layers were washed with brine (30 ml), dried 
over Mg2SO4 and concentrated. A solution of methyl 2-bromododecanoate 48 (59 mg, 
0.2 mnmol, 1 eq) in dry DMF (0.5 ml) was added to a mixture of crude product and K2CO3 
(28 mg, 0.2 mmol, 1 eq) in dry DMF (0.5 ml) under an argon atmosphere. The reaction 
mixture was stirred at 80 °C overnight and after allowing the mixture to cool to rt, it was 
filtered through Celite® and concentrated. The crude product together with LiOH.H2O 
(13 mg, 0.3 mmol, 1.5 eq) was stirred in a 1:1 mixture of H2O (1 ml) and THF (1 ml) at rt 
for 24 h. The mixture was acidified to pH 2-3 with 1N HCl and the aqueous phase was 
extracted with DCM (3 × 5 ml). The organic extracts were collected, dried over MgSO4 and 
concentrated. Flash column chromatography (12 g silica gel, Et2O then DCM:MeOH 19:1) 
afforded the title product (17 mg, 10 %) as a colourless semi solid. 
 
νmax (ATR): 2925, 2854, 1746 (C=O), 1638 (C=O), 1607, 1356, 1150 cm-1; δH (CDCl3, 400 
MHz): 8.68 – 8.35 (m, 1H, 2’’-H), 8.33 - 7.92 (m, 2H, 4’’-H, 6’’-H), 7.91 – 7.62 (m, 1H, 5’’-
H), 6.83 (s, 1H, 3’-H), 6.79 (d, J = 2.2 Hz, 1H, 8’-H), 6.49 (d, J = 2.2 Hz, 1H, 6’-H), 4.84 (t, 
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J = 5.2 Hz, 1H, 2-H), 3.96 (s, 3H, OCH3), 3.15 (s, 3H, SO2CH3), 2.25 - 2.05 (m, 2H, 3-H2), 
1.64 - 1.45 (m, 2H, 4-H2), 1.41 - 1.19 (m, 14H, 7 × CH2), 0.93 - 0.82 (m, 3H, 12-H3); δC 
(CDCl3, 101 MHz): 178.5 (C-4’), 172.3 (C-1), 165.3 (C-7’), 160.3 (C-8a’), 159.5 (C-5’), 
158.9 (C-2’), 142.1 (C-3’’), 132.7 (C-1’’), 131.2 (ArC), 130.6 (C-5’’), 130.4 (ArC), 125.2 (C-
2’’), 109.6 (C-3’), 109.5 (C-4a’), 101.7 (C-6’), 95.2 (C-8’), 81.9 (C-2), 56.5 (OCH3), 44.7 
(SO2CH3), 33.0 (C-3), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 
(CH2), 24.8 (C-4), 22.8 (CH2), 14.3 (C-12); HRMS (ES+) found [M+H]+ 545.2211, 
C29H37O8S requires M 545.2209. 
 
5-Hydroxy-2-(4’-methanesulfonylphenyl)-7-methoxy-4H-chromen-4-one 123 
 
BBr3 (1 M solution in DCM, 0.3 ml, 0.3 mmol, 1.5 eq) was added to a solution of 
2-(4’-methanesulfonylphenyl)-5,7-dimethoxy-4H-chromen-4-one 121 (72 mg, 0.2 mmol, 
1 eq) in dry 1,2-dichloroethane (2 ml) under a nitrogen atmosphere, while cooling in a dry 
ice/acetone-bath. The reaction mixture was allowed to warm to rt and stirred for 2.5 h, 
before pouring over a 1:1 mixture of ice and H2O (approx. 20 ml). The product was 
extracted with DCM (3 × 20 ml) and the combined organic layers were washed with brine 
(30 ml), dried over Mg2SO4 and concentrated. The title product (46 mg, 66%) was afforded 
as a yellow solid by flash column chromatography (12 g silica gel, DCM:MeOH 0:1 - 9:1). 
 
m.p.: 251 – 253 °C (decomposition); νmax (ATR): 3070 (OH), 1661 (C=O), 1623, 1272, 
1143, 822, 778 cm-1; δH (CDCl3, 400 MHz): 12.53 (s, 1H, OH), 8.22 - 7.99 (m, 4H, 4 × ArH), 
6.74 (s, 1H, 3-H), 6.53 (d, J = 2.2 Hz, 1H, 8-H), 6.41 (d, J = 2.2 Hz, 1H, 6-H), 3.90 (s, 3H, 
OMeO
OH O
S
O O
  Experimental Part 
  242 
OCH3), 3.12 (s, 3H, SO2CH3); δC (CDCl3, 101 MHz): 182.2 (C-4), 166.2 (C-7), 162.5 (C-5), 
161.6 (C-2), 157.8 (C-8a), 143.3 (C-4’), 136.6 (C-1’), 128.4 (2 × ArC), 127.3 (2 × ArC), 
108.0 (C-3), 106.00 (C-4a), 98.7 (C-6), 93.1 (C-8), 56.1 (OCH3), 44.6 (SO2CH3).; HRMS 
(ES+) found [M+H]+ 347.0585, C17H15O6S requires M 347.0589.  
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2-{[2’-(4’’-Methanesulfonylphenyl)-7’-methoxy-4’-oxo-4’H-chromen-5’-yl]oxy}dodecanoic 
acid 125 
 
A solution of methyl 2-bromododecanoate 48 (59 mg, 0.2 mnmol, 2 eq) in dry DMF 
(0.5 ml) was added to a mixture of 5-hydroxy-2-(4’-methanesulfonylphenyl)-7-methoxy-4H-
chromen-4-one 123 (35 mg, 0.1 mmol, 1 eq) and K2CO3 (28 mg, 0.2 mmol, 2 eq) in dry 
DMF (0.5 ml) under an argon atmosphere. The reaction mixture was stirred at 60 °C for 
20 h and at 80 °C for another 20 h. After allowing the reaction mixture to cool to rt, it was 
filtered through Celite® and concentrated. The crude product together with LiOH.H2O 
(13 mg, 0.3 mmol, 3 eq) was stirred in a 1:1 mixture of H2O (1 ml) and THF (1 ml) at rt 
overnight. The mixture was acidified to pH 2-3 with 1N HCl and the aqueous phase was 
extracted with DCM (3 × 5 ml). The organic extracts were collected, dried over MgSO4 and 
concentrated. Flash column chromatography (12 g silica gel, Et2O then DCM:MeOH 19:1) 
afforded the title product (20 mg, 37 %) as a colourless semi solid. 
 
νmax (ATR): 2924, 2854, 1745 (C=O), 1636 (C=O), 1601, 1356, 1152, 1111 cm-1; δH 
(CDCl3, 400 MHz): 8.22 - 7.97 (m, 4H), 6.84 (s, 1H), 6.75 (d, J = 2.2 Hz, 1H), 6.49 (d, J = 
2.2 Hz, 1H), 4.85 (t, J = 5.2 Hz, 1H), 3.95 (s, 3H), 3.12 (s, 3H), 2.22 - 2.08 (m, 2H), 1.64 - 
1.45 (m, 2H), 1.42 - 1.14 (m, 18H), 0.86 (t, J = 6.8 Hz, 3H); δC (CDCl3, 101 MHz): 178.5 
(C-4’), 172.3 (C-1), 165.3 (C-7’), 160.4 (C-8a’), 159.5 (C-5’), 159.0 (C-2’), 143.3 (C-4’’), 
136.1 (C-1’’), 128.4 (2 × ArC), 127.3 (2 × ArC), 110.2 (C-3’), 109.5 (C-4a’), 101.5 (C-6’), 
95.2 (C-8’), 81.8 (C-2), 56.4 (OCH3), 44.6 (SO2CH3), 32.9 (C-3), 32.0 (CH2), 29.7 (CH2), 
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29.7 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 24.7 (C-4), 22.8 (CH2), 14.3 (C-12); HRMS 
(ES+) found [M+H]+ 545.2204, C29H37O8S requires M 545.2209. 
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5,7-Dimethoxy-2-(2’-methylphenyl)-4H-chromen-4-one 126 
 
In a microwave vial 2-chloro-5,7-dimethoxy-4H-chromen-4-one 21 (120 mg, 0.5 mmol, 
1 eq) o-tolylboronic acid (136 mg, 1 mmol, 2 eq), Pd2(dba)3 (14 mg, 3 mol%), CyJohnPhos 
(11 mg, 6 mol%) and Cs2CO3 (489 mg, 1.5 mmol, 3 eq) were suspended in dioxane 
(2.5 ml) under a nitrogen atmosphere. The reaction mixture was heated in the microwave 
to 150 °C for 30 min. After allowing to cool to rt, the crude mixture was filtered through 
Celite® and concentrated The residue was dissolved in H2O (15 ml) and EtOAc (15 ml). 
The layers were separated and the aqueous layer was extracted two more times with 
EtOAc (2 × 25 ml). The combined organic layers were washed with H2O (25 ml), dried over 
Mg2SO4 and concentrated. The title product (112 mg, 76%) was afforded by reversed 
phase column chromatography (H2O:MeCN 0:1 - 1:0, 0.1% TFA) 
 
m.p.: 107 – 109 °C; νmax (ATR): 1642 (C=O), 1605, 1333, 1158, 1102, 723 cm-1; δH 
(CDCl3, 400 MHz): 7.55 - 7.46 (m, 1H, 6’-H), 7.44 - 7.35 (m, 1H, 4’-H), 7.35 - 7.27 (m, 2H, 
3’-H, 5’-H), 6.48 (d, J = 2.3 Hz, 1H, 8-H), 6.39 (d, J = 2.3 Hz, 1H, 6-H), 6.36 (s, 1H, 3-H), 
3.96 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 2.47 (s, 3H, CH3); δC (CDCl3, 101 MHz): 177.7 (C-
4), 164.3 (C-7), 163.4 (C-2), 161.1 (C-5), 160.3 (C-8a), 136.8 (C-2’), 132.4 (C-1’), 131.3 
(ArC), 130.6 (C-4’), 129.2 (C-6’), 126.3 (ArC), 113.5 (C-3), 109.2 (C-4a), 96.4 (C-6), 92.8 
(C-8), 56.6 (OCH3), 55.9 (OCH3), 20.7 (CH3); HRMS (ES+) found [M+H]+ 297.1132, 
C18H17O4 requires M 297.1127.  
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5-Hydroxy-7-methoxy-2-(2’-methylphenyl)-4H-chromen-4-one 127 
 
BBr3 (1 M solution in DCM, 0.45 ml, 0.45 mmol, 1.5 eq) was added to a solution of 
5,7-dimethoxy-2-(2’-methylphenyl)-4H-chromen-4-one 126 (89 mg, 0.3 mmol, 1 eq) in dry 
1,2-dichloroethane (2.5 ml) under a nitrogen atmosphere, while cooling in a dry 
ice/acetone-bath. The reaction mixture was allowed to warm to rt and stirred for 3 h, before 
pouring over a 1:1 mixture of ice and H2O (approx. 20 ml). The product was extracted with 
DCM (3 × 20 ml) and the combined organic layers were washed with brine (30 ml), dried 
over Mg2SO4 and concentrated. The title product (47 mg, 55%) was afforded as a yellow 
solid by flash column chromatography (12 g silica gel, DCM:MeOH 19:1). 
 
m.p.: 148 – 150 °C; νmax (ATR): 3077 (OH), 3004, 2925, 1658 (C=O), 1618, 1377, 1157, 
812 cm-1; δH (CDCl3, 400 MHz): 12.72 (s, 1H, OH), 7.53 - 7.47 (m, 1H, 6’-H), 7.46 - 7.39 
(m, 1H, 4’-H), 7.36 - 7.29 (m, 2H, 3’-H, 5’-H), 6.42 (d, J = 2.3 Hz, 1H, 8-H), 6.39 (d, J = 2.3 
Hz, 1H, 6-H), 6.34 (s, 1H, 3-H), 3.87 (s, 3H, OCH3), 2.48 (s, 3H, CH3); δC (CDCl3, 101 
MHz): 182.5 (C-4), 166.7 (C-2), 165.8 (C-7), 162.4 (C-5), 158.2 (C-8a), 137.0 (C-2’), 132.3 
(C-1’), 131.5 (ArC), 131.1 (C-4’), 129.3 (C-6’), 126.4 (ArC), 110.4 (C-3), 105.7 (C-4a), 98.3 
(C-6), 92.7 (C-8), 56.0 (OCH3), 20.7 (CH3); HRMS (ES+) found [M+H]+ 283.0961, C17H15O4 
requires M 283.0970. 
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2-{[7’-Methoxy-2’-(2’’-methylylphenyl)-4’-oxo-4’H-chromen-5’-yl]oxy}dodecanoic acid 128 
 
A solution of methyl 2-bromododecanoate 48 (59 mg, 0.2 mmol, 2 eq) in dry DMF (0.5 ml) 
was added to a mixture of 5-hydroxy-7-methoxy-2-(2’-methylylphenyl)-4H-chromen-4-one 
127 (28 mg, 0.1 mmol, 1 eq) and K2CO3 (28 mg, 0.2 mmol, 2 eq) in dry DMF (0.5 ml) 
under an argon atmosphere. The reaction mixture was stirred at 60 °C for 20 h and at 
80 °C for another 20 h. After allowing the reaction mixture to cool to rt, it was filtered 
through Celite® and concentrated. The crude product together with LiOH.H2O (13 mg, 
0.3 mmol, 3 eq) was stirred in a 1:1 mixture of H2O (1 ml) and THF (1 ml) at rt overnight. 
The mixture was acidified to pH 2-3 with 1N HCl and the aqueous phase was extracted 
with DCM (3 × 5 ml). The organic extracts were collected, dried over MgSO4 and 
concentrated. Flash column chromatography (12 g silica gel, Et2O then DCM:MeOH 19:1) 
afforded the title product (17 mg, 35 %) as a colourless semi solid. 
νmax (ATR): 2924, 2854, 1747 (C=O), 1635 (C=O), 1607, 1354, 1162, 1105 cm-1; δH 
(CDCl3, 400 MHz): 13.65 (s, 1H), 7.53 - 7.38 (m, 2H), 7.37 - 7.27 (m, 2H), 6.63 (d, J = 2.2 
Hz, 1H), 6.48 (d, J = 2.2 Hz, 1H), 6.44 (s, 1H), 4.84 (t, J = 5.3 Hz, 1H), 3.91 (s, 3H), 2.48 
(s, 3H), 2.22 - 2.09 (m, 2H), 1.65 - 1.46 (m, 2H), 1.41 - 1.20 (m, 14H), 0.90 - 0.83 (m, 3H); 
δC (CDCl3, 101 MHz): 178.9 (C-4’), 172.50 (C-1), 165.4 (C-7’), 164.9 (C-2’), 159.8 (C-8a’), 
159.0 (C-5’), 136.9 (C-2’’), 131.9 (C-1’’), 131.5 (ArC), 131.2 (C-4’’), 129.3 (C-6’’), 126.5 
(ArC), 112.8 (C-3’), 109.4 (C-4a’), 101.4 (C-6’), 95.1 (C-8’), 81.9 (C-2), 56.2 (OCH3), 33.0 
(C-3), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.8 (C-4), 
22.8 (CH2), 20.7 (CH3), 14.3 (C-12); HRMS (ES+) found [M+H]+ 481.2599, C29H37O6 
requires M 481.2590. 
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3’,5’-Dimethoxyphenylpropanoate 129 
 
3,5 Dimethoxyphenol 17 (4.62 g, 30 mmol, 1 eq), DMAP (370 mg, 3 mmol, 0.1 eq) and 
propionic acid (2.46 ml, 33 mmol, 1.1 eq) were dissolved in a 5:1 mixture of DCM (25 ml) 
and DMF (5 ml) under an argon atmosphere and cooled to 0 °C. N,N’-
Diisopropylcarbodiimide (4.65 ml, 30 mmol, 1 eq) was added dropwise and after 5 min, the 
reaction mixture was allowed to warm to rt and stirred for another 3.5 h. The mixture was 
filtered through Celite® and washed with 1 M HCl (2 × 50 ml), sat. aqueous NaHCO3 (2 × 
50 ml) and with brine (50 ml). The organic layer was dried over Na2SO4 and concentrated. 
The title product (5.53 g, 88%) was afforded by flash column chromatography (80 g silica 
gel, hexane:EtOAc 20:1-4:1) as a colourless oil. 
 
νmax (ATR): 1758, 1594 (C=O), 1126, 1050 cm-1; δH (CDCl3, 700 MHz): 6.34 (t, J = 2.3 Hz, 
1H, 4’-H), 6.26 (d, J = 2.3 Hz, 2H, 2’-H, 6’-H), 3.77 (s, 6H, 2 × OCH3), 2.57 (q, J = 7.6 Hz, 
2H, 2-H2), 1.26 (t, J = 7.6 Hz, 3H, 1-H3).; δC (CDCl3, 175 MHz): 172.9 (C-3), 161.3 (C-3’, C-
5’), 152.5 (C-1’), 100.3 (C-2’, C-6’), 98.4 (C-4’), 55.6 (2 × OCH3), 27.9 (C-2), 9.2 (C-1); 
HRMS (ES+) found [M+H]+ 211.0965, C11H15O4 requires M 211.0970.  
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3-(2’-Hydroxy-4’,6’-dimethoxyphenyl)propan-3-one183 130 
 
3’,5’-Dimethoxyphenylpropanoate 129 (5.28 g, 25.1 mmol, 1 eq) was dissolved in dry 
1,2-dichloroethane (300 ml) and added to a slurry of AlCl3 (5.69 g, 42.7 mmol, 1.7 eq) in 
dry 1,2-dichloroethane (100 ml) under an argon atmosphere at 0 °C. Then the reaction 
mixture was heated under reflux and stirred for 3.5 h. After cooling to rt, the mixture was 
poured over a 1:1 mixture of ice and 1 M HCl (approx. 500 ml) and stirred for 30 min. The 
organic layer was separated and the aqueous layer was extracted with DCM (3 × 200 ml). 
The combined organic layers were washed with H2O (200 ml) and brine (200 ml), dried 
over Na2SO4 and concentrated. The title product (2.38 g, 45%) was obtained by flash 
column chromatography (80 g silica gel, toluene) as a colourless solid. 
 
m.p.: 108 – 109 °C (lit.183 m.p. 106 – 107 °C); νmax (ATR): 2974, 2927, 1592 (C=O), 1422, 
1217, 1155, 1116, 824 cm-1; δH (CDCl3, 400 MHz): 14.10 (s, 1H, OH), 6.07 (d, J = 2.4 Hz, 
1H, 3’-H), 5.92 (d, J = 2.4 Hz, 1H, 5’-H), 3.85 (s, 3H, OCH3), 3.82 (s, 3H, OCH3), 3.02 (q, J 
= 7.2 Hz, 2H, 2-H2), 1.15 (t, J = 7.2 Hz, 3H, 1-H3); δC (CDCl3, 100 MHz): 206.5 (C-3), 167.7 
(C-2’), 165.9 (C-4’), 163.0 (C-6’), 105.9 (C-1’), 93.8 (C-3’), 90.9 (C-5’), 55.7 (2 × OCH3), 
37.6 (C-2), 8.7 (C-1); m/z LC-MS (ES+) 211 [M+H]+. 
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5,7-Dimethoxy-3-methyl-2-phenyl-4H-chromen-4-one184 131 
 
1,1,1,3,3,3-Hexamethyldisilazane (7.21 g, 44.7 mmol, 5.25 eq) was dissolved in dry THF 
(30 ml) under an argon atmosphere. The solution was cooled to -78 °C and n-BuLi 
(17.02 ml of a 2.5 M solution in hexane, 42.5 mmol, 5 eq) was added dropwise over 
20 min. The reaction mixture was stirred for 10 min, then it was allowed to warm to 0 °C 
and stirred a further 20 min. The solution of in situ synthesised LiHMDS was added to a 
solution of 3-(2’-hydroxy-4’,6’-dimethoxyphenyl)propan-3-one 130 (1.79 g, 8.5 mmol, 1 eq) 
in dry toluene (45 ml) at 0 °C. The mixture was stirred for 30 min at 0 °C and after the 
addition of benzoyl chloride (1.28 ml, 11.1 mmol, 1.3 eq) the reaction mixture was allowed 
to warm to rt and stirred for 20 h. Conc. HCl (30.6 ml) was carefully added and the reaction 
mixture was stirred for another 25 h at rt, before pouring over a 1:1 mixture of ice and H2O 
(approx. 300 ml). The product was extracted with EtOAc (3 × 200 ml) and the combined 
organic layers were dried over Na2SO4 and concentrated. Two flash column 
chromatography purifications (80 g silica gel, DCM:MeOH 10:0-9:1, and 80 g silica gel, 
hexane:EtOAc 5:1-0:1) yielded the title product (1.78 g, 70%) as a colourless solid. 
m.p.: 181 - 183°C (lit.184 m.p. 178 °C); νmax (ATR): 1609 (C=O), 1349, 1201, 1107, 695 
cm-1; δH (CDCl3, 400 MHz): 7.65 - 7.59 (m, 2H, 2’-H, 6’-H), 7.54 - 7.46 (m, 3H, 3’-H, 4’-H, 
5’-H), 6.44 (d, J = 2.3 Hz, 1H, 8-H), 6.35 (d, J = 2.3 Hz, 1H, 6-H), 3.95 (s, 3H, OCH3), 3.86 
(s, 3H, OCH3), 2.09 (s, 3H, CH3); δC (CDCl3, 100 MHz): 177.9 (C-4), 163.9 (C-5), 161.0 (C-
7), 159.9 (C-8a), 158.4 (C-2), 133.6 (C-1’), 130.0 (C-4’), 129.0 (C-2’, C-6’), 128.5 (C3’, 
C5’), 118.6 (C3), 108.3 (C-4a), 96.0 (C-6), 92.4 (C-8), 56.5 (OCH3), 55.8 (OCH3), 11.8 
(CH3); m/z LC-MS (ES+) 297 [M+H]+.  
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5-Hydroxy-7-methoxy-3-methyl-2-phenyl-4H-chromen-4-one185 132 
 
BBr3 (2.25 ml of a 1 M solution in DCM, 2.25 mmol, 1.5 eq) was added to a solution of 
5,7-dimethoxy-3-methyl-2-phenyl-4H-chromen-4-one 131 (450 mg, 1.5 mmol, 1 eq) in dry 
1,2-dichloroethane (12.5 ml) under an argon atmosphere, while cooling in a dry 
ice/acetone-bath. The reaction mixture was allowed to warm to rt and stirred for 15 h, 
before pouring over a 1:1 mixture of ice and H2O (approx. 80 ml). The product was 
extracted with EtOAc (3 × 100 ml) and the combined organic layers were washed with 
brine (60 ml), dried over Na2SO4 and concentrated. The title product (310 mg, 73%) was 
afforded by flash column chromatography (24 g silica gel, DCM:MeOH 10:0-9:1) as a 
colourless solid. 
 
m.p.: 163 - 164 °C (lit.185 m.p. 157 °C); νmax (ATR): 3012 (OH), 2845 (OH), 1658 (C=O), 
1602, 1348, 1203, 1152, 773, 696 cm-1; δH (CDCl3, 400 MHz): 12.94 (s, 1H, OH), 7.65 - 
7.59 (m, 2H, 2’-H, 6’-H), 7.55 - 7.50 (m, 3H, 3’-H, 4’-H, 5’-H), 6.39 (d, J = 2.3 Hz, 1H, 8-H), 
6.37 (d, J = 2.3 Hz, 1H, 6-H), 3.86 (s, 3H, OCH3), 2.12 (s, 3H, CH3); δC (CDCl3, 100 MHz): 
182.9 (C-4), 165.6 (C-7), 162.2 (C-2), 161.6 (C-5), 157.9 (C-8a), 133.1 (C-1’), 130.6 (C-4’), 
129.1 (C-2’, C-6’), 128.7 (C3’, C5’), 116.0 (C3), 104.9 (C-4a), 98.1 (C-6), 92.1 (C-8), 55.9 
(OCH3), 11.0 (CH3); m/z LC-MS (ES+) 283 [M+H]+. 
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Methyl 2-(7’-methoxy-4’-oxo-3’-methyl-2’-phenyl-4’H-chromen-5’-oxy)dodecanoate 133 
 
 
A solution of methyl 2-bromododecanoate 48 (312 mg, 1.06 mmol, 2 eq) in dry DMF (1 ml) 
was added to a mixture of 5-hydroxy-7-methoxy-3-methyl-2-phenyl-4H-chromen-4-one 132 
(0.150 g, 0.53 mmol, 1 eq) and K2CO3 (147 mg, 1.06 mmol, 2 eq) in dry DMF (4 ml) under 
an argon atmosphere. The reaction mixture was stirred at rt for 24 h. K2CO3 was collected 
by filtration through Celite® and the solvent was removed under reduced pressure. Flash 
column chromatography (12 g silica gel, hexane:EtOAc 20:1-4:1) yielded the title product 
(222 mg, 84%) as a colourless solid. 
m.p.: 66 - 67°C; νmax (ATR): 2920, 2849, 1744 (C=O), 1645 (C=O), 1609, 1336, 1165, 
1142, 1116, 821 cm-1; δH (CDCl3, 400 MHz): 7.64 - 7.56 (m, 2H, 2’’-H, 6’’-H), 7.54 - 7.45 
(m, 3H, 3’’-H, 4’’-H, 5’’-H), 6.47 (d, J = 2.3 Hz, 1H, 8’-H), 6.22 (d, J = 2.3 Hz, 1H, 6’-H), 
4.69 (dd, J = 7.3, 5.4 Hz, 1H, 2-H), 3.82 (s, 3H, OCH3), 3.74 (s, 3H, OCH3), 2.22 - 2.00 (m, 
5H, CH3, 3-H2), 1.67 - 1.56 (m, 2H, 4-H2), 1.43 - 1.20 (m, 14H, 7 × CH2), 0.87 (t, J=6.8 Hz, 
3H, 12-H3); δC (CDCl3, 100 MHz): 177.3 (C-4’), 172.0 (C-1), 163.5 (C-7’), 159.9 (C-8a’), 
159.1 (C-5’), 158.3 (C-2’), 133.6 (C-1’’), 130.0 (C-4’’), 129.0 (C-2’’, C-6’’), 128.5 (C-3’’, C-
5’’), 118.5 (C-3’), 108.8 (C-4a’), 98.6 (C-6’), 93.6 (C-8’), 78.3 (C-2), 55.8 (OCH3), 52.3 
(COOCH3), 32.9 (C-3), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 
(CH2), 25.1 (C-4), 22.8 (CH2), 14.3 (C-12), 11.8 (CH3); HRMS (ES+) found [M+H]+ 
495.2738, C30H39O6 requires M 495.2747.  
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2-(7’-Methoxy-4’-oxo-3’-methyl-2’-phenyl-4’H-chromen-5’-oxy)dodecanoic acid 134 
 
Methyl 2-(7-methoxy-4-oxo-3-methyl-2-phenyl-4H-chromen-5-oxy)dodecanoate 133 
(145 mg, 0.29 mmol, 1 eq) was dissolved in a 1:1 mixture of THF (7.5 ml) and H2O (7.5 ml) 
and LiOH.H2O (25 mg, 0.58 mmol, 2 eq) was added. The reaction mixture was stirred for 
17 h at rt. The mixture was acidified with 1M HCl to pH 6 and extracted with EtOAc (3 × 
15 ml). The combined organic layers were washed with brine (20 ml), dried over Na2SO4 
and the solvent was removed under reduced pressure. Flash column chromatography 
(24 g silica gel, DCM:MeOH 1:0-9:1) afforded the title product (111 mg, 79%) as a 
colourless solid. 
m.p.: 103 - 105 °C; νmax (ATR): 2920, 2854, 1732 (C=O), 1604 (C=O), 1359, 1202, 1161, 
1107, 690 cm-1; δH (CDCl3, 700 MHz): 13.81 (s, 1H, COOH), 7.64 - 7.58 (m, 2H, 2’’-H, 6’’-
H), 7.56 - 7.49 (m, 3H, 3’’-H, 4’’-H, 5’’-H), 6.59 (d, J = 2.2 Hz, 1H, 8’-H), 6.44 (d, J = 2.3 
Hz, 1H, 6’-H), 4.81 (t, J = 5.4 Hz, 1H, 2-H), 3.89 (s, 3H, OCH3), 2.18 - 2.10 (m, 5H, CH3, 3-
H2), 1.63 - 1.48 (m, 2H, 4-H2), 1.40 - 1.20 (m, 14H, 5-H2, 6-H2, 7-H2, 8-H2, 9-H2, 10-H2, 11-
H2), 0.87 (t, J = 7.1 Hz, 3H, 12-H3); δC (CDCl3, 175 MHz): 179.2 (C-4’), 172.6 (C-1), 164.5 
(C-7’), 160.6 (C-2’), 159.3 (C-8a’), 158.9 (C-5’), 132.8 (C-1’’), 130.6 (C-4’’), 129.0 (C-2’’, C-
6’’), 128.7 (C-3’’, C-5’’), 118.3 (C-3’), 108.3 (C-4a’), 101.3 (C-6’), 94.7 (C-8’), 82.0 (C-2), 
56.1 (OCH3), 33.1 (C-3), 32.0 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 
(CH2), 24.9 (C-4), 22.8 (CH2), 14.2 (C-12), 11.8 (CH3); HRMS (ES+) found [M+H]+ 
481.2599, C29H37O6 requires M 481.2590.  
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4-(2’-Methoxyethoxy)-1-butene 138 
 
3-Buten-1-ol (5.16 ml, 60 mmol, 1.5 eq) was added to a slurry of NaH (60% dispersed in 
mineral oil, 2.88 g, 72 mmol, 1.8 eq) in dry DMF (50 ml) at 0 °C under an argon 
atmosphere and the resulting mixture was stirred for 45 min at 0 °C. 2-Bromoethyl methyl 
ether 135 (3.76 ml, 40 mmol, 1 eq) was added and the mixture was stirred another 20 h at 
rt. The mixture was neutralized with 1 N HCl and extracted with Et2O (3 × 100 ml). The 
combined organic layers were washed with brine, dried over Na2SO4 and concentrated. 
Flash column chromatography (80 g silica gel, hexane:EtOAc 1:0-7:3) afforded the title 
product (2.55 g, 33%) as a colourless oil. 
 
νmax (ATR): 2873, 1099, 751 cm-1; δH (CDCl3, 700 MHz): 5.82 (ddt, J = 17.2, 10.2, 6.7 Hz, 
1H, 2-H), 5.09 (dq, J = 17.2, 1.7 Hz, 1H, 1-H), 5.03 (ddt, J = 10.2, 2.1, 1.2 Hz, 1H, 1-H), 
3.62 - 3.57 (m, 2H, 1’-H2), 3.56 - 3.50 (m, 4H, 4-H2, 2’-H2), 3.39 (s, 3H, OCH3), 2.36 (qt, J = 
6.9, 1.4 Hz, 2H, 3-H2); δC (CDCl3, 175 MHz): 13C NMR (176 MHz, CDCl3) δ 135.3 (C-2), 
116.5 (C-1), 72.1 (C-2’), 70.9 (C-4), 70.2 (C-1’), 59.2 (OCH3), 34.2 (C-3). 
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Ethyl 2-hydroxy-6-(2’-methoxyethoxy)hexanoate 140 
 
To a solution of (+)-diethyl L-tartrate 80 (0.38 ml, 2.2 mmol, 0.6 eq) in dry Et2O (2 ml) at 
0 °C, periodic acid (501 mg, 2.2 mmol, 0.6 eq) was slowly added over 30 min. The reaction 
mixture was stirred another 20 min at rt, filtered through Celite® and concentrated. The 
crude product was dissolved in dry DCM (10 ml) and added to a slurry of ferric chloride 
(1.946 g, 12 mmol, 3 eq) in dry DCM (12 ml) and H2O (0.19 ml, 12 mmol, 3 eq). The 
mixture was cooled to 0 °C and 4-(2’-methoxyethoxy)-1-butene (521 mg, 4 mmol, 1 eq) 
dissolved in dry DCM (10 ml) was added before the mixture was stirred for 3 h at rt. The 
reaction mixture was washed with 0.1 N HCl (25 ml), dried over MgSO4, filtered through 
silica gel and concentrated. A flask was charged with Crabtree catalyst (64 mg, 2 mol%) 
and the crude product from the previous step, dissolved in dry DCM (16 ml). The flask was 
purged with nitrogen and then flushed with hydrogen and stirred with a hydrogen balloon 
attached for 2.5 h at rt. The reaction mixture was concentrated and the title product 
(255 mg, 27%) was afforded as a colourless oil by flash column chromatography (80 g 
silica gel, chloroform:EtOAc 9:1 – 7:3). 
νmax (ATR): 3446 (OH), 2867, 1733 (C=O), 1111 cm-1; δH (CDCl3, 700 MHz): 4.26 - 4.20 
(m, 2H, OCH2CH3), 4.15 (dt, J = 7.6, 4.7 Hz, 1H, 2-H), 3.60 - 3.49 (m, 4H, 1’-H2, 2’-H2), 
3.46 (t, J = 6.7 Hz, 2H, 6-H2), 3.37 (s, 3H, OCH3), 2.81 (d, J = 5.5 Hz, 1H, OH), 1.83 - 1.77 
(m, 1H, 3-H), 1.69 - 1.56 (m, 3H, 3-H, 5-H2), 1.54 - 1.41 (m, 2H, 4-H2), 1.29 (t, J = 7.1 Hz, 
3H, OCH2CH3); δC (CDCl3, 101 MHz): 175.4 (C-1), 72.1 (C-2’), 71.3 (C-6), 70.5 (C-2), 70.2 
(C-1’), 61.8 (OCH2CH3), 59.2 (OCH3), 34.3 (C-3), 29.4 (C-5), 21.6 (C-4), 14.3 (OCH2CH3); 
HRMS (ASAP) found [M+H]+ 235.1544, C11H23O5 requires M 235.1545. 
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Ethyl 6-(2’-methoxyethoxy)-2-(((trifluoromethyl)sulfonyl)oxy)hexanoate 141 
 
Ethyl 2-hydroxy-6-(2’-methoxyethoxy)hexanoate 140 (100 mg, 0.43 mmol, 1 eq) was 
dissolved in dry DCM (0.9 ml) at 0 °C under a nitrogen atmosphere. 2,6-Lutidine (0.06 ml, 
0.51 mmol, 1.2 eq) and subsequently triflic anhydride (0.08 ml, 0.47 mmol, 1.1 eq) were 
added and the reaction was stirred at 0 °C for 2.5 h. H2O was slowly added and the two 
layers were separated. The organic layer was dried over MgSO4 and concentrated. Flash 
column chromatography (12 g silica gel, hexane:EtOAc 1:0 - 4:1) afforded the title product 
(105 mg, 67%) as a colourless oil. 
 
νmax (ATR): 2934, 1760 (C=O), 1417, 1204, 1144, 928 cm-1; δH (CDCl3, 700 MHz): 5.10 (t, 
J = 6.1 Hz, 1H, 2-H), 4.34 - 4.25 (m, 2H, OCH2CH3), 3.61 - 3.51 (m, 4H, 1’-H2, 2’-H2), 3.47 
(t, J = 6.3 Hz, 2H, 6-H2), 3.38 (s, 3H, OCH3), 2.06 - 2.00 (m, 2H, 3-H2), 1.70 - 1.60 (m, 2H, 
5-H2), 1.58 - 1.50 (m, 2H, 4-H2), 1.32 (t, J = 7.1 Hz, 3H, OCH2CH3); δC (CDCl3, 101 MHz): 
167.2 (C-1), 118.6 (q, 1JCF = 321.3 Hz, CF3), 83.8 (C-2), 72.1 (C-1’), 70.8 (C-6), 70.3 (C-
2’), 62.8 (OCH2CH3), 59.2 (OCH3), 31.9 (C-3), 28.9 (C-5), 21.5 (C-4), 14.1 (OCH2CH3); δF 
(CDCl3, 376 MHz): -74.88;  
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5.1.5 Synthesis of photoaffinity labels 
2-(4’-Benzoylphenyl)-5,7-dimethoxy-4H-chromen-4-one 143 
 
2-Chloro-5,7-dimethoxy-4H-chromen-4-one 21 (120 mg, 0.5 mmol, 1 eq), 
4-benzoylphenylboronic acid (226 mg, 1 mmol, 2 eq), Pd2(dba)3 (13.8 mg, 3 mol%), 
CyJohnPhos (10.6 mg, 6 mol%) and Cs2CO3 (489 mg, 1.5 mmol, 3 eq) were suspended in 
dioxane (2.5 ml) under an argon atmosphere. The reaction mixture was heated to 100 °C 
and stirred for 17 h. After allowing to cool to rt, the crude mixture was filtered through 
Celite® and concentrated The residue was dissolved in H2O (20 ml) and EtOAc (20 ml). 
The layers were separated and the aqueous layer was extracted two more times with 
EtOAc (2 × 50 ml). The combined organic layers were washed with H2O (50 ml), dried over 
Na2SO4 and concentrated. The title product (173 mg, 90%) was obtained by flash column 
chromatography (4 g silica gel, DCM:EtO2:MeOH 1:1:0-2:2:1) as a colourless solid. 
m.p.: 187 - 188 °C; νmax (ATR): 1641 (C=O), 1605 (C=O), 1279, 1160, 1117, 831, 699 cm-
1; δH (CDCl3, 400 MHz): 8.02 - 7.94 (m, 2H, 2’-H, 6’-H), 7.95 - 7.87 (m, 2H, 3’-H, 5’-H), 7.86 
- 7.76 (m, 2H, 2’’-H, 6’’-H), 7.67 - 7.57 (m, 1H, 4’’-H), 7.55 - 7.46 (m, 2H, 3’’-H, 5’’-H), 6.76 
(s, 1H, 3-H), 6.60 (d, J = 2.3 Hz, 1H, 8-H), 6.40 (d, J = 2.3 Hz, 1H, 6-H), 3.97 (s, 3H, 
OCH3), 3.93 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 195.9 (C=O), 177.4 (C-4), 164.4 (C-7), 
161.1 (C-5), 160.0 (C-8a), 159.5 (C-2), 139.8 (C-4’), 137.2 (C-1’’), 135.2 (C-1’), 133.0 (C-
4’’), 130.6 (C-3’, C-5’), 130.2 (C-2’’, C6’’), 128.6 (C-3’’, C-5’’), 126.0 (C-2’, C-6’), 110.5 (C-
3), 109.5 (C-4a), 96.5 (C-6), 93.0 (C-8), 56.6 (OCH3), 56.0 (OCH3); HRMS (ES+) found 
[M+H]+ 387.1241, C24H19O5 requires M 387.1232. 
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2-(4’-Benzoylphenyl)-5-hydroxy-7-methoxy-2-4H-chromen-4-one 144 
 
BBr3 (0.34 ml of a 1 M solution in heptanes, 0.34 mmol, 1.5 eq) was added to a solution of 
2-(4-benzoylphenyl)-5,7-dimethoxy-4H-chromen-4-one 143 (87 mg, 0.23 mmol, 1 eq) in 
dry 1,2-dichloroethane (2 ml) under an argon atmosphere, while cooling in a dry 
ice/acetone-bath. The reaction mixture was allowed to warm to rt and stirred for 2.5 h, 
before pouring over a 1:1 mixture of ice and H2O (approx. 25 ml). The product was 
extracted with DCM (3 × 30 ml) and the combined organic layers were washed with brine 
(40 ml), dried over Na2SO4 and concentrated. The title product (75 mg, 90%) was afforded 
by flash column chromatography (12 g silica gel, CHCl3:MeOH 1:0-9:1) as a colourless 
solid. 
m.p.: 189 - 191°C; νmax (ATR): 1648 (C=O), 1617 (C=O), 1277, 1158, 699 cm-1; δH 
(CDCl3, 400 MHz): 12.63 (s, 1H, OH), 8.03 - 7.97 (m, 2H,2’-H, 6’-H), 7.96 - 7.90 (m, 2H, 3’-
H, 5’-H), 7.86 - 7.80 (m, 2H, 2’’-H, 6’’-H), 7.67 - 7.60 (m, 1H, 4’’-H), 7.55 - 7.49 (m, 2H, 3’’-
H, 5’’-H), 6.74 (s, 1H, 3-H), 6.53 (d, J = 2.3 Hz, 1H, 8-H), 6.39 (d, J = 2.2 Hz, 1H, 6-H), 
3.89 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 195.7 (C=O), 182.4 (C-4), 166.0 (C-7), 162.7 (C-
2), 162.4 (C-5), 157.9 (C-8a), 140.3 (C-4’), 137.1 (C-1’’), 134.8 (C-1’), 133.1 (C-4’’), 130.7 
(C-3’, C-5’), 130.2 (C-2’’, C-6’’), 128.7 (C-3’’, C-5’’), 126.3 (C-2’, C-6’), 107.2 (C-3), 106.0 
(C-4a), 98.5 (C-6), 92.9 (C-8), 56.0 (OCH3).; HRMS (ES+) found [M+H]+ 373.1081, 
C23H17O5 requires M 373.1076. 
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2-(2’-(4’’-Benzoylphenyl)-7’-methoxy-4’-oxo-2-4H-chromen-5’-oxy)dodecanoic acid 145 
 
A solution of methyl 2-bromododecanoate 48 (95 mg, 0.32 mmol, 2 eq) in dry DMF (1 ml) 
was added to a mixture of 2-(4-benzoylphenyl)-5-hydroxy-7-methoxy-2-4H-chromen-4-one 
144 (60 mg, 0.16 mmol, 1 eq) and K2CO3 (45 mg, 0.32 mmol, 2 eq) under an argon 
atmosphere. The reaction mixture was stirred at 60 °C for 17 h. H2O (10 ml) was added 
and the product was extracted with EtOAc (3 × 10 ml). The combined organic layers were 
washed with H2O (20 ml), dried over Na2SO4 and concentrated. The crude product was 
dissolved in a 1:1 mixture of THF (4 ml) and H2O (4 ml) and LiOH.H2O (14 mg, 0.32 mmol, 
2 eq) was added. The reaction mixture was stirred for 2.5 h at rt. The mixture was acidified 
with 1M HCl to pH 5 - 6 and extracted with EtOAc (3 × 10 ml). The combined organic 
layers were washed with brine (10 ml), dried over Na2SO4 and concentrated. Flash column 
chromatography (12 g silica gel, Et2O, then DCM:MeOH 9:1) afforded the title product 
(59 mg, 65%) as a colourless semi-solid. 
νmax (ATR): 2923, 2852, 1742 (C=O), 1634 (C=O), 1599, 1277, 1107, 698 cm-1; δH 
(CDCl3, 400 MHz): 13.48 (s, 1H, COOH), 8.07 - 7.98 (m, 2H, 2’’-H, 6’’-H), 7.98 - 7.90 (m, 
2H, 3’’-H, 5’’-H), 7.86 - 7.78 (m, 2H, 2’’’-H, 6’’’-H), 7.69 - 7.58 (m, 1H, 4’’’-H), 7.55 – 7.50 
(m, 2H, 3’’’-H, 5’’’-H), 6.84 (s, 1H, 3’-H), 6.75 (d, J = 2.2 Hz, 1H, 8’-H), 6.49 (d, J = 2.2 Hz, 
1H, 6’-H), 4.85 (t, J = 5.3 Hz, 1H, 2-H), 3.95 (s, 3H, OCH3), 2.24 - 2.08 (m, 2H, 3-H2), 1.66 
- 1.45 (m, 2H, 4-H2), 1.43 - 1.16 (m, 14H, 5-H2, 6-H2, 7-H2, 8-H2, 9-H2, 10-H2, 11-H2), 0.87 
(t, J = 6.8 Hz, 3H, 12-H3); δC (CDCl3, 100 MHz): 195.7 (C=O), 178.7 (C-4’), 172.4 (C-1), 
165.1 (C-7’), 161.6 (C-8a’), 159.6 (C-2’), 159.0 (C-5’), 140.4 (C-4’’), 137.0 (C-1’’’), 134.4 
(C-1’’), 133.2 (C-4’’’), 130.7 (C-3’’, C-5’’), 130.2 (C-2’’’, C-6’’’), 128.7 (C-3’’’, C-5’’’), 126.3 
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(C-2’’, C-6’’), 109.6 (C-4a’), 109.6 (C-3’), 101.5 (C-6’), 95.2 (C-8’), 81.9 (C-2), 56.3 (OCH3), 
33.0 (C-3), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.8(C-
4), 22.8 (CH2), 14.3 (C-12); HRMS (ES+) found [M+H]+ 571.2683, C35H39O7 requires M 
571.2696. 
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trans-3-(4’-Allyloxyphenyl)-1-(2’’-hydroxy-4’’,6’’-dimethoxyphenyl)-propenone145 146 
 
KOH (20 ml of a 3M solution in EtOH, 60 mmol, 6 eq) was added to a mixture of 
2-hydroxy-4,6-dimethoxyacetophenone 7 (1.96 g, 10 mmol, 1 eq) and 
4-allyloxybenzaldehyde 151 (1.62 g, 10 mmol, 1 eq). The reaction mixture was stirred for 
18 h at rt and subsequently acidified to pH 5 with 1M HCl and extracted with DCM (3x 50 
ml). The combined organic layers were dried over Na2SO4 and concentrated. The title 
product (2.05 g, 60%) was obtained by flash column chromatography (50 g silica gel, 
CHCl3) as a yellow solid. 
 
m.p.:106 - 108 °C(lit.145 m.p. 99 – 100 °C); νmax (ATR):3114 (OH), 2974, 2355, 1603 
(C=O), 1542, 1203, 1151, 825 cm-1; δH (CDCl3, 400 MHz): 14.41 (s, 1H, OH), 7.81 (d, J = 
15.5 Hz, 2-H), 7.66 (d, J = 15.5 Hz, 3-H), 7.59 - 7.52 (m, 2H, 2’-H, 6’-H), 6.98 - 6.91 (m, 
2H, 3’-H, 5’-H), 6.11 (d, J = 2.4 Hz, 1H, 3’’-H), 6.10 - 6.01 (m, 1H, CH=CH2), 5.97 (d, J = 
2.4 Hz, 1H, 5’’-H), 5.43 (ap dq, J = 17.2, 1.5 Hz, 1H, O-CH2-CH=CHtransH), 5.32 (ap dq, J 
= 10.5, 1.5 Hz, 1H, O-CH2-CH=CHHcis), 4.59 (ap dt, J = 5.3, 1.5 Hz, 2H, O-CH2-
CH=CH2), 3.92 (s, 3H, OCH3), 3.84 (s, 3H, OCH3); δC (CDCl3, 100 MHz): 192.7 (C-1), 
168.5 (C-2’’), 166.2 (C-4’’), 162.6 (C-6’’), 160.5 (C-4’), 142.6 (C-3), 133.0 (O-CH2-
CH=CH2), 130.2 (C-2’, C-6’), 128.6 (C-1’), 125.3 (C-2), 118.2 (O-CH2-CH=CH2), 115.3 (C-
3’, C-5’), 106.5 (C-1’’), 94.0 (C-3’’), 91.4 (C-5’’), 69.0 (O-CH2-CH=CH2), 56.0 (OCH3), 55.7 
(OCH3); m/z LC-MS (ES+) 341 [M+H]+. 
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5,7-Dimethoxy-2-(4’-allyloxyphenyl)-4H-chromen-4-one145 147 
 
Iodine (45 mg, 0.3 mol%) was added to a stirred solution of trans-3-(4’’-allyloxyphenyl)-1-
(2’-hydroxy-4’,6’-dimethoxyphenyl)-propenone 146 (1.85 g, 5.4 mmol, 1 eq) in DMSO at 
50 °C. Then the reaction mixture was heated to 140 °C and stirred for 2 h. After cooling to 
rt, H2O (40 ml) and DCM (40 ml) were added. The layers were separated and the aqueous 
layer was extracted two more times with DCM (2 × 40 ml). The combined organic layers 
were washed with an aqueous Na2S2O3 solution (0.5%, 50 ml), dried over Na2SO4 and 
concentrated. The title product (1.75 g, 95%) was obtained by flash column 
chromatography (12 g silica gel, EtO2:MeOH 1:0-4:1) as a colourless solid. 
 
m.p.: 169 - 171 °C (lit.145 m.p. 171 – 172 °C); νmax (ATR): 1640 (C=O), 1603, 1163, 1104, 
825 cm-1; δH (CDCl3, 400 MHz): 7.86 - 7.80 (m, 2H, 2’-H, 6’-H), 7.05 - 6.98 (m, 2H, 3’-H, 5’-
H), 6.72 (s, 1H, 3-H), 6.57 (d, J = 2.3 Hz, 1H, 8-H), 6.38 (d, J = 2.3 Hz, 1H, 6-H), 6.07 (ddt, 
J = 17.3, 10.5, 5.3 Hz, 1H, CH=CH2), 5.44 (ap dq, J = 17.3, 1.5 Hz, 1H, O-CH2-
CH=CHtransH), 5.33 (ap dq, J = 10.5, 1.5 Hz, 1H, O-CH2-CH=CHHcis), 4.62 (ap dt, J = 
5.3, 1.5 Hz, 2H, O-CH2-CH=CH2), 3.96 (s, 3H, OCH3), 3.92 (s, 3H, OCH3); δC (CDCl3, 100 
MHz): 177.8 (C-4), 164.3 (C-7), 161.4 (C-4’’), 161.2 (C-5), 161.1 (C-2), 160.0 (C-8a), 132.7 
(O-CH2-CH=CH2), 127.9 (C-2’, C-6’), 123.9 (C-1’), 118.4 (O-CH2-CH=CH2), 115.3 (C-3’, C-
5’), 109.0 (C-4a), 107.4 (C-3), 96.4 (C-6), 93.0 (C-8), 69.1 (O-CH2-CH=CH2), 56.6 (OCH3), 
55.9 (OCH3); m/z LC-MS (ES+) 339 [M+H]+.  
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5,7-Dimethoxy-2-(4’-hydroxyphenyl)-4H-chromen-4-one186 148 
 
A suspension of 5,7-dimethoxy-2-(4’-allyloxyphenyl)-4H-chromen-4-one 147 (1.55 g, 
5.2 mmol, 1 eq), Pd(PPh3)4 (180 mg, 3 mol%) and K2CO3 (2.87 g, 20.8 mmol, 4 eq) in dry 
MeOH (90 ml) was stirred at reflux for 4,5 h under an argon atmosphere. After cooling the 
reaction mixture to rt, excess K2CO3 was removed by filtration through Celite®. The filtrate 
was added to H2O (100 ml) and the solution was acidified to pH 3 with 1M HCl. An off-
white precipitate was formed, which was collected by filtration and dried under reduced 
pressure. The title product, a yellow solid, (1.32 g, 85%) was used for upcoming steps 
without further purification. 
 
m.p.: 290 – 292 °C (lit.186 m.p. 289 – 290 °C); νmax (ATR): 3172 (OH), 1631 (C=O), 1596, 
1349, 1107, 829 cm-1; δH (d6-DMSO, 400 MHz): 10.22 (s, 1H, OH), 7.91 - 7.85 (m, 2H, 2’-
H, 6’-H), 6.93 - 6.87 (m, 2H, 3’-H, 5’-H), 6.83 (d, J = 2.3 Hz, 1H, 8-H), 6.59 (s, 1H, 3-H), 
6.49 (d, J = 2.3 Hz, 1H, 6-H), 3.89 (s, 3H, OCH3), 3.82 (s, 3H, OCH3); δC (d6-DMSO, 100 
MHz): 175.6 (C-4), 163.5 (C-7), 160.5 (C-4’’), 160.2 (C-2) , 160.0 (C-5), 159.1 (C-8a), 
127.8 (C-2’, C-6’), 121.3 (C-1’), 115.8 (C-3’, C-5’), 108.2 (C-4a), 106.1 (C-3), 96.1 (C-6), 
93.3 (C-8), 56.1 (OCH3), 55.9 (OCH3); m/z LC-MS (ES+) 299 [M+H]+. 
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5-Hydroxy-2-(4’-hydroxyphenyl)-7-methoxy-4H-chromen-4-one187 149 
 
BBr3 (3.02 ml of a 1 M solution in DCM, 3 mmol, 1.5 eq) was added to a solution of 
5,7-dimethoxy-2-(4’-hydroxyphenyl)-4H-chromen-4-one 148 (600 mg, 2 mmol, 1 eq) in dry 
1,2-dichloroethane (18 ml) under an argon atmosphere, while cooling in a dry ice/acetone-
bath. The reaction mixture was allowed to warm to rt and stirred for 3 h, before adding H2O 
(approx. 50 ml). The product was collected by filtration and dried under reduced pressure. 
The filtrate was further extracted with DCM (2 × 30 ml) and the combined organic layers 
were dried over Na2SO4 and concentrated. The resulting solid was combined with the 
collected precipitate and recrystallized from methanol to yield the title product (293 mg, 
51%). 
 
m.p.: 289 – 291 °C (lit.188 m.p.: 290 – 292 °C); νmax (ATR): 3251 (OH), 1663 (C=O), 1589, 
1499, 1161, 818 cm-1; δH (CD3OD, 400 MHz): 7.92 - 7.85 (m, 2H, 2’-H, 6’-H), 6.97 - 6.90 
(m, 2H, 3’-H, 5’-H), 6.67 (d, J = 2.3 Hz, 1H, 8-H), 6.65 (s, 1H, 3-H), 6.36 (d, J = 2.3 Hz, 1H, 
6-H), 3.90 (s, 3H, OCH3); δC (d6-DMSO, 176 MHz): 181.9 (C-4), 165.1 (C-7), 164.0 (C-2), 
161.3 (C-4’), 161.2 (C-5), 157.2 (C-8a), 128.5 (C-2’, C-6’), 121.0 (C-1’), 115.9 (C-3’, C-5’), 
104.6 (C-4a), 103.0 (C-3), 97.9 (C-6), 92.7 (C-8), 56.0 (OCH3); m/z LC-MS (ES+) 285 
[M+H]+. 
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4-Allyloxybenzaldehyde 189 151 
 
K2CO3 (6.79 g, 49.1 mmol, 3 eq) and allyl bromide (2.13 ml, 24.6 mmol, 1.5 eq) were 
added to a solution of 4-hydroxybenzaldehyde 150 (2.00 g, 16.4 mmol, 1 eq) in acetone 
(20 ml). The reaction mixture was stirred at rt for 2 h and subsequently heated to reflux for 
another 2 h. The solvent was removed under reduced pressure and flash column 
chromatography (24 g silica gel, hexane:EtOAc 1:0-7:3) afforded the title product (2.38 g, 
89%) as a colourless oil. 
 
νmax (ATR): 1694 (C=O), 1683, 1601, 1576, 1508, 1313, 1258, 1163, 996, 833 cm-1 δH 
(CDCl3, 400 MHz): 9.88 (s, 1H, CHO), 7.89 - 7.78 (m, 2H, 2-H, 6-H), 7.08 - 6.97 (m, 2H, 3-
H, 5-H), 6.05 (ddt, J = 17.2, 10.5, 5.3 Hz, 1H, CH=CH2), 5.43 (ap dq, J = 17.2, 1.5 Hz, 1H, 
CH=CHtransH), 5.33 (ap dq, J = 10.5, 1.5 Hz, 1H, CH=CHHcis), 4.62 (ap dt, J = 5.3, 1.5 
Hz, 2H, CH2-CH=CH2); δC (CDCl3, 100 MHz): 190.9 (CHO), 163.7 (C-4), 132.4 (CH=CH2), 
132.1 (C-2, C-6), 130.2 (C-1), 118.5 (CH=CH2), 115.1 (C-3, C-5), 69.1 (CH2-CH=CH2); m/z 
LC-MS (ES+) 163 [M+H]+. 
 
  
O
O
H
  Experimental Part 
  266 
2-{4’-[2’’-(4’’’-Benzoylphenoxy)ethoxy]phenyl}-5-hydroxy-7-methoxy-4H-chromen-4-one 
152 
 
4-(2’’-Bromoethoxy)benzophenone 155 (343 mg, 1.125 mmol, 1.5 eq) was added to a 
suspension of 5-hydroxy-7-methoxy-2-(4’-hydroxyphenyl)-4H-chromen-4-one 149 
(213 mg, 0.75 mmol, 1 eq) and K2CO3 (207 mg, 1.5 mmol, 2 eq) in dry DMF (2 ml) under 
an argon atmosphere and the reaction mixture was stirred at rt overnight. H2O (10 ml) was 
added and the product was extracted with EtOAc (3 × 10 ml). The combined organic layers 
were washed with brine (20 ml), dried over Na2SO4 and concentrated. The title product 
(236 mg, 62%) was afforded by flash column chromatography (24 g silica gel, DCM:Et2O 
9:1-1:1) as a light yellow solid. 
m.p.: 181 – 184 °C; νmax (ATR): 1644 (C=O), 1599, 1250, 1158, 833 cm-1; δH (CDCl3, 700 
MHz): 12.79 (s, 1H), 7.90 - 7.80 (m, 4H, 3’-H, 5’-H, 2’’’-H, 6’’’-H), 7.78 - 7.73 (m, 2H, 2’’’’-H, 
6’’’’-H), 7.60 - 7.55 (m, 1H, 4’’’-H), 7.51 - 7.45 (m, 2H, 3’’’’-H, 5’’’’-H), 7.12 - 7.06 (m, 2H, 2’-
H, 6’-H), 7.05 - 7.00 (m, 2H, 3’’’-H, 5’’’-H), 6.59 (s, 1H, 3-H), 6.49 (d, J = 2.3 Hz, 1H, 8-H), 
6.37 (d, J = 2.3 Hz, 1H, 6-H), 4.49 - 4.40 (m, 4H, 1’’-H2, 2’’-H2), 3.88 (s, 3H, OCH3); δC 
(CDCl3, 176 MHz): 195.6 (C=O), 182.6 (C-4), 165.6 (C-7), 163.9 (C-2), 162.4 (C-5), 162.2 
(C-1’’’), 161.6 (C-4’), 157.9 (C-8a), 138.3 (C-1’’’’), 132.7 (C-2’’’, C-6’’’), 132.2 (C-4’’’’), 130.9 
(C-4’’’), 129.9 (C-2’’’’, C-6’’’’), 128.4 (C-3’’’’, C-5’’’’), 128.3 (C-3’, C-5’), 124.3 (C-1’), 115.3 
(C-2’, C-6’), 114.3 (C-3’’’, C-5’’’), 105.7 (C-4a), 104.7 (C-3), 98.2 (C-6), 92.8 (C-8), 66.7 
(CH2), 66.6 (CH2), 56.0 (OCH3); HRMS (ES+) found [M+H]+ 509.1615, C31H25O7 requires M 
509.1600.   
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2-[(2’-{4’’-[2’’’-(4’’’’-Benzoylphenoxy)ethoxy]phenyl}-7’-methoxy-4’-oxo-4’H-chromen-5’-
yl)oxy]dodecanoic acid 153 
 
A solution of methyl 2-bromododecanoate 48 (136 mg, 0.46 mmol, 2 eq) in dry DMF 
(0.5 ml) was added to a mixture of 2-{4’-[2’’-(4’’’-benzoylphenoxy)ethoxy]phenyl}-5-
hydroxy-7-methoxy-4H-chromen-4-one 152 (118 mg, 0.23 mmol, 1 eq) and K2CO3 (64 mg, 
0.46 mmol, 2 eq) in dry DMF (1 ml) under an argon atmosphere. The reaction mixture was 
stirred at 60 °C for 17 h. H2O (10 ml) was added and the product was extracted with EtOAc 
(3 × 10 ml). The combined organic layers were washed with brine (20 ml), dried over 
Na2SO4 and concentrated. The crude intermediate was dissolved in a 1:1 mixture of THF 
(5 ml) and H2O (5 ml) and LiOH.H2O (19 mg, 0.46 mmol, 2 eq) was added. The reaction 
mixture was stirred for 3 h at rt. The mixture was acidified with 1M HCl to pH 4-5 and 
extracted with EtOAc (3 × 10 ml). The combined organic layers were dried over Na2SO4 
and concentrated. Flash column chromatography (4 g silica gel, DCM:MeOH 1:0-9:1) 
afforded the title product (150 mg, 92%) as a colourless semi-solid. 
νmax (ATR): 3025 (COO-H), 2919, 2851, 1739 (C=O), 1628 (C=O), 1598, 1244, 1163, 
1111, 831 cm-1; δH (CDCl3, 600 MHz): 7.91 - 7.82 (m, 4H, 2’’’’-H, 6’’’’-H, 2’’-H, 6’’-H), 7.80 - 
7.74 (m, 2H, 2’’’’’-H, 6’’’’’-H), 7.61 - 7.55 (m, 1H, 4’’’’’-H), 7.52 – 7.45 (m, 2H, 3’’’’’-H, 5’’’’’-
H), 7.13 - 7.07 (m, 2H, 3’’-H, 5’’-H), 7.06 - 7.00 (m, 2H, 3’’’’-H, 5’’’’-H), 6.71 (d, J = 2.3 Hz, 
1H, 8’-H), 6.69 (s, 1H, 3’-H), 6.47 (d, J = 2.3 Hz, 1H, 6’-H), 4.83 (t, J = 5.3 Hz, 1H, 2-H), 
4.46 (s, 4H, 1’’’-H2, 2’’’-H2), 3.93 (s, 3H, OCH3), 2.19 - 2.07 (m, 2H, 3-H), 1.66 - 1.46 (m, 
1H, 4-H), 1.42 - 1.18 (m, 14H, 7 × CH2), 0.87 (t, J = 7.0 Hz, 3H, 12-H3); δC (CDCl3, 151 
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MHz): 195.6 (C=O), 178.9 (C-4’), 172.6 (C-1), 164.7 (C-7’), 162.8 (C-2’), 162.2 (C-1’’’’), 
161.7 (C-4’’), 159.5 (C-8a’), 159.0 (C-5’), 138.3 (C-1’’’’’), 132.7 (C-3’’’’, C-5’’’’), 132.2 (C-
4’’’’’), 130.9 (C-4’’’’), 129.9 (C-2’’’’’, C-6’’’’’), 128.4 (C-3’’’’’, C-5’’’’’), 128.2 (C-2’’, C-6’’), 
123.8 (C-1’’), 115.4 (C-3’’, C-5’’), 114.3 (C-2’’’’, C-6’’’’), 109.5 (C-4a’), 107.0 (C-3’), 101.4 
(C-6’), 95.3 (C-8’), 82.1 (C-2), 66.8 (C-1’’’), 66.6 (C-2’’’), 56.2 (OCH3), 33.1 (CH2), 32.0 
(CH2), 29.7 (CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.9 (C-4), 22.8 (CH2), 
14.3 (C-12); HRMS (ES+) found [M+H]+ 707.3232, C43H47O9 requires M 707.3220. 
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4-(2’’-Bromoethoxy)benzophenone190 155 
 
1,2-Dibromoethane (5.18 ml, 60 mmol, 6 eq) was added to a suspension of 
4-hydroxybenzophenone 154 (1.98 g, 10 mmol, 1 eq) and K2CO3 (2.76 g, 20 mmol, 2 eq) 
in dry DMF (30 ml) under an argon atmosphere and the reaction mixture was stirred at rt 
for 41 h. H2O (50 ml) was added and the product was extracted with DCM (3 × 50 ml). The 
combined organic layers were washed with H2O (100 ml) and brine (100 ml), dried over 
Na2SO4 and concentrated. The title product (1.10 g, 36%) was afforded by flash column 
chromatography (24 g silica gel, hexane:EtOAc 1:0-4:1) as a colourless solid. 
 
m.p.: 72 – 74 °C (lit.190 m.p.: 74 – 75 °C); νmax (ATR): 1652 (C=O), 1600, 1253, 697 cm-1; 
δH (CDCl3, 700 MHz): 7.88 - 7.80 (m, 2H, 2-H, 6-H), 7.79 - 7.71 (m, 2H, 2’-H, 6’-H), 7.60 - 
7.54 (m, 1H, 4’-H), 7.51 - 7.44 (m, 2H, 3’-H, 5’-H), 7.03 - 6.94 (m, 2H, 3-H, 5-H), 4.38 (t, J 
= 6.2 Hz, 2H, 1’’-H2), 3.68 (t, J = 6.2 Hz, 2H, 2’’-H2); δC (CDCl3, 176 MHz): 195.6 (C=O), 
161.8 (C-4), 138.3 (C-1’), 132.7 (C-2, C-6), 132.1 (C-4’), 131.0 (C-1), 129.9 (C-2’, C-6’), 
128.4 (C-3’, C-5’), 114.3 (C-3, C-5), 68.0 (C-1’’), 28.8 (C-2’’); HRMS (ES+) found [M+H]+ 
305.0202, C15H14O279Br requires M 305.0177. 
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7-[2’-(4’’-Benzoylphenoxy)ethoxy]-5-hydroxy-2-phenyl-4H-chromen-4-one 156 
 
A flask was charged with 4-(2’’-bromoethoxy)benzophenone 155 (153 mg, 0.5 mmol, 
1 eq), chrysin 45 (0.127 g, 0.5 mmol, 1 eq) and K2CO3 (0.138 g, 1 mmol, 2 eq) in dry DMF 
(2 ml) under an argon atmosphere and the reaction mixture was stirred at rt overnight and 
another 24 h at 40 °C. H2O (10 ml) was added and the product was extracted with DCM 
(3 × 10 ml). The combined organic layers were dried over Na2SO4 and concentrated. The 
title product (185 mg, 77%) was afforded by flash column chromatography (12 g silica gel, 
DCM:MeOH 0:1-9:1) as a light yellow solid. 
m.p.: 186 – 187 °C; νmax (ATR): 1657 (C=O), 1604, 1350, 1259, 1166 cm-1; δH (CDCl3, 
600 MHz): 12.76 (s, 1H, OH), 8.00 - 7.79 (m, 4H, 2’’’’-H, 6’’’’-H, 3’’-H, 5’’-H), 7.80 - 7.71 (m, 
2H, 2’’’-H, 6’’’-H), 7.68 - 7.40 (m, 6H, 4’’’-H, 4’’’’-H, 3’’’-H, 5’’’-H, 3’’’’-H, 5’’’’-H), 7.07 - 6.97 
(m, 2H, 2’’-H, 6’’-H), 6.69 (s, 1H, 3-H), 6.57 (d, J = 2.3 Hz, 1H, 8-H), 6.44 (d, J = 2.3 Hz, 
1H, 6-H), 4.45 (s, 4H, 1’-H2, 2’-H2); δC (CDCl3, 151 MHz): 195.6 (C=O), 182.7 (C-4), 164.5 
(C-7), 164.3 (C-2), 162.5 (C-5), 162.1 (C-1’’), 157.9 (C-8a), 138.3 (C-1’’’’), 132.7 (C-3’’, C-
5’’), 132.1 (C-4’’’’), 132.1 (C-4’’’), 131.4 (C-1’’’’), 130.9 (C-4’’), 129.9 (C-2’’, C-6’’), 129.3 (C-
3’’’, C-5’’’), 128.4 (C-3’’’’, C-5’’’’), 126.5 (C-2’’’’, C-6’’’’), 114.3 (C-2’’, C-6’’), 106.2 (C-4a), 
106.1 (C-3), 98.7 (C-6), 93.6 (C-8), 67.0 (C-1’), 66.4 (C-2’); HRMS (ES+) found [M+H]+ 
479.1499, C30H23O6 requires M 479.1495. 
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2-({7’-[2’’-(4’’’-Benzoylphenoxy)ethoxy]-4’-oxo-2’-phenyl-4’H-chromen-5’-yl}oxy)dodecanoic 
acid 157 
 
A solution of methyl 2-bromododecanoate 48 (123 mg, 0.42 mmol, 2 eq) in dry DMF 
(0.5 ml) was added to a mixture of 7-[2’-(4’’-benzoylphenoxy)ethoxy]-5-hydroxy-2-phenyl-
4H-chromen-4-one (0.100 g, 0.21 mmol, 1 eq) and Cs2CO3 (0.136 g, 0.42 mmol, 2 eq) in 
dry DMF (2 ml) under an argon atmosphere. The reaction mixture was stirred at 60 °C for 
19 h. H2O (10 ml) was added and the product was extracted with DCM (3 × 10 ml). The 
combined organic layers were dried over Na2SO4 and concentrated. The crude 
intermediate was dissolved in a mixture of THF and H2O (1:1, 5 ml) and LiOH.H2O (18 mg, 
0.42 mmol, 2 eq) was added. The reaction mixture was stirred for 6 h at rt. The mixture 
was acidified with 1M HCl to pH 4-5 and extracted with DCM (3 × 10 ml). The combined 
organic layers were dried over Na2SO4 and concentrated. Flash column chromatography 
(12 g silica gel, Et2O:MeOH 1:0-9:1) afforded the title product (78 mg, 55%) as a 
colourless semi-solid. 
 
νmax (ATR): 2922, 2851 1742 (C=O), 1630 (C=O), 1590, 1252, 1256, 1168 cm-1; δH 
(CDCl3, 600 MHz): 13.60 (s, 1H, COOH), 8.06 - 7.80 (m, 4H, 2’’’’’-H, 6’’’’’-H, 3’’’-H, 5’’’-H), 
7.80 - 7.71 (m, 2H, 2’’’’-H, 6’’’’-H), 7.64 - 7.40 (m, 6H, 4’’’’-H, 4’’’’’-H, 3’’’’-H, 5’’’’-H, 3’’’’’-H, 
5’’’’’-H), 7.07 - 6.98 (m, 2H, 2’’’-H, 6’’’-H), 6.79 (d, J = 2.2 Hz, 1H, 8’-H), 6.77 (s, 1H, 3’-H), 
6.54 (d, J = 2.2 Hz, 1H, 6’-H), 4.84 (t, J = 5.3 Hz, 1H, 2-H), 4.49 (s, 4H, 1’’-H2, 2’’-H2), 2.22 
- 2.08 (m, 2H, 3-H2), 1.65 - 1.48 (m, 2H, 4-H2), 1.42 - 1.16 (m, 14H, 7 × CH2), 0.86 (t, J = 
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7.0 Hz, 3H, 12-H3); δC (CDCl3, 151 MHz): 195.6 (C=O), 178.9 (C-4’), 172.4 (C-1), 163.7 (C-
7’), 163.0 (C-2’), 161.9 (C-1’’’), 159.5 (C-8a’), 159.1 (C-5’), 138.2 (C-1’’’’’), 132.8 (C-3’’’, C-
5’’’), 132.2 (C-4’’’’’), 132.2 (C-4’’’’), 131.1 (C-4’’’), 131.0 (C-1’’’’’), 129.9 (C-2’’’’, C-6’’’’), 
129.3 (C-3’’’’, C-5’’’’), 128.4 (C-3’’’’’, C-5’’’’’), 126.4 (C-2’’’’’, C-6’’’’’), 114.3 (C-2’’’, C-6’’’), 
109.9 (C-4a’), 108.4 (C-3’), 101.7 (C-6’), 95.9 (C-8’), 82.0 (C-2’), 67.3 (C-1’’), 66.3 (C-2’’), 
33.0 (C-3), 32.0 (CH2), 29.7 (CH2), 29.7(CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 24.8 (C-
4), 22.8 (CH2), 14.3 (C-12); HRMS (ES+) found [M+H]+ 677.3135, C42H45O8 requires M 
677.3114. 
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Ethyl 12-(4’-benzoylphenoxy)-2-hydroxydodecanoate 158 
 
A mixture of 4-hydroxybenzophenone 154 (178 mg, 0.9 mmol, 1.5 eq), ethyl 12-bromo-2-
hydroxydodecanoate 82 (194 mg, 0.6 mmol, 1 eq) and K2CO3 (166 mg, 1.2 mmol, 2 eq) in 
dry DMF (5 ml) under a nitrogen atmosphere was stirred at 60 °C overnight. H2O (5 ml) 
was added and the aqueous phase extracted with EtOAc (3 × 5 ml). The organic extracts 
were collected, washed with brine, dried over MgSO4 and concentrated. The title product 
(171 mg, 65%) was afforded by reversed phase column chromatography (H2O:MeCN 0:1 - 
1:0, 0.1% TFA) as a colourless solid. 
 
m.p.: 50 – 52 °C; νmax (ATR): 3488 (OH), 2919, 2850, 1724 (C=O), 1639 (C=O), 1603, 
1254, 692 cm-1; δH (CDCl3, 400 MHz): 7.87 - 7.78 (m, 2H, 3’-H, 5’-H), 7.79 - 7.71 (m, 2H, 
2’’-H, 6’’-H), 7.60 - 7.52 (m, 1H, 4’’-H), 7.52 - 7.40 (m, 2H, 3’’-H, 5’’-H), 7.02 - 6.87 (m, 2H, 
2’-H, 6’-H), 4.24 (qd, J = 7.2, 1.1 Hz, 2H, O-CH2-CH3), 4.16 (dt, J = 7.2, 5.0 Hz, 1H, 2-H), 
4.03 (t, J = 6.5 Hz, 2H, 12-H2), 2.74 (d, J = 5.0 Hz, 1H, OH), 1.86 - 1.71 (m, 3H, 3-H, 11-
H2), 1.69 - 1.57 (m, 1H, 3-H), 1.55 - 1.14 (m, 17H, 7 × CH2, O-CH2-CH3); δC (CDCl3, 101 
MHz): 195.7 (C=O), 175.6 (C-1), 163.0 (C-1’), 138.5 (C-1’’), 132.7 (C-3’, C-5’), 132.0 (C-
4’’), 130.0 (C-4’), 129.9 (C-2’’, C-6’’), 128.3 (C-3’’, C-5’’), 114.1 (C-2’, C-6’), 70.6 (C-2), 
68.4 (C-12), 61.8 (O-CH2-CH3), 34.6 (C-3), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 
29.3 (CH2), 26.1 (CH2), 24.9 (CH2), 14.4 (O-CH2-CH3); HRMS (ES+) found [M+H]+ 
441.2653, C27H37O5 requires M 441.2641. 
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Ethyl 12-(4’-benzoylphenoxy)-2-(((trifluoromethyl)sulfonyl)oxy)dodecanoate 159 
 
Ethyl 12-(4’-benzoylphenoxy)-2-hydroxy-dodecanoate 158 (132 mg, 0.3 mmol, 1 eq) was 
dissolved in dry DCM (0.5 ml) at 0 °C under a nitrogen atmosphere. 2,6-Lutidine (0.04 ml, 
0.36 mmol, 1.2 eq) and subsequently triflic anhydride (0.06 ml, 0.33 mmol, 1.1 eq) were 
added and the reaction was stirred at 0 °C for 1.5 h. H2O was slowly added and the two 
layers separated. The organic layer was dried over MgSO4 and concentrated. Flash 
column chromatography (12 g silica gel, iso-hexane:EtOAc 1:0 – 4:1) afforded the title 
product (125 mg, 73%) as a colourless oil. 
 
νmax (ATR): 2930, 2856, 1760 (C=O), 1653 (C=O), 1599, 1252, 1202, 1144, 921 cm-1; δH 
(CDCl3, 400 MHz): 7.88 - 7.79 (m, 2H, 3’-H, 5’-H), 7.78 - 7.70 (m, 2H, 2’’-H, 6’’-H), 7.60 - 
7.53 (m, 1H, 4’’-H), 7.51 - 7.43 (m, 2H, 3’’-H, 5’’-H), 6.99 - 6.90 (m, 2H, 2’-H, 6’-H), 5.10 (t, 
J = 6.1 Hz, 1H, 2-H), 4.37 - 4.23 (m, 2H, O-CH2-CH3), 4.04 (t, J = 6.5 Hz, 2H, 12-H2), 2.06 
- 1.95 (m, 2H, 3-H2), 1.87 - 1.76 (m, 2H, 11-H2), 1.56 - 1.21 (m, 17H, 7 × CH2, O-CH2-CH3); 
δC (CDCl3, 101 MHz): 195.8 (C=O), 167.3 (C-1), 163.0 (C-1’), 138.5 (C-1’’), 132.8 (C-3’, C-
5’), 132.0 (C-4’’), 130.0 (C-4’), 129.9 (C-2’’, C-6’’), 128.3 (C-3’’, C-5’’), 118.6 (q, J = 321.7 
Hz, CF3), 114.2 (C-2’, C-6’), 83.9 (C-2), 68.4 (C-12), 62.8 (O-CH2-CH3), 32.1 (C-3), 29.6 
(CH2), 29.5 (CH2), 29.5 (CH2), 29.3 (CH2), 29.3 (CH2), 28.9 (CH2), 26.1 (CH2), 24.6 (CH2), 
14.1 (O-CH2-CH3); δF (CDCl3, 376 MHz): -74.89;  
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12-(4’-Benzoylphenoxy)-2-[(7’’’-methoxy-4’’’-oxo-2’’’-phenyl-4’’’H-chromen-5’’’-
yl)oxy]dodecanoic acid 160 
 
A mixture of 5-hydroxy-7-methoxy-2-phenyl-4H-chromen-4-one 46 (101 mg, 0.375 mmol, 
1.5 eq), ethyl 12-(4-benzoylphenoxy)-2-[hydroxy-dioxo-(trifluoromethyl)-
sulfanyl]dodecanoate 160 (143 mg, 0.25 mnmol, 1 eq) and K2CO3 (104 mg, 0.75 mmol, 
3 eq) in dry MeCN (1 ml) under a nitrogen atmosphere was stirred at rt overnight. H2O 
(2 ml) was added to the reaction mixture. The aqueous phase was extracted with EtOAc 
(3 × 2 ml), the organic extracts collected, washed with brine, dried over MgSO4 and 
concentrated. The crude product together with LiOH.H2O (0.031 g, 0.75 mmol, 3 eq) was 
stirred in a 1:1 mixture of H2O (3 ml) and THF (3 ml) at rt for 3h. The mixture was acidified 
to pH 2-3 with 1N HCl and the aqueous phase was extracted with DCM (3 × 5 ml). The 
organic extracts were collected, dried over MgSO4 and concentrated. Flash column 
chromatography (12 g silica gel, EtO2 then DCM:MeOH 19:1) gave the title product 
(50 mg, 30 %) as a colourless semi solid. 
 
νmax (ATR): 2925, 2854, 1743 (C=O), 1633 (C=O), 1595, 1253, 1162, 909, 728 cm-1; δH 
(CDCl3, 400 MHz): 13.70 (br. s, 1H, COOH), 7.99 - 7.85 (m, 2H, 2’’’’-H, 6’’’’-H), 7.85 - 7.72 
(m, 4H, 3’-H, 5’-H, 2’’-H, 6’’-H), 7.60 - 7.41 (m, 6H, 4’’-H, 4’’’’-H, 3’’-H, 5’’-H, 3’’’’-H, 5’’’’-H), 
7.00 - 6.88 (m, 2H, 2’-H, 6’-H), 6.76 (s, 1H, 3’’’-H), 6.73 (d, J = 2.2 Hz, 1H, 8’’’-H), 6.47 (d, 
J = 2.2 Hz, 1H, 6’’’-H), 4.84 (t, J = 5.3 Hz, 1H, 2-H), 4.03 (t, J = 6.6 Hz, 2H, 12-H2), 3.94 (s, 
3H, OCH3), 2.24 - 2.08 (m, 2H, 3-H2), 1.87 - 1.75 (m, 2H, 11-H2), 1.65 - 1.25 (m, 14H, 7 × 
CH2); δC (CDCl3, 101 MHz): 195.7 (C=O), 179.0 (C-4’’’), 172.5 (C-1), 164.9 (C-7’’’), 163.0 
OMeO
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(C-1’), 163.0 (C-2’’’), 159.6 (C-8a’’’), 159.0 (C-5’’’), 138.5 (C-1’’), 132.7 (C-3’, C-5’), 132.1 
(C-4’’’’), 132.0 (C-4’’), 131.1 (C-1’’’’), 130.0 (C-4’), 129.9 (C-2’’, C-6’’), 129.3 (C-3’’’’, C-5’’’’), 
128.3 (C-3’’, C-5’’), 126.4 (C-2’’’’, C-6’’’’), 114.2 (C-2’, C-6’), 109.6 (C-4a’’’), 108.4 (C-3’’’), 
101.5 (C-6’’’), 95.2 (C-8’’’), 82.0 (C-2), 68.4 (C-12), 56.2 (OCH3), 33.0 (C-3), 29.6 (CH2), 
29.5 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 29.3 (CH2), 26.1 (CH2), 24.8 (CH2); HRMS 
(ES+) found [M+H]+ 663.2961, C41H43O8 requires M 663.2958. 
 
2-{[7’-Methoxy-2’-(2’’-methylylphenyl)-4’-oxo-4’H-chromen-5’-yl]oxy}dodecanoic acid 168 
 
A solution of methyl 2-bromododecanoate 48 (107 mg, 0.36 mmol, 2 eq) in dry DMF 
(0.6 ml) was added to a mixture of 5-hydroxy-7-methoxy-2-(1’,3’-thiazol-2’-yl)-4H-chromen-
4-one 114 (50 mg, 0.18 mmol, 1 eq) and K2CO3 (50 mg, 0.36 mmol, 2 eq) under an argon 
atmosphere. The reaction mixture was stirred at 60 °C for 18 h. H2O (5 ml) was added and 
the product was extracted with DCM (3 × 5 ml). The combined organic layers were dried 
over Na2SO4 and concentrated. The crude product was dissolved in a 2:1 mixture of 
MeOH (2 ml) and H2O (1 ml) and KOH (61 mg, 1.08 mmol, 2 eq) added. The reaction 
mixture was stirred for 3.5 h at rt. The mixture was acidified with 1M HCl to pH 3 - 4 and 
extracted with DCM (3 × 5 ml). The combined organic layers were dried over Na2SO4 and 
concentrated. Flash column chromatography (12 g silica gel, hexane:(EtOAc:EtOH 3:1) 
4:1-0:1) afforded the title product (34 mg, 40 %) as a colourless semi-solid. 
νmax (ATR): 2924, 2854, 1749 (C=O), 1635 (C=O), 1600, 1409, 1347, 1165, 1104 cm-1; δH 
(CDCl3, 700 MHz): 8.06 (d, J = 3.1 Hz, 1H, 4’’-H), 7.67 (d, J = 3.1 Hz, 1H, 3’’-H), 7.14 (s, 
1H 3’-H), 6.73 (d, J = 2.2 Hz, 1H, 8’-H), 6.48 (d, J = 2.2 Hz, 1H, 6’-H), 4.84 (t, J = 5.2 Hz, 
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1H, 2-H), 3.94 (s, 3H, OCH3), 2.21 - 2.07 (m, 2H, 3-H2), 1.62 – 1.47 (m, 2H, 4-H2), 1.40 - 
1.19 (m, 14H, 7 × CH2), 0.87 (t, J=7.1 Hz, 3H, 12-H3); δC (CDCl3, 100 MHz): 178.4 (C-4’), 
172.3 (C-1), 165.2 (C-7’), 159.1 (C-8a’), 158.9 (C-5’), 158.8 (C-1’’), 156.3 (C-2’), 145.5 (C-
4’’), 123.4 (C-3’’), 110.0 (C-4a’), 109.0 (C-3’), 101.5 (C-6’), 95.2 (C-8’), 81.8 (C-2), 56.3 
(OCH3), 32.9 (C-3), 32.0 (CH2), 29.7 (CH2), 29.7 (CH2), 29.5 (CH2), 29.5 (CH2), 29.4 (CH2), 
24.7 (CH2), 22.8 (CH2), 14.3 (C-12); HRMS (ES+) found [M+H]+ 474.1937, C25H32NO6S 
requires M 474.1950. 
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5.2 Biological Testing 
5.2.1 General Notes 
Chemicals: All chemicals and molecular biology reagents were purchased from 
commercial suppliers and were used without further purification unless otherwise stated. 
Buffers were made using ultrapure water (ddH2O), purified by a Milli-Q® Integral Water 
Purification System for Ultrapure Water. 
5.2.2 Preparation of buffers and other solutions 
Luria-Bertani broth (LB) 
Tryptone (5.0 g), yeast extract (2.5 g) and sodium chloride (5.0 g) were added to distilled 
water (500 ml) and the pH was adjusted to 7 with NaOH solution. The resulting solution 
was heated in an autoclave for 20 min. 
 
HEPES buffer I (20 mM HEPES, 150 mM NaCl, 1 mM EDTA-NaOH, pH 7.6) 
HEPES free acid (4.77 g) and sodium chloride (8.77 g) were dissolved in 800 ml ddH2O 
and 4 ml of EDTA (0.25 M solution, pH 8) were added. The pH was adjusted to 7.6 with 
10 N NaOH and the volume was brought up to 1 l with ddH2O. 
 
HEPES buffer II (20 mM HEPES-NaOH, 150 mM NaCl, pH 7.6) 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (4.77 g) and sodium chloride 
(8.77 g) were dissolved in 800 ml ddH2O and the pH was adjusted to pH 7.6 with 10 N 
NaOH. Subsequently the volume was brought up to 1 l with ddH2O. 
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Potassium phosphate buffer (0.1 M, pH 6.5) 
K2HPO4 (33 ml of a 1 M solution in H2O) and KH2PO4 (67 ml of 1 M solution in H2O) were 
mixed and the pH was adjusted to 6.5. The combined stock solutions were diluted to 1 l 
with ddH2O and the pH was checked again. 
 
Phosphate-buffered saline (PBS buffer) (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 
1.8 mM KH2HPO4, pH 7.4) 
Sodium chloride (8.01 g), potassium chloride (0.20 g), Na2HPO4 (1.41 g) and KH2PO4 
(0.24 g) were dissolved in 800 ml ddH2O and the pH was adjusted to pH 7.4. Subsequently 
the volume was brought up to 1 l with ddH2O. 
 
5.2.3 Protein expression and purification 
Transforming E. coli cells 
Competent cells (Rosetta™ 2(DE3)) were defrosted on ice, plasmid DNA, AmGSTF1 
containing a Strep-tag, cloned into a pET Strep vector, (2 µl) was added and the cells were 
left on ice for about 30 min. The cells were heat shocked by putting them in a 42 °C water 
bath for 1 min, then they were transferred back on ice and cooled for 2 min. 1 ml of LB 
(prewarmed to 37 °C) was added and the cells were incubated for 1 h at 37 °C. Inoculated 
(50 µg/ml kanamycin, 35 µg/ml chloramphenicol) agar plates were streaked using a sterile 
inoculation loop over the flame of a Bunsen burner. The plates were incubated at 37 °C 
overnight. 
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Expression of AmGSTF1 
Kanamycin (final concentration 50 µg/ml) and chloramphenicol (final concentration 
35 µg/ml) were added to 10 ml of LB. A colony from a LB-agar plate was selected and 
added to the inoculated LB using a sterile pipette tip. The mixture was incubated at 37 °C 
overnight, shaking at 200 rpm. The culture was then added to inoculated (50 µg/ml 
kanamycin, 35 µg/ml chloramphenicol) LB (500 ml) and incubated again at 37 °C till OD600 
reached 0.5 to 0.8. 
In order to induce the expression of AmGSTF1, IPTG (50 µl of a 1 M solution in H2O) was 
added to the culture and it was further incubated at 37 °C overnight at 150 rpm. The whole 
procedure was carried out over the flame of a Bunsen burner. The cells were obtained by 
centrifugation (5000 rpm, 15 min) and the media was decanted off. The cell pellets were 
stored at -20 °C. 
 
Purification of AmGSTF1 
The frozen cells were thawed and suspended in HEPES buffer I. A 5 ml aliquot of the re-
suspended E. coli cells in a 15 ml falcon tube was taken and sonicated at 0 °C (3 × 30 s). 
Dithiothreitol (DTT) (10 µl of a 1 M solution in H2O) and avidin (10 µl of a 1 mg/ml solution 
in 10% glycerol) were added to the lysate and the mixture was centrifuged (4000 rpm, 
15 min). Protein purification was carried out on an ÄKTA-FPLC system (GE Healthcare 
Life Sciences). The supernatant was loaded onto a 1 mL Strep-tactin Superflow High 
Capacity column which was pre-equilibrated with HEPES buffer I at a flow rate of 1 ml/min. 
All unbound protein was removed from the column. Addition of desthiobiotin (DTB) (5 mL 
of a 2.5 mM solution in HEPES buffer I) eluted AmGSTF1 and single fractions (1 ml) were 
collected which were stored at 4 °C. The column was regenerated with 
2-(4-hydroxyphenylazo)benzoic acid (HABA) (5 ml of a 1 mM solution in HEPES buffer I). 
The concentration of the protein fractions was determined by absorbance measurements 
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at 280 nm (NanoDrop 2000 spectrophotometer, Thermo Scientific). Purity was checked by 
SDS-PAGE. In some cases, AmGSTF1 was further purified using a GSTrap™ 4B column 
(GE Healthcare). AmGSTF1 was buffer exchanged into either HEPES buffer II or PBS 
buffer for storage at -80 °C. The dialysis procedure was performed with an approx. 100-
fold dilution in a GeBaFlex-tube (molecular weight cut-off: 6000 - 8000) at 4 °C overnight.  
 
SDS-PAGE: SDS-PAGE was performed according to the method described by 
Laemmli.191 The gels were composed of 12% resolving gel and 4% stacking gel (Mini-
PROTEAN® TGX™ Precast Gel) and ran at constant voltage of 200 V for 30 min in a Mini-
PROTEAN Tetra cell. After electrophoretic separation, the gel was stained with 
InstantBlue™. A prestained SDS-PAGE Standard (Bio-Rad, low range) was used for 
molecular weight estimation. 
 
Figure 90: SDS PAGE gel (separating gels: 12% T) of AmGSTF1, obtained 
from the final purification step. Four different fractions were analysed (1-4) 
and the gel was stained with Coomassie Blue. 
 
5.2.4 CDNB assay 
Potassium phosphate buffer (890 µl, 0.1 M, pH 6.5) was warmed to 30 °C in a 1 ml cuvette 
and AmGSTF1 (25 µl of a 1 mg/ml solution in HEPES buffer II (pH 7.6)) and CDNB (25 µl 
of a 40 nM solution in EtOH) added. Inhibitor (10 µl of a 10 mM, 1 mM or 100 µM solution 
[kDa] 
 
103® 
77® 
 
50® 
 
34.3® 
28.8® 
 
20.7® 
 1     2       3          4 
 
 
  Experimental Part 
  282 
in DMSO, leading to a final concentration of 100 µM, 10 µM or 1 µM respectively) was 
added and the cuvette transferred to a Beckman DU 530 UV-Vis spectrophotometer. 
Following the addition of GSH (50 µl of a 100 mM solution in H2O), the increase in UV 
absorbance was measured at 340 nm over 30 s and converted to a reaction rate. Using 
DMSO instead of the inhibitor solution and HEPES buffer II instead of the enzyme solution 
determined the chemical reaction rate. The specific enzyme activity was measured in the 
absence of inhibitor. All measurements were carried out in triplicate and the chemical 
reaction rate was deducted from the other measurements in order to remove the 
background chemical reaction. Values were reported as % inhibition of the specific 
enzyme activity.  
5.2.5 Thermal Shift Assay 
4 µl 5000X SYPRO Orange in DMSO were added to 1 ml of a 2 mg/ml solution of 
AmGSTF1 in HEPES buffer I. 10 µl of the resulting solution were pipetted into each well of 
a standard 96 well PCR plate (Starlab, semi-skirted PCR plates (FAST)). 10 μl of inhibitor 
solution (2 or 20 µM, ddH2O + 2% DMSO) were added into the 96 well plates for a final 
inhibitor concentration of 1 or 10 µM. The plate was sealed and spun at 1000 rpm for 2 
min. Fluorescence data was collected on an Applied Biosystems 7500 FAST Real-Time 
PCR System with excitation at 485 nm and the emission at 510 nm was used for data 
analysis. Temperature was held for 1 minute per degree from 24 to 95 degrees. The data 
was analysed using the data analysis program NAMI.162 
5.2.6 Photoaffinity labelling 
UV-absorbance measurements 
UV-absorbance of the photoaffinity labels (solution in H2O + 2% DMSO) was measured 
with an ATI UNICAM UV2 UV/Vis spectrometer at room temperature.  
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Labelling experiments 
AmGSTF1 (100 µl, 1 mg/ml in PBS buffer) was incubated with a solution of compound 145 
or 160 (100 µl, 200 µM in PBS buffer + 2% DMSO) for 10 min on ice. Irradiation was 
performed with a UV-LED (365 nm, 100 mW) for 30 min or a laser (355 nm, Q-switched 
Nd: YAG laser (Spectra Physics GER-150-10), 10 ns pulse, 10 Hz, 50 mJ per pulse) for 10 
or 30 min at rt. Control experiments with no label were performed to rule out protein 
damage from the irradiation. 
 
ESI-MS Analysis: Samples were desalted prior to mass spectrometry with a Waters 
MassPREP on-line desalting cartridge (2.1 x 10 mm) used with an Acquity UPLC (Waters 
Ltd, UK) (mobile phase gradient of water containing formic acid (0.1%) (A):acetonitrile (B): 
2 min 5% B, then up to 80% B after 4 min, constant 80% B till 5 min, further up to 95% B at 
5.1 min, back down to 5% B after 6 min and constant 5% B till 9 min; constant flow rate of 
0.4 ml/min). ESI-MS measurements were then carried out on a QToF Premier mass 
spectrometer (Waters Ltd, UK) with an electrospray ion source. Protein data were 
processed using Masslynx 4.1 and deconvoluted using MaxEnt 1 to show the nominal 
neutral mass of the protein. 
5.2.7 Native protein gel 
AmGSTF1 (0.5 mg/ml) was incubated on ice for 30 min with two different concentrations of 
inhibitor 3 (10 and 500 µM final concentration). Native PAGE was carried out in a non-
denaturing 4 – 20% polyacrylamide gel (Mini-PROTEAN® TGX™ Precast Gel). The gel 
was run at 4 °C in a Tris-glycine buffer (100 ml of Bio-Rad 10 × Tris/glycine diluted to 1 l, 
25 mM Tris, 192 mM glycine) at 200 V in a Mini-PROTEAN Tetra cell. Samples were 
diluted with an equal volume of native sample buffer (Bio-Rad premixed protein sample 
buffer for native PAGE, containing 62.5 mM Tris-HCl, pH 6.8, 40% glycerol, 0.01% 
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bromophenol blue), before loaded onto the gel. After electrophoretic separation, the gel 
was stained with Coomassie Blue. Invitrogen™ Novex™ NativeMARK™ unstained protein 
standard was used to check if a good separation was achieved. 
 
5.2.8 Fluorescence anisotropy 
Labeling of AmGSTF1 with HiLyte Fluor™ 488 
AmGSTF1 (1 mg/ml) was reduced with a 10-fold molar excess of tris(2-carboxyethyl) 
phosphine (TCEP) and then incubated at rt for 2 h with 400 µM HiLyte Fluor™ 488 C2 
maleimide (AnaSpec) in the presence of PBS buffer. The solution was passed through two 
gel filtration chromatography columns (disposable PD 10 desalting column, GE 
Healthcare). The fractions containing the labelled protein were analysed for their protein 
content by absorbance at 280 nm (NanoDrop 2000 spectrophotometer, Thermo Scientific). 
The contribution of HiLyte Fluor™ 488 to the absorption was estimated by the absorption 
value at 507 nm multiplied by 0.2 and subtracted from the total absorbance before 
calculation of protein concentration using an extinction coefficient of 42525 M-1 cm-1 for the 
GST monomer. 
Fluorescence anisotropy measurements 
100 µl of the HiLyte Fluor™ 488 labelled AmGSTF1 solution (40 nm or 200 nm) in PBS-
buffer were pipetted into each well of a standard 96 well plate. 100 μl solution of inhibitor 3 
(2, 20, 200 or 400 µM, PBS-buffer + 4% DMSO) were added into the 96 well plates for a 
final inhibitor concentration of 1, 10, 100 and 200 µM. Fluorescence anisotropy 
experiments were performed on a BioTek Synergy™ H4 Hybrid Microplate Reader. The 
HiLyte Fluor™ 488 fluorescence anisotropy was measured with lex at 485 nm ± 20 nm and 
lem at 528 nm ± 20 nm. Each anisotropy value is the average of eight replicates. 
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5.2.9 Synergist tests on plants 
Maize 
For all experiments maize of the Garland variety was used, provided by Syngenta. The 
seeds were soaked in water overnight and then individually sown at the surface of peat 
pellets with the tip cap showing up. For faster germination the pellets were placed on a 
tray and covered with cling film for the first two days. The maize was grown in a growth 
room at 25 °C during day (16 h) and 22 °C during night (8 h).  
For the spray trials on maize a modified Potter Precision spray tower, a chemical spraying 
apparatus, was used. In order to accommodate a plant, the spray tower was increased in 
height by 10 cm (cf. Chapter 3.2.2.3.1). Spray trials were conducted using optimised 
concentrations of active ingredients, as follows: 
Entry Compound Compound Number Role Concentrations 
1 Mesotrione 157 Herbicide 30 µM, 250 µM 
2 Nicosulfuron 158 Herbicide 30 µM, 250 µM 
3 Chlortoluron 159 Herbicide 30 µM, 60 µM 
4 Pinoxaden 155 Herbicide 7.5 µM, 15 µM 
5 Clodinafop-propargyl 160 Herbicide 7.5 µM, 15 µM 
6 Flavonoid 3 Synergist 2 mM 
7 CNBF 1 Synergist 1 mM, 2 mM 
Table 16: All compounds formulated using DMSO (2%) and Agridex (0.5%). 
 
20 ml of the synergist or formulation only emulsions were sprayed onto the plant 7 days 
after sowing. 24 h later the same amount of herbicide or formulation only solution was 
applied. The modified Potter spray tower was used at 15 psi. The plants were assessed 7 
days after the treatment. 
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Black grass 
Seeds for the MHR bitotype of black grass (Peldon) and the respective herbicide-
susceptible WT black grass were provided by Syngenta. Black grass seeds were sown 
densely in a tray on top of compost (John Innes No. 2), which was pressed down prior to 
sowing and approximately 0.5 – 1 cm of vermiculite were sprinkled on top of the seeds. 
Plants were grown in a growth chamber (Environmental test chamber MLR-350H, Sanyo 
Ltd.) with a 16 h light/8 h dark cycle at 20 °C during days and 16 °C during nights. After 5 
days (WT black grass) or 7 days (MHR black grass) respectively the plants germinated 
and 5 days later seedlings were transplanted into individual pots (6 cm diameter). 
The optimised concentrations of active ingredients used for synergism experiments are 
summarized in Table 17. 
Entry Compound Role Concentrations 
1 Pinoxaden Herbicide 5 µM, 15 µM 
2 Flavonoids Synergist 2 mMa 
Table 17: All compounds formulated using acetone (5%) and Adigor (0.5%).  
a Additionally a synergist concentration of 0.2, 0.6 and 6 mM was tested for 
thiazole 102. 
 
Five 2 µl drops of the synergist or formulation only emulsions were applied with a 
micropipette 14 days after germination at the two leave stage. As some of the synergists 
are not completely soluble under these conditions, they were applied as suspensions and 
sonicated prior to use. The drops were distributed evenly on each plant, two drops on each 
leave and one at the node. 24 h later 10 µl of herbicide or formulation only solution was 
applied in the same way. The plants were assessed 21 days after the treatment. 
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